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Melanoma has one of the fastest rising incidence rates of any cancer. It accounts for a small percentage of skin cancer cases but is responsible for the majority of skin cancer deaths.
Although history-taking and visual inspection of a suspicious lesion by a clinician are usually the first in a series of ‘tests’ to diagnose skin cancer, dermoscopy has become an important
tool to assist diagnosis by specialist clinicians and is increasingly used in primary care settings. Dermoscopy is a magnification technique using visible light that allows more detailed
examination of the skin compared to examination by the naked eye alone. Establishing the additive value of dermoscopy over and above visual inspection alone across a range of
observers and settings is critical to understanding its contribution for the diagnosis of melanoma and to future understanding of the potential role of the growing number of other high-
resolution image analysis techniques.
Objectives
To determine the diagnostic accuracy of dermoscopy for the detection of cutaneous invasive melanoma and atypical intraepidermal melanocytic variants in adults, and to compare its
accuracy with that of visual inspection alone. Studies were separated according to whether the diagnosis was recorded face-to-face (in-person) or based on remote (image-based)
assessment.
Search methods
We undertook a comprehensive search of the following databases from inception up to August 2016: Cochrane Central Register of Controlled Trials; MEDLINE; Embase; CINAHL;
CPCI; Zetoc; Science Citation Index; US National Institutes of Health Ongoing Trials Register; NIHR Clinical Research Network Portfolio Database; and the World Health Organization
International Clinical Trials Registry Platform. We studied reference lists and published systematic review articles.
Selection criteria
Studies of any design that evaluated dermoscopy in adults with lesions suspicious for melanoma, compared with a reference standard of either histological confirmation or clinical
follow-up. Data on the accuracy of visual inspection, to allow comparisons of tests, was included only if reported in the included studies of dermoscopy.
Data collection and analysis
Two review authors independently extracted all data using a standardised data extraction and quality assessment form (based on QUADAS-2). We contacted authors of included
studies where information related to the target condition or diagnostic threshold were missing. We estimated accuracy using hierarchical summary ROC methods. Analysis of studies
allowing direct comparison between tests was undertaken. To facilitate interpretation of results, we computed values of sensitivity at the point on the SROC curve with 80% fixed
specificity and values of specificity with 80% fixed sensitivity. We investigated the impact of in-person test interpretation; use of a purposely developed algorithm to assist diagnosis;
observer expertise; and dermoscopy training.
Main results
A total of 104 study publications reporting on 103 study cohorts with 42,788 lesions (including 5700 cases) were included, providing 354 datasets for dermoscopy. The risk of bias was
mainly low for the index test and reference standard domains and mainly high or unclear for participant selection and participant flow. Concerns regarding the applicability of study
findings were largely scored as ‘High’ concern in three of four domains assessed. Selective participant recruitment, lack of reproducibility of diagnostic thresholds and lack of detail on
observer expertise were particularly problematic.
The accuracy of dermoscopy for the detection of invasive melanoma or atypical intraepidermal melanocytic variants was reported in 86 datasets; 26 for evaluations conducted in-person
(dermoscopy added to visual inspection) and 60 for image-based evaluations (diagnosis based on interpretation of dermoscopic images). Analyses of studies by prior testing revealed
no obvious effect on accuracy; analyses were hampered by the lack of studies in primary care, lack of relevant information and the restricted inclusion of lesions selected for biopsy or
excision. Accuracy was higher for in-person diagnosis compared to image-based evaluations (relative diagnostic odds ratio (RDOR) of 4.6; 95% CI 2.4, 9.0, P<0.001).
Accuracy was compared for (a) in-person evaluations of dermoscopy (26 evaluations; 23,169 lesions and 1664 melanomas) versus visual inspection alone (13 evaluations; 6740
lesions and 459 melanomas) and for (b) image-based evaluations of dermoscopy (60 evaluations; 13,475 lesions and 2851 melanomas) versus image-based visual inspection (11
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evaluations; 1740 lesions and 305 melanomas). For both comparisons, meta-analysis found dermoscopy to be more accurate than visual inspection alone, with RDORs of (a) 4.7 (95%
CI: 3.0 to 7.5; P < 0.001) and (b) 5.6 (95% CI: 3.7 to 8.5; P < 0.001). These effects correspond to predicted differences in sensitivity of (a) 16% (95% CI: 8%, 23%) (92% for
dermoscopy+visual inspection vs 76% for visual inspection) and (b) 35% (95% CI 24% to 46%) (81% for dermoscopy vs 47% for visual inspection) at a fixed specificity of 80%; and to
predicted differences in specificity of (a) 20% (95% CI 7%, 33) (95% for dermoscopy plus visual inspection vs 75% for visual inspection) and (b) 40% (95% CI 27, 57) (82% for
dermoscopy vs 42% for visual inspection) at a fixed sensitivity of 80%.
Using the median prevalence of disease in each set of studies ((a) 12% for in-person and (b) 24% for image-based) for a hypothetical population of 1000 lesions, an increase in
sensitivity of (a) 16% (in-person) and (b) 35% (image-based) from using dermoscopy at a fixed specificity of 80% equates to a reduction in the number of melanomas missed of (a) 19
and (b) 81 with (a) 176 and (b) 152 false positive results. An increase in specificity of (a) 20% (in-person) and (b) 40% (image-based) at a fixed sensitivity of 80% equates to a reduction
in the number of unnecessary excisions from using dermoscopy of (a) 176 and (b) 304 with (a) 24 and (b) 48 melanomas missed.
The use of a named or published algorithm to assist dermoscopy interpretation (as opposed to no reported algorithm or reported use of pattern analysis) had no significant impact on
accuracy either for in-person (RDOR 1.4, 95% CI 0.34, 5.6; P=0.17) or image-based (RDOR 1.4, 95% CI 0.60, 3.3; P=0.22) evaluations. This result was supported by subgroup
analysis according to algorithm used. Higher accuracy for observers reported as having high experience and for those classed as ‘expert consultants’ in comparison to those considered
to have less experience in dermoscopy was observed, particularly for image-based evaluations. Evidence for the effect of dermoscopy training on test accuracy was very limited but
suggested associated improvements in sensitivity.
Authors' conclusions
Despite the observed limitations in the evidence base, dermoscopy is a valuable tool to support the visual inspection of a suspicious skin lesion for the detection of melanoma and
atypical intraepidermal melanocytic variants, particularly in referred populations and in the hands of experienced users. Data to support its use in primary care is limited however it may
assist in triaging suspicious lesions for urgent referral when employed by suitably trained clinicians. Formal algorithms may be of most use for dermoscopy training purposes and for
less expert observers, however reliable data comparing approaches using dermoscopy in-person are lacking.
 
Plain language summary
What is the diagnostic accuracy of dermoscopy in comparison to visual inspection of skin lesions for the diagnosis of melanoma in
adults?
What is the aim of the review?
The aim of this Cochrane Review was to find out the accuracy of dermoscopy for the diagnosis of melanoma in comparison to visual inspection of suspicious skin lesions with the naked
eye. The Review also investigated whether diagnostic accuracy using dermoscopy on a patient in-person differed to the accuracy of diagnosis using dermoscopic images of suspicious
skin lesions. Researchers in Cochrane included 104 studies to answer this question.
Why is improving the diagnosis of melanoma important?
Melanoma is one of the most dangerous forms of skin cancer. Not recognising a melanoma when it is present (a false negative test result) delays surgery to remove it, risking cancer
spreading to other organs in the body and possibly death. Diagnosing a skin lesion as a melanoma when it is not (a false positive result) may result in unnecessary surgery, further
investigations and patient anxiety. Visual inspection of suspicious skin lesions by a clinician using the naked eye is usually the first of a series of ‘tests’ to diagnose melanoma.
Magnification techniques can be used by skin cancer specialists to allow a more detailed examination of suspicious skin lesions than can be achieved using the naked eye alone.
What was studied in the review?
Dermoscopy is a handheld device using visible light (such as from incandescent or LED bulbs) that can be used as part of the clinical examination of suspicious skin lesions.
Dermoscopy has become an important tool to assist diagnosis by specialist clinicians and is also increasingly used in primary care settings. Knowing the diagnostic accuracy of
dermoscopy added to visual inspection alone is important to understanding who it should be used by and in which healthcare settings.
Researchers sought to find out the diagnostic accuracy of dermoscopy of suspicious skin lesions on a patient in-person and using dermoscopic images compared to visual inspection
alone. Researchers also sought to find out whether diagnostic accuracy was improved by use of a dermoscopy checklist or by an increase in level of clinical expertise.
What are the main results of the review?
The review included 104 studies reporting data for people with lesions suspected of melanoma. The main results for the diagnosis of melanoma (including very early melanomas) are
based on 86 of the studies, 26 of which provide information on the accuracy of dermoscopy added to in-person visual inspection of a skin lesion and 60 provide information based on
examination of dermoscopic images without the patient being present.
The 26 in-person studies provide the most relevant data for the use of dermoscopy in practice and their results are summarised here. A total of 23,169 suspicious skin lesions were
included in the 26 studies and 13 of them also provided information on the accuracy of visual inspection of a lesion without the use of dermoscopy. The results suggest that dermoscopy
is more accurate than visual inspection on its own both for identifying melanoma correctly and excluding things that are not melanoma.
The studies used different ways of deciding whether a skin lesion was a melanoma or not which means that we cannot be exactly sure about how much better dermoscopy is compared
to visual inspection alone. Instead we can give an illustrative example of the expected effect of the increase in accuracy using a group of 1000 lesions, of which 120 (12%) are
melanoma. In order to see how much better dermoscopy is in identifying melanoma correctly when compared to just looking at the skin, we have to assume that both lead to the same
number of lesions being falsely diagnosed as melanoma (we assumed that 176 of the 880 lesions without melanoma would have an incorrect diagnosis of melanoma). In this fixed
situation, adding dermoscopy to visual inspection would correctly identify an extra 19 melanomas (110 compared with 91) that would have been missed by just looking at the skin alone.
In other words, more melanomas would be correctly identified.
In order to see how much better dermoscopy is in deciding if a skin lesion is not a melanoma when compared to just looking at the skin, we have to assume that both lead to the same
number of melanomas being correctly diagnosed (in this case we assumed that 96 out of the 120 melanomas would be correctly diagnosed). In this situation, adding in dermoscopy to
visual inspection would reduce the number of lesions being wrongly diagnosed as being melanoma by 176 (a reduction from 220 in the visual inspection group to 44 lesions in the
dermoscopy group). In other words, more lesions that were not melanoma would be correctly identified and less people would end up being sent for surgery.
Value of visual inspection checklists and effect of observer expertise
There was no evidence that use of a checklist to help dermoscopy interpretation changed diagnostic accuracy. Accuracy was better (with fewer missed melanomas and fewer people
having unnecessary surgery) when the diagnosis was made by people with more clinical expertise and training.
How reliable are the results of the studies of this review?
In the majority of included studies, the diagnosis of melanoma was made by lesion biopsy and the absence of melanoma was confirmed by biopsy or by follow up over time to make
sure the skin lesion remained negative for melanoma, both of which are likely to have been a reliable method for deciding whether patients really had melanoma. In a few studies, the
absence of melanoma was made by expert diagnosis, which is unlikely to have been a reliable method for deciding whether patients really had melanoma. Poor reporting of study
conduct made assessment of the reliability of studies difficult. Selective participant recruitment, lack of detail regarding the threshold for deciding on a positive test result were
particularly problematic.
Who do the results of this review apply to?
Sixty-six studies were undertaken in Europe (77%), with the remainder undertaken in North America (n=6), Asia (n=4), Oceania (n=4), or were multicentre (n=7). Mean age ranged from
30 to 58 years (reported in 26 studies). The percentage of individuals with melanoma ranged between 1% and 41% for dermoscopy in-person studies (median 12%) and between 3%
and 61% in studies using dermoscopy images (median 24%). Almost all of the studies were carried out in referral settings rather than in primary care. In the majority of studies the
lesions were unlikely to be representative of the range of those seen in practice, for example only including skin lesions of a certain size or with a specific appearance. In addition
variation in the expertise of clinicians performing visual inspection and the definition used for a positive dermoscopy test result across studies makes it unclear as to how dermoscopy
should be carried out and by people with different levels of clinical expertise in order to achieve the accuracy observed in studies.
What are the implications of this review?
When used by specialists, dermoscopy is better at diagnosing melanoma compared to inspection of a suspicious skin lesion using the naked eye alone. Dermoscopy is more accurate
when interpreted with the patient present rather than using dermoscopy images. Dermoscopy might help general practitioners to correctly identify people with suspicious lesions who
need to be seen by a specialist. Checklists to help interpret dermoscopy might improve the accuracy of people with less expertise and training. Further, well reported studies assessing
the diagnostic accuracy of dermoscopy when used in primary care and to identify the best way of delivering dermoscopy training are needed.
How up-to-date is this review?
The review authors searched for and used studies published up to August 2016.
*In these studies biopsy, clinical follow up or specialist clinician diagnosis were the reference standards.
Background
This review is one of a series of Cochrane Diagnostic Test Accuracy (DTA) reviews on the diagnosis and staging of melanoma and keratinocyte skin cancers conducted for the National
Institute for Health Research (NIHR) Cochrane Systematic Reviews Programme. Appendix 1 shows the content and structure of the programme.
Target condition being diagnosed
Melanoma is one of the most aggressive forms of skin cancer, with the potential to metastasise to other parts of the body via the lymphatic system and blood stream. It accounts for a
small percentage of skin cancer cases but is responsible for up to 75% of skin cancer deaths (Boring 1994; Cancer Research UK 2017a).
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Melanoma arises from uncontrolled proliferation of melanocytes - the epidermal cells that produce pigment or melanin. It most commonly arises in the skin but can occur in any organ
that contains melanocytes, including mucosal surfaces, the back of the eye, and lining around the spinal cord and brain. Cutaneous melanoma refers to a skin lesion with malignant
melanocytes present in the dermis, and includes superficial spreading, nodular, acral lentiginous, and lentigo maligna melanoma variants (see Figure 1). Melanoma in situ refers to
malignant melanocytes that are contained within the epidermis and have not yet invaded the dermis, but are at risk of progression to melanoma if left untreated. Lentigo maligna, a
subtype of melanoma-in-situ in chronically sun-damaged skin, denotes another form of proliferation of abnormal melanocytes. Lentigo maligna can progress to invasive melanoma if its
growth breaches the dermo-epidermal junction during a vertical growth phase (when it becomes known as 'lentigo maligna melanoma'), however its rate of malignant transformation is
both lower and slower than for melanoma in situ (Kasprzak 2015). Melanoma in situ and lentigo maligna are both atypical intraepidermal melanocytic variants.
The incidence of melanoma rose to over 200,000 newly diagnosed cases worldwide in 2012 (Erdmann 2013; Ferlay 2015), with an estimated 55,000 deaths (Ferlay 2015). The highest
incidence is observed in Australia with 11,405 new cases of melanoma of the skin (ACIM 2014) and in New Zealand with 2,341 registered cases (HPA and MelNet NZ 2014) in 2010.
For 2014 in the USA, the predicted incidence was 73,870 per annum and the predicted number of deaths 9,940 (Siegel 2015). The highest rates in Europe are seen in north-western
Europe and the Scandinavian countries, with highest incidence reported in Switzerland of 25.8 per 100,000 in 2012. Rates in the UK have trebled from 4.6 and 6.0 per 100,000 in men
and women, respectively in England in 1990, to 18.6 and 19.6 per 100,000 in 2012 (EUCAN 2012). In the UK, melanoma has one of the fastest rising incidence rates of any cancer, and
has the biggest projected increase in incidence between 2007 and 2030 (Mistry 2011). In the decade leading up to 2013, age standardised incidence increased by 46%, with 14,500
new cases in 2013 and 2,459 deaths in 2014 (Cancer Research UK 2017b). While overall incidence rates are higher in women than in men, the rate of incidence in the latter is
increasing faster than in women (Arnold 2014).
The rising incidence in melanoma is thought to be primarily related to an increase in recreational sun exposure and tanning bed use and an increasingly ageing population with higher
lifetime ultraviolet (UV) exposure, in conjunction with possible earlier detection (Linos 2009; Belbasis 2016). Putative risk factors are reviewed in detail elsewhere (Belbasis 2016), but
can be broadly divided into host or environmental factors. Host factors include fair skin and light hair or eye colour; older age (Geller 2002); male sex (Geller 2002); previous skin cancer
history (Tucker 1985); predisposing skin lesions, e.g., high melanocytic naevus counts (Gandini 2005), clinically atypical naevi (Gandini 2005), or large congenital naevi (Swerdlow
1995); genetically inherited skin disorders e.g., xeroderma pigmentosum (Lehmann 2011); and a family history of melanoma (Gandini 2005). Environmental factors include recreational
and occupational exposure to sunlight (both cumulative and episodic burning) (Gandini 2005; Armstrong 2017); artificial tanning (Boniol 2012); and immunosuppression, e.g., in organ
transplant recipients or human immunodeficiency virus (HIV)-positive individuals (DePry 2011). Lower socioeconomic class may be associated with delayed presentation and thus more
advanced disease at diagnosis (Reyes-Ortiz 2006).
A database of over 40,000 US patients from 1998 onwards which assisted the development of the 8th American Joint Committee on Cancer (AJCC) Staging System indicated a five-
year survival of 99% for very early stage melanoma, dropping to anything between 32% and 93% in stage III disease depending on tumour thickness, the presence of ulceration and
number of involved nodes (Gershenwald 2017). Before the advent of targeted and immunotherapies, disseminated melanoma (to distant sites / visceral organs) was associated with
median survival of six to nine months, one year survival rate of 25%, and three year survival of 15% (Balch 2009; Korn 2008).
Between 1975 and 2010, five year relative survival for melanoma (i.e. not including deaths from other causes) in the US increased from 80% to 94%, with survival for localised, regional,
and distant disease estimated at 99%, 70%, and 18%, respectively in 2010 (Cho 2014). However, mortality rates showed little change, at 2.1 per 100,000 deaths in 1975 and 2.7 per
100,000 in 2010 (Cho 2014). Increasing incidence in localised disease over the same period (from 5.7 to 21 per 100,000) suggests that much of the observed improvement in survival
may be due to earlier detection and heightened vigilance (Cho 2014). New targeted therapies for advanced (stage IV) melanoma (e.g. BRAF inhibitors) have improved survival and
immunotherapies are evolving such that long term survival is being documented (Pasquali 2018; Rozeman 2017). No new data regarding the survival prospects for patients with stage
IV disease were analysed for the AJCC 8 staging guidelines due to lack of contemporary data (Gershenwald 2017).
Treatment of melanoma
For primary melanoma, the mainstay of definitive treatment is early detection and excision of the lesion, to remove both the tumour and any malignant cells that might have spread into
the surrounding skin (Sladden 2009; Marsden 2010; NICE 2015a; Garbe 2016; SIGN 2017). Recommended surgical margins vary according to tumour thickness (Garbe 2016) and
stage of disease at presentation (NICE 2015a).
Index test(s)
For the purposes of our series of reviews, each component of the diagnostic process, including visual inspection or clinical examination, is considered a diagnostic or index ‘test', the
accuracy of which can be established in comparison with a reference standard of diagnosis, either alone or in combination with other available technologies that may assist the
diagnostic process. In this review, although dermoscopy is the primary focus, two index tests are in fact under consideration, namely visual inspection and dermoscopy both of which
can be undertaken in-person (face-to-face with the patient) or image-based (remote from the patient using images). As dermoscopy is added to visual inspection of a skin lesion when it
is undertaken in-person, we effectively have three index tests: visual inspection alone (in-person or using images), visual inspection plus dermoscopy (in-person dermoscopy), and
dermoscopy alone (image-based dermoscopy).
As visual inspection of a lesion is always undertaken first in a face-to-face patient-consultation, in this section we first consider visual inspection alone before going on to describe the
addition of dermoscopy.
Visual inspection
Clinical history taking to identify risk factors and visual inspection of the lesion, surrounding skin and comparison with other lesions on the rest of the body, is fundamental to the
diagnosis of skin cancer. In the UK, clinical examination is typically done at two decision points – first in the general practice (GP) surgery where a decision is made to refer or not to
refer, and then a second time by a dermatologist or other secondary care clinician where a decision is made to biopsy or not.
Visual inspection of a lesion relies on both non-analytical and analytical pattern recognition strategies (Elstein 2002; Norman 1989; Norman 2009). Non-analytical pattern recognition
formulates an initial hypothesis hidden from the conscious view of the diagnostician, while analytical pattern recognition uses more explicit rules based on conscious analytical
reasoning (Norman 2009). The balance between non-analytical and analytical reasoning varies between clinicians, according to factors such as constitutional reasoning style
preference, experience and familiarity with the diagnostic question. Various attempts have been made to formalise the “mental rules” involved in analytical pattern recognition for
melanoma, ranging from setting out criteria that should be considered (e.g. ‘pattern analysis’; Friedman 1985; Sober 1979) to formal scoring systems with explicit numerical thresholds
(MacKie 1985; MacKie 1990). These variants on visual inspection strategies, and their comparative accuracy, are reviewed in detail in a separate systematic review in this series
(Dinnes 2018a). Data on the accuracy of visual inspection has been included in this review only where both visual inspection and dermoscopy were evaluated in the same lesions in
order to robustly estimate the comparative accuracy of adding dermoscopy to visual inspection compared to visual inspection alone, so that the benefit of dermoscopy can be
quantified.
Visual inspection of a digital photograph (or ‘macroscopic’ image) of a suspicious skin lesion can also be undertaken as part of a teledermatology consultation whereby photographs,
dermoscopic images, or both are taken by non-specialist clinicians and forwarded to a dermatologist, to obtain a specialist opinion (Chuchu 2018a). Images can also be encompassed
in a store-and-forward smartphone application whereby a photograph of a concerning lesion is taken by the smartphone user and forwarded for an assessment of skin cancer risk by a
specialist clinician (Chuchu 2018b). Images are often accompanied by a summary of the medical history and demographic information as part of a consultation package (Ndegwa
2010). According to UK guidelines, both clinical and dermoscopic images must be sent for ‘full dermatology’, i.e. as a replacement for a face-to-face consultation, whereas for ‘triage
teledermatology’ dermoscopic images should be sent where facilities permit (BAD 2013).
Dermoscopy
Dermoscopy (also referred to as dermatoscopy or epiluminescence microscopy or ELM) has become a widely used tool for the specialist clinician and is increasingly being used in
primary care settings. It uses a hand-held microscope and incident light (with or without oil immersion) to reveal subsurface images of the skin at increased magnification of x 10 to x
100 (Kittler 2011). Used alongside clinical examination, dermoscopy has been shown in some studies to increase the sensitivity of clinical diagnosis of melanoma from around 60% to
as much as 90% (Kittler 1999; Carli 2002; Bono 2006; Stanganelli 2000) with much smaller effects in others (Benelli 1999; Bono 2002).
The visual nature of dermoscopic interpretation means that when used on an in-person basis, dermoscopy is essentially added to visual inspection of a skin lesion and similar non-
analytical and analytical pattern recognition strategies are also employed to reach a diagnosis. Pattern analysis (Steiner 1987; Pehamberger 1993) is thought to be the most specific
and reliable technique to aid dermoscopy interpretation when used by specialists (Maley 2014); however, dermoscopic histological correlations have been established and diagnostic
algorithms developed based on colour, aspect, pigmentation pattern, and skin vessels. One of the first formal scoring systems was the ABCD rule for dermoscopy (Nachbar 1994; Stolz
1994), which includes 21 different features to be considered and scored (two based on asymmetry of the lesion, 8 on lesion border, 6 related to lesion colour and five to differential
structures), and has reported sensitivity ranging between 84% and 93% (Nachbar 1994; Stolz 1994). Subsequently published algorithms attempt to simplify assessment without missing
melanomas, for example, the Menzies tool (Menzies 1996), the seven-point dermoscopy checklist (Annessi 2007; Argenziano 1998; Argenziano 2001; Gereli 2010, amongst others),
and the three-point checklist (Gereli 2010). However, dermoscopy can fail to diagnose atypical or early or featureless melanomas (Skvara 2005). These and other identified algorithms
are described in detail in Appendix 2.
In modern practice, dermoscopic images are almost always obtained for skin lesions that are recommended for excision and are also obtained for lesions that have not yet met the
diagnostic threshold for excision but are to be monitored over time in case of any further suspicious changes. Dermoscopic images are also a key component of teledermatology
consultations, usually accompanied by digital photographs and other pertinent information (Chuchu 2018a), as discussed above.
The accuracy of dermoscopy has been suggested to vary with examiner experience (Kittler 2011), and results when used by untrained or less experienced examiners are potentially no
better than clinical inspection alone (Binder 1997; Kittler 2002). Training in dermoscopy use can comprise from a single one-hour lecture (Benvenuto-Andrade 2006) to an intensive
course lasting a week or more (De Giorgi 2011), often supplemented with web-based learning or using textbooks or CD-ROMs (Carli 2003; Menzies 2009; Tan 2009). The most effective
means of training health professionals in dermoscopy remains to be established. Evidence from Australia suggests that it takes time to train non-expert clinicians in the use of
dermoscopy, and dropout rates from training programmes may be up to 40% (Menzies 2009).
Clinical Pathway
The diagnosis of melanoma can take place in primary, secondary, and tertiary care settings by both generalist and specialist healthcare providers. In the UK, people with concerns
about a new or changing lesion will usually present first to their general practitioner or less commonly directly to a specialist in secondary care, which could include a dermatologist,
plastic surgeon, general surgeon or other specialist surgeon (such as an ear, nose, and throat (ENT) specialist or maxillofacial surgeon), or ophthalmologist (Figure 2). Current UK
guidelines recommend that all suspicious pigmented lesions presenting in primary care should be assessed by taking a clinical history and visual inspection using the weighted seven-
point checklist (MacKie 1990); lesions suspected to be melanoma should be referred for appropriate specialist assessment within two weeks (Chao 2013; Marsden 2010; NICE 2015a).
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There are currently no recommendations promoting the use of dermoscopy in primary care in the UK, although the 2015 NICE suspected cancer recognition and referral guidelines
states that people should be referred “using a suspected cancer pathway referral (for an appointment within 2 weeks) if dermoscopy suggests melanoma of the skin” (NICE 2015a).
Studies from France (Chappuis 2016) and the Netherlands (Ahmadi 2017) suggest that around 8% of GPs use dermoscopy compared to as many as 40% of GPs in Australia reported
to using a dermoscope in their routine practice (Youl 2007).
Theoretically, teledermatology consultations may aid appropriate triage of lesions into urgent referral; non-urgent secondary care referral (e.g., for suspected basal cell carcinoma); or
where available, referral to an intermediate care setting, e.g. clinics run by GPs with a special interest in dermatology. The distinction between setting and examiner qualifications and
experience is important as specialist clinicians might work in primary care settings (for example, in the UK, general practitioners (GPs) with a special interest in dermatology and skin
surgery who have undergone appropriate training), and generalists might practice in secondary care settings (for example, plastic surgeons who do not specialise in skin cancer). The
level of skill and experience in skin cancer diagnosis will vary for both generalist and specialist care providers and will also impact on test accuracy.
Following referral, a specialist clinician will also use history-taking and visual inspection of the lesion (in comparison with other lesions on the skin), usually in conjunction with
dermoscopic examination, to inform a clinical decision. If melanoma is suspected, then urgent excision biopsy is recommended; for suspected cutaneous squamous cell carcinoma
(cSCC) urgent excision with predetermined surgical margins. Other lesions such as basal cell carcinoma (BCC), suspected dysplastic naevi or pre-malignant lesions such as lentigo
maligna may also be referred for a diagnostic biopsy, followed by appropriate treatment, further surveillance or reassurance and discharge.
Prior test(s)
Although smartphone applications and community-based teledermatology services can increasingly be directly accessed by people who have concerns about a skin lesion, visual
inspection of a suspicious lesion by a clinician is usually the first in a series of tests to diagnose skin cancer. In the UK this usually takes place in primary care, however in some
countries people with suspicious lesions can present directly to a specialist setting (NICE 2015b). Dermoscopy is likely to be added to visual inspection of a lesion in secondary care
and referral settings, however, it is increasingly used in primary care, particularly in countries such as Australia (Youl 2007).
Consideration of the degree of prior testing that study participants have undergone is key to interpretation of test accuracy indices, as these are known to vary according to the disease
spectrum (or case-mix) of included participants (Lachs 1992; Moons 1997; Leeflang 2013; Usher-Smith 2016). Spectrum effects are often observed when tests that are developed
further down the referral pathway have lower sensitivity and higher specificity when applied in settings with participants with limited prior testing (Usher-Smith 2016). Studies of
individuals with suspicious lesions at the initial clinical presentation stage ('test naïve') are likely to have a wider range of differential diagnoses and include a higher proportion of people
with benign diagnoses compared with studies of participants who have been referred for a specialist opinion on the basis of visual inspection (with or without dermoscopy) by a
generalist practitioner. Furthermore, studies in more specialist settings may focus on equivocal or difficult to diagnose lesions rather than lesions with a more general level of clinical
suspicion. However this direction of effect is not consistent across tests and diseases, the mechanisms in action often being more complex than prevalence alone and can be difficult to
identify (Leeflang 2013). A simple categorisation of studies according to primary, secondary or specialist setting therefore may not always adequately reflect this difference in disease
spectrum.
Role of index test(s)
Although visual inspection and history-taking are key to diagnosing skin cancer and are always undertaken as part of a clinical examination, dermoscopy has become an important tool
to assist diagnosis by specialist clinicians and is increasingly used in primary care settings. For the majority of generalist practitioners, the primary goal is to identify people with benign
lesions and appropriately reassure them, thereby minimising the proportion of people who are referred unnecessarily, while still identifying those lesions that require referral and expert
assessment. For the specialist, the aim is not only to identify those in need of urgent excision due to invasive cancer, but also to identify high risk lesions with considerable potential to
progress to invasive disease, such as those with severe dysplasia or in situ disease e.g. lentigo maligna, for example.
When diagnosing potentially life-threatening conditions such as melanoma, the consequences of falsely reassuring a person that they do not have skin cancer can be serious and
potentially fatal, as the resulting delay to diagnosis means that the window for successful early treatment may be missed. To minimise such false-negative diagnoses, a good diagnostic
test will demonstrate high sensitivity and a high negative predictive value (NPV), where very few of those with a negative test result will actually have a melanoma. False positive test
results from a test with poor specificity will result in the removal of many benign lesions. Unneccessary surgery is arguably less of an error than missing a potentially fatal melanoma,
but is costly: false-positive diagnoses not only cause unnecessary scarring from the biopsy or excision procedure, but also increase patient anxiety whilst they await the definite
histology results and increase healthcare costs as the number needed to remove to yield one melanoma diagnosis increases.
The additive value of dermoscopy over and above visual inspection alone is likely to vary with differences in setting, prior testing and selection of participants, and observer
qualifications, experience and training. Furthermore dermoscopic images of lesions are increasingly taken by non-expert clinicians or by non clinicians, sometimes using mobile phone
applications, and are forwarded to specialist clinics or to commercial organisations for interpretation, sometimes accompanied by a clinical image of the lesion and/or with varying
amounts of patient information (such as age, gender, and location of the lesion). With skin cancer rates continuing to rise, the increasing availability of dermoscopy for generalist use,
and with a growing number of other high-resolution image analysis techniques particularly for specialist use, it is important to understand the relative accuracy and appropriate place of
available tests in the diagnostic pathway (whether as replacements for dermoscopy, or as add-on diagnostic tools).
Although the accuracy of image-based dermoscopy interpretation will be examined in this review, studies conducted specifically in a teledermatology context are the subject of a
separate systematic review (Chuchu 2018a). Similarly, studies of mobile phone applications where the intended users are members of the general public rather than clinicians are the
subject of further review (Chuchu 2018b).
Alternative test(s)
A number of other tests which may have a role in the diagnosis of melanoma in a specialist setting have been reviewed as part of our series of systematic reviews, including reflectance
confocal microscopy (RCM) (Dinnes 2018b), optical coherence tomography (OCT) (Ferrante di Ruffano 2018a), and computer-aided diagnosis (CAD) techniques applied to various
types of images including those generated by dermoscopy, diffuse reflectance spectrophotometry (DRS) and electrical impedance spectroscopy (EIS) (Ferrante di Ruffano 2018b), and
high frequency ultrasound (Dinnes 2018c). Other tests reviewed include teledermatology (Chuchu 2018a) and mobile phone applications (Chuchu 2018b). Evidence permitting, the
accuracy of available tests will be compared in an overview review, exploiting within-study comparisons of tests and allowing the analysis and comparison of commonly used diagnostic
strategies where tests may be used singly or in combination.
We also considered and excluded a number of tests from this review such as tests used for monitoring people (e.g. total body photography of those with large numbers of typical or
atypical naevi). We also did not assess histopathological confirmation following lesion excision because it is the established reference standard for melanoma diagnosis and will be one
of the standards against which the index tests are evaluated in these reviews.
Rationale
This series of reviews of diagnostic tests used to assist clinical diagnosis in either clinical practice or in a research setting, aims to identify the most accurate approaches to diagnosis
and provide clinical and policy decision-makers with the highest possible standard of evidence on which to base diagnostic and treatment decisions. With increasing rates of melanoma
and a trend to adopt the use of dermoscopy and other high-resolution image analysis in primary care, the anxiety around missing early cases needs to be balanced against the risk of
over referrals, to avoid sending too many people with benign lesions for a specialist opinion. It is questionable whether all skin cancers identified by sophisticated techniques contribute
to morbidity and mortality or whether newer technologies run the risk of increasing false-positive diagnoses. The full impact of use of these technologies cannot be understood without
an understanding of the accuracy of more established techniques such as dermoscopy, in comparison to visual inspection. It is also possible that widespread use of dermoscopy in
primary care with inadequate training could result in harm from missed melanomas, particularly if used as a replacement for traditional history-taking and clinical examination of the
entire skin. Many branches of medicine have noted the danger of such "gizmo idolatry" amongst doctors (Leff 2008). The trend towards remote interpretation of clinical images (whether
macroscopic or dermoscopic images of lesions) and the use of remote technologies that do not involve clinicians without substantive evidence could further disrupt clinical pathways
and healthcare payments as they may attract custom from the worried well, leaving an ever decreasing pool of qualified doctors to pick up any resulting problems.
There are a number of available systematic reviews in the field. Some are limited by now out-of-date search periods, for example searches in Rajpara 2009 were carried out up to 2007,
and in Vestergaard 2008 up to 2008. Others are focused on specific clinical questions, for example, selected health care professionals (Corbo 2012 including only direct comparisons of
the accuracy of primary care physicians versus dermatologists, and Loescher 2011 reviewing the skin cancer detection skills of advanced practice nurses) or settings (Herschorn 2012
including direct comparisons of visual inspection versus dermoscopy in primary care). More recently, Harrington and colleagues (Harrington 2017) published a systematic review of
clinical prediction rules (or published algorithms) to assist the diagnosis of melanoma (both for clinical examination and for dermoscopy) and included studies published up to May 2015.
This review did not consider whether diagnoses were made based on images or were conducted in-person, nor did it consider variations in the definition of the target condition, and
furthermore no comparison was made for diagnosis with and without the use of an algorithm.
The critical question about the accuracy of dermoscopy in addition to visual inspection and the impact of examiner, prior patient testing, underlying risk status and the use of images for
diagnosis needs to be answered before the potential contribution of other diagnostic tests can be set in context and appropriately placed in the diagnostic pathway.
This review follows a generic protocol which covers the full series of Cochrane DTA reviews for the diagnosis of melanoma (Dinnes 2015a). The Background and Methods sections of
this review therefore use some text that was originally published in the protocol (Dinnes 2015a) and text that overlaps some of our other reviews (Dinnes 2018a; Dinnes 2018b).
Appendix 3 provides a glossary of terms used.
Objectives
To determine the diagnostic accuracy of dermoscopy alone, or when added to visual inspection of a skin lesion, for the detection of cutaneous invasive melanoma and atypical
intraepidermal melanocytic variants in adults.
Accuracy was estimated separately according to the prior testing undergone by study participants comparing those with limited prior testing with those referred for further evaluation of a
suspicious lesion. We originally aimed to estimate the effect on accuracy of diagnosis based on a face-to-face (in-person) encounter versus a remote (image-based) assessment as a
secondary objective, however given the considerable difference in nature of an in-person consultation compared to the viewing of an image, accuracy was estimated separately for
each approach to diagnosis. We therefore aimed to compare tests in the following way:
To estimate incremental accuracy for the diagnosis of invasive melanoma and atypical intraepidermal melanocytic variants in adults, a) from dermoscopy added to in-person visual
inspection of a skin lesion, or b) from dermoscopic image-based assessment in comparison to visual inspection of a clinical photograph.
Secondary objectives
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For the identification of cutaneous invasive melanoma and atypical intraepidermal melanocytic variants:
i. To compare the accuracy of dermoscopy to visual inspection alone, where both tests have been evaluated in the same studies (direct test comparisons)
ii. To determine the diagnostic accuracy of individual algorithms used to assist dermoscopy; and
iii. To determine the effect of observer experience on diagnostic accuracy
iv. To determine the effect of dermoscopy training on diagnostic accuracy
For the alternative definitions of the target condition:
v. To determine the diagnostic accuracy of dermoscopy alone, or added to visual inspection of a skin lesion, for the detection of invasive melanoma only in adults, and to estimate
incremental accuracy a) from dermoscopy added to in-person visual inspection of a skin lesion, or b) from dermoscopic image-based assessment in comparison to visual inspection of a
clinical photograph.
vi. To determine the diagnostic accuracy of dermoscopy alone, or added to visual inspection of a skin lesion, for the detection of any skin cancer or skin lesion with a high risk of
progression to melanoma in adults, and to estimate incremental accuracy a) from dermoscopy added to in-person visual inspection of a skin lesion, or b) from dermoscopic image-
based assessment in comparison to visual inspection of a clinical photograph.
Investigation of sources of heterogeneity
We set out to address a range of potential sources of heterogeneity for investigation across our series of reviews, as outlined in our generic protocol (Dinnes 2015a) and described in
Appendix 4, however our ability to investigate these was necessarily limited by the available data on each individual test reviewed.
The sources of heterogeneity that were investigated for dermoscopy were:
prior testing: comparing those at initial presentation versus referred patients
in-person versus image-based evaluations
type of reference standard: histology alone versus histology plus clinical follow-up or other reference standard
use of a diagnostic algorithm: no algorithm reported versus any named algorithm used
lesion type: pigmented versus melanocytic lesions
number of observers making the diagnosis: single observer versus consensus of two or more
disease prevalence: 0 to 5%; >5 to 10%, >10 to 20%, >20%
Methods
Criteria for considering studies for this review
Types of studies
We included test accuracy studies that allow comparison of the result of the index test with that of a reference standard, including the following:
studies where all participants receive a single index test and a reference standard;
studies where all participants receive more than one index test(s) and reference standard;
studies where participants are allocated (by any method) to receive different index tests or combinations of index tests and all receive a reference standard (between-person
comparative studies (BPC));
studies that recruit series' of participants unselected by true disease status (referred to as case series for the purposes of this review);
diagnostic case-control studies that separately recruit diseased and non-diseased groups (see Rutjes 2005);
both prospective and retrospective studies; and
studies where previously acquired clinical or dermoscopic images were retrieved and prospectively interpreted for study purposes.
We excluded studies from which we could not extract 2x2 contingency data or if they included less than five melanoma cases or less than five benign lesions. The size threshold of five
is arbitrary. However such small studies are unlikely to add precision to estimate of accuracy.
Participants
We included studies in adults with pigmented skin lesions or lesions suspicious for melanoma or those at high risk of developing melanoma, including those with a family history or
previous history of melanoma skin cancer, atypical or dysplastic naevus syndrome, or genetic cancer syndromes.
We excluded studies that recruited only participants with malignant diagnoses and studies that compared test results in participants with malignancy compared with test results based
on 'normal' skin as controls, due to the inherent bias in such comparisons (Rutjes 2006).
We excluded studies conducted in children or which clearly reported inclusion of more than 50% of participants aged 16 and under.
Index tests
Studies reporting accuracy data for dermoscopy, with diagnosis made either in-person (face-to-face diagnosis) or image-based (diagnosis based on dermoscopic images, remotely from
the study participant) were eligible for inclusion. All established algorithms or checklists to assist diagnosis were included.
Studies developing new algorithms or methods of diagnosis (i.e., derivation studies) were included if they:
used a separate independent 'test set' of participants or images to evaluate the new approach, or
investigated lesion characteristics that had previously been suggested as associated with melanoma and the study reported accuracy based on the presence or absence of specific
combinations of characteristics.
Studies were excluded if they:
used a statistical model to produce a data driven equation, or algorithm based on multiple diagnostic features, with no separate test set.
used cross-validation approaches such as 'leave-one-out' cross-validation (Efron 1983)
evaluated the accuracy of the presence or absence of individual lesion characteristics or morphological features, with no overall diagnosis of malignancy
reported accuracy data for ‘clinical diagnosis’ with no clear description as to whether the reported data related to visual inspection alone or included dermoscopy in all study
participants
were based on the experience of a skin cancer-specific clinic, where dermoscopy may or may not have been used on an individual patient basis.
Although primary care clinicians can have a specialist interest in skin cancer, for the purposes of this review we considered primary care physicians as generalist practitioners and
dermatologists as specialists. Within each group, we extracted any reporting of special interest or accreditation in skin cancer.
Target conditions
The primary target condition was defined as the detection of:
any form of invasive cutaneous melanoma , or atypical intraepidermal melanocytic variants (i.e. including melanoma in situ, or lentigo maligna, which has a risk of progression to
invasive melanoma).
Two additional definitions of the target condition were considered in secondary analyses, namely the detection of:
any form of invasive cutaneous melanoma alone
any skin lesion requiring excision. This latter definition includes other forms of skin cancer, such as basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), as
well as melanoma in situ, lentigo maligna, and lesions with severe melanocytic dysplasia.
The diagnosis of the keratinocyte skin cancers, basal cell carcinoma, and squamous cell carcinoma as primary target conditions using visual inspection and/or dermoscopy are the
subject of a separate review (Dinnes 2018d).
Reference standards
The ideal reference standard is histopathological diagnosis in all eligible lesions. A qualified pathologist or dermatopathologist should perform histopathology. Ideally, reporting should
be standardised detailing a minimum dataset to include the histopathological features of melanoma to determine the American Joint Committee on Cancer (AJCC) Staging System (e.g.
Slater 2014). We did not apply this as a necessary inclusion criterion, but extracted any pertinent information.
Partial verification (applying the reference test only to a subset of those undergoing the index test) was of concern given that lesion excision or biopsy are unlikely to be carried out for
all benign-appearing lesions within a representative population sample. Therefore to reflect what happens in reality, we accepted clinical follow-up of benign-appearing lesions as an
eligible reference standard, whilst recognising the risk of differential verification bias (as misclassification rates of histopathology and follow-up will differ).
Additional eligible reference standards included cancer registry follow-up and 'expert opinion' with no histology or clinical follow-up. Cancer registry follow-up is considered less
desirable than active clinical follow-up, as follow-up is not carried out within the control of the study investigators. Furthermore, if participant-based analyses as opposed to lesion-based
analyses are presented, it may be difficult to determine whether the detection of a malignant lesion during follow-up is the same lesion that originally tested negative on the index test.
All of the above were considered eligible reference standards with the following caveats:
all study participants with a final diagnosis of the target disorder must have a histological diagnosis, either subsequent to the application of the index test or after a period of clinical
follow-up, and
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at least 50% of all participants with benign lesions must have either a histological diagnosis or clinical follow-up to confirm benignity.
Search methods for identification of studies
Electronic searches
The Information Specialist (SB) carried out a comprehensive search for published and unpublished studies. A single large literature search was conducted to cover all topics in the
programme grant (see Appendix 1 for a summary of reviews included in the programme grant). This allowed for the screening of search results for potentially relevant papers for all
reviews at the same time. A search combining disease-related terms with terms related to the test names, using both text words and subject headings was formulated (Appendix 5). The
search strategy was designed to capture studies evaluating tests for the diagnosis or staging of skin cancer. As the majority of records were related to the searches for tests for staging
of disease, a filter using terms related to cancer staging and to accuracy indices was applied to the staging test search, to try to eliminate irrelevant studies, for example, those using
imaging tests to assess treatment effectiveness. A sample of 300 records that would be missed by applying this filter was screened and the filter adjusted to include potentially relevant
studies. When piloted on MEDLINE, inclusion of the filter for the staging tests reduced the overall numbers by around 6000. The final search strategy, incorporating the filter, was
subsequently applied to all bibliographic databases as listed below. The final search result was cross-checked against the list of studies included in five systematic reviews; our search
identified all but one of the studies, and this study is not indexed on MEDLINE. The Information Specialist devised the search strategy, with input from the Information Specialist from
Cochrane Skin. No additional limits were used.
We searched the following bibliographic databases to 29 August 2016 for relevant published studies:
MEDLINE via OVID (from 1946);
MEDLINE In-Process & Other Non-Indexed Citations via OVID; and
EMBASE via OVID (from 1980).
We searched the following bibliographic databases to 30 August 2016 for relevant published studies:
the Cochrane Central Register of Controlled Trials (CENTRAL) Issue 7, 2016, in the Cochrane Library;
the Cochrane Database of Systematic Reviews (CDSR) Issue 8, 2016 in the Cochrane Library;
Cochrane Database of Abstracts of Reviews of Effects (DARE) Issue 2, 2015;
CRD HTA (Health Technology Assessment) database Issue 3, 2016;
CINAHL (Cumulative Index to Nursing and Allied Health Literature via EBSCO from 1960).
We searched the following databases for relevant unpublished studies:
CPCI (Conference Proceedings Citation Index) via Web of Science™ (from 1990);
Zetoc (from 1993)
SCI Science Citation Index Expanded™ via Web of Science™ (from 1900, using the "Proceedings and Meetings Abstracts" Limit function).
We searched the following trials registers:
The US National Institutes of Health Ongoing Trials Register (www.clinicaltrials.gov);
NIHR Clinical Research Network Portfolio Database (http://www.nihr.ac.uk/research-and-impact/nihr-clinical-research-network-portfolio/);
The World Health Organization International Clinical Trials Registry Platform (apps.who.int/trialsearch/).
We aimed to identify all relevant studies regardless of language or publication status (published, unpublished, in press, or in progress). No date limits were applied.
Searching other resources
We have included information about potentially relevant ongoing studies in the 'Characteristics of ongoing studies' tables. We have screened relevant systematic reviews identified by
the searches for their included primary studies, and included any missed by our searches. We have checked the reference lists of all included papers, and subject experts within the
author team have reviewed the final list of included studies. No citation searching has been conducted.
Data collection and analysis
Selection of studies
Titles and abstracts were screened by at least one author (JDi or NC), with any queries discussed and resolved by consensus. A pilot screen of 539 MEDLINE references showed good
agreement (89% with a kappa of 0.77) between screeners. Primary test accuracy studies and test accuracy reviews (for scanning of reference lists) of any test used to investigate
suspected melanoma, BCC, or cSCC were included at initial screening. Inclusion criteria (Appendix 6) were applied independently by both a clinical reviewer (from one of a team of
twelve clinician reviewers) and a methodologist reviewer (JDi or NC) to all full text articles, disagreements were resolved by consensus or by a third party (JDe, CD, HW, and RM).
Authors of eligible studies were contacted when insufficient data were presented to allow for the construction of 2x2 contingency tables.
Data extraction and management
One clinical (as detailed above) and one methodologist reviewer (JDi, NC or LFR) independently extracted data concerning details of the study design, participants, index test(s) or test
combinations and criteria for index test positivity, reference standards, and data required to populate a 2x2 diagnostic contingency table for each index test using a piloted data
extraction form. Data were extracted at all available index test thresholds. Disagreements were resolved by consensus or by a third party (JDe, CD, HW, and RM).
Authors of included studies were contacted where information related to final lesion diagnoses or diagnostic threshold were missing. In particular, invasive cSCC (included as disease
positive for one of our secondary objectives) is not always differentiated from ‘in situ’ variants such as Bowens disease (which we did not consider as disease positive for any of our
definitions of the target condition). Authors of conference abstracts published from 2013 to 2015 were contacted to ask whether full data were available. If no full paper was identified,
we marked conference abstracts as 'pending' and will revisit them in a future review update.
Dealing with multiple publications and companion papers
Where multiple reports of a primary study were identified, we maximised yield of information by collating all available data. Where there were inconsistencies in reporting or overlapping
study populations, we contacted study authors for clarification in the first instance. If this contact with authors was unsuccessful, we used the most complete and up-to-date data source
where possible.
Assessment of methodological quality
We assessed risk of bias and applicability of included studies using the QUADAS-2 checklist (Whiting 2011), tailored to the review topic (see Appendix 7). The modified QUADAS-2 tool
was piloted on a small number of included full text articles. One clinical (as detailed above) and one methodologist reviewer (JDi, NC or LFR) independently assessed quality for the
remaining studies; any disagreement was resolved by consensus or by a third party where necessary (JDe, CD, HW, and RM).
Statistical analysis and data synthesis
Separate analyses were planned according to the point that study participants have reached in the clinical pathway (numbered from 1 to 7 in Figure 3), the clarity with which the
pathway could be determined (clear or unclear), and the evaluation of in-person versus image-based diagnosis.
Our unit of analysis was the lesion rather than the patient. This is because (i) in skin cancer initial treatment is directed to the lesion rather than systemically (thus it is important to be
able to correctly identify cancerous lesions for each person), and (ii) it is the most common way in which the primary studies reported data. Although there is a theoretical possibility of
correlations of test errors when the same people contribute data for multiple lesions , most studies include very few people with multiple lesions and any potential impact on findings is
likely to be very small, particularly in comparison with other concerns regarding risk of bias and applicability. For each analysis, only one dataset was included per study to avoid
multiple counting of lesions. Where multiple algorithms were assessed in an individual study, datasets were selected on the following preferential basis:
i. ‘no algorithm’ reported; data presented for clinician’s overall diagnosis or management decision
ii. pattern analysis or pattern recognition
iii. ABCD algorithm (or derivatives of)
iv. 7-point checklist (7PCL; also referred to as Glasgow/Mackie checklist)
v. Menzies algorithm
vi. 3-point checklist (3PCL)
For each index test, algorithm or checklist under consideration, estimates of sensitivity and specificity were plotted on coupled forest plots and in receiver operating characteristic (ROC)
space. For tests where commonly used thresholds were reported we estimated summary operating points (summary sensitivities and specificities) with 95% confidence and prediction
regions using the bivariate hierarchical model (Chu 2006; Reitsma 2005). Where inadequate data were available for the model to converge the model was simplified, first by assuming
no correlation between estimates of sensitivity and specificity and secondly by setting estimates of near zero variance terms to zero (Takwoingi 2015). Where all studies reported 100%
sensitivity (or 100% specificity) the number with disease (or no disease) was summed across studies and used to compute a binomial exact 95% confidence interval. Where reported,
missing or indeterminate results were usually excluded by study authors such that data could not be included in our analyses. Where study authors reported missing or indeterminate
results in more detail, these results were excluded by us for consistency.
Data on the accuracy of visual inspection, to allow comparisons of tests, was included only if reported in the studies of dermoscopy due to the known substantial unexplained
heterogeneity in all studies of the accuracy of visual inspection (Dinnes 2018a). Comparisons were made between visual inspection results with dermoscopy data from all dermoscopy
studies, and then only using dermoscopy data from studies that also reported visual inspection data for the same patients to enable a robust direct comparison (Takwoingi 2013).
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We made comparisons between tests by comparing summary ROC curves using the hierarchical summary receiver-operator curves (HSROC) model (Rutter 2001) rather than by
estimating average operating points as this approach allows incorporation of data at different thresholds and from different algorithms or checklists. We used an HSROC model that
assumed a constant SROC shape between tests and subgroups (allowing for asymmetry in shape) and modelled differences in threshold and accuracy by addition of covariates. The
significance of the differences between tests was assessed by the likelihood ratio test (LR test) assessing differences in both accuracy and threshold. Simpler models were fitted when
convergence was not achieved due to small numbers of studies, first assuming symmetric SROC curves (setting the shape term to zero), and then setting random effects variance
estimates to zero.
Estimates of accuracy from HSROC models are presented as diagnostic odds ratios (estimated where the SROC curve crosses the sensitivity=specificity line) with 95% confidence
intervals. Differences between tests and subgroups from HSROC analyses are presented as relative diagnostic odds ratios with 95% confidence intervals. To facilitate interpretation in
terms of rates of false positive and false negative diagnoses, values of sensitivity at the point on the SROC curve with 80% specificity and of specificity at the point on the SROC curve
with 80% sensitivity have been computed. These 80% values were chosen as they lie within the estimates for the majority of analyses. These results should only be considered as
illustrative examples of possible sensitivities (and specificities) and differences in sensitivities (and specificities) that could be expected. Confidence intervals for these estimates of
sensitivity and specificity were computed assuming normal distribution of sampling error on logit scales; confidence intervals for differences in sensitivity and specificity were computed
assuming normal distributions of sampling error on untransformed scales.
For computation of likely numbers of true positive, false positive, false negative and true negative findings in the summary of findings tables these indicative values were applied to
lower quartile, median and upper quartiles of the prevalence observed in the study groups.
Bivariate models were fitted using the xtmelogit command in STATA 15 and HSROC models fitted using the NLMIXED procedure in the SAS statistical software package (SAS 2012,
version 9.3; SAS Institute, Cary, NC, USA) and the metadas macro (Takwoingi 2010).
Investigations of heterogeneity
Investigations of heterogeneity, comparisons between algorithms and according to observer experience and qualifications were also made by comparing summary ROC curves using
the hierarchical summary receiver-operator curves (HSROC) model (Rutter 2001) with additional covariates for differences in threshold and accuracy as used for comparing tests. Small
subgroups were omitted from models where parameter estimates could not be obtained due to convergence problems.
Sensitivity analyses
Sensitivity analyses were planned, restricting analyses to studies where
both dermoscopy (added to visual inspection) and visual inspection alone were evaluated in the same study (direct test comparisons as discussed above)
partial verification was avoided (restricting to studies including follow-up of benign lesions)
for studies using follow-up of benign appearing lesions, the interval between the index test and the reference standard was at least 3 months
for direct test comparisons, the period of application between the index tests was within one month
concerns around applicability for participant selection are low
low risk of bias for the index test
low risk of bias for the reference standard
Assessment of reporting bias
Because of uncertainty about the determinants of publication bias for diagnostic accuracy studies and the inadequacy of tests for detecting funnel plot asymmetry (Deeks 2005), we did
not perform tests to detect publication bias.
Results
Results of the search
A total of 34,347 unique references were identified and screened for inclusion. Of these, 1051 full text papers were reviewed for eligibility for any one of the suite of reviews of tests to
assist in the diagnosis of melanoma or keratinocyte skin cancer. Of the 1051 full text papers assessed, 848 were excluded from all reviews in our series (see Figure 4 PRISMA flow
diagram of search and eligibility results).
Of the 340 studies tagged as potentially eligible for this review of dermoscopy, 104 publications were included. Exclusions were mainly due to the inability to construct a 2x2
contingency table based on the data presented (n=43); the use of ineligible index tests (n=19) (for example: reporting of data for ‘clinical diagnosis’ or for serial use of the index test in a
follow-up context); assessment of individual lesion characteristics (n=28); or derivation type studies developing new algorithms or checklists without a separate training and test set of
lesions (n=30). Other reasons for exclusion included not meeting our requirements for an eligible reference standard (n=15), ineligible study populations (n=21) (for example, recruiting
only malignant or only benign lesions), inadequate sample size (n=22), ineligible definition of the target condition (n=18) or with test interpretation by medical students or laypersons
(n=3). A list of the 236 publications excluded from this review with reasons for exclusion is provided in Characteristics of excluded studies, with a list of all studies excluded from the full
series of reviews available as a separate pdf.
The authors of 17 publications were contacted for further data to allow study inclusion in the review; responses were received from four authors with regard to seven publications. Two
authors provided additional data but this was insufficient to allow inclusion of the studies (Cabrijan 2008; Warshaw 2009; Warshaw 2009a; Warshaw 2010), one replied indicating that
dermoscopy was not necessarily used in all study participants (Youl 2007; Youl 2007a) and one replied but was unable to access the data needed (Fabbrocini 2008). The authors of a
further 20 included studies were contacted for further details of study methods. Responses were received in regard to 10 studies, 8 providing further information regarding the
diagnostic thresholds used (Blum 2003; Blum 2004; Bono 2006; Bourne 2012; Carrera 2016; Durdu 2011; Kittler 1999; Stanganelli 2000), one providing full anonymised study data
(Rosendahl 2011) and one unable to provide the information requested, although the study could still be included (Menzies 2009).
Of the 104 included study publications, two provide data for two separate cohorts of lesions: Guitera 2009 reports data for one cohort of lesions recruited in Modena, Italy (denoted
Guitera 2009a (Modena)) and one cohort recruited in Sydney (denoted Guitera 2009b (Sydney)); Haenssle 2010 reports data for one cohort of lesions examined on participants first
visit (denoted Haenssle 2010a (FV)) and one cohort of lesions identified during patient follow-up (denoted Haenssle 2010b (FU)). One further cohort is reported on in four different
publications; data from one publication (Blum 2004b) have been included in the primary analyses with data from Blum 2003, Blum 2003b and Blum 2004 providing results for different
algorithms or thresholds for the same set of lesions. The total number of cohorts of lesions described in the 104 study publications is therefore 103 (104 plus 2 minus 3). The 104 study
publications provided a total of 354 dermoscopy datasets (each publication often providing more than one 2x2 contingency table according to the use of different algorithms, different
test thresholds or different observers) for 42,788 lesions and 5700 malignancies. The total number of study participants with suspicious lesions cannot be estimated due to lack of
reporting in study publications (reported in only 44 studies with 9591 participants). A third of study publications (n=31; 30%) also reported accuracy data for diagnosis using visual
inspection; these provided 61 datasets for 9025 lesions and 959 malignancies. A systematic review of the accuracy of visual inspection per se is reported in Dinnes 2018a. A further 29
of the 104 included study publications reported data for tests other than dermoscopy or visual inspection including: teledermatology (n=3), reflectance confocal microscopy (RCM)
(n=7), exfoliative cytology (n=1) and computer-assisted diagnosis (CAD) techniques (n=18).
Methodological quality of included studies
The overall methodological quality of all included studies (regardless of target condition) is summarized according to in-person or image-based approaches to dermoscopy or to visual
inspection. A total of 35 in-person evaluations are presented in Figure 5 with results per study presented in Figure 6. A total of 74 image-based evaluations of dermoscopy are
presented in Figure 7 with results per study presented in Figure 8. The total number of entries in Figure 6 and Figure 8 sums to 109 (35 + 74) instead 103 (as per the number of
included cohorts) for the following reasons: a) three publications (Carli 2002; Dummer 1993; Unlu 2014) reported both in-person and image-based data and therefore appear in both the
in-person and image-based plots (making 106 entries) and b) one cohort was reported on in four papers (Blum 2003; Blum 2003b; Blum 2004; Blum 2004b) which have all contributed
data to the review analyses and therefore have been quality assessed four times (making 109 entries).
In-person evaluations
Risk of bias was judged to be ‘Low’ for the majority of studies in only two of five quality domains assessed (dermoscopy index test, reference standard); the majority of studies were at
High or Unclear risk of bias for the remaining three domains (participant selection, visual inspection index test flow and timing) (Figure 5). Applicability of study findings were scored as
of ‘High’ or ‘Unclear’ concern in all four domains (participant selection, dermoscopy and visual inspection index tests, reference standards) assessed.
For participant selection, 11 studies (31%) were judged at low risk of bias (Carli 1994; Dreiseitl 2009; Duff 2001; Grimaldi 2009; Langley 2007; Menzies 2009; Morales Callaghan 2008;
Nachbar 1994; Soyer 2004; Stanganelli 2000; Unlu 2014); and 8 (23%) were considered high risk (Figure 6) due to exclusion of lesions by size (Bono 2002b; Bono 2006; Kittler 1999)
or type (Ahnlide 2016; Cristofolini 1994; Guitera 2009a (Modena); Haenssle 2010a (FV); Haenssle 2010b (FU)). The study by Haenssle and colleagues excluded participants showing
melanoma development on pre-existing pigmented lesions during the following 12 months after the analysed time frame. Twelve studies (34%) did not report the method of participant
selection and 15 (43%) did not clearly describe exclusions from the study. Almost all cohorts (91%; n = 32) were considered at high concern for applicability of participants. In the
majority of cases (n = 30), this was due to restricted study populations such as inclusion of only melanocytic (n = 10) lesions or inclusion of lesions selected for excision based on the
clinical or dermoscopic diagnosis (n = 28). Only four cohorts (11%) were judged to have included a representative patient population (Dreiseitl 2009; Grimaldi 2009; Menzies 2009;
Stanganelli 2000). Eight cohorts (23%) also included multiple lesions per participant (Durdu 2011; Gokdemir 2011; Grimaldi 2009; Haenssle 2010b (FU); Haenssle 2010a (FV); Kittler
1999; Morales Callaghan 2008; Stanganelli 2000) and 12 others (34%) did not clearly report number of included participants.
For the index test domain, there are 33 evaluations of in-person dermoscopy and 16 evaluations of in-person visual inspection (Figure 5). For dermoscopy, 24 evaluations (73%) were
considered at low risk of bias (Ahnlide 2016; Argenziano 2006; Ascierto 2010; Bauer 2000; Benelli 1999; Bono 2002; Bono 2002b; Bono 2006; Broganelli 2005; Carli 1994; Carli 2002;
Coras 2003; Cristofolini 1994; Durdu 2011; Feldmann 1998; Grimaldi 2009; Guitera 2009a (Modena); Haenssle 2010a (FV); Haenssle 2010b (FU); Langley 2007; Menzies 2009;
Morales Callaghan 2008; Stanganelli 2000; Viglizzo 2004 and two evaluations (6%) were judged high risk (Kittler 1999; Nachbar 1994); 7 (21%) did not provide sufficient information to
allow the risk of bias to be fully judged. All studies were judged to have made the diagnosis blinded to the reference standard result given that this is always undertaken prior to
histology; 25 (76%) also clearly reported pre-specification of the diagnostic threshold - 20 using named algorithms or pattern analysis (Ahnlide 2016; Argenziano 2006; Ascierto 2010;
Benelli 1999; Bono 2006; Broganelli 2005; Carli 1994; Carli 2002; Coras 2003; Cristofolini 1994; Durdu 2011; Feldmann 1998; Grimaldi 2009; Guitera 2009a (Modena); Haenssle 2010a
(FV); Haenssle 2010b (FU); Langley 2007; Morales Callaghan 2008; Soyer 1995; Stanganelli 2000) and five (15%) (Bauer 2000; Bono 2002; Bono 2002b; Menzies 2009; Viglizzo 2004)
describing the process by which the diagnosis was reached. Two studies (6%) developed new algorithms (Nachbar 1994) or evaluated multiple thresholds for test positivity (Kittler
1999).
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All 16 visual inspection evaluations were also considered to have made the diagnosis blinded to the reference standard result. One (6%) was at high risk of bias due to evaluation of
several different ABCDE algorithm thresholds (Benelli 1999) and 9 (56%) were judged unclear as to the diagnostic thresholds used.
High concern for the applicability of the index tests was recorded for 16 in-person evaluations of dermoscopy (48%) (Figure 5), primarily due to a lack of description of the diagnostic
thresholds used (n=8, but also as a result of presentation of average (Argenziano 2006) or consensus diagnoses (Bauer 2000; Benelli 1999; Carli 1994; Carli 2002; Haenssle 2010b
(FU); Haenssle 2010a (FV); Morales Callaghan 2008) as opposed to the diagnosis of a single observer. Six studies (18%) did not provide sufficient information to judge the clinical
applicability of the dermoscopy diagnosis and observer expertise in dermoscopy could not be fully judged in five evaluations.
High concern for the applicability of the index tests was recorded for 14 of the 16 (88%) visual inspection evaluations Argenziano 2006; Benelli 1999; Bono 2002; Bono 2002b; Bono
2006; Carli 2002; Dummer 1993; Grimaldi 2009; Krahn 1998; Menzies 2009; Morales Callaghan 2008; Soyer 1995; Unlu 2014; Viglizzo 2004(, due to the threshold for diagnosis not
detailed in 12 (75%), reporting of average (Argenziano 2006) or consensus (Benelli 1999; Carli 2002; Morales Callaghan 2008) diagnoses, or diagnosis by non-expert observers
(Menzies 2009; Grimaldi 2009).
Of the 35 included in-person evaluations, 29 were judged at low risk of bias for the reference standard due to the use of an acceptable reference standard (83%) (Ahnlide 2016;
Argenziano 2006; Ascierto 2010; Bauer 2000; Benelli 1999; Bono 2002; Bono 2002b; Bono 2006; Broganelli 2005; Carli 1994; Carli 2002; Coras 2003; Cristofolini 1994; Duff 2001;
Dummer 1993; Durdu 2011; Feldmann 1998; Gokdemir 2011; Guitera 2009a (Modena); Kittler 1999; Krahn 1998; Langley 2007; Morales Callaghan 2008; Nachbar 1994; Piccolo 2000;
Soyer 1995; Soyer 2004; Unlu 2014; Viglizzo 2004) (Figure 5). Five (14%) did not meet our criteria for an acceptable reference standard, with more than 20% of the benign lesions
undergoing follow-up rather than excision (Grimaldi 2009; Haenssle 2010b (FU); Haenssle 2010a (FV); Menzies 2009; Stanganelli 2000) and one study was judged at unclear risk of
bias due to lack of reporting of the number of patients with a histological reference standard and number with follow-up (Dreiseitl 2009). Blinding of the reference standard to the index
test (in this case the pathology referral diagnosis) was recorded but did not contribute to the overall risk of bias for this domain. No blinding of the reference standard was implemented
in Menzies 2009 and blinding was not described in 34 studies (97%). The applicability of the reference standard was of low concern in 7 evaluations (20%) (Argenziano 2006; Duff
2001; Feldmann 1998; Krahn 1998; Langley 2007; Nachbar 1994; Unlu 2014), high in one (Menzies 2009)and unclear for 27 (77%). In Menzies 2009, high concern was due to the use
of expert opinion for classifying the final diagnosis of some lesions. Only 7 studies reported histopathology interpretation by an experienced histopathologist or by a dermatopathologist
(Argenziano 2006; Duff 2001; Feldmann 1998; Krahn 1998; Langley 2007; Nachbar 1994; Unlu 2014).
In terms of flow and timing, 15 of the 35 cohorts were judged at high risk of bias (43%) (Ahnlide 2016; Argenziano 2006; Coras 2003; Dreiseitl 2009; Dummer 1993; Durdu 2011;
Feldmann 1998; Grimaldi 2009; Guitera 2009a (Modena); Haenssle 2010a (FV); Haenssle 2010b (FU); Kittler 1999; Langley 2007; Menzies 2009; Stanganelli 2000), 6 (17%) at low risk
(Ascierto 2010; Bauer 2000; Benelli 1999; Carli 1994; Morales Callaghan 2008; Soyer 2004) and 13 (37%) did not provide enough information on which to judge this domain (Figure 5).
Of those at high risk, 6 evaluations did not use the same reference standard for all participants (differential verification) (Dreiseitl 2009; Grimaldi 2009; Haenssle 2010a (FV); Haenssle
2010b (FU); Menzies 2009; Stanganelli 2000), and 10 did not include all participants in the analysis (Ahnlide 2016; Argenziano 2006; Coras 2003; Dreiseitl 2009; Dummer 1993;
Feldmann 1998; Guitera 2009a (Modena); Kittler 1999; Langley 2007; Menzies 2009). A further 23 (66%) cohorts were unclear on the interval between the application of the index test
and excision for histology with only 6 (34%) reporting consecutive diagnosis and excision or biopsy (Ahnlide 2016; Ascierto 2010; Benelli 1999; Carli 1994; Durdu 2011; Feldmann 1998;
Guitera 2009a (Modena); Haenssle 2010a (FV); Haenssle 2010b (FU); Langley 2007; Morales Callaghan 2008; Soyer 2004).
Image-based evaluations
Across the 74 image-based dermoscopy evaluations, risk of bias was judged to at High or Unclear in all domains apart from the dermoscopy index test domain (Figure 7 and Figure 8).
Applicability of study findings were scored as of ‘High’ concern in almost all studies for three out of four domains assessed, only the reference standard domain raised few concerns
about applicability.
For participant selection, 38 of the 74 evaluations (51%) were judged at high risk of bias (Arevalo 2008; Argenziano 2011; Benelli 2000; Binder 1994; Blum 2003b; Blum 2004; Carli
2003b; Carrera 2016; di Meo 2016; Feci 2015; Ferrari 2015; Friedman 2008; Gereli 2010; Guitera 2009b (Sydney); Hauschild 2014; Kittler 2001; Malvehy 2014; Menzies 2005; Menzies
2008; Menzies 2013; Piccolo 2014; Pizzichetta 2002; Pizzichetta 2004; Pupelli 2013; Rosendahl 2011; Rubegni 2012; Sboner 2004; Seidenari 1998; Skvara 2005; Stanganelli 1998;
Stanganelli 1999; Stolz 1994; Tan 2009; Tenenhaus 2010; Troyanova 2003; Wells 2012; Westerhoff 2000; Winkelmann 2016) and 27 (36%) did not provide sufficient information to
judge this domain (Figure 7). Nineteen evaluations (26%) implemented a case-control type design with separate sampling of melanoma and non melanoma lesions, and 25 (34%)
excluded lesions: on the basis of size or thickness (n = 6); type of lesion (n = 8); lesion site (n = 3); equivocal pathology (n = 4); or inadequate image quality (n = 8). Twenty-nine
evaluations (39%) did not report the method of participant selection and 31 (42%) did not clearly describe exclusions from the study. All evaluation cohorts were considered at high
concern for applicability of participants. In the majority of cases, this was due to restricted study populations such as inclusion of only melanocytic (n = 35), amelanotic (n = 2), nodular
(n = 1), regressing (n = 1) or acral (n = 1) lesions, or inclusion of lesions selected for excision based on the clinical or dermoscopic diagnosis (n = 57). Nineteen evaluations clearly
reported including similar numbers of participants and lesions, seven reported inclusion of multiple lesions per participant and 48 did not report the number of participants.
For the index test domain, there are 74 evaluations of image-based dermoscopy and 15 evaluations of visual inspection of clinical images (Figure 7). For dermoscopy, 50 evaluations
(68%) were considered at low risk of bias (Annessi 2007; Arevalo 2008; Argenziano 1998; Argenziano 2011; Benelli 2000; Benelli 2001; Binder 1994; Binder 1995; Binder 1999; Blum
2004; Blum 2004b; Bourne 2012; Carli 2002; Carli 2003; Carli 2003b; Carrera 2016; Dal Pozzo 1999; di Meo 2016; Dolianitis 2005; Dummer 1993; Feci 2015; Ferrari 2015; Friedman
2008; Gereli 2010; Guitera 2009b (Sydney); Kreusch 1992; Lorentzen 1999; Lorentzen 2000; Lorentzen 2008; Malvehy 2014; Menzies 1996; Menzies 2008; Menzies 2013; Nilles 1994;
Pagnanelli 2003; Piccolo 2014; Pizzichetta 2002; Pizzichetta 2004; Pupelli 2013; Rao 1997; Rosendahl 2011; Rubegni 2012; Rubegni 2016; Seidenari 2005; Skvara 2005; Stanganelli
2015; Stolz 1994; Tan 2009; Unlu 2014; Zalaudek 2006) and two evaluations were judged high risk, both appearing to report new algorithms or lesion scoring based on their own study
data (Blum 2003; Blum 2003b). Twenty-two evaluations (30%) did not provide sufficient information to allow the risk of bias to be fully judged. All studies were judged to have made the
diagnosis blinded to the reference standard result; 50 (68%) also clearly reported pre-specification of the diagnostic threshold (40 using named algorithms or pattern analysis, four
reporting new algorithms developed using training and test sets (Dal Pozzo 1999; Menzies 1996; Nilles 1994; Stolz 1994) and six providing an indication as to how the diagnosis was to
be reached (Annessi 2007; Binder 1995; Carli 2003b; Carrera 2016; Friedman 2008; Lorentzen 1999; Malvehy 2014)).
All 15 image-based visual inspection evaluations were also considered to have made the diagnosis blinded to the reference standard result. hree were considered at low risk of bias
due to use of named algorithms with pre-specified thresholds (Benelli 2000; Benelli 2001; Rao 1997) and two ( Pizzichetta 2004; Rosendahl 2011) provided some a prior indication as to
how the diagnosis was to be reached in the study. The remaining 10 were judged unclear as to pre-specification of the diagnostic thresholds used.
High concern for the applicability of the index tests was recorded for 67 (91%) image-based evaluations of dermoscopy (Alarcon 2014; Annessi 2007; Arevalo 2008; Argenziano 1998;
Argenziano 2011; Benelli 2000; Benelli 2001; Binder 1994; Binder 1995; Binder 1999; Blum 2003; Blum 2003b; Blum 2004; Bourne 2012; Carli 2002; Carli 2002b; Carli 2003; Carli
2003b; Carrera 2016; Dal Pozzo 1999; di Meo 2016; Dolianitis 2005; Feci 2015; Ferrari 2015; Ferris 2015; Friedman 2008; Gereli 2010; Gilmore 2010; Glud 2009; Guitera 2009b
(Sydney); Hauschild 2014; Kittler 1998; Kittler 2001; Kreusch 1992; Lorentzen 1999; Lorentzen 2000; Lorentzen 2008; Malvehy 2014; Menzies 1996; Menzies 2005; Menzies 2008;
Menzies 2013; Nilles 1994; Pagnanelli 2003; Piccolo 2002; Piccolo 2014; Pizzichetta 2002; Rigel 2012; Rubegni 2012; Rubegni 2016; Sboner 2004; Seidenari 1998; Seidenari 2005;
Seidenari 2007; Skvara 2005; Stanganelli 1998; Stanganelli 1999; Stanganelli 2005; Stanganelli 2015; Stolz 1994; Tan 2009; Troyanova 2003; Unlu 2014; Wells 2012; Westerhoff 2000;
Winkelmann 2016; Zalaudek 2006) (Figure 7), primarily due to blinded interpretation of dermoscopic images without reference to a macro photograph or other patient information (n =
51) or the presentation of average or consensus diagnoses as opposed to for a single observer (n = 35). Twenty five evaluations did not provide sufficient detail regarding the diagnostic
threshold used and four were judged to have reported data for non expert observers. The seven evaluations judged as having unclear concern for the applicability of dermoscopy
reported data for single observers with the clinical image of the lesion provided alongside the dermoscopic image (Blum 2004b; Lorentzen 2000; Pizzichetta 2004; Pupelli 2013; Rao
1997; Rosendahl 2011; Tenenhaus 2010). All except Tenenhaus 2010 also detailed the diagnostic thresholds used and four clearly described image interpretation by an expert observer
(Blum 2004b; Lorentzen 2000; Rosendahl 2011; Tenenhaus 2010).
High concern for the applicability of the index tests was recorded for all 15 visual inspection evaluations due to the image-based nature of test interpretation; only three of these clearly
reported diagnosis by a single observer (Pizzichetta 2004; Rao 1997; Rosendahl 2011), the remaining 12 reported average (n = 10) or consensus (n = 2) diagnoses. Thirteen
evaluations also did not detail the threshold for diagnosis (all apart from Benelli 2000 and Benelli 2001). Eight evaluations clearly described diagnosis by expert observers (Benelli 2001;
Carli 2002b; Carli 2003b; Lorentzen 1999; Rao 1997; Rosendahl 2011; Stanganelli 2005; Troyanova 2003).
Of the 74 included image-based evaluations, 63 (85%) were judged at low risk of bias for the reference standard due to the use of an acceptable reference standard (Alarcon 2014;
Annessi 2007; Arevalo 2008; Argenziano 1998; Benelli 2000; Benelli 2001; Binder 1994; Binder 1995; Binder 1999; Blum 2003; Blum 2003b; Blum 2004; Carli 2002; Carli 2002b; Carli
2003; Carli 2003b; Dal Pozzo 1999; di Meo 2016; Dummer 1993; Feci 2015; Ferrari 2015; Ferris 2015; Friedman 2008; Gereli 2010; Gilmore 2010; Glud 2009; Guitera 2009b (Sydney);
Hauschild 2014; Kittler 1998; Lorentzen 1999; Lorentzen 2000; Lorentzen 2008; Malvehy 2014; Menzies 1996; Nilles 1994; Pagnanelli 2003; Piccolo 2002; Piccolo 2014; Pizzichetta
2002; Pizzichetta 2004; Pupelli 2013; Rao 1997; Rigel 2012; Rosendahl 2011; Rubegni 2012; Rubegni 2016; Sboner 2004; Seidenari 1998; Seidenari 2005; Seidenari 2007; Skvara
2005; Stanganelli 1998; Stanganelli 1999; Stanganelli 2005; Stanganelli 2015; Stolz 1994; Tan 2009; Troyanova 2003; Unlu 2014; Wells 2012; Westerhoff 2000; Winkelmann 2016;
Zalaudek 2006) (Figure 7). Seven evaluations were at high risk of bias, having more than 20% of the benign lesions undergoing follow-up rather than excision (Argenziano 2011; Blum
2004b; Kittler 2001; Menzies 2005) or including some lesions with expert diagnosis only and no follow-up (Bourne 2012; Dolianitis 2005; Menzies 2005; Tenenhaus 2010). Blinding of
the reference standard to the index test (in this case the pathology referral diagnosis) was recorded but did not contribute to the overall risk of bias for this domain. Blinding of the
reference standard to the original clinical diagnosis was implemented in only one study (Friedman 2008) and was not reported for remainder.
The applicability of the reference standard was: of low concern in 20 evaluations (27%) (all of which reported histopathology interpretation by an experienced histopathologist or by a
dermatopathologist) (Alarcon 2014; Annessi 2007; Carli 2003b; di Meo 2016; Ferrari 2015; Ferris 2015; Friedman 2008; Gilmore 2010; Glud 2009; Hauschild 2014; Lorentzen 2000;
Malvehy 2014; Piccolo 2002; Pupelli 2013; Rao 1997; Rubegni 2012; Rubegni 2016; Stanganelli 2015; Unlu 2014; Wells 2012); was of high concern in four (5%) (due to the use of
expert opinion for classifying the final diagnosis of some lesions) (Bourne 2012; Dolianitis 2005; Menzies 2005; Tenenhaus 2010) and unclear for 50 (68%). In terms of flow and timing,
26 cohorts were judged at high risk of bias (35%) (Alarcon 2014; Arevalo 2008; Argenziano 2011; Blum 2004b; Bourne 2012; Carrera 2016; di Meo 2016; Dolianitis 2005; Dummer
1993; Feci 2015; Ferrari 2015; Guitera 2009b (Sydney); Kittler 2001; Kreusch 1992; Lorentzen 1999; Lorentzen 2008; Malvehy 2014; Menzies 2005; Menzies 2008; Menzies 2013;
Pizzichetta 2004; Rosendahl 2011; Stanganelli 2005; Tenenhaus 2010; Westerhoff 2000; Zalaudek 2006), 16 at low risk (22%) (Annessi 2007; Binder 1995; Binder 1999; Blum 2003;
Blum 2003b; Blum 2004; Carli 2002b; Ferris 2015; Glud 2009; Hauschild 2014; Lorentzen 2000; Pizzichetta 2002; Rao 1997; Skvara 2005; Stanganelli 2015; Wells 2012) and 32 (43%)
did not provide enough information on which to judge this domain (Figure 7). Of those at high risk, 15 evaluations did not use the same reference standard for all participants
(differential verification), and 16 did not include all participants in the analysis. Eighteen cohorts (24%) were unclear on the interval between the application of the index test and lesion
excision with only 8 (11%) considered to report consecutive diagnosis and excision or biopsy.
Findings
Unless otherwise stated, all analyses were undertaken using HSROC models.
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1. Target condition: invasive melanoma and melanocytic intraepidermal variants
Eighty-three study publications reported accuracy data for dermoscopy for the detection of primary target condition - invasive melanoma and intraepidermal melanocytic variants. Two
study publications each reported data for two different sets of lesions (Guitera 2009a (Modena); Guitera 2009b (Sydney); Haenssle 2010a (FV); Haenssle 2010b (FU)); and one study
(Carli 2002) provided one dataset for in-person dermoscopy and one for image-based interpretation of dermoscopic images. A total of 86 datasets were selected for the primary
analyses; 26 for evaluations conducted in-person and 60 for image-based evaluations. Twenty-four of the 83 study publications provided direct comparisons of dermoscopy with visual
inspection alone (i.e. data for both tests reported for the same study population). Eleven studies compared in-person visual inspection with in-person visual inspection plus dermoscopy;
11 studies compared diagnosis based on clinical images with diagnosis based on dermoscopic images of the same lesions; and 2 studies compared in-person visual inspection with
image-based dermoscopy.
Analyses by clinical pathway and in-person vs image-based design
Summary details of the in-person and image-based studies are provided in Appendix 8 and Appendix 9. Results for the primary analyses are presented in Table 1 and Table 2 with
heterogeneity investigations presented in Table 3. Forest plots of study data for each analysis Table 1 are given in Figure 9 and Figure 10; summary estimates for in-person
comparisons are depicted in Figure 11 and Figure 12 and for image-based comparisons in Figure 13 and Figure 14.
Clear differences in accuracy were noted between studies undertaken in-person and those which evaluated images, with the accuracy of diagnosis using dermoscopic images and
visual inspection of photographs being significantly lower in image-based studies. For dermoscopy, the diagnostic odds ratio for in-person diagnosis was more than 4 times that of
image-based diagnosis (RDOR 4.6; 95% CI: 2.4, 9.0, P < 0.001) (Table 3; Figure 15). The high magnitude and importance of this observed difference drive our decision to undertake all
analyses separately for in-person and image-based analyses as a primary objective of the review.
Of the 26 evaluations conducted on an in-person basis, 11 contained enough information to describe where on the clinical pathway participants were assessed (coded as ‘clear’ on
pathway), and 15 were considered not to have provided sufficient information to allow the pathway to be identified (coded ‘unclear’ on pathway). Pathway positions were coded between
1 (test-naïve participants) and 7 (participants identified as high risk for developing melanoma with lesions undergoing follow-up surveillance) (see Figure 3 for diagram of the clinical
pathway). For the 60 image-based evaluations, 11 were coded as ‘clear’ on the pathway and 49 were coded ‘unclear’. Across both sets of studies, only 5% (4/86) were considered to
have included participants who were presenting for a first structured clinical assessment of a suspicious lesion, the remaining datasets came from studies in participants referred for
specialist assessment.
Although there were significant differences between studies undertaken at different points on the pathway, for both in-person (Table 1a; Figure 9) and image-based (Table 1b; Figure 10)
approaches there was no clear trend in the estimates of accuracy of dermoscopy according to the degree of prior testing of study participants (as represented by study position on the
pathway). Accuracy did appear to be lowest (in terms of DORs) in studies in limited prior testing of the participants (Bourne 2012; Grimaldi 2009; Menzies 2009; Rosendahl 2011) and in
those with lesions undergoing follow-up (Haenssle 2010b (FU); Kittler 2001; Skvara 2005; Stanganelli 2015), however, the data were too scarce to draw any firm conclusions.
Classification of evaluations by position on the clinical pathway was not further considered analytically.
Dermoscopy added to visual inspection of a skin lesion (in-person evaluations)
Of the 26 in-person evaluations of dermoscopy (Appendix 8 and Figure 9), 11 compared visual inspection alone to visual inspection plus dermoscopy (including two which compared
both tests to a CAD-based test (Bono 2002) and one which reported data for a teledermatology consultation (Grimaldi 2009)) and 15 presented data only for dermoscopy in addition to
visual inspection (with no data for visual inspection alone), including four which compared in-person dermoscopy to the accuracy of other tests including RCM (Langley 2007; Guitera
2009a (Modena)), exfoliative cytology (Durdu 2011) and CAD (Bauer 2000). Two studies compared the accuracy of different dermoscopy algorithms (Kittler 1999; Menzies 2009).
Two evaluations were conducted in limited prior testing populations (Grimaldi 2009; Menzies 2009). Of those in referred populations, two were considered to have been conducted in
participants with equivocal lesions (Carli 2004; Soyer 1995) and one in participants at high risk for developing melanoma with lesions undergoing surveillance (Haenssle 2010b (FU)).
The latter study also reported data separately for the same participants at their first visit for lesion assessment (Haenssle 2010a (FV)). Seventeen evaluations were prospective case
series, 5 were retrospective (Ahnlide 2016; Bono 2006; Carli 2002; Duff 2001; Stanganelli 2000), and four did not clearly report the design (Bauer 2000; Carli 1994; Gokdemir 2011;
Soyer 1995). One study included all melanomas observed across the recruitment period but only a random sample of 50% of observed benign naevi (Guitera 2009a (Modena)).
Eighteen evaluations included only pigmented lesions and eight restricted inclusion to lesions considered to be melanocytic in nature. Eighteen of the 26 evaluations (69%) clearly
reported including in situ melanomas as disease positive, the remaining 8 describing only 'melanomas' not broken down by invasive or in situ ( Broganelli 2005; Cristofolini 1994; Durdu
2011; Gokdemir 2011; Grimaldi 2009; Morales Callaghan 2008; Nachbar 1994; Stanganelli 2000). The prevalence of invasive melanoma plus atypical intraepidermal melanocytic
variants ranged from less than 1% (Haenssle 2010a (FV)) to 41% (Guitera 2009a (Modena); Soyer 1995); median 12% (IQR 5, 21%).
Diagnosis was clearly reported to be conducted on an in-person basis in 24 evaluations (89%) and was assumed in three studies which did not clearly report the use of images or face-
to-face diagnosis (Broganelli 2005; Gokdemir 2011; Stanganelli 2000). Diagnosis was recorded by primary care physicians in two studies (7%) (Grimaldi 2009; Menzies 2009), by
dermatology residents (trainees) under the supervision of a senior dermatologist (Haenssle 2010b (FU); Haenssle 2010a (FV)) or by a mixed group of dermatology residents and
consultants (Ahnlide 2016) in 3 (11%), by dermatologists or presumed to be dermatologists (based on author’s institutions) in 17 (63%), by plastic surgeons (Duff 2001) or oncologists
(Bono 2002; Bono 2002b; Bono 2006) in four (15%), or was not reported (4%) (Feldmann 1998). Where reported (n=22), the number of observers ranged from 1 to 63 (median 2, IQR
1.25, 4). Test accuracy was reported for a single observer in 48% of evaluations (n=13), for a consensus of two or three observers in 30% (n=8), and this information could not be
derived for the remaining 6 evaluations. No formal algorithm to assist diagnosis was reported in 30% of studies (n=8) and 33% (n=9) reported using pattern analysis. The remaining
studies used formal algorithms to assist diagnosis: the ABCD algorithm (n=5), the seven-point checklist (n=3), the Menzies criteria (n=1) and seven features for melanoma (n=1) (see
Appendix 2 for details of the algorithms used).
Across the 27 evaluations the sensitivity of dermoscopy ranged from 53% to 100% and specificity from 28% to 100% (Figure 9). The low specificities of 28% (Guitera 2009a (Modena)
and 56% (Carli 1994) appeared as outliers, all other studies having specificities of 69% or above. Guitera 2009a (Modena) included a relatively high proportion of Spitz naevi in the
disease negative group than might be expected in routine clinical practice (19%) while Carli 1994 primarily aimed to distinguish atypical from typical melanocytic lesions and reported
accuracy for the decision to excise a lesion as opposed to accurate diagnosis of melanoma.
Results were pooled across algorithms and thresholds as a summary ROC curve (23,487 lesions and 1737 melanomas; Figure 11). Estimates of accuracy obtained from the curve
suggest that the specificity of dermoscopy would be 95% (95% CI: 90, 98) at a fixed threshold of 80% sensitivity, and sensitivity would be 92% (95% CI: 87, 95) at a fixed threshold of
80% specificity (Table 2). These 80% fixed values were chosen as they lie within the estimates for the majority of analyses and should only be considered as illustrative examples of the
values that might be achieved based on the observed data (see Statistical analysis and data synthesis).
Incremental accuracy from dermoscopy added to in-person visual inspection alone
Of the 13 available in-person evaluations of visual inspection, 11 were reported in these in-person dermoscopy studies and two (Dummer 1993; Unlu 2014) compared in-person visual
inspection to image-based dermoscopy (see results for image-based dermoscopy below). Of the 13 evaluations, 77% (n = 10) reported using no algorithm to assist visual inspection
diagnosis and three used the ABCD (Stanganelli 2000) or ABCDE (Benelli 1999; Cristofolini 1994) algorithm.
Sensitivities for visual inspection ranged from 38% to 100%; specificities ranged from 45% to 99% (Appendix 10 and Figure 11). The accuracy of visual inspection was compared with
the accuracy of dermoscopy estimated from (a) all 26 dermoscopy studies (23,169 lesions and 1664 melanomas) and all 13 in-person visual inspection studies (6740 lesions and 459
melanomas) (Figure 11) and (b) estimated from direct comparisons in the subset of 11 studies that evaluated both visual inspection and dermoscopy on an in-person basis (5854
lesions and 412 melanomas; Figure 12). In both comparisons the accuracy of dermoscopy in addition to visual inspection exceeded that of visual inspection alone (Table 2). In (a) the
diagnostic odds ratio (DOR) for dermoscopy was 4.7 (95% CI: 3.0 to 7.5; P < 0.001) times that of visual inspection alone, in (b) it was 4.8 (95% CI: 2.8 to 8.1; P < 0.001) times that of
visual inspection alone. These effects correspond to predicted differences in specificity of (a) 20% (95% CI 7, 33%) (based on specificity with dermoscopy of 95% vs 75% for visual
inspection) and (b) 21% (95% CI: 2, 39%) (based on specificity with dermoscopy of 96% vs 75% for visual inspection) at a fixed sensitivity of 80% (Table 2) and predicted differences in
sensitivity of (a) 16% (95% CI: 8, 23%) (based on sensitivity with dermoscopy of 92% vs 76% for visual inspection) and (b) 15% (95% CI: 7, 23%) (based on sensitivity with dermoscopy
of 92% vs 77% for visual inspection) at a fixed specificity of 80% (Table 2).
Dermoscopic images (image-based evaluations)
Of the 60 image-based evaluations of dermoscopy (Appendix 9 and Figure 10), 30 presented data only for dermoscopy, 14 compared diagnosis based on clinical images to diagnosis
based on dermoscopic images, 19 compared dermoscopy to the accuracy of other tests including RCM (Alarcon 2014; Ferrari 2015; Guitera 2009b (Sydney); Pupelli 2013; Stanganelli
2015) and CAD based tests (Binder 1994; Blum 2004b; Ferris 2015; Friedman 2008; Glud 2009; Hauschild 2014; Malvehy 2014; Menzies 2005; Piccolo 2002; Piccolo 2014; Rigel 2012;
Stanganelli 2005; Wells 2012; Winkelmann 2016). Studies that evaluated dermoscopy images rather than using real-time in-person dermoscopy tended to have been undertaken for
reasons of efficiency and not as evaluations of a remote-imaging service, for example, 18 (30%) evaluations compared the accuracy of different dermoscopy algorithms and 13 (22%)
compared the accuracy of different observers (see Analyses by observer experience).
Two evaluations recruited participants from limited prior testing populations (Bourne 2012; Rosendahl 2011). Of those in referred populations, nine were considered to have been
conducted in participants with equivocal lesions (Alarcon 2014; Annessi 2007; Carli 2003b; Dummer 1993; Ferrari 2015; Kittler 1998; Pupelli 2013; Rubegni 2012; Stolz 1994) and three
in participants with lesions undergoing follow-up (Kittler 2001; Skvara 2005; Stanganelli 2015). Seven (12%) evaluations were prospective case series, 33 (55%) were retrospective
case series, 17 (28%) used a case-control type design and in (3%) two the design was not clearly reported. All studies prospectively re-interpreted previously acquired dermoscopic
images for the purposes of the study. The majority of studies recruited either pigmented (26; 43%) or melanocytic (30; 50%) lesions, including one restricted to melanocytic acral lesions
only (Rubegni 2012). Two studies (3%) recruited any lesion selected for excision (Malvehy 2014; Zalaudek 2006) and two (3%) included only amelanotic (Pizzichetta 2004) or
amelanotic or hypomelanotic (Menzies 2008) lesions. Forty-four of the 60 evaluations (73%) clearly reported including in situ melanomas as disease positive, the remaining 16
describing only 'melanomas' not broken down by invasive or in situ (Binder 1994; Binder 1995; Ferrari 2015; Gilmore 2010; Kittler 1998; Malvehy 2014; Pagnanelli 2003; Piccolo 2002;
Pizzichetta 2002; Rigel 2012; Rubegni 2016; Seidenari 1998; Seidenari 2005; Stanganelli 1998; Stanganelli 2005; Unlu 2014). The prevalence of disease ranged from 3% (Dummer
1993) to 61% (Stolz 1994) (median 24%, IQR 18, 39%). Prevalence was generally higher in case control type studies (median 37%, IQR 25, 50%) compared to other designs (median
23%, IQR 18% to 33%).
Diagnosis was recorded by dermatologists or assessors presumed to be dermatologists in 80% of studies (n=48), by dermatology residents in one (Carli 2003), and by observers with
mixed qualifications in 17% (n=10) including one where all observers were primary care based (three GPS and a clinical nurse in Bourne 2012. Observer qualifications were not
reported in one study (Stolz 1994). Where reported (n=56), the number of observers ranged from 1 to 179 (median 3, IQR 2, 8). Test accuracy was reported for a single observer in 42%
of evaluations (n=25), for a consensus of two or three observers in 15% (n=9), for a consensus of at least 50% of all observers in one study (Carrera 2016) and for the median or
average across observers in 32% of evaluations (n=19); this information could not be derived for the remaining 6 evaluations. Dermoscopic image interpretation was blinded in half of all
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evaluations (n=30); the associated clinical (n=17), RCM (n=2) or baseline dermoscopy image (n=1) was provided to assist diagnosis in a further third (n=20). Four evaluations provided
information on lesion site, or patient age or gender and the remaining 6 did not describe the provision of additional information. No formal algorithm to assist diagnosis was reported in
38% of studies (n=23) and 32% (n=19) reported using pattern analysis. The remaining 18 studies used formal algorithms to assist diagnosis: the ABCD algorithm (n=6), the seven-point
checklist (n=3) or a revised version thereof (n=1), the three point checklist (n=3) the Menzies criteria (n=1) and seven features for melanoma (n=3), or the observers own choice of
algorithm (n=1) (Appendix 9).
Across the 60 image-based dermoscopy evaluations, the sensitivity ranged from 22% to 100% and specificity from 31% to 99%. Results were pooled across algorithms and thresholds
as a summary ROC curve (13,475 lesions and 2851 melanomas; Figure 13). Estimates of accuracy obtained from the curve suggest that the specificity of dermoscopy would be 82%
(95% CI: 75, 87) at a fixed threshold of 80% sensitivity and sensitivity would be 81% (95% CI: 76, 86) at a fixed threshold of 80% specificity (Table 2).
Incremental accuracy of dermoscopic image-based diagnosis compared to visual inspection of images
Of the 11 visual inspection evaluations based on interpretation of clinical images, 82% (n=9) reported using no algorithm to assist image interpretation and two used the ABCD algorithm
(Benelli 2000; Benelli 2001). Seven studies reported blinded interpretation of the clinical image with no further patient or lesion information provided, one study allowed observers to
view both the clinical and dermoscopic image simultaneously (Pizzichetta 2004), and three did not clearly describe blinding between the clinical and dermoscopic images (Benelli 2000;
Stanganelli 2005; Winkelmann 2016).
Sensitivities for image-based visual inspection ranged from 21% to 80%; specificities ranged from 53% to 97% (Figure 13). The accuracy of visual inspection was compared with the
accuracy of dermoscopy estimated from (a) all 60 dermoscopy studies (13,475 lesions and 2851 melanomas) and the 11 image-based visual inspection studies (1740 lesions and 305
melanomas) (Figure 13) and estimated from direct comparisons in (b) the subset of 11 studies that evaluated both clinical and dermoscopic images (1740 lesions and 305 melanomas;
Figure 14). In both comparisons, the accuracy of dermoscopy exceeded that of visual inspection alone (Table 2). In (a) the diagnostic odds ratio (DOR) for dermoscopy was 5.6 (95%
CI: 3.7 to 8.5; P < 0.0001) times that of visual inspection alone, in (b) it was 5.3 (95% CI: 3.5 to 8.0; P < 0.0001) times that of visual inspection alone. These effects correspond to
predicted differences in specificity of (a) 40% (95% CI: 27, 57%) (based on specificity with dermoscopy of 82% vs 42% for visual inspection) and (b) 34% (95% CI: 15, 53%) (based on
specificity with dermoscopy of 83% vs 48% for visual inspection) at a fixed sensitivity of 80% (Table 2) and predicted differences in sensitivity of (a) 35% (95% CI: 24, 46%) (based on
sensitivity with dermoscopy of 81% vs 47% for visual inspection) and (b) 36% (95% CI: 20, 52%) (based on sensitivity with dermoscopy of 83% vs 47% for visual inspection) at a fixed
specificity of 80% (Table 2).
Secondary analyses for the detection of invasive melanoma and melanocytic intra-epidermal variants
Covariate investigations
Table 3 and Table 4 report the results of the heterogeneity investigations. Given the large difference in accuracy for in-person evaluations compared to those based on the assessment
of dermoscopic images, we elected to undertake all subsequent covariate investigations for in-person (Table 3) and image-based (Table 4) studies separately. In four of the covariate
investigations (apart from that by disease prevalence), subgroups with small number of studies were dropped to allow a comparison between the two larger subgroups.
In-person evaluations
Further analysis of the 26 in-person evaluations found no clearly significant relationships between accuracy and the five covariates considered. Some evidence of differences were
noted for choice of reference standard and disease prevalence (Table 3).
Choice of reference standard: Observed accuracy was lower in studies that relied on a histological reference standard (n=18), as opposed to those (n=7) that included follow-up of
some benign lesions although the difference was not statistically significant (RDOR 0.27; 95% CI: 0.06, 1.22; P = 0.23). Theoretically, the inclusion of a follow-up reference standard has
the potential to lower sensitivity (as any melanomas missed on the index clinic visit that are identified on follow-up would be considered as false negatives) and increase specificity (as
lesions considered benign and not recommended for excision on the index clinic visit and that do not show any changes on follow-up will increase the number of true negative results).
The data observed did demonstrate the anticipated effect on specificity (with specificities at 80% sensitivity increasing from 94% in histology only studies to 99% in histology or follow-up
evaluations), however the effect on sensitivity at 80% fixed specificities was the opposite to that anticipated (sensitivity was 6% higher in the histology or follow-up group compared to
histology alone). Three of the six in-person evaluations using histology or follow-up as a reference standard reported sensitivities of over 95% (Duff 2001; Dreiseitl 2009; Grimaldi 2009).
Of the 9 false negative cases in Duff 2001, 8 melanomas were identified during follow-up (between 5 to 41 months after the initial diagnosis), however with high overall prevalence of
disease, sensitivity remained high at 98%. Dreiseitl 2009 and Grimaldi 2009 did not report any melanomas picked up during follow-up (at 1 year and 6 months follow-up, respectively).
The perfect sensitivity in Grimaldi 2009 is likely due to lesions classified as positive if they were ‘suspicious for melanoma’ as opposed to being a likely or definite melanoma. For
Dreiseitl 2009 the high sensitivity is likely explained by diagnosis by an expert clinician, and with more than 6 lesions examined per patient assisting diagnosis.
Disease prevalence: Observed accuracy was somewhat higher where disease prevalence of melanoma was 5% or less (RDOR 5.4; 95% CI 0.80, 36.6), and where prevalence was
greater than 20% (RDOR 5.0; 95% CI 0.78, 32.4) compared to those with disease prevalence between 5% and 10% (LR test for differences between groups: P = 0.008). No obvious
explanation for these results could be derived from the study characteristics (Table 3).
Other investigations: The RDOR for use of no algorithm to aid diagnosis compared to a named algorithm was 1.4 (95% CI 0.34, 5.6; P = 0.17), for a single observer compared to a
consensus of two or more observers was 1.0 (95% CI 0.18, 5.8; P = 0.30), and for evaluations including only melanocytic lesions compared to any pigmented lesion was 0.48 (95% CI
0.12, 2.0; P = 0.60) (Table 3).
Image-based evaluations
For the 60 image-based evaluations, no clearly significant relationships were noted between accuracy and the five covariates. The choice of reference standard showed an effect in the
opposite direction to that observed for the in-person evaluation (Table 4). Observed accuracy was higher in studies that relied on a histological reference standard (n=48), as opposed
to those (n=8) that included follow-up of some benign lesions (RDOR 2.8; 95% CI 0.92, 8.9; P = 0.19). At a fixed specificity of 80%, observed sensitivity in studies using a follow-up
reference standard was lower (65%) compared to those using histology alone (84%) as might be expected, however at a fixed sensitivity of 80%, specificities in studies that included
follow-up of some benign lesions was also lower (64%) compared to those using histology alone (84%). This effect is likely due to a combination of reasons that cannot be derived from
the data due to heterogeneity in participants, tests and observers.
Disease prevalence: Disease prevalence was higher in image based studies than in person studies and a different grouping for prevalence was used. Observed accuracy appeared
highest where disease prevalence of melanoma was 20% or less (RDOR 30.7; 95% CI 1.51, 6.24) compared to prevalence >20-30% and higher.
For the other characteristics investigated, similar results to those obtained for in-person evaluations were observed for use of a named algorithm, the effect from restriction to
melanocytic lesions only was in the opposite direction although non-significant (P = 0.16), and results to a greater order of magnitude were observed for diagnosis by a single observer
compared to a consensus of two or more observers.
1.1.1. Analyses by algorithms used to assist dermoscopy
Details of the algorithms used to assist diagnosis are provided in Appendix 2. Results by algorithm used (or not used) are reported in Table 5 for each of the target conditions under
consideration in this review. All analyses in this section were undertaken using the bivariate normal model.
In-person evaluations of dermoscopy added to visual inspection
The 26 in-person evaluations of dermoscopy added to visual inspection of a lesion provide a total of 40 datasets using different algorithms or diagnostic thresholds for the detection of
invasive melanoma or atypical intraepidermal melanocytic variants. Nine of the datasets did not report the use of any algorithm to assist diagnosis, 8 reported data for pattern analysis,
and the remaining 23 datasets used one or more of 7 different formally developed algorithms (Table 5a).
A pooled sensitivity of 88% (95% CI 75, 95%) and specificity of 87% (95% CI 80, 92%) was estimated for observer diagnosis without the use of a formal algorithm (n=8 datasets; 4707
lesions, 849 melanomas). The approach to diagnosis was not well described; however, most studies in this dataset reported accuracy for the clinician’s correct diagnosis of melanoma
rather than the decision to biopsy or excise a lesion (Appendix 8). Pooled results for studies using pattern analysis were similar but with narrower confidence intervals for sensitivity
(sensitivity 92%, 95% CI 87, 95%; specificity 92%, 95% CI 68, 98%; 6 datasets with 4307 lesions and 296 melanomas).
Of the more formal algorithms for melanoma diagnosis, results could be pooled for only two. Five datasets (1438 lesions and 160 melanomas) using the ABCD algorithm at a threshold
of >5.45 produced a sensitivity of 81% (95% CI 62, 92%) and specificity of 92% (95% CI 82, 97). Two evaluations (11,137 lesions and 127 melanomas) reported data for the seven point
checklist (7PCL) at a threshold of >=3, giving a sensitivity of 67% (95% CI 46, 83) and specificity of 96% (95% CI 88, 99%). The latter result is based on a single study publication which
reports results for 8449 lesions detected on a patient's first clinic visit (Haenssle 2010a (FV)) and separately for 2373 lesions examined during follow-up (Haenssle 2010b (FU)). The
ABCDE algorithm, seven features for melanoma (7FFM) and the Menzies criteria were each assessed in a single study on an in-person basis; results were generally similar to those
observed above (Table 5a).
Image-based evaluations of dermoscopic images
The 60 evaluations of dermoscopic images provide a total of 113 datasets using different algorithms or diagnostic thresholds for the detection of invasive melanoma or atypical
intraepidermal melanocytic variants. Twenty-eight of the datasets did not report the use of any algorithm to assist diagnosis (4 studies reporting data at two thresholds), 22 report data
for pattern analysis (2 studies reporting data at two thresholds), and the remaining 63 datasets used one or more of 14 different formally developed algorithms (Table 5a).
For observer diagnosis without the use of a formal algorithm, diagnostic thresholds (i.e. the clinical decision that was recorded by the clinician concerned) were poorly reported;
however, we attempted to differentiate between those studies reporting the observer’s correct diagnosis of melanoma from those reporting the decision to excise a lesion. Pooling all
data regardless of threshold (24 datasets; 4498 lesions and 941 melanomas) gave a sensitivity of 76% (95% CI 70, 82%) and specificity of 79% (95% CI 71, 85%). Restricting the
analysis to the 18 datasets reporting data for observers correctly diagnosing melanoma (4118 lesions; 795 melanomas) gave a sensitivity of 77% (95% CI 69, 83) and specificity of 84%
(95% CI 76, 89%). For the 10 datasets that reported data for the decision to excise a lesion (831 lesions; 263 melanomas), sensitivity was similar at 79% (95% CI 69, 86%) but
specificity reduced to 55% (95% CI 50, 61%). Pooled results for 20 evaluations (4621 lesions and 989 melanomas) reporting use of pattern analysis resulted in higher sensitivity (83%,
95% CI 76, 88%) and specificity (87%, 95% CI 80, 92%) compared to the no algorithm reported studies but results were both lower in comparison to the in-person valuations.
Sufficient data were available to allow pooling for seven different formal algorithms to assist diagnosis (Table 5a); all summary estimates showed either lower sensitivity or lower
specificity, or both, in comparison to either the no algorithm or pattern analysis datasets. The ABCD checklist at a threshold of > 5.45 (7 datasets; 2471 lesions and 406 melanomas)
had a sensitivity of 81% (95% CI 60, 92%) and specificity of 81% (95% CI 69, 89%). At the lower threshold of > 4.75 for diagnosis of melanoma, sensitivity remained at 81% (95% CI
67, 90%) with narrower confidence intervals with a lower specificity of 72% (95% CI 93, 80%) (10 datasets; 4242 lesions and 816 cases).
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The 7PCL was evaluated in 11 datasets at a threshold of >= 3 (3408 lesions and 798 melanomas), pooled sensitivity was 80% (95% CI 63, 91%) and specificity 67% (95% CI 51, 80).
Four evaluations that did not report the threshold used with the 7PCL demonstrated lower sensitivity (72%, 95% CI 56, 84%) but higher specificity (79%, 95% CI 61, 90).
The 7FFM tool was assessed in four datasets with 2200 lesions and 340 melanomas, sensitivity was 89% (95%CI 76, 96%) with specificity 84% (95%CI 78, 89%). The Menzies criteria
was evaluated in four datasets using the method described in the original Menzies 1996 paper, pooled sensitivity was 78% (95% CI 38, 96) and specificity 63% (95% CI 39, 81) (1856
lesions and 317 melanomas).
Seven evaluations of the 3PCL at a threshold of >= 2 were pooled (1505 lesions and 363 melanomas), summary sensitivity was 74% (95% CI 61, 85) and specificity 60% (95% CI 42,
76%). Sixteen additional datasets reporting data for other algorithms or at different thresholds are reported in Table 5a, however study numbers are too small to describe results in any
detail.
1.1.2. Analyses by observer experience and qualifications
Table 6 and Table 7 report results for the effect of observer experience and qualifications. Observer experience was generally poorly described in the study reports (see Appendix 8 and
Appendix 9), however we attempted broad classifications by expertise in dermoscopy and reported qualifications with the ‘consultant’ category in the latter analysis separated into
‘Expert consultant’ (for any study describing observers as expert or experienced) and ‘Consultant’ where experience or expertise was not otherwise reported (for example for those that
described observers as dermatologists). Results are described separately for in-person (Figure 16; Figure 17) and image-based evaluations (Figure 18; Figure 19).
For the in-person evaluations, the majority of observers were classified as having high dermoscopy experience (n= 14) or as experience not reported (n=10). Two studies reported data
for GPs provided with some dermoscopy training for the purposes of the study (Grimaldi 2009; Menzies 2009). No statistically significant differences were found between groups (Table
6) although the poorest performance was noted in the GP training group.
The 60 image-based evaluations provided 77 datasets according to observer experience; 13 evaluations providing data for more than one observer (Argenziano 1998; Benelli 2001;
Binder 1995; Ferris 2015; Hauschild 2014; Menzies 2005; Pagnanelli 2003; Piccolo 2002; Piccolo 2014; Seidenari 1998; Seidenari 2005; Stanganelli 1999; Tan 2009). The LR test for
differences between groups was statistically significant (P < 0.001). Using the high experience group as the reference (34 datasets; 8933 lesions and 1956 melanomas), the RDOR for
the observers where experience was not reported (11 datasets; 2777 lesions and 465 melanomas) was 2.0 (95% CI 0.8, 4.9), while the RDORs for the lower experience groups all
suggested lower accuracy (Table 6; Figure 17). The RDORs for each group in comparison to the high experience group were: moderate experience 0.64 (95% CI 0.37, 1.1; 5 datasets,
678 lesions and 193 melanomas); ‘low’ experience 0.30 (95% CI 0.15, 0.58; 6 datasets; 448 lesions and 123 melanomas); for the ‘mixed’ experience group was 0.25 (95% CI 0.07,
0.81; 5 datasets, 473 lesions and 117 melanomas); and for the 'trained' group was 0.51 (95% CI 0.25, 1.02; 11 datasets, 1087 lesions and 240 melanomas).
Similar trends were observed when evaluations were sub-grouped according to reported observer qualifications, however data for clinicians other than consultant or ‘consultant experts’
were relatively sparse, especially for the in-person evaluations where no statistically significant differences between groups was determined (Table 7; Figure 18). For the image-based
evaluations accuracy was highest for the ‘Expert consultant’ group (DOR 19.4, 95% CI 13.1, 28.8; 33 datasets, 8664 lesions and 1854 melanomas) (Figure 19). Relative DORs in
comparison to the ‘expert’ group were 0.61 (95% CI 0.40, 0.92) for observers described as ‘dermatologists’ (25 datasets; 4589 lesions and 955 melanomas), 0.31 (95% CI 0.14, 0.71 for
registrar (trainee) or resident level observers (5 datasets; 927 lesions and 138 observers), and 0.10 (95% CI 0.04, 0.25) for the GP group (3 datasets; 288 lesions and 55 melanomas).
Results for the GP group may simply be attributed to small sample sizes; however, the lowest sensitivity for detection of melanoma (22%) was observed for Bourne 2012 in which seven
of nine included melanomas in situ or lentigo maligna and lowest specificity (44%) was observed for Piccolo 2014 which included a relatively high percentage of Spitz naevi (14% of the
disease negative group) which may have been more difficult to differentiate from melanomas. Both studies also implemented blinded dermoscopy image interpretation whereas the third
study in this group (Menzies 2005) also provided the clinical image and information on patient history to the interpreting clinicians.
1.1.3. Results of sensitivity analyses
A number of sensitivity analyses were planned in our generic protocol. One, restricting comparisons between dermoscopy and visual inspection alone to studies where both tests have
been evaluated in the same study (direct comparisons), was discussed alongside the main test comparisons above (Table 2). For completeness, the results of these are included in
Table 8 (in-person evaluations) and Table 9 (image-based evaluations) along with the results of all other sensitivity analyses.
In-person evaluations
Analyses restricting studies to those avoiding partial verification (including only those which allowed histology or follow-up) increased the relative benefit from adding dermoscopy to
visual inspection from an RDOR of 4.7 (95% CI 3.0, 7.5) to 14.4 (95% CI 4.4, 7.6) however study numbers were small and the increase in sensitivity at 80% specificity and in specificity
at 80% sensitivity remained similar (Table 8). Limited differences were observed for the analyses restricting studies to those with low risk of bias for the index test or low risk of bias for
the reference standard. An additional post hoc analysis restricting studies to those with low risk of bias for flow and timing resulted in small study numbers and did not appear to have a
large impact on accuracy. Planned analyses restricting to studies with at least a three month interval between the index test and the reference standard was at least three months, and
where concerns around applicability for participant selection are low, were not possible due to lack of studies.
Image-based evaluations
Sensitivity analyses for image-based evaluations were more difficult to interpret in terms of the differences between diagnosis using dermoscopic images versus visual inspection of
images due to small study numbers for visual inspection in comparison to the numbers for dermoscopy (Table 9), e.g. for restriction to those which allowed histology or follow-up as a
reference standard (7 datasets for dermoscopy compared to 0 for visual inspection), for low risk of bias for the index test (40 for dermoscopy vs 3 for visual inspection) and for low risk
of bias for flow and timing (11 datasets for dermoscopy vs 1 for visual inspection). Restriction to studies with low risk of bias for the reference standard made very little difference to the
accuracy of either test or to the RDOR for dermoscopy versus visual inspection.
Planned analyses restricting to studies with at least a three month interval between the index test and the reference standard was at least three months and where concerns around
applicability for participant selection are low were again not possible due to lack of studies.
An additional post hoc sensitivity analysis restricting studies to those which did not use a case-control design increased the accuracy of visual inspection of images from a DOR of 3.2
(95% CI 1.9, 5.4) to DOR 7.2 (95% CI 3.5, 14.8) for the 7 remaining datasets, and increased the DOR for diagnosis using dermoscopic images from 17.8 (95% CI 12.3, 25.7) to 24.3
(95% CI 15.2, 39.0) for the remaining 37 datasets; the RDOR between tests reduced from 5.6 (95% CI 3.7, 78.5) to 3.4 (95% CI 1.8, 6.4) (Table 9). From the sensitivities and
specificities estimated from SROC curves, this fall in RDOR appears to be primarily related to an increase in accuracy for diagnosis based on visual inspection of images rather than a
fall in accuracy for dermoscopic due to the exclusion of case-control studies. The direction of this finding is contrary to the standard expectation that case-control studies over-estimate
test accuracy compared to other designs (Rutjes 2006).
2. Target condition: invasive melanoma only
In this section we present the results for studies of dermoscopy for the identification of invasive melanoma, according to the approach taken for diagnosis: in-person or image-based
evaluations. Summary characteristics of studies are presented in Appendix 11, with forest plots of study data in Appendix 12 and results of meta-analyses in Table 10 and Figure 20 and
Figure 21.
Dermoscopy added to visual inspection of a skin lesion (in-person evaluations)
Six studies evaluated the accuracy of in-person dermoscopy for the detection of invasive melanoma only, one of which also reported data for the primary target condition (Feldmann
1998) and two of which presented data for visual inspection (Krahn 1998; Viglizzo 2004). All studies were case series based in secondary care or specialist units apart from Coras 2003
which was based in a private dermatology clinic. All recruited participants with pigmented lesions, Viglizzo 2004 restricting to melanocytic lesions only. Four studies did not report using
any formal algorithm to assist dermoscopy diagnosis (Coras 2003; Krahn 1998; Piccolo 2000; Viglizzo 2004); Feldmann 1998 used the ABCD checklist and Ascierto 2010 a modified
version of the Kenet risk stratification approach (referenced to Ascierto 1998). The prevalence of melanoma ranged from 5% (Feldmann 1998) to 49% (Krahn 1998). All studies used a
histological reference standard.
The sensitivity of in-person dermoscopy ranged from 64% to 100% and specificities ranged from 93% to 98% (Appendix 12). In meta-analysis the DOR was 129 (95% CI 19.2, 870)
(789 lesions and 115 melanomas). The specificity of in-person dermoscopy at 80% fixed sensitivity was 97% (95% CI: 94, 98) and sensitivity at 80% fixed specificity was also 97%
(95% CI 46, 100) (Table 10). Again, these sensitivities and specificities at fixed values should be taken as illustrative of the data observed.
In Feldmann 1998, the sensitivity for the detection of invasive melanoma alone was 11% higher compared to sensitivity for the detection of invasive melanoma or atypical intraepidermal
melanocytic variants (64% vs 53%) because the 5 included melanoma in situ lesions were all classified as negative for melanoma on dermoscopy and were classed as true negative
results for the detection of invasive melanoma alone.
Incremental accuracy from dermoscopy added to in-person visual inspection alone
The two studies providing direct comparisons of visual inspection alone and visual inspection plus dermoscopy reported using no algorithm to assist visual inspection diagnosis (Krahn
1998; Viglizzo 2004). Observers in both studies were assumed to be dermatologists based on reported authors’ institutions.
Sensitivities for visual inspection were 79% (Krahn 1998) and 67% (Viglizzo 2004); specificities were 78% and 95%, respectively (Appendix 12). The accuracy of visual inspection was
compared with the accuracy of dermoscopy estimated from (a) all 6 dermoscopy studies (789 lesions and 115 melanomas) and both in-person visual inspection studies (147 lesions
and 51 melanomas) and estimated from (b) direct comparisons in the subset of 2 studies that evaluated both visual inspection and dermoscopy on an in-person basis (147 lesions and
51 melanomas). In both comparisons the accuracy of dermoscopy added to visual inspection exceeded that of visual inspection alone (Table 10). In (a) the diagnostic odds ratio (DOR)
for dermoscopy was 6.2 (95% CI: 1.5 to 26.6; P = 0.015) times that of visual inspection alone, in (b) it was 11.3 (95% CI: 1.4 to 89.8; P = 0.015) times that of visual inspection alone.
These effects correspond to predicted differences in specificity of (a) 13% (95% CI: -1, 27%) (based on sensitivity with dermoscopy of 97% vs 84% for visual inspection) and (b) 24%
(95% CI: -21, 69%) (based on sensitivity with dermoscopy of 99% vs 75% for visual inspection) at a fixed sensitivity of 80% (Table 10); and predicted differences in sensitivity of (a) 13%
(95% CI: -0, 27%) (based on specificity with dermoscopy of 97% vs 84% for visual inspection) and (b) 15% (95% CI: 2, 29%) (based on specificity with dermoscopy of 94% vs 78% for
visual inspection) at a fixed specificity of 80% (Table 10).
Dermoscopic images (image-based evaluations)
Thirteen datasets reported the accuracy of image-based dermoscopy for the detection of invasive melanoma, none of which reported data for the primary target condition. Eight
evaluations included series of lesions observed in secondary care or specialist clinic settings (prevalence 10% to 36%). The remaining five evaluations used a case control type design,
with separate sampling of melanoma and benign lesion images (prevalence ranged from 27% to 65%). Studies used the ABCD checklist (Lorentzen 2000; Menzies 2013), the Menzies
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algorithm (Arevalo 2008; Menzies 1996; Westerhoff 2000) or their own algorithm (Kreusch 1992; Nilles 1994) to assist dermoscopic diagnosis. Six evaluations did not report using any
algorithm to assist diagnosis.
Five evaluations presented only the dermoscopic image with no further patient information (Arevalo 2008; Lorentzen 2008; Menzies 1996; Nilles 1994; Troyanaova 1993), five
presented observers with a concurrent clinical image of the lesion (Hauschild 2014; Lorentzen 1999; Lorentzen 2000; Rao 1997; Westerhoff 2000); two provided only lesion site
(Kreusch 1992) or site, age and gender (Friedman 2008), and one did not describe any further information (Menzies 2013). Images were interpreted by dermatologists or assumed to
be by dermatologists in ten studies, by dermatologists or melanoma fellows in Rao 1997, by GPs in Westerhoff 2000 and by mixed secondary care clinicians in Friedman 2008.
Sensitivities ranged from 48% to 100%; specificities ranged from 49% to 97% (Appendix 12). In meta-analysis the DOR was 27.5 (95% CI: 12.2, 61.7) (5618 lesions and 1092
melanoma cases). Specificity at 80% fixed sensitivity was 87% (95% CI 75, 94%) and sensitivity at 80% fixed specificity was 88% (95% CI 75, 94%) (Table 10).
Incremental accuracy of dermoscopic image-based diagnosis compared to visual inspection of images
The four studies providing direct comparisons of diagnosis based on clinical images and diagnosis based on dermoscopic images reported using no algorithm to assist visual inspection
diagnosis (Lorentzen 1999; Troyanova 2003; Westerhoff 2000) or use of the ABCD algorithm (Rao 1997). Observers were dermatologists (Lorentzen 1999; Troyanova 2003), a
melanoma fellow (Rao 1997) or GPs (Westerhoff 2000).
Sensitivities for visual inspection ranged from 62% to 86%; and specificities from 54% to 89%, respectively (Appendix 12). The accuracy of visual inspection was compared with the
accuracy of dermoscopy estimated from (a) all 13 dermoscopy studies (5618 lesions and 1092 melanomas) and the four visual inspection studies (454 lesions and 145 melanomas)
and estimated from direct comparisons in (b) with the subset of four studies that evaluated both visual inspection and dermoscopy on an image-based basis (454 lesions and 145
melanomas). In both comparisons the accuracy of diagnosis based on dermoscopic images exceeded that based on clinical images (Table 10). In (a) the diagnostic odds ratio (DOR)
for dermoscopy was 2.5 (95% CI: 1.2 to 5.1; P = 0.032) times that of visual inspection alone, in (b) it was 3.4 (95% CI: 1.0 to 11.1; P = 0.049) times that of visual inspection alone.
These effects correspond to predicted differences in specificity of (a) 13% (95% CI -1, 28%) (based on sensitivity with dermoscopy of 87% vs 74% for visual inspection) and (b) 44%
(95% CI -20, 100%) (based on sensitivity with dermoscopy of 89% vs 45% for visual inspection) at a fixed sensitivity of 80% (Table 10) and predicted differences in sensitivity of (a) 15%
(95% CI -1, 30%) (based on specificity with dermoscopy of 88% vs 72% for visual inspection) and (b) 11% (95% CI 1, 22%) (based on specificity with dermoscopy of 83% vs 72% for
visual inspection) at a fixed specificity of 80% (Table 10).
3. Target condition: any skin lesion requiring excision
In this section we present the results for studies of visual inspection for the identification of any skin lesion requiring excision (for each study data could only be extracted for the
detection of any skin cancer), according to the approach taken for diagnosis: in-person or image-based evaluations. Summary characteristics of studies are presented in Appendix 13,
with forest plots of study data in Figure 22 and Figure 23 and results of meta-analyses in Table 11. Heterogeneity was too high and data too sparse to make formal statistical
comparisons between tests, thus the analysis focuses on describting the observed accuracy. Only meta-analytical models assuming underlying symmetric SROC curves could be fitted
to these data.
Dermoscopy added to visual inspection of a skin lesion (in-person evaluations)
Four datasets evaluated the accuracy of in-person dermoscopy for the detection of any skin lesion requiring excision (Argenziano 2006; Durdu 2011; Stanganelli 2000; Soyer 2004),
one of which also reported data for the primary outcome (Durdu 2011) and two reported data for visual inspection alone (Argenziano 2006; Stanganelli 2000). Studies were based in
primary care (with diagnosis by GPs) (Argenziano 2006) or secondary care or specialist referral clinics with diagnosis by dermatologists. The prevalence of skin cancer ranged from 3%
(Stanganelli 2000) to 51% (Argenziano 2006). Studies used the ABCD algorithm (Durdu 2011), the 3PCL (Argenziano 2006), pattern analysis (Stanganelli 2000) or no algorithm (Soyer
2004) to assist diagnosis. Stanganelli 2000 supplemented a histological reference standard with clinical follow-up, and the others reported data compared to histology alone.
Sensitivities ranged from 85% to 98%; specificities ranged from 26% to 100% (Figure 22). In meta-analysis the DOR was 232 (95% CI: 16.0, 3354) (3880 lesions and 260 skin cancer
cases). No formal comparison with in-person visual inspection could be made due to heterogeneity and sparsity of data; however, the DOR for the two studies reporting data for visual
inspection alone (3457 lesions and 151 skin cancers) was 15.0 (95% CI: 0.18, 1225) (Argenziano 2006; Stanganelli 2000), compared to 88.1 (95% CI: 1.1, 7338) for in-person
dermoscopy in these same two studies (3449 lesions and 137 skin cancers; the total number of lesions and melanomas differs because Argenziano 2006 was a between person
comparison study with a different number of lesions randomised to each arm). Sensitivities at 80% fixed specificity and specificities at 80% fixed sensitivity were both 17% higher using
dermoscopy (both 96% with dermoscopy compared to 79% for visual inspection alone) due to the use of symmetric ROC curves for these analyses.
The lowest sensitivity and specificity for dermoscopy were observed in Argenziano 2006, however 2x2 data for the GP diagnosis using the 3PCL could only be included for the 77
lesions selected for excision by an expert dermatologist as the remaining 1126 for which GP diagnosis was recorded did not have an adequate reference standard for inclusion in our
review. In Durdu 2011 specificity estimates were not affected by the wider definition of the target condition, however sensitivity increased from 80% for detection of melanoma or atypical
intraepidermal melanocytic variants to 98% for detection of any lesion requiring excision, as all 34 BCCs were correctly identified.
Dermoscopic images (image-based evaluations)
Five datasets reported the accuracy of image-based visual inspection for the detection of any skin lesion requiring excision (Carli 2002b; Lorentzen 2008; Rosendahl 2011; Stanganelli
1998; Zalaudek 2006), all of which also reported data for the primary target condition or for the detection of invasive melanoma alone (Lorentzen 2008) and three reported data for
diagnosis based on clinical images (Carli 2002b; Rosendahl 2011; Stanganelli 1998). Studies selected images from secondary care clinics or specialist units (Carli 2002b; Lorentzen
2008; Stanganelli 1998), one from a primary care practice (Rosendahl 2011) and was not clearly reported in Stanganelli 1998. The prevalence of lesions suitable for excision ranged
from 22% (Rosendahl 2011) to 47% (Stanganelli 1998); the latter selecting images for use in a dermoscopy training study. Diagnosis was based on the 3PCL (Zalaudek 2006), pattern
analysis (Rosendahl 2011) or no formal algorithm. Data were presented for a single dermatologist (Rosendahl 2011), for a consensus of two dermatologists (Carli 2002b), for the
average across 20 dermatologists (Stanganelli 1998) or 150 dermatologists (Zalaudek 2006) or was not clearly reported (Lorentzen 2008). Observers were also provided with the
clinical image for the same lesion (Rosendahl 2011; Stanganelli 1998), with lesion site, and patient age and gender (Zalaudek 2006) or with no further clinical information to assist
diagnosis (Carli 2002b; Lorentzen 2008).
Sensitivities ranged from 78% to 100%; specificities ranged from 72% to 96% (Figure 23). In meta-analysis the DOR was 37.5 (95% CI 8.8, 161) (815 lesions and 217 skin cancer
cases). No formal comparison with diagnosis based on clinical images could be made due to heterogeneity and sparsity of data, however the DOR for the three studies reporting image-
based visual inspection (547 lesions and 138 skin cancers) was 12.1 (95% CI 5.4, 26.7) (Carli 2002b; Rosendahl 2011; Stanganelli 1998), compared to 18.4 (95% CI 8.1, 41.7) for
image-based dermoscopy in these same 3 studies. Sensitivities at 80% fixed specificity and specificities at 80% fixed sensitivity were 7% higher using dermoscopy (both 82% with
dermoscopy compared to 75% for visual inspection of clinical images).
The wider definition of the target condition to include any skin lesion requiring excision led to increased sensitivities and lower specificities in three studies due to classification of BCCs
as true positives rather than false negatives (Carli 2002b; Rosendahl 2011; Stanganelli 1998). Data for Rosendahl 2011 and Stanganelli 1998 were also extracted for the correct
diagnosis of any malignancy rather than correct diagnosis of each individual type of skin cancer, which led to considerable increased in sensitivity in both studies.
4. Evaluations of dermoscopy training
Observer accuracy using dermoscopy was evaluated before and after a dermoscopy training intervention in six studies; two reported data for detection of invasive melanoma alone
(Troyanova 2003; Westerhoff 2000) and four reported data for the detection of invasive melanoma and atypical intraepidermal melanocytic variants (Pagnanelli 2003; Piccolo 2014;
Stanganelli 1999; Tan 2009). A further 14 studies reported the delivery of some form of dermoscopy training either prior to the study commencing (Kittler 1998; Seidenari 2007) or within
the context of the study itself (Argenziano 1998; Argenziano 2006; Binder 1999; Carli 2003; Dolianitis 2005; Grimaldi 2009; Kittler 1998; Menzies 2008; Menzies 2009; Seidenari 2007;
Stanganelli 1998; Zalaudek 2006). Six of the latter group of studies compared the accuracy of diagnosis based on visual inspection alone (pre-dermoscopy training) to visual inspection
and dermoscopy (post-dermoscopy training); these data are incorporated into the visual inspection versus dermoscopy comparisons reported above.
Details of the training interventions provided in the six eligible studies are provided in Appendix 14. Results of the analyses are reported in Table 12 and Figure 24. All studies were
image-based evaluations.
For the detection of invasive melanoma or atypical intraepidermal melanocytic variants, all four evaluations (Pagnanelli 2003; Piccolo 2014; Stanganelli 1999; Tan 2009) demonstrated
an increase in the average sensitivity of dermoscopy of between 13 and 15% (pre-training sensitivity ranged from 36% to 80% and post-training from 73% to 93%). No change in
average specificity was observed following dermoscopy training for three studies and specificity fell from 70% pre-training to 44% post-training in Piccolo 2014. The pooled analysis
showed no impact accuracy from dermoscopy training (RDOR 1.4, 95% CI 0.38, 5.3).
Three of the four studies reported the training of dermatologists (n = 83 in Stanganelli 2000) or of a mixed group of dermatologists, registrars or residents (n = 16 in Pagnanelli 2003; n =
6 in Tan 2009). Pagnanelli 2003 also included 3 medical students in their group of ‘16 trainees’. These three studies provided web-based interactive training (Pagnanelli 2003; Tan
2009), with an expectation of a time commitment of 1 hour per day for two weeks (Pagnanelli 2003) or with a dermatoscope provided for use in clinical practice for 10 months between
tests (Tan 2009), or in-person dermoscopy training workshops (Stanganelli 1999). In Piccolo 2014 however, the ‘trainee’ was a single GP who undertook similar online training using an
interactive atlas of dermoscopy, which may explain the outlying result for specificity.
For the detection of invasive melanoma, both evaluations demonstrated an increase in the average sensitivity of dermoscopy in the order of 16 to 18% following dermoscopy training
(from 76% to 92% in Troyanova 2003’s study of 32 dermatologists and from 58% to 76% in Westerhoff 2000’s study of 74 GPs), with minimal impact on specificity (84% before and after
training in Troyanova 2003 and 56% before and 58% after training in Westerhoff 2000). The pooled analysis showed a non statistically significant increase in accuracy after training of
3.1 times that before training (95% CI 0.94, 10.6, P = 0.06; 150 lesions and 75 cases). As well as the differences in clinician qualifications, the content and duration of the training
programmes also varied. Troyanova 2003 provided 6 hours of in-person teaching daily for two consecutive days; the test using clinical and dermoscopic images of 50 lesions was
undertaken at the beginning and at the end of the course. In Westerhoff 2000, GPs were provided with a pictorial atlas outlining the Menzies approach to dermoscopic diagnosis and
given a one hour presentation on the method; the pre- and post-tests were undertaken at the leisure of the individual GPs.
Discussion
Summary of main results
Dermoscopy to assist the diagnosis of melanoma has been evaluated in a range of study populations, on an in-person basis added to visual inspection of a skin lesion and using
dermoscopic images, and both with and without the use of published algorithms to assist diagnosis. Wide variations in both sensitivity and specificity for dermoscopy use were observed
for all definitions of the target condition. In terms of methodological quality, many studies were at high or unclear risk of bias for participant selection and for timing of diagnosis in
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relation to reference standard diagnosis, but were at low risk of bias for the index test and reference standard. Concern around the applicability of studies was almost universally poor
due to restricted inclusion of lesions (for example inclusion of only melanocytic lesions or of lesions selected for excision based on the clinical or dermoscopic diagnosis), and lack of
reproducibility of diagnostic thresholds. Poor reporting in the primary studies hindered attempts to analyse studies according to their position on the clinical pathway and to fully assess
sources of heterogeneity and methodological quality.
In this review we have estimated the incremental accuracy of dermoscopy in comparison to visual inspection using summary ROC curves rather than by estimating average sensitivity
and specificity operating points. We have reported points from the fitted SROC curves (the sensitivity at 80% specificity, and the specificity at 80% sensitivity), however these are for
illustrative purposes and should not be quoted as the actual performance of dermoscopy. Whilst it may not be possible to estimate the absolute accuracy of dermoscopy, nor to make
any clear recommendations to ensure that dermoscopy is used in such a way as to maximise sensitivity, we can make a strong comparison between dermoscopy and visual inspection
alone despite the limitations and heterogeneity of included studies, particularly from the studies which make within patient comparisons between diagnostic strategies of visual
inspection alone, and visual inspection supplemented by dermoscopy. We also present results separately for in-person and image-based studies, as we observed clear differences in
their findings. We choose to emphasise the in-person findings over the image-based studies as these are more applicable to typical practice.
Thus whilst we cannot answer the overall question of how accurate dermoscopy is, we are able to assess the incremental gain in accuracy of using dermoscopy, and identify some
characteristics which increase or decrease its accuracy.
Five main findings can be drawn from our review:
1) On average, the addition of dermoscopy to in-person visual inspection of a lesion increases both sensitivity and specificity by a considerable margin.
Approximately one third of eligible studies presented data for in-person dermoscopy (26/86) for the primary target condition of invasive melanoma or atypical intraepidermal melanocytic
variants. A range of study populations were included and a number of different algorithms to assist interpretation were employed, such that considerable heterogeneity in both sensitivity
and specificity was observed for both visual inspection alone and for visual inspection plus dermoscopy. The Summary of findings table 1 presents key results and translates summary
estimates to a hypothetical cohort of 1000 lesions.
Sensitivity: At a fixed specificity of 80%, the use of dermoscopy increased the sensitivity of in-person visual inspection by 26%, from 76% to 92%. Assuming melanoma or atypical
intraepidermal melanocytic variant prevalences of 5%, 12% and 21%, a test sensitivity of 92% with the added use of dermoscopy would reduce the number of melanomas missed in
comparison to using visual inspection alone by 8, 19 and 33 (resulting in 4, 10 and 17 melanomas missed). An assumed test specificity of 80% (for both visual inspection and visual
inspection plus dermoscopy) would result in 190, 176 and 158 false positive test results (or unnecessary excisions).
Specificity: At a fixed sensitivity of 80%, the use of dermoscopy increased the specificity of in-person visual inspection by 20%, from 75% to 95%. Applying these results to a cohort of
1000 lesions at the same three prevalences of disease, both tests would miss between 10 and 42 melanomas, with the addition of dermoscopy reducing false positives (or reducing the
number of excisions that would be performed) by 191, 176 and 158 per 1000 (compared with 238, 220 and 198 unnecessary excisions with visual inspection alone).
We noted very similar findings between the analysis of all studies, and the analyses restricted to studies which made within-person comparisons of strategies of visual inspection alone
and visual inspection aided by dermoscopy. The same difference was evident for our secondary analyses for the detection of invasive melanoma alone and for the detection of any skin
lesion requiring excision.
2) In-person dermoscopy is substantially more accurate than image-based assessments
Much of the available evidence for the diagnostic accuracy of dermoscopy is based on the interpretation of dermoscopic images (60/86) as opposed to ‘real time’ diagnosis face-to-face
with the patient concerned. Formal comparison of test accuracy found in-person dermoscopy to be substantially more accurate compared to diagnosis based on dermoscopic images
(RDOR 4.6, 95% CI 2.4, 9.0; P<0.001). Although there may be a number of contributing factors, including differences in study populations, different algorithms to assist test
interpretation and differences in observer experience, it is likely that, as for visual inspection of a clinical image (Dinnes 2018a), remote test interpretation cannot approximate a
physical, face-to-face patient to clinician interaction. In particular, total body skin examination is likely to have a significant impact on the decision to excise a lesion suspected to be
melanoma (Grob 1998; Argenziano 2012; Aldridge 2013). Across the 60 image-based evaluations, half (30/60) were blinded to all other patient information and only 17 (28%) provided
observers with the clinical image of the same lesion to assist test interpretation.
Nevertheless, given the increasing trend towards remote test interpretation (or teledermatology) it is important to try to understand the potential impact from image-based assessments.
From the data observed, at a fixed specificity of 80%, diagnosis based on dermoscopic images was 34% more sensitive than diagnosis based on clinical images alone (an increase
from 47% to 81% sensitivity). Assuming melanoma or intraepidermal melanocytic variant prevalences of 18%, 24% and 39%, these results translate to 164, 152 and 122 false positive
test results, with 34, 46 and 74 melanomas missed (false negatives) using dermoscopic images (a reduction of 61, 81 and 133 compared to diagnosis based on clinical images alone).
At a fixed sensitivity of 80%, test specificity for diagnosis based on dermoscopic images would be 40% higher compared to that based on clinical images (specificity of 82% compared
to 42%). Applying these results to a cohort of 1000 lesions would miss between 36 and 78 melanomas, with 148, 137 and 110 false positive results based on dermoscopic image
interpretation (a reduction of 328, 304 and 244 in comparison to the evaluation of clinical images alone).
A post hoc analysis restricting study inclusion to those which did not use a case-control design appeared to increase the accuracy of image-based visual inspection and, to a lesser
extent, the accuracy of diagnosis based on dermoscopic images. Nevertheless the observed accuracy of in-person dermoscopy was still greater than that using dermoscopic images. It
is also important to note that none of the included image-based dermoscopy evaluations purported to be an evaluation of teledermatology. Such evaluations are included in a separate
systematic review of teledermatology for the diagnosis of skin cancer (Chuchu 2018a). Although the results for image-based dermoscopy from this review have some bearing on the
accuracy that might be achieved by the remote assessment of dermoscopic images, we suggest that future studies should not be undertaken which evaluate dermoscopic images to
approximate to in-person evaluation. We have retained the image-based studies in the review as they do enable comparisons of different aspects of dermoscopic diagnosis (see below),
but they could potentially be excluded from future reviews.
3) No effect from prior testing of participants or study position on the clinical pathway could be determined, and there is insufficient evidence to assess the accuracy of dermoscopy in a
primary care setting.
Less than half of in-person evaluations (42%; 11/26) and only 18% of image-based evaluations (11/60) contributing to analyses for the primary target condition contained enough
information to describe the position of participants on the clinical pathway. This figure is lower than for our review of visual inspection for the detection of melanoma, where two thirds of
in-person evaluations were clearly positioned on the clinical pathway (Dinnes 2018a). The majority of evaluations of dermoscopy however appear to have been conducted in referral
settings, with only four eligible studies conducted in primary care populations; two in-person evaluations and two image-based, thus our planned comparison between initial
presentation versus referred patients is underpowered. Within the referred population studies there was some (largely non-significant) indication of higher accuracy in equivocal lesions
and lower accuracy in studies of patients with lesions undergoing follow-up, particularly in image-based studies. The classification of study populations was dependent on the
terminology used by the study authors and the groupings may not fully reflect differences between study populations.
4) There is no clear evidence that accuracy is improved by the use of any named or published algorithm to assist diagnosis.
The use of a named or published algorithm to assist dermoscopy interpretation (as opposed to no reported algorithm or reported use of pattern analysis) had no significant impact on
accuracy either for in-person (RDOR 1.4, 95% CI 0.34, 5.6; P = 0.17) or image-based (RDOR 1.4, 95% CI 0.60, 3.3; P = 0.22) evaluations. This result was supported by subgroup
analysis according to algorithm used. Although the vast majority of data comparing algorithms came from image-based evaluations there is no reason to suggest that the relative
accuracy of different approaches to diagnosis would vary according to whether the evaluation was image-based as opposed to in-person, even if in absolute terms accuracy is higher
for latter group of studies.
In this instance, data could be pooled separately according to algorithm and threshold used therefore the bivariate normal model was employed rather than the summary ROC
approach. For in-person evaluations most of the data related to no algorithm (8 datasets), to pattern analysis (6 datasets) or to the ABCD approach at a threshold of >5.45 (5 datasets).
Test sensitivities and specificities were broadly similar for no algorithm (88%, 95% CI 75, 95% and 87%, 95% CI 80, 92%) and for pattern analysis (92%, 95% CI 87, 95% and 92%,
95% CI 68, 98%); use of the ABCD algorithm produced similar specificity (92%, 95% CI 82, 97%) but lower sensitivity (81%, 95% CI 62, 92%), although confidence intervals were wide
and overlapping. At the median prevalence of melanoma of 12% observed across the in-person evaluations, the number of melanomas missed per 1000 lesions tested ranged between
10 and 23 with false positives of 70 to 114 (Summary of findings table 1). For image-based evaluations, test sensitivities and specificities were again broadly similar for no algorithm
(76%, 95% CI 70, 82% and 79%, 95% CI 71, 85%) and for pattern analysis (83%, 95% CI 76, 88% and 87%, 95% CI 80, 92%). The formal algorithms with the most data included
ABCD at >5.45 (7 datasets), the seven point checklist at >=3 (11 datasets) and the three point checklist (7 datasets), sensitivities were broadly similar with overlapping confidence
intervals (ranging from 74% to 81%), with generally lower specificities but again with overlapping confidence intervals (summary estimates ranging from 60% to 81%). At the median
prevalence of melanoma of 24% observed across the image-based evaluations, the number of melanomas missed per 1000 lesions tested ranged between 41 and 62 with false
positives of 61 for no algorithm to 304 for the three point checklist (Summary of findings table 1).
The lack of reporting of diagnostic thresholds in the studies that did not use algorithms to assist diagnosis ('no algorithm' studies) means that we have not been able to clearly compare
accuracy for the diagnosis of melanoma in comparison to a clinician's decision to excise a skin lesion; the latter perhaps being more clinically relevant in practice. Data from image-
based studies appears to show similar sensitivity for correct diagnosis of melanoma and for the decision to excise a lesion but considerably lower specificity for the decision to excise a
lesion, when the target condition was defined as melanoma or atypical intraepidermal melanocytic variants. For the target condition of any skin cancer or lesion with a high risk of
progression to melanoma, sensitivities and specificities were both over 90% in three of the four studies reporting data for dermoscopy added to in-person visual inspection, suggesting
that clinicians may be better at identifying skin lesions that require some intervention than at correctly identifying melanomas, however the data are too limited to allow strong
conclusions to be drawn.
5) Observer expertise and training in dermoscopy improves diagnostic accuracy
Observer experience and expertise in using dermoscopy to assess pigmented lesions is likely to impact on test accuracy, however this information was often not provided in great
detail, particularly for the in-person evaluations. Broad classifications of reported experience in dermoscopy and by observer qualifications were made which, on the whole, led to
statistically significantly higher accuracy for observers reported as having high experience and for those classed as ‘expert consultants’ in comparison to those considered to have less
experience in dermoscopy. Much of the evidence for the effect of observer expertise was again provided by image-based dermoscopy interpretations as opposed to those conducted in-
person, however similar patterns were observed for both sets of studies. Only 2 in-person and 3 image-based studies evaluated dermoscopy in the hands of GPs; these showed lower
accuracy (RDOR 0.21 (95% CI 0.01, 3.12) for in-person and RDOR 0.09 (95% CI 0.04, 0.24) for image-based studies) than expert consultants.
Six studies assessed the effect of dermoscopy training on test accuracy in a limited number of participants. Despite differences in the type and length of training interventions, all of the
six eligible evaluations resulted in increased sensitivity following training with limited effects on specificity in five of the six studies.
7/13/2018 #164 Dermoscopy, with and without visual inspection, for the diagnosis of melanoma in adults
https://archie.cochrane.org/popups/view.jsp?url=%2Fsections%2Fdocuments%2Fview%3Fdocument%3Dz150121160448282956572792131… 14/255
Strengths and weaknesses of the review
The strengths of this review include an in-depth and comprehensive electronic literature search, systematic review methods including double extraction of papers by both clinicians and
methodologists, and contact with authors to allow study inclusion or clarify data. A clear analysis structure focusing on estimating incremental gains in accuracy was adopted. A detailed
and replicable analysis of methodologic quality was undertaken.
For our main analyses however, summary ROC curves were estimated rather than average sensitivity and specificity operating points. This approach was undertaken to facilitate
pooling across the heterogeneous mixture of thresholds and scoring systems, however it does mean that quoted sensitivities and specificities are at best illustrative and do not reflect
the actual performance of dermoscopy. As a result, although we can assess the incremental gain from dermoscopy added to visual inspection, we cannot make any clear
recommendations regarding how dermoscopy should be used in order to ensure that melanomas are not missed.
In comparison to other available systematic reviews, our review extends the time period searched for eligible studies, and includes all eligible studies regardless of availability of a direct
comparison with visual inspection alone (Vestergaard 2008), requirement for an algorithm or ‘clinical prediction rule’ (Harrington 2017), or focus on specific health care professionals or
study settings (Corbo 2012; Loescher 2011; Herschorn 2012). Our review of a single large literature search and concurrent systematic review of a number of other tests for the
diagnosis of melanoma has led to the identification of additional dermoscopy datasets and inclusion of a much greater of number of studies (i.e. 104 compared to 23 in Rajpara 2009; 9
in Vestergaard 2008; and 43 in Harrington 2017). We also explicitly considered whether diagnoses were made based on dermoscopic images or were conducted in-person and
considered variations in the definition of the target condition. Most importantly perhaps our review considers the accuracy of dermoscopy both in comparison to visual inspection and for
diagnosis with and without the use of a formal algorithm. As for considerations of the accuracy of visual inspection of a lesion per se (Dinnes 2018a), unless the accuracy of diagnostic
decisions made without the use of a formal algorithm can be established, the added contribution of such algorithms cannot be fully understood.
Our stringent application of review inclusion criteria meant that some studies included in previous reviews were excluded. For example, those reporting accuracy data for ‘clinical
diagnosis’ where dermoscopy may or may not have been used to assist diagnosis were not included. Of the nine studies included in the Vestergaard 2008 review, we excluded two due
to the inclusion of less than five melanomas (Carli 2003a; Carli 2004) and of the 23 in Rajpara 2009 we excluded one due lack of clarity on the 2x2 contingency table (Ascierto 2000).
Seven of the 43 studies included in the Harrington review were also excluded due to lack of clear data to construct a 2x2 contingency table (Argenziano 2003) or reporting of data in
brief letter format (Blum 2004a; Strumia 2003), the serial use of the algorithm in the context of lesion follow-up (Buhl 2012), the derivation aspect to the study (Henning 2008; MacKie
2002) or diagnosis by laypersons (Luttrell 2012).
The main concerns for the review are a result of the poor reporting of primary studies, in particular limiting assessment of methodological quality, and limiting both the assessment of
studies by prior testing of participants and by observer expertise in dermoscopy. Our review of visual inspection alone for the diagnosis of melanoma identified a general trade-off
between sensitivity and specificity along the clinical pathway with higher sensitivity and lower specificity in limited prior testing studies compared to those in referred populations (Dinnes
2018a). The lack of data from limited prior testing populations in this review and the lack of detailed information on the prior testing of participants included in referred populations meant
that no clear patterns in sensitivity or specificity could be derived. Some evidence of higher accuracy by more specialist or experienced observers was identified however better study
descriptions of observers would assist such investigations.
Applicability of findings to the review question
There are clear concerns regarding the clinical applicability of studies included in this review. Approximately three quarters of studies only provided data from evaluations of
dermoscopic images (with or without data from visual inspection of clinical photographs) such that resulting accuracy estimates cannot be extrapolated to in-person assessments of skin
lesions. Furthermore, almost all in-person evaluations of dermoscopy used in conjunction with visual inspection had high concerns for the applicability of the included population and
half had high concern for the applicability of the test. The restriction of including only excised lesions and the small number of studies conducted in a limited prior testing population
mean that our results cannot be extrapolated to a primary care population.
Authors' conclusions
Implications for practice
Due to methodological limitations of the included studies and heterogeneity in study methods and results, the sensitivity and specificity of dermoscopy either with or without visual
inspection cannot be explicitly estimated, however, we can conclude that the incremental benefit of dermoscopy over and above visual inspection alone is consistent and considerable.
Dermoscopy is therefore a valuable tool to support visual inspection of a suspicious skin lesion for the detection of melanoma and atypical intraepidermal melanocytic variants,
particularly in referred populations and in the hands of experienced users. Data to support its use in a primary care population is limited; however, it is likely to be of some benefit for
triaging suspicious lesions for urgent referral when employed by suitably trained clinicians. Overall, the use of formal algorithms to assist diagnosis does not appear to improve
accuracy, however, neither is there sufficient evidence to suggest that the ‘no algorithm’ approach should be preferred in all settings. Formal algorithms may be more useful for
dermoscopy training purposes and for less expert observers, however reliable data from in-person evaluations of dermoscopy are lacking.
Implications for research
Given the vast volume of research that has been funded to evaluate dermoscopy, further research into the added value of established dermoscopy algorithms per se is unlikely to be
warranted. Further evaluation of dermoscopy use in the primary care setting and to identify the optimal approach to dermoscopy training may be warranted, however. Such evaluations
should be conducted on an in-person basis with prospective recruitment of consecutive series of participants and with systematic follow-up of non-excised lesions to avoid over-reliance
on a histological reference standard. A clear identification of the level of training and experience required to achieve good results is required. Any future research study needs to be
clear about the diagnostic pathway followed by study participants prior to study enrolment, and should conform to the updated Standards for Reporting of Diagnostic Accuracy (STARD)
guideline (Bossuyt 2015).
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Differences between protocol and review
We set out to review visual inspection and dermoscopy for the detection of melanoma in a single review, however due to the volume of evidence identified, two separate reviews were
prepared: one for visual inspection alone and one for dermoscopy. This review of dermoscopy includes data for the accuracy of visual inspection but only where both tests were
evaluated in the same studies (direct comparisons).
Primary objectives and primary target condition have been changed from detection of cutaneous invasive melanoma alone, to the detection of cutaneous invasive melanoma and
atypical intraepidermal melanocytic variants, as the latter is more clinically relevant to the practicing clinician. The detection of the target condition of invasive melanoma alone has
instead been included as a secondary objective. The primary objectives were also amended to conduct separate analyses by in-person/image-based diagnosis rather than to
investigate the effect on accuracy as a secondary objective, as originally proposed in the generic protocol. This decision was taken very early in the review process and was based on
the fact that a diagnosis based on a dermoscopic image or clinical photograph cannot approximate the context of a face-to-face patient clinician consultation.
Secondary objectives have been tailored to the individual test, with two objectives added: to determine the diagnostic accuracy of individual algorithms for dermoscopy; to determine the
effect of observer experience; and to determine the effect on accuracy of observer training in dermoscopy.
Sources of heterogeneity that could be investigated (as listed in the protocol) were restricted due to lack of data.
Studies using cross-validation, such as ’leave-one-out’ cross-validation were excluded rather than included as these methods are not sufficiently robust and are likely to produce
unrealistic estimates of test accuracy.
To improve clarity of methods, this text from the protocol "We will include studies developing new algorithms or methods of diagnosis (i.e., derivation studies) if they use a separate
independent ’test set’ of participants or images to evaluate the new approach.We will also include studies using other forms of cross validation, such as 'leave-one-out' cross-validation
(Efron 1983). We will note for future reference (but not extract) any data on the accuracy of lesion characteristics individually, e.g., the presence or absence of a pigment network or
detection of asymmetry" has been replaced with the following: "Studies developing new algorithms or methods of diagnosis (i.e., derivation studies) were included if they:
used a separate independent 'test set' of participants or images to evaluate the new approach, or
investigated lesion characteristics that had previously been suggested as associated with melanoma and the study reported accuracy based on the presence or absence of
particular combinations of characteristics.
Studies were excluded if they:
used a statistical model to produce a data driven equation, or algorithm based on multiple diagnostic features, with no separate test set.
used cross-validation approaches such as 'leave-one-out' cross-validation (Efron 1983)
evaluated the accuracy of the presence or absence of individual lesion characteristics or morphological features, with no overall diagnosis of malignancy
reported accuracy data for ‘clinical diagnosis’ with no clear description as to whether the reported data related to visual inspection alone or included dermoscopy in all study
participants·
were based on the experience of a skin cancer-specific clinic, where dermoscopy may or may not have been used on an individual patient basis."
We proposed to supplement the database searches by searching the annual meetings of appropriate organisations (e.g., British Association of Dermatologists Annual Meeting,
American Academy of Dermatology Annual Meeting, European Academy of Dermatology and Venereology Meeting, Society for Melanoma Research Congress, World Congress of
Dermatology, European Association of Dermato Oncology), however due to volume of evidence retrieved from database searches and time restrictions we were unable to do this.




Characteristics of included studies
Ahnlide 2016
Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Excised melanocytic skin lesions with recorded dermoscopy ABCD score and clinician's preliminary diagnosis.
 
Setting: Secondary (general dermatology)
Prior testing: Clinical and/or dermatoscopic suspicion
 
Setting for prior testing: Secondary (general dermatology)
Exclusion criteria: Previously biopsied lesions and wide excisions not included; other exclusion prior to enrolment included: invalid report or missing data
(n=34); visiting residents data (n=66); non-melanocytic on histology or benign melanocytic lesions with special patterns (e.g. papillomatous, congenital naevi
and mucosal lesions) (n=658)
Sample size (patients): NR
Sample size (lesions): No. eligible: 1135/ No. included: 309
Participant characteristics: NR
Lesion characteristics: NR
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests Dermoscopy No algorithm (Clinician's preliminary diagnosis); ABCD
Method of diagnosis: In person diagnosis
Prior test data: Clinical examination and/or case notes
Diagnostic threshold: ABCD >4.75 or >5.45 (calculated automatically based on clinician scoring presence/absence of ABCD criteria into computerized
patient file)
Preliminary preoperative diagnosis was based on physical examination and dermoscopic assessment (including application of ABCD algorithm)
Diagnosis based on: Single observer (n=13);
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Observer qualifications: Dermatology residents (n=6; "residents were encouraged to consult the specialists in difficult cases"); Dermatologists (n=7)
Experience in practice: Not described
Experience with dermoscopy: Not reported per observer, but assumed High given training described; describe use of dermoscopy and ABCD at
department for more than 10 years; reports "repeated joint feedback sessions evaluating the preoperative dermoscopy photographs of excised lesions,
enrolment in dermoscopy courses for both residents and senior consultants and daily continuous education in dermoscopy for residents."
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? No
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard - Histological diagnosis alone; histopathological diagnosis was recorded postoperatively in the patient file by a nurse.
Disease positive: 46; Disease negative: 263
Target condition (Final diagnoses)
Melanoma (invasive): 23; Melanoma (in situ): 23
Benign naevus: 263
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: Missing scoring (n=57); wrongly scored due to pre-op non-melanocytic diagnosis (n=5); lesions with preliminary diagnosis of lentigo
maligna or Spitz naevus (n=5); ambiguous histology (n=1).
 
Time interval to reference test: Not reported-but likely consecutively as dermoscopy was used pre-operatively
 
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less? Yes
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective; dermoscopic images assessed remotely from the patient




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Dermoscopically equivocal pigmented lesions, assumed to be melanocytic, seen at Melanoma Unit
 
Setting: Specialist unit (skin cancer/pigmented lesions clinic) Melanoma Unit of the Hospital Clinic of Barcelona.
Prior testing: Dermatoscopic suspicion in all cases
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: Non-melanocytic appearance
Sample size (patients): No. eligible: unclear/ No. included: 264
Sample size (lesions): No. eligible: 343/ No. included: 264
Participant characteristics: Median age (yrs): 54.7 (8-89y); 51.5% Male;
Lesion characteristics: Fitzpatrick phototype: I to II - 42%; III to IV 50%; Lesion site: Head/Neck: 73; 27.7%; Trunk: 135; 51.1%; Limbs: 49; 18.6%;
Describe if other 7; 7% (acral). Lesion thickness: ≤1mm: 86 of 92 melanoma
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes




Method of diagnosis: Dermoscopic images
Prior test data: Clinical examination and/or case notes - lesion site and age provided plus RCM images. Dermoscopy and RCM interpretation appear to
have been conducted by same observer with no indication of blinding
Diagnostic threshold: Not reported; no details
Diagnosis based on: Single observer (n=3)
 
Observer qualifications: Dermatologist. All the images were interpreted independently by one of the three dermatologists with expertise in RCM
Experience in practice: Not described
Experience with dermoscopy: Assumed High experience; three dermatologists with expertise in RCM
Any other detail All of the lesions were imaged with a digital camera (Canon PowerShot G10; Canon, Tokyo, Japan) and a high-resolution dermatoscope
dermatoscope (DermLite Photo; 3Gen LLC, Dana Point, CA, U.S.A.).
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis plus follow-up.
Histology (n=264); Follow-up (n=79); selection for excision based on RCM diagnosis otherwise all would have been excised
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 92; BCC: 12
Benign naevus: 107; 53 SK and AK
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval for reference: Appears consecutive; "Data regarding age, sex, anatomical location, melanoma risk factors and dermoscopic diagnosis were
collected before the RCM examination and histopathological analyses were performed"
 
Time interval between index test(s): Not specified but appears consecutive application of dermoscopy and RCM
 
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
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If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Not reported




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Consecutive atypical macular melanocytic lesions; all larger than 5 mm in diameter, with a flat or barely elevated surface and at least 3 of
the following features: (a) asymmetry, (b) irregular margins, (c) ill-defined borders, and (d) color variegation.
 
Setting: Specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: Clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: None reported
Sample size (patients): No. included: 195
Sample size (lesions): No. included: 198
Participant characteristics: Mean age: 43 years; Male: (106 males) 54%
 
Lesion characteristics: all <=1mm thickness; mean 0.3mm; all >5mm diameter
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy. Pattern analysis; 7-point checklist ; ABCD
Method of diagnosis: Dermoscopic images
Prior test data: Unclear; clinical and ELM digital images taken but unclear what was actually presented to observers
Diagnostic threshold: Reported only for ABCD - Melanocytic lesions with ABCD scores between 4.76 and 5.45 (suspect lesions) were considered test
positive
Diagnosis based on: Consensus (n=2)
Observer qualifications: Described as "ELM-experienced dermatologists"
Experience in practice: High experience or ‘Expert’
Experience with dermoscopy: High experience /‘Expert’ users
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? Unclear
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias




Reference standard Histological diagnosis alone; conducted in Dermatopathology laboratory
Disease positive: 96; Disease negative: 102
Target condition (Final diagnoses)
Melanoma (invasive): 72 ; Melanoma (in situ): 24
Benign naevi: 102 - described as Clark's melanocytic nevi (68 junctional and 34 compound)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: None described
 
Time interval to reference test: Appears consecutive; "After ELM assessment, all lesions were excised and processed for routine histopathologic
examination"
 
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC? Unclear
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Melanocytic lesions imaged at the Sydney Melanoma Unit with a histopathologic diagnosis or that remained unchanged following short-
term (5-4.5 months) digital monitoring (diagnosed as benign)
 
Setting: Specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: Selected for excision (no further detail); Changes on digital monitoring
Setting for prior testing: Not reported
Exclusion criteria: Lentigo maligna and lentigo malignant melanoma
 
Sample size (patients): NR
Sample size (lesions): No. eligible: 3367 melanocytic lesions/ No. included: 3367
Participant characteristics: NR
Lesion characteristics NR
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear




Method of diagnosis: Dermoscopic images
Prior test data: No further information used
Diagnostic threshold: lesion must have none of the 2 negative features of symmetry of pattern or single colour, and must have 1 or more of the following 9
positive features of melanoma; blue-white veil, pseudopods, radial streaming, peripheral black dots or globules, multiple brown dots, multiple blue-gray dots,
scar like depigmentation, broadened network and multiple colours.
Diagnosis based on: Unclear; appears to be consensus (n=2); all lesions scored independently by 2 observers blinded to the diagnosis, with referral to a
third observer if there was a disagreement.
 
Observer qualifications: Not reported; likely dermatologists
Experience in practice: Not described
Experience with dermoscopy: Not described
Any other detail The images were obtained using a dermoscopic camera (Dermaphot; Heine Ltd) or a digital imaging device (Solarscan).
 
Visual Inspection - in-person
A. Risk of Bias
7/13/2018 #164 Dermoscopy, with and without visual inspection, for the diagnosis of melanoma in adults
https://archie.cochrane.org/popups/view.jsp?url=%2Fsections%2Fdocuments%2Fview%3Fdocument%3Dz150121160448282956572792131… 20/255
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard - Histological diagnosis plus follow up
Further details: Not described in detail; Only included lesions with histopathology or those that remained unchanged following short-term (2.5-4.5 months)
Target condition (Final diagnoses)
Melanoma (invasive): 341
'Benign' diagnoses: 3026
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: Poor quality index test image as exclusion criterion
 
Time interval to reference test: Not reported
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC? No
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Unclear
Data collection: Retrospective image selection / Prospective interpretation




Test set derived Three hundred forty two lesions were randomly divided into a training set of 57 CMs and 139MN and a test set of 60 CMs and 86MN.
 
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Atypical melanocytic skin lesions with dermoscopic images that had undergone biopsy due to clinician suspicion
 
Setting: Not reported
Prior testing: Dermatoscopic suspicion in all cases
Setting for prior testing: Secondary (general dermatology)
Exclusion criteria: None reported
Sample size (patients): NR
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Sample size (lesions): No. eligible: 342/ No. included: 342
Participant characteristics: NR
Lesion characteristics: Lesion thickness - ≤1mm: 28%; 68 CMs <0.76 mm; 49 CMs >0.75 mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy Pattern analysis (Not described but classified by clinical reviewer); 7-point checklist (derived and evaluated in this study); ABCD
 
Method of diagnosis: Dermoscopic images; in vivo photography as x10 magnification with special photography equipment after being covered in
immersion oil.
Prior test data: No further information used; "In a blind study"- implies no information beyond the dermoscopic images available.
Diagnostic threshold: Pattern analysis - 'overall ELM diagnosis; 'ABCD - Score >4.75; 7-point checklist - Score of 3 or more.
 
Diagnosis based on: Single (n=2; less experienced observers) and Consensus (2 observers) (n=3; ELM-experienced observers)
 
Observer qualifications: Dermatologist
Experience in practice: Not described.
Experience with dermoscopy: High experience - 3 ELM-experienced; Moderate/trained - less experienced dermatologists (who underwent "short formal
ELM training of 9 hours")
Any other detail: Training set used to derive 7-point checklist. Initially two models were developed. One using multivariate analysis to create a formula for
calculating the probability of each lesion belonging to the group of melanomas but was deemed too complex for clinical use. The second model used the
odds ratios (ORs) from the multivariate analysis to create a simpler diagnostic method based on identification of major and minor ELM criteria. A score of 2
was given to the 3 criteria with ORs>5 (major criteria) and a score of 1 was given to the 4 criteria with OR< 5 (minor criteria); a total score of 3 or more set to
id melanoma. Major criteria included atypical pigment network (presence of an irregular and prominent pigment network), gray-blue areas and atypical
vascular pattern. Minor criteria: streaks, blotches, irregular dots and globules, and regression pattern (presence of white areas or peppering).
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? Unclear
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone (not further described)
Disease positive: 117; Disease negative: 225
Target condition (Final diagnoses)
Melanoma (invasive): 99; Melanoma (in situ): 18
'Benign' diagnoses: 114 atypical nevi111 common nevi
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: None reported
 
Time interval to reference test: Not reported
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less? Yes
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
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Comparative





A. Risk of Bias
Patient Sampling
Study design: Randomised controlled trial allocating primary care physicians to use either visual inspection alone or visual inspection plus dermoscopy
(only excised lesions can be included for each arm)
Data collection: Prospective
Period of data collection May 2003 to Sept 2004
 
Country Italy and Spain
 
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Patients asking for screening or exhibiting one or more skin tumours as seen during routine physical examination (patient-finding
screening) were considered for inclusion; those undergoing excision were included in this review (i.e. those deemed sufficiently suspicious by the Expert
evaluation). PCPs were invited to participate in the trial; only those who attended the training sessions and who then screened patients and referred them to
the Pigmented Lesion Clinics were randomised.
 
Setting: Primary
Prior testing: No prior testing
Setting for prior testing: N/A
Exclusion criteria: NR
Sample size (patients): No. eligible: 3271 patients screened; 1325 patients allocated to Naked Eye observation and 1197 patients allocated to dermoscopy
observation; No. included: 162 received histology after Expert evaluation at the PLC
Sample size (lesions): 85 in VI arm and 77 in Dermoscopy arm underwent excision
Participant characteristics: Based on full sample: mean age 40, range 2-90 (visual inspection group)/ 41, range 3-94 (dermoscopy group). Male 498
(38%) : VI group / 451 (38%) dermoscopy
 
Lesion characteristics NR
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Visual inspection (VI) ABCD (control arm of RCT)
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: Qualitative NR; Described in Intro as: simple morphologic features summarized by the asymmetry, border irregularity, color
variegation, and diameter 5 mm (ABCD)
Diagnosis based on: Average (n=37)
 
Observer qualifications: Primary care physicians
Experience in practice: Not described
Experience with dermoscopy: Not described
Other detail: Pre-randomisation all participating PCPs underwent training in ABCD rule for clinical diagnosis and 3-point checklist for dermoscopy (see
below).
 
Dermoscopy 3-point rule (intervention arm of RCT)
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: >=2 chars present (algorithm is based on the recognition of only three individual features: dermoscopic asymmetry (in color and/or
structure, not in shape), atypical network (pigmented network with thick lines and irregular distribution), and blue-white structures (presence of any blue
and/or white color within the lesion). Each PCP in both groups examined the individual lesions and scored the patient outcome, as banal or suggestive of
skin cancer
Diagnosis based on: Average (n=36)
 
Observer qualifications: Primary care physicians
Experience in practice: Not described
Experience with dermoscopy: Not described
Dermoscopy training: All PCPs received training (2 hour session) on the clinical ABCD rule for diagnosis of melanoma, basic recognition of nonmelanoma
skin cancers including BCC and SCC plus a 2 hour session describing the dermoscopy 3-point checklist.
 
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - in-person
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
All lesions considered suggestive of skin cancer at the PLC were excised and subsequently diagnosed histopathologically. Equivocal lesions by
histopathologic examination were reviewed by a second independent pathologist and a final diagnosis made.
 Disease positive: 92 malignant tumours; Disease negative: 70 benign tumours
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 12; BCC: 66; cSCC: 14
Sebhorrheic keratosis: 13; Melanocytic nevi = 51; Other: 6
 
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: only those patients who were considered to have lesions suggestive of skin cancer had histology and were included. All the rest
had expert diagnosis (not included in the final 2x2 data extracted)
 
Time interval to reference test: Not reported
 
Time interval between index test(s): N/A (RCT)
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative RCT examining effect of making dermoscopy available to primary care practitioners
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? Yes
Was the interval between application of the index tests less than one month? Yes
Are there any concerns that the test comparison could have introduced bias? Low risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? Yes





A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Randomly sampled 100 melanomas and 100 excised melanocytic naevi from a digital collection of lesions screened between 2006 and
2008 at the Department of Dermatology of the Second University of Naples; also randomly sampled 100 melanocytic naevi that showed no relevant changes
to warrant excision during the follow up period from a larger database of monitored naevi
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Setting: Secondary (general dermatology)
Prior testing: Retrospective study of a random sample of dermoscopic images collected in departmental database.100/349 excised melanomas 100/1512
excised naevi
Setting for prior testing: Not reported
Exclusion criteria: Excluded non-melanocytic lesions, lesions on certain anatomical sites (facial, acral, mucosal and nail lesions), lesions larger than 15
mm, and lesions with conflicting histopathological features
Sample size (patients): NR
Sample size (lesions): No. included: 300
Participant characteristics: NR
Lesion characteristics: NR
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy Pattern analysis; 7-point checklist; revised 7-point checklist
 
Method of diagnosis: Dermoscopic images
Prior test data: No further information used; "No additional information was provided, to avoid the possible bias that clinical information may give to the
assessment on morphological criteria."
 
Diagnostic threshold: Pattern analysis - classify as naevus/melanoma/ or lesion to be excised. 7-point checklist - individual criteria scored. Original 7-point
- score >=3 merits excision (based on three major criteria with 2 points each (atypical network, blue-white veil and atypical vascular pattern) and four minor
criteria with 1 point each (irregular dots ⁄globules, irregular streaks, irregular blotches and regression structures). Revised 7-point checklist: score>=1 merits
excision (each criterion is given a score of 1 point).
Diagnosis based on: Average; (n=8)
Observer qualifications: Dermatologist
Experience in practice: High; 'Experienced dermatologists'
Experience with dermoscopy: High; Dermatologists specifically trained in dermoscopy
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? Unclear
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis plus follow up; 200/300 had histology. 100/300 were naevi that had been followed up 1-3 years (median 22
months; range 1-3 years).
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 100; not clear if in situ included.
Excised naevi included: 57 Clark naevi, 28 Spitz naevi, 10 small congenital naevi and 5 blue naevi.
The remaining 100 monitored lesions were reported as 74 reticular naevi and 26 globular naevi;
Is the reference standards likely to correctly classify the target condition? No
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: None reported
 
Time interval to reference test: Unknown
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC? Yes
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If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less? Unclear
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Clinically relevant cutaneous pigmented lesions, undergoing dermoscopy and excision; only melanocytic lesions meeting at least two
clinical ABCDE criteria underwent dermoscopy
 
Setting: Specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: Clinical examination with ABCDE
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: None reported
Sample size (patients): No. eligible: 54/ No. included: 54
Sample size (lesions): NR
Participant characteristics: Median age 41 (19-73y); 19 males
 
Lesion characteristics NR
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy Risk stratification (modified Kenet et al)
Method of diagnosis: In person diagnosis; all patients underwent total body skin examination
Prior test data: Clinical examination and/or case notes
Diagnostic threshold: Very high risk - Lesion with a pigment network and any of the classical ELM features specific for melanoma (pseudopods, radial
streaming, blue-gray veil, atypical vessel, etc.). High risk - Lesion with a pigment network and subtle new ELM features that may suggest melanoma but
often are also seen in atypical nevi.
Diagnosis based on: Unclear, assumed Single observer per pt (n=3)
Observer qualifications: Dermatologist
Experience in practice: High; "evaluations made by expert dermatologists (at least 3 years of experience)"
Experience with dermoscopy: Assumed High
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone (not further described)
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Disease positive: 12 MM; Disease negative: 42
TARGET CONDITION (Final diagnoses)
Melanoma (invasive) 12
'Benign' diagnoses: 42
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Exclusions: none reported
Time interval to reference test: " Before surgery, all patients were investigated by clinical and epiluminescence microscopy (ELM) screenings;"
 
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Not reported. Appears retrospective.




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Pigmented skin lesions examined and excised during a campaign for the early diagnosis of cutaneous melanoma (CM)
 
Setting: Secondary (general dermatology); From authors' institution
Prior testing: Not reported "campaign for the early diagnosis of cutaneous melanoma (CM)"
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): No. included: 311
Sample size (lesions): No. included: 315
Participant characteristics: NR
Lesion characteristics: Thickness: 14 <0.75 mm, 10 0.75 to 1.5 mm, and 6 >1.5 mm (n=42 melanoma)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy. No algorithm; possibly based on Pattern analysis
 
Method of diagnosis: In person diagnosis
Prior test data: Clinical examination based on ABCD
Diagnostic threshold: Presence of malignancy; ELM parameters considered included irregular and multi component pigmentary network pattern,
peripheral dark network patches, sharp network margin, pseudopods, radial streaming, blue-grey areas, pigment dots (blotches, black dots, brown globules),
black dots at periphery, whitish veil, depigmentation and hypopigmented areas, erythema, telangiectasia, comedo-like openings, milia-like cysts, red-blue
areas.
Diagnosis based on: Consensus (3 observers) "diagnosis was made by consensus amongst the dermatologists (Stanganelli 2005) ... when they disagreed
a fourth dermatologist, an expert in the diagnosis of PSLs, was consulted."; n=4
 
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with dermoscopy: Assumed High - all dermatologists were "trained in the recognition of PSLs during a training course on the clinical diagnosis
of naevi and melanomas"; with referral of disagreements to PSL expert
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
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Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone (not further described)
Disease positive: 42; Disease negative: 273
TARGET CONDITION (Final diagnoses)
Melanoma (invasive): 30; Melanoma (in situ): 12
Severe dysplasia: 25 'atypical' dysplastic; Benign naevus: 212; 36 nonmelanocytic
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Particpant exclusions: None reported
Index test to reference standard interval: After diagnosis, "all lesions were then excised and examined histologically
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: All pigmented skin lesions observed and excised at the Dermatologic Surgery Department
 
Setting: Dermatologic Surgery Department
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Dermatologic Surgery Department
Exclusion criteria: None reported
Sample size (patients): NR
Sample size (lesions): No. included: 401
Participant characteristics: NR
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Lesion characteristics: Thickness 42 < 0.75 mm thick, 80.76-1.5 mm thick. 4 1.5-4 mm thick (mean 0.60 mm, median 0.55 mm. max 1.9 mm, min 0.10
mm, SD 0.45).
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Visual inspection (VI) ABCDE
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: Data given for accuracy of each potential score (1-5); score estimation described in detail




Experience in practice: Not described
Experience with dermoscopy: Not described
#
Dermoscopy 7FFM
Method of diagnosis: In person diagnosis
Prior test data: Clinical and dermoscopic evaluations made in-person by 2 dermatologists prior to excision. Decision to excise the lesions was take prior to
this by 3 different dermatologists.
Diagnostic threshold: 2x2 available for 77FM on its own, and for 77FM + each of 5 clinical features, and also for 77FM + each of 5 clinical scores (1-5).;
score estimation described in detail
Test observers as described for Visual Inspection (above)
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 60 (15%) lesions; Disease negative: 340 (non melanoma) + 1 BCC
Target condition (Final diagnoses)
Melanoma (invasive): 54 (13.5%); Melanoma (in situ): 6 (1.5%); BCC: 1 (0.4%)
Sebhorrheic keratosis: 1 (0.4%); Melanocytic nevi: 316; Epithelioid and/or spindle cell nevi: 18 (4.5%); Lentigo simplex: 5 (1.2%)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing




Time interval to reference test: same day
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Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative
Blinding between tests: Clinical and dermoscopic evaluations made in-person by 2 dermatologists prior to excision.
Time interval between index test(s): same day
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? No
Was the interval between application of the index tests less than one month? Yes
Are there any concerns that the test comparison could have introduced bias? Low risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No





A. Risk of Bias
Patient Sampling
Study design: Case-control
Data collection: Retrospective image selection / Prospective interpretation
Period of data collection: Jan 1993 to Dec 1998 (melanomas); Sep 1997 to Sept 1999 (melanocytic nevi)
Country: Italy
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: All small (<= 6 mm) melanomas and melanocytic nevi consecutively excised over two different time periods
Setting: Secondary (general dermatology)
Prior testing: NR; all excised
Setting for prior testing: NR
Exclusion criteria: Size > 6mm
Sample size (patients): NR
Sample size (lesions): 600
Participant characteristics: Mean age 44y (range 20-79)
Lesion characteristics: NR
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Visual inspection (VI) ABCDE
Method of diagnosis: Image-based
Prior test data: Unclear whether dermoscopic image also shown at same time
Diagnostic threshold: >=2 chars present
Diagnosis based on: Consensus of 3 (evaluated by 3 different observers; in case of disagreement , the majority view prevailed)
Observer qualifications: Dermatologist (assumed from authors institution)
Experience in practice: NR
Experience with dermoscopy: NR
#
Dermoscopy: 7FFM
Method of diagnosis: Image-based
Prior test data: Unclear whether clinical image also shown at same time
Diagnostic threshold: >=2
Test observers: as described for Visual Inspection (above)
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
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For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histology alone; no further details
Target condition (Final diagnoses)
Melanoma (invasive or in situ) 76 (8/468 melanomas in full sample were in situ; NR for <= 6 mm group)
Benign nevi 524
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: None reported
Time interval to reference test: NR
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? Unclear
Was the interval between application of the index tests less than one month? Unclear
Are there any concerns that the test comparison could have introduced bias? Unclear risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner?





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Slides of pigmented skin tumours were slected for evaluation during a training course on dermoscopy. Lesions not located on head,
palms or soles histological slide available
 
Setting: Training images; Authors institution. Institute of Dermatologic Sciences, University of Milan
Prior testing: Slides of pigmented skin tumours were selected for evaluation during a training course on dermoscopy
Setting for prior testing: Unspecified
Exclusion criteria: None reported
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Sample size (patients): Not reported
Sample size (lesions): No. included: 49 (paper reports 50 but only 49 accounted for in text)
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Visual inspection (VI) ABCDE
Method of diagnosis: Clinical photographs
Prior test data: No further information used
Diagnostic threshold: ABCDE Score >/=2; presence of 2 criteria; ABCDE Score >/=3; presence of 3 criteria. All criteria described in full




Experience in practice: Expert author; Not described for participating dermatologists




Method of diagnosis: Dermoscopic images
Prior test data: No further information used although clinicians had evaluated clinical images for the same 50 lesions earlier the same day
Diagnostic threshold: Malignant if 7FFM Score >/=2; i.e. presence of one major feature or concurrent presence of two minor features. All criteria described
in full
Test observers: as described for Visual Inspection (above)
#
Dermoscopy training: 3 one day dermatoscopy courses held to inform dermatologists about authors' own new dermoscopy algorithm (7FFM). Each course
lasted 6 hours. Morning session participants executed pre-test interpretation of clinical images using ABCDE. Then principles of dermatoscopy were
presented during the course and as post-test, participants evaluated 50 dermoscopic slides of same lesions using 7FFM
 
Length of training 1 day (6 hours)
 
Post-training experience: <6months
Training format In-person teaching
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? Unclear
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 12/49 melanomas (paper reports 50 but only 49 accounted for in text)
 
Target condition (Final diagnoses)
Melanoma (invasive): 10; Melanoma (in situ): 2; BCC: 2 pigmented BCC
3 seborrhoeic keratoses, 2 pigmented basal cell carcinoma, 1 blue nevus, 2 angiokeratoma, 5 Spitz nevus, 5 junctional nevi, 9 compound nevi, 10 nevi
undergoing regression.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
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Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: None reported
 
Time interval to reference test: Unclear
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative
Blinding between tests: Clinical images interpreted in the morning and dermoscopic images in the afternoon
Time interval between index test(s): image capture NR
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? Unclear
Was the interval between application of the index tests less than one month? Unclear
Are there any concerns that the test comparison could have introduced bias? Unclear risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No





A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective image selection / Prospective interpretation




Test set derived From a sample of 200 PSL, two databases were randomly created for learning and testing purposes. The database was also provided with
the histological diagnosis.
 
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Images of pigmented skin lesions randomly selected from a pigmented skin lesion image database.
 
Setting: Secondary (general dermatology)
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): NR
Sample size (lesions): NR
Participant characteristics: NR
Lesion characteristics: NR
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy (Modified) pattern analysis
Method of diagnosis: Dermoscopic images
Prior test data: No further information used; no additional clinical information was provided
Diagnostic threshold: Observer correct diagnosis of melanoma; presence/absence of 8 ELM criteria were judged (pigment network, brown globules, radial
streaming, pseduopods, black dots, margin regularity, pigmentation, depigmentation) and individual diagnosis made.
Diagnosis based on: Consensus (2 observers); n=3. Images were examined independently by each observer; presence/absence of each ELM criterion
decided by agreement of at least 2/3 observers
 
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’
Experience with dermoscopy: High experience - described as 'ELM experienced dermatologists'
Any other detail The images were obtained by photographing the PSL on 24x36 mm colour slide film, with oil immersion, using a Wild binocular
stereomicroscope M 650 (Wild Heerbrugg AG, Switzerland) at a final magnification of x16 using flashlight illumination.
 
Visual Inspection - in-person
A. Risk of Bias
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B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone (no further details)
Disease positive: 40; Disease negative: 60
TARGET CONDITION (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 40
Benign naevus: 60
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported 
Time interval to reference test: not reported 
Time interval between index test(s): not reported 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Pigmented skin lesions with available dermoscopy images, both with and without oil immersion, and histological confirmation of
diagnosis.
 
Setting: Secondary (general dermatology)
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): NR
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Sample size (lesions): No. included: 240
Participant characteristics: NR
Lesion characteristics: Median thickness 0.7mm, IQR 0.48 to 0.76mm; all less than 1cm diameter
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear




Method of diagnosis: Dermoscopic images of lesions with and without oil immersion (*results with oil immersion used for primary analysis); images
randomly presented to prevent consecutive presentation of slides for the same lesion. Each image was shown for 20 seconds with a 20 minute break after
240 slides
Prior test data: No further information presented
Diagnostic threshold: Correct diagnosis of melanoma. For each PSL image only one diagnosis was allowed (MM or not MM)
Diagnosis based on: Average (n=19); 6 ELM experts and 13 randomly picked dermatologist 'nonexperts'
 
Observer qualifications: Dermatologist
Experience in practice: High - all certified dermatologists, experienced in clinical diagnosis
Experience with dermoscopy: Mixed. 'Nonexperts' had no formal ELM training; ‘Expert’ users had been working scientifically in the development of ELM
for at least 3 years
Any other detail Images were obtained by photographing the PSLs on 24X36-mm color-slide film with ELM and without oil immersion (surface microscopy
ISM]) using a binocular stereomicroscope (M 650, Wild AG, Hcerbrugg, Switzerland) at a final magnification of X 16 using flashlight illumination
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone (not further described)
Disease positive: 57; Disease negative: 183
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not reported): 57; BCC: 8
Severe dysplasia: 42; other 'Benign' : 133
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Reference interval: appears consecutive; "After photographing, all lesions were excised"
Excluded participants: None reported
 
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability






A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Randomly selected, histologically proven pigmented skin lesions with digital dermoscopy images
 
Setting: Secondary (general dermatology)
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): NR
Sample size (lesions): No. included: 250
Participant characteristics: NR
Lesion characteristics: Thickness; 7 (17%) of the 41 melanomas were in situ lesions, 24 (59%) <0.75 mm, and 10 (24%) ranged from 0.76 to 1.8 mm.;
Lesion size: all <=8mm diameter
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy: ABCD; Pattern analysis/no algorithm
Method of diagnosis: Dermoscopic images
Prior test data: No further information used. Computer presented images in random order.
Diagnostic threshold: ABCD classification (score> 5.45, >4.75); sensitivity and specificity also estimated at Q*.
Subjective diagnosis (based on certainty of melanoma between 1 and 5) also recorded using pattern analysis (experts) or subjective rating (first-year
residents)
Diagnosis based on: Average (n=17)
Observer qualifications: Dermatology residents - 5; Dermatologist (board-certified) - 12
Experience in practice: Mixed. First-year residents (n=5); practicing board-certified dermatologists with experience ranging from 4 to 15 years (n=8), and 4
board-certified recognized as experts mainly working at PSL units (n=4)
Experience with dermoscopy: Mixed experience "Ten of the 17 raters (58.8%) reported on previous usage of the ABCD score, at least for testing
purposes of the method."
#
Dermoscopy training: Written materials "Before testing all readers were instructed how to apply the ABCD criteria according to the literature published"
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? Unclear
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 41 (16.4%) lesions; Disease negative: 209 (83.3%) lesions
Target condition (Final diagnoses)
Melanoma (invasive): 34 lesions; Melanoma (in situ): 7 lesions
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Benign naevus: 96 nevocellular nevi of the compound type, 62 junctional type, 24 dermal type, 13 Spitz nevi; 14 lentigines
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index to reference interval: Consecutive; "After photography all lesions were excised"
Time interval between algorithms: same time; image-based
 
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less? Yes
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation





Test set derived: Study develops a simplified version of ABCD algorithm; describes full data set "randomly divided into 2 groups (N0 and N1)" but new
algorithm development was based on full dataset
 
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Melanocytic skin lesions to be excised because of clinically and/or dermoscopically clear or suspicious malignancy, or by the wish of the
patient after clear benign diagnosis
 
Setting: Secondary (general dermatology)
Prior testing: Clinical and/or dermatoscopic suspicion; Patient request for evaluation/excision
Setting for prior testing: Not reported
Exclusion criteria: Consecutive images of one lesion and external recorded images were not included. Images from all parts of the bodies were taken
except of subungual and mucosal sites.
 
Sample size (patients): 269
Sample size (lesions): 269
Participant characteristics: Male: (45/84)
Lesion characteristics: Median Breslow thickness 0.96mm (SD 0.70mm) for all melanomas
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy modified ABCD (with and without 'E' for evolution); denoted by authors as ABC-point list; plus 7FFM; 7 point checklist; Menzies criteria;
original ABCD not included due to lesion overlap with Blum 2004b
Method of diagnosis: Dermoscopic images
Prior test data: Unclear; study describes image acquisition and storage but does not described image interpretation
Diagnostic threshold: Not reported for established algorithms "performed according to the criteria given in literature".
For ABC-point list: >=4 points. A - Asymmetry of the outer shape in at least 1 axis (+1) (as per (Stolz; Nachbar); (A) - Asymmetry of the differential structures
inside the lesion in at least 1 axis (+1) (new item); B - Abrupt cutoff of network at the border of the lesion in at least 1 quarter of the circumference (+1); C -
Three or more colors (+1); D - Three or more differential structures (+1); E - Evolution/change noticed by the patient during the last 3 mo (+1); No or
uncertain information +0; No change in the last 3 mo (-1)
Diagnosis based on: Unclear (n=NR)
 
Observer qualifications: Not reported; likely dermatologists
Experience in practice: Not described
Experience with dermoscopy: Not described.
 
Visual Inspection - in-person
A. Risk of Bias
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B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? Yes
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Target condition (Final diagnoses)
Melanoma (invasive): 71; Melanoma (in situ): 9; Lentigo maligna 4
'Benign' diagnoses: 185
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
 
Time interval to reference test: appears consecutive; consent given "for the recording and the following operation under local anaesthesia"
 
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less? Unclear
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: All lesions of patients with multiple atypical naevi excised due to suspicious clinical and/or dermoscopic features were included
 
Setting: Specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: lesions located on soles, palms, subungual and mucosal sites were excluded
Sample size (patients): No. included: 205
Sample size (lesions): No. eligible: 254/ No. included: 254
Participant characteristics: Median age: 39.2 (1.6-86.4y); Male: 97 (47.3%)
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Lesion characteristics: NR
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy.New algorithm (based on criteria of Hofmann-Wellenhof 2001)
Method of diagnosis: Dermoscopic images
Prior test data: Unclear; looks like blinded test interpretation
Diagnostic threshold: lesions were classified into six different types according to morphological criteria of the new classification of atypical naevi (Clark
naevi): reticular, globular and homogeneous or combinations of two of these types (Hofman Wellenhof 2001). If reticular, globular and homogeneous
structures were found in one melanocytic lesion, this lesion was classified as a three-structure type
Diagnosis based on: Consensus (2 observers); n=2
Observer qualifications: Not reported; likely dermatologists - "All images were viewed by two investigators"
Experience in practice: Not described
Experience with dermoscopy: Not described
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 75 MM; Disease negative: 179
Target condition (Final diagnoses)
Melanoma (invasive): 63; Melanoma (in situ): 12
Benign naevus: Recurrent naevus 6; Splitz or Reed naevus 6; Congenital naevus 4; Blue naevus 3; Naevus without dysplasia 64; Dysplastic naevus 96
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported;
Time interval between index and reference: Assumed consecutive; "All patients gave written informed consent for the digital documentation and the
following operation under local anaesthesia"
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less? Yes
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative
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Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective





Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Pigmented skin lesions excised due to suspicious clinical and / or dermoscopic features
 
Setting: Pigmented lesion clinic
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: "Consecutive (repeat) images of one lesion were not included"; Malignant epithelial tumours (basal cell carcinoma, squamous cell
carcinoma) were excluded.
 
Sample size (patients): No. eligible: 157/ No. included: 157
Sample size (lesions): No. eligible: 162/ No. included: 157
Participant characteristics: Median age: 38.9 years (2 to 87 years); 45.2% male
 
Lesion characteristics No change in the past 3 months was reported by 87 (55.4%) patients, followed by an observed change in 39 (24.8%) patients and
no clear clinical history was given by 31 (19.7%) patients.Lesion site: Face/Ears: 9 (5.7%); Trunk: 102 (65%); Limbs: 38(24.2%); Acral 6(3.8%), mucosal
sites 2(1.2%); Lesion thickness ≤1mm: 23 CMs (2 in-situ, 29 invasive) median Breslow thickness 0.86mm (standard deviation 0.54 mm; range 0.30-40 mm)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes





Method of diagnosis: Dermoscopic images
Prior test data: Images interpreted with and without clinical information (clinical history, age, sex of the patients and location of the tumour).
Diagnostic threshold: Diagnosis of suspect CM made when the level of suspicion was 'roughly 50% or more'. " Clinical history was scored as positive
"when any morphological change was recognized by the patient in the past 3 months. Morphological changes included change in size, colour or shape or
any sign of ulceration or spontaneous bleeding. Possible dermoscopic classifications were benign nevi, atypical nevi, cutaneous melanoma and other
benign epithelial tumours (e.g. seborrhoeic keratosis, angioma)"
Diagnosis based on: Single observer (n=3)
 
Observer qualifications: Not described; likely dermatologists
Experience in practice: Not described
Experience with dermoscopy: High/Moderate/Low "Three investigators ... with different experiences in dermoscopy: excellent (A), average (B) and
beginner (C)."
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? Unclear
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
TARGET CONDITION (Final diagnoses)
Melanoma (invasive): 29; Melanoma (in situ): 2
Benign naevus: 53; 59 dysplastic naevi; 13 'epithelial benign tumours'
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
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Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: Consecutive images of one lesion were not included - assumed to be repeated images of same lesion; 162 images originally with 5
excluded to give a total study number of 157 lesion
Index to reference interval: Assumed consecutive; ""All patients gave their written consent for the digital documentation and the following operation under
local anaesthesia"
 
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective; dermoscopic images assessed remotely from the patient




Test set derived For validation of a new CAD procedure the complete collection (837 melanocytic lesions) was divided into two equal random subgroups n1
(training set) and n2(test set).
 
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Melanocytic skin lesions imaged prospectively at the Pigmented Lesion Clinic of the Department of Dermatology, University of
Tuebingen, Germany.
 
Setting: Specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: Not reported
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: images from mucous membrane areas were excluded
 
Sample size (patients): NR
Sample size (lesions): No. eligible: 837/ No. included: 837
Participant characteristics: NR
Lesion characteristics: Median breslow thickness for all melanomas 0.78mm (range 0.10-3.50)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy: 7FFM; 7 point checklist; ABCD; Menzies criteria
Method of diagnosis: Dermoscopic images.
Prior test data: Not clearly reported; results using new CAD algorithm were "compared with established dermoscopic classification rules applied to the
same image material as the diagnostic computer algorithm."
Diagnostic threshold: Not reported; original algorithms cited "established dermoscopic classification rules"; authored confirmed published standard
thresholds of the mentioned algorithms were used.
Diagnosis based on: Single observer; n= 1
 
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with dermoscopy: Not described, assumed High; "lesions were prospectively classified as benign or malignant melanocytic lesions by the
principal investigator (A.B.)"
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
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B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? Unclear
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis plus follow up
Histology Disease positive: 84; Disease negative: 185
Clinical FU plus histology of suspicious lesions - unexcised lesions were analysed independently by two of the investigators 2-3 times in 6 months on the
basis of dermoscopic criteria. These lesions were classified as benign without any suspicion of malignancy by dermoscopic criteria, and follow-up records
for at least 6 months showed no evidence of malignancy; n=568
TARGET CONDITION (Final diagnoses)
Melanoma (invasive): 71; Melanoma (in situ): 9; Lentigo maligna 4
'Benign' diagnoses: 766
Is the reference standards likely to correctly classify the target condition? No
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
 
Time interval to reference test: appears consecutive; "After obtaining informed written patient consent, 269 melanocytic skin lesions were excised under
local anaesthesia and the diagnosis was established by histopathology"
 
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC? Yes
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less? Unclear
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective




Test set derived A training set was separately derived using data obtained from 237 previously studies lesions (ref Farina 2000)
 
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Cutaneous pigmented lesions with clinical and/or dermatoscopic features that suggested a more or less important suspicion for CM
 
Setting: Specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: Location/site of lesion - Awkwardly situated lesions eg interdigital space, ears, nose or eyelids. Lesions on scalp excluded due to hair
interference with reflectance - lesion size obvious large, thick melanomas
Sample size (patients): No. included: 298
Sample size (lesions): No. included: 313
Participant characteristics: Mean age: 40y (10-86y); Male: 122; 41%
Lesion characteristics: Lesion site: Head/Neck: 3%; Trunk: 61%; Limbs: 36%; Thickness ≤1mm: 70% (46/66); for 55 invasive MM: median thickness
0.64mm, range 0.17-3.24mm. Median diameter: 11mm (3-31mm)
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Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm (Training in the unit is based on ABCD but subjective experience of the clinician used for diagnosis)
 
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: Clinical diagnostic criteria based on subjective experience; emphasise lesion colour over dimensions. Diagnosis of suspect CM
made when the level of suspicion was 'roughly 50% or more'.ABCD (asymmetry, border, colour, dimension) criteria have been the basis of training at the
unit, but is not implemented in diagnosis; preferred emphasis on colour rather than dimensional character
Diagnosis based on: Single observer; (n=1)
 
Observer qualifications: Surgical oncologists
Experience in practice: High experience or ‘Expert’; over 5 years
Experience with dermoscopy: Assumed high experience; over 5 years
#
Dermoscopy No algorithm
Method of diagnosis: In person diagnosis
Prior test data: Clinical examination and/or case notes
Diagnostic threshold: Presence of at least one of the following criterion: radial streaming, pseudopods, grey-blue veil, regression and erythema, whitish
veil, black dots at the periphery (if network present), thick irregular network or milky-red background with red dots.
Test observers as described for Visual Inspection (above)
Dermatoscopy performed by a hand-held monocular microscope equipped with an achomatic lens permitting a magnification of x10 (Heine Delta 10).
 
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
TARGET CONDITION (Final diagnoses)
Melanoma (invasive): 55; Melanoma (in situ): 11; BCC: 6
'Benign' diagnoses: 241;151 compound naevus, 24 junctional naevus, 12 dermal naevus, 12 lentigo simplex, 10 dysplastic naevus, 8 spindle-cell naevus, 8
sebhorrheic keratosis, 5 blue naevus, 3 spitz naevus, 8 other.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: NR
Interval between index and reference: NR
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
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Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative
Same clinician undertook both diagnoses (in-person)
Time interval between index test(s): Appears consecutive but not fully clear
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? No
Was the interval between application of the index tests less than one month? Yes
Are there any concerns that the test comparison could have introduced bias? Low risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Consecutive cutaneous pigmented lesions that were <=6mm in diameter and required surgical biopsy for diagnosis based on clinical or
dermoscopic suspicion of CMM
 
Setting: Specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Not reported
Exclusion criteria: lesion size >6mm; non-pigmented
Sample size (patients): No. eligible: 349/ No. included: 157
Sample size (lesions): No. eligible: 375/ No. included: 161
Participant characteristics: Mean age 38y (14-82); Male: 61 (39%)
 
Lesion characteristics: Site: head/Neck: 14 (9%); trunk: 88 (55%); limbs: 59 (36%); Lesion size: median: 5mm (1mm to 6mm)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Visual inspection (VI). No algorithm (ABCD (asymmetry, border, colour, dimension) criteria have been the basis of training at the unit, but is not
implemented in diagnosis; preferred emphasis on colour rather than dimensional character)
 
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: A diagnosis of suspect CM is made when the level of suspicion is roughly 50% or more; lesions at a lower index of suspicion were
considered benign for the purposes of this study. ABCD (asymmetry, border, colour, dimension) criteria have been the basis of training at the unit, but is not
impleneted in diagnosis; preferred emphasis on colour rather than dimensional character
Diagnosis based on: Single observer diagnostic criteria based on the subjective experience of the single clinician examining the pigmented lesion (n=2)
 
Observer qualifications: surgical oncologists
Experience in practice: High experience or ‘Expert’; described as “expert in the recognition of pigmented lesions"
Experience with dermoscopy: High experience /‘Expert’ users
Other detail: Diagnostic criteria were based on the subjective experience of the single clinician examining the pigmented lesion, although the ABCD criteria
have been the basis of training at the unit, they did not consider the ABCD mnemonic an essential formula for diagnosis of CM. They did not take into




Method of diagnosis: In person diagnosis
Prior test data: Clinical examination and/or case notes in-person; dermoscopy performed by the same two clinicians who firstly made and registered the
clinical diagnosis
Diagnostic threshold: Dermatoscopic criteria for diagnosis of malignancy were radial streaming, pseudopods, grey-blue veil, regression and erythema,
whiteish veil, black dots at periphery (if network present), thick irregular network, or milky-red background with red dots. A lesion was suspected for CM
when positive for at least one criterion.
Test observers as described for Visual Inspection (above)
Any other detail This technique was performed by a hand-held monocilar microscope equipped with an achromatic lens permitting a magnification of 10x
(heine Delta 10).
 
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
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For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 13 CM; Disease negative: 148 n
Target condition (Final diagnoses)
Melanoma (invasive): 10; Melanoma (in situ): 3; BCC: 2(1.2%)
Mild/moderate dysplasia: 26 (16.1%); Sebhorrheic keratosis: 4(5%); Benign naevus: compound nevus 57(35.4%), junctional nevus 38(23.6%), spindle-cell
nevus 6(3.7%), spitz nevus 5(3.1%), blue nevus 2(1.2%), other 6(3.7%), Lentigo simplex 2 (1.2%)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
 
Time interval to reference test: not reported
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative
Dermoscopy performed by the same two clinicians who firstly made and registered the clinical diagnosis
Time interval between index test(s): appears consecutive
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? No
Was the interval between application of the index tests less than one month? Yes
Are there any concerns that the test comparison could have introduced bias? Low risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? Yes





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective
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Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Consecutive patients with pigmented skin lesions with a maximum diameter of <=3mm undergoing excision. The decision for diagnostic
excision was based on clinical and/or dermoscopic features suggesting a more or less important suspicion for CM
 
Setting: Specialist unit (skin cancer/pigmented lesions clinic) Melanoma and Sarcoma Unit; Istituto NazionaleTumori of Milan
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: - lesion size >3mm
Sample size (patients): No. eligible: 204/ No. included: 204
Sample size (lesions): No. eligible: 206/ No. included: 206
Participant characteristics: Median age: 40 (6-74); Male: 71 (35%)
Lesion characteristics Head/Neck: 8 (4%); Trunk: 84 (41%); Limbs: 114 (55%). Median size: 2mm (1 to 3mm)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: A diagnosis of suspicious CM is made when the level of suspicion is roughly 50% or more; lesions at a lower index of suspicion were
considered not CM; ABCD (asymmetry, border, colour, dimension) criteria have been the basis of training at the unit, but is not implemented in diagnosis;
preferred emphasis on colour rather than dimensional character
Diagnosis based on: Single observer; n= 1
 
Observer qualifications: Not reported (assumed Oncologist as per Bono 2002 and Bono 2002b); "single clinician examining the pigmented lesion"
Experience in practice: Not described
Experience with dermoscopy: Not described
#
Dermoscopy Menzies criteria
Method of diagnosis: In person diagnosis
Prior test data: Clinical examination and/or case notes
Diagnostic threshold: Dermoscopic criteria for diagnosis of malignancy were those of Menzies et al. (1996, 2003)
Test observers as described for Visual Inspection (above)
A hand-held monocular microscope equipped with an achromatic lens permitting a magnification of 10x (Heine Delta 20 microscope; Heine Ltd, Herrsching,
Germany).
 
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Details: The slides were evaluated according to widely accepted criteria for the histopathological diagnosis of the various pigmented lesions.
 Disease positive: 23; Disease negative: 183
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Target condition (Final diagnoses)
Melanoma (invasive): 19 (9.2%); Melanoma (in situ): 4 (0%)
Mild/moderate dysplasia: dysplastic naevus 10 (4.9%); junctional naevus 76 (36.9%); compound naevus 50 (24.3%); dermal naevus 12 (5.8%); blue naevus
11 (5.3%); reed naevus 7 (3.4%); spitz naevus 3 (1.5%); halo naevus 3 (1.5%); lentigo simplex 7 (3.4%)Other 4 (1.9%)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? No
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none
 Time interval to reference test: not reported
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative
Single observer performed both tests
Time interval between index test(s): not reported
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? No
Was the interval between application of the index tests less than one month? Yes
Are there any concerns that the test comparison could have introduced bias? Low risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? Yes





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: All skin lesions consecutively excised at a skin cancer practice to exclude skin cancer and common lesions assessed as clearly benign
and not biopsied were included
 
Setting: Private; "a dedicated skin cancer practice in Brisbane, Australia"
Prior testing: Clinical and/or dermatoscopic suspicion. Prior testing to assemble the test set occurs in secondary care by an experienced skin cancer
doctor, then the images are tested on primary care professionals
 
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: clinically obvious basal cell carcinomas which could be easily diagnosed without dermoscopy were not included in the collection set.
 
Sample size (patients): No. eligible: 46/ No. included: 46
Sample size (lesions): No. eligible: 50/No. included: 50
Participant characteristics: Mean age: 58 (30 -60); Male: 22
 
Lesion characteristics: Face = 8; Neck = 1; Chest = 3; Back = 21; Shoulder = 2; Arm = 3; Thigh = 4; Leg = 7; Foot plantar = 1
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests Visual inspection (VI) No algorithm
Method of diagnosis: Clinical photographs
Prior test data: No further information used; Image assessments were done on four occasions, each time using a different diagnostic approach.
Diagnostic threshold: Not reported clinicians provided with Excel answer sheets for each method listing the various criteria used in that algorithm but no
algorithm was cited for VI
Diagnosis based on: Average (n=4)
Observer qualifications: 3 GPs and 1 clinical nurse
Experience in practice: Mixed; described as varying levels of dermatoscopic experience
Experience with dermoscopy: Mixed; described as varying levels of dermatoscopic experience
#
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Dermoscopy 3-point rule; Menzies criteria
Method of diagnosis: Dermoscopic images
Prior test data: No further information used; Image assessments were done on four occasions, each time using a different diagnostic approach.
Diagnostic threshold: Not reported in paper; author communications states that standard thresholds were used - >=2 for the 3-Point checklist and Menzies
method as described in original paper
Test observers as described for Visual Inspection (above)
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? Unclear
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis plus other
Histopathological examination (n=46); Expert diagnosis as benign (n=3); Digital follow up (n=1)
Target condition (Final diagnoses)
Melanoma (invasive): 1; Melanoma (in situ): 7; BCC: 6; Lentigo maligna 1
Sebhorrheic keratosis: 5; 'Benign' diagnoses: Banal nevus 10, Blue naevus 1, Nevus and seborrhoeic keratosis/solar lentigo collison 3, Solar lentigo 4,
LPLK 4, Dermatofibroma 1, Psoriasis 1, Solar keratosis 2, Intraepidermal carcinoma 3, Regressed keratoacanthoma 1
Is the reference standards likely to correctly classify the target condition? No
Were the reference standard results interpreted without knowledge of the results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have introduced bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard No
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? High
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: As two of the methods (Menzies and 3 point checklist) related to only pigmented lesions, the 5 non-pigmented specimens in the set
of 50 were excluded from the contingency tables for these methods.
 
Time interval to reference test: "all skin lesions consecutively excised to exclude skin cancer were recorded"
 
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? No
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC? Unclear
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less? Yes
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative tbc
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? Yes
Was the interval between application of the index tests less than one month? Yes
Are there any concerns that the test comparison could have introduced bias? Low risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No
Are there concerns that the test comparison differs from the review question? High






A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Pigmented skin lesions excised at Dept of Dermatology; all lesions considered suspicious on clinical
parameters (on at least one of ABCDE parameters apart from diameter) underwent dermoscopy; 2x2 for melanocytic only included
 
Setting: Secondary (general dermatology)
Prior testing: Clinical suspicion only; decision to excise "follows the dermoscopic diagnosis"
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: None reported
Sample size (patients): NR
Sample size (lesions): No. included: 638 melanocytic lesions
Participant characteristics: Age range: between 2 months and 90 years
Lesion characteristics NR
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear





Method of diagnosis: Unclear. Study describes 'day-to-day' office activity, but ELM interpretation referred to as evaluating 'recorded images' to split into
melanocytic and non-melanocytic lesions. "Melanocytic lesions were investigated on the basis of a pattern analysis and those that revealed altered
dermoscopic parameters were distinguished between minor and major criteria"
Prior test data: Unclear what additional information was available
Diagnostic threshold: > 1 alteration in minor criteria or >= 1 major char present; not further described. Based on data in Argenziano 1998, this is akin to a
score of >=2 as major criteria score 2 points and minor ones score 1 each
Diagnosis based on: Unclear appears to be in clinic diagnoses
n=: NR
Observer qualifications: Not reported likely dermatologists
Experience in practice: Not described
Experience with dermoscopy: Not described
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard - Histological diagnosis alone
Details: "lesions were fixed with formaline and included in paraffin
for histological examination. For some of them serial sections were made"
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 108
'Benign' diagnoses: non-melanomas= 530
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Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
 
Time interval to reference test: not reported
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Unclear




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Clinically suspicious melanocytic lesions undergoing excision for diagnostic purposes
 
Setting: Secondary (general dermatology)
Prior testing: Clinical suspicion of malignancy based on: recent lesion changes or presence of at least two of: diameter > 6 mm, asymmetric, irregular
feathery edges, uneven or 'very' dark colour, 'increased or disappearance of skin outline'.
Setting for prior testing: Secondary (general dermatology)
Exclusion criteria: Clinically obvious melanomas excluded
 
Sample size (patients): No. included: 67
Sample size (lesions): No. included: 67
Participant characteristics: Mean age 36y; median age 33; all >20 years; Male: 31%
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy: Pattern analysis; criteria derived from a number of other studies (citations include Steiner 1993, Pehamberger 1987, Steiner 1981, Nachbar
1994, Bahmer 1990, Kenet 1993, Stolz 1989, Soyer 1987, Dal Pozzo 1993)
 
Method of diagnosis: In person diagnosis
Prior test data: Clinical examination
Diagnostic threshold: A pigment network that was irregular, accentuated, wide-meshed, with distinct borders, plus at least one of the following parameters
:- Inhomogeneous depigmentation present at the periphery;- Presence of unevenly distributed black dots;- Uneven brown globules, with irregular
distribution;- Presence of radial streaks;- Presence of pseudopods;- The presence of gray-blue veil.
Diagnosis based on: Consensus (2 observers); n=2
 
Observer qualifications: NR; likely dermatologist
Experience in practice: High - described as "two experienced observers"
Experience with dermoscopy: High - as above
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
7/13/2018 #164 Dermoscopy, with and without visual inspection, for the diagnosis of melanoma in adults
https://archie.cochrane.org/popups/view.jsp?url=%2Fsections%2Fdocuments%2Fview%3Fdocument%3Dz150121160448282956572792131… 50/255
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histology (not further described) 
Disease positive: 5; Disease negative: 63
Target condition (Final diagnoses) 
Melanoma (invasive): 3; Melanoma (in situ): 2
'Benign' diagnoses: Atypical melanocytic hyperplasia 2; Nevi with architectural atypia 14; Nevi with ‘cyto’-architectural atypia 7; No atypia 40
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Time interval to reference test: ELM performed at the time of excision of the lesion
 
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective for clinical examination and in-vivo dermoscopy; retrospective image selection / Prospective interpretation for ex-vivo
dermoscopic evaluation




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Clinically equivocal and suspicious pigmented skin lesions subjected to excisional biopsy at the Institute of Dermatology
 
Setting: Secondary (not further specified)
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Secondary
Exclusion criteria: None reported
Sample size (patients): NR
Sample size (lesions): 256
Participant characteristics: None reported
Lesion characteristics Of the cutaneous melanomas, 14 (25.9%) were in situ melanoma (Clark level I), 18 (33.3%) were invasive with less than 0.75 mm
thickness, 19 (35.3%) were of intermediate thickness (0.76–1.50 mm) and three (5.5%) were thicker than 1.5 mm. The median thickness of invasive
melanomas was 0.94 mm ± 0.5 (SD) (range 0.2–6).
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High




Visual inspection (VI) No algorithm
Method of diagnosis: In person diagnosis
Prior test data: Unclear
Diagnostic threshold: Not reported
Diagnosis based on: Consensus (2 observers); final clinical diagnosis was based on agreement between the two observers. In case of disagreement, the
opinion of a third observer was considered to be the judge for the diagnosis
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’; described as “dermatologists with extensive experience in both clinical and dermoscopic diagnosis of
pigmented skin lesions”
Experience with dermoscopy: High experience /‘Expert’ users
#
Dermoscopy Pattern analysis
Method of diagnosis: In person diagnosis and image-based diagnosis. Clinical examination and in vivo dermoscopy were performed before excision by
two trained dermatologists and diagnosis reached. Dermoscopic images were re-analysed by the same two observers at the end of the inclusion period
(December 1998), blind to the previous clinical and histological diagnoses.
 
Prior test data: N/A for in-person; For image-based: slides of dermoscopic images were evaluated using a viewer that made it impossible to analyse the
clinical features of the lesion; both observers had access to clinical information, including the age of the patient, the site of the lesion, the history of change
over time as reported by the patient at the time of in vivo examination.
Diagnostic threshold: dermoscopic diagnosis was based on the ELM pattern analysis criteria, using the same diagnostic categories used for clinical
diagnosis; characteristics investigated included pigment network, pigmentation, hypopigmentation, brown globules, black dots, pseudopods, radial
streaming, grey-blue veil, atypical vascular pattern
Test observers as described for Visual Inspection (above)
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Target condition (Final diagnoses)
Melanoma (invasive): 40; Melanoma (in situ): 14
 BCC: 5
Sebhorrheic keratosis: 4; Benign naevus: 90 common melanocytic naevi; 78 melanocytic naevi; 9 blue naevi; 16 Spitz reed naevi
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
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Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
 Time interval to reference test: not reported
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative
In person clinical examination and dermoscopy
Time interval between index test(s): the interval between the time in-vivo dermoscopy and re-evaluation of dermoscopic images was reported as 1 year
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? No
Was the interval between application of the index tests less than one month? Yes
Are there any concerns that the test comparison could have introduced bias? Low risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Not reported




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Clinically suspicious or equivocal pigmented skin lesions undergoing excision for diagnostic purposes; only lesions with a diameter of 14
mm or less were included
 
Setting: Secondary (general dermatology)
Prior testing: Clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: Secondary (general dermatology)
Exclusion criteria: None reported
Sample size (patients): No. included: NR
Sample size (lesions): No. included: 57
Participant characteristics: None reported
Lesion characteristics: thickness ≤1mm: 11 cases (5 in situ 6 invasive); All <=14mm diameter
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: Clinical photographs; Fixed focus distance of 10cm; images observed using a viewer in two separate diagnostic sessions
Prior test data: No further information used; Contact (dermoscopic) images viewed first and then distant images (clinical), without knowing the classification
of the contact image of the individual lesions.
Diagnostic threshold: Not reported
Diagnosis based on: Consensus (2 observers); n=2
 
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’; States 'with experience in the field of PSL'
Experience with dermoscopy: High experience /‘Expert’ users; 'experienced in the field of PSLs'




Method of diagnosis: Dermoscopic images
Prior test data: No further information used; Contact (dermoscopic) images viewed first and then distant images (clinical), without knowing the classification
of the contact image of the individual lesions.
Diagnostic threshold: Not reported
Test observers as described for Visual Inspection (above)
Any other detail Dermaphot device placed directly on the lesion without previous application of oil; only lesions with a diameter of 14 mm or less were
included in the study. The image has an automatic, original magnification of x 10.
 
Visual Inspection - in-person
A. Risk of Bias
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B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histology (not further described) 
Disease positive: 21; Disease negative: 36
Target condition (Final diagnoses)
Melanoma (invasive): 6; Melanoma (in situ): 5; BCC: 10
'Benign' diagnoses: 36
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: No exclusions reported
Time interval to reference test: Photographic procedures performed consecutively prior to surgery
 
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative Photographic procedures performed consecutively prior to surgery
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? Yes
Was the interval between application of the index tests less than one month? Yes
Are there any concerns that the test comparison could have introduced bias? Low risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation
Period of data collection NR
 
Country Italy (from authors' institution)
 
Was a consecutive or random sample of patients enrolled? Unclear
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Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Melanocytic lesions <14 mm in diameter, excised because they were clinically suspicious or equivocal
 
Setting: Secondary (general dermatology)
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: Non melanocytic lesions
 
Sample size (patients): NR
Sample size (lesions): No. included: 200
Participant characteristics: None reported
Lesion characteristics: All < 14 mm in diameter
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy Pattern analysis; 7-point checklist; ABCD
Method of diagnosis: Dermoscopic images
Prior test data: No further information used; "Dermoscopic images were examined using a viewer"
Diagnostic threshold: For ABCD: >5.45; For the seven-point check-list: >=3; Pattern analysis: threshold not described
Diagnosis based on: Single observer (n=5); Average also presented
Observer qualifications: Dermatology residents working out of the pigmented lesion clinic: 3 working predominantly in the inpatient units and in mycology
laboratories, 1 working in dermato-allergology and 1 in the general outpatient units of the dermatology clinic.
Experience in practice: Low experience or recently qualified
Experience with dermoscopy: Low experience / novice users - considered as 'Trained'; All had undergone training in dermoscopy; one had previously
taken part in a study on dermoscopy based both on pattern analysis and on the ABCD rule while the others had had no previous experience in practical
dermoscopy during work in other fields of dermatology.
#
Dermoscopy training: Length of training 8 h formal lessons plus Interactive CD of Dermoscopy
 
Post-training experience: 4h practice at pigmented lesion clinic
Training format In-person teaching; CD-Rom tutorial;
Any other detail: images taken at x10 magnification using a Dermaphot (Heine Optotechnik, Germany) mounted on a Nikon F50 camera.
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? Unclear
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histology (not further described) 
Disease positive: 44; Disease negative: 156
Target condition (Final diagnoses)
Melanoma (invasive): 30; Melanoma (in situ): 14
Benign naevus: 156
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
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A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Reference interval not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less? Yes
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Clinically difficult to diagnose or equivocal melanocytic lesions randomly selected from image database; all melanomas less than 1mm
thickness.
 
Setting: Secondary (general dermatology)
Prior testing: Clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: Secondary (general dermatology)
Exclusion criteria: >/=1mm thick melanomas, non-melanocytic lesions, easy to diagnose, dermoscopically peculiar lesions (eg Blue nevi or Spitz nevi)
 
Sample size (patients): NR
Sample size (lesions): No. included: 200
Participant characteristics: None reported
Lesion characteristics ≤1mm thickness: 64; median thickness 0.3mm, 25th-75th centile 0.00-0.58mm; Mean diameter 7.4 (SD79) mm; Median: 7mm (2-
16mm)
Any other detail: Same lesions appear to be reported in De Giorgi 2011 but with a different set of 8 observers (De Giorgi 2011 excluded from review on this
basis)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: Clinical photographs
Prior test data: No further information used
Diagnostic threshold: Not reported
Diagnosis based on: Average; n= 8
 
Observer qualifications: Dermatology registrar; 2 final year residents. Dermatologist 6
Experience in practice: Mixed experience - 2 senior experts, 4 practicing dermatologists, 2 last year resident dermatologists. Both latter groups formally
trained in dermoscopy.
Experience with dermoscopy: Classified as 'high' due to expertise/training in dermoscopy use
Other detail: Any other detail Clinical photos using Nikon F40 with macro lens at 15cm.
#
 
Dermoscopy. No algorithm (own choice)
Method of diagnosis: Clinical photographs and dermoscopic images
Prior test data: Unclear
Diagnostic threshold: Not reported. All observers familiar with pattern analysis, ABCD and 7-point checklist, each was free to choose method of choice
Test observers as described for Visual Inspection (above)
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 64; Disease negative: 136
Target condition (Final diagnoses)
Melanoma (invasive): 40; Melanoma (in situ): 24
Other: 136 melanocytic nevi
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: No exclusions reported
Time interval to reference test: Interval not described
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? No
Was the interval between application of the index tests less than one month? Yes
Are there any concerns that the test comparison could have introduced bias? Low risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No





A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective image selection / Prospective interpretation. Each PLC provided up to 50 lesions with a 1:3 ratio of melanomas to nevi. Each
contributor randomly selected either polarized or non-polarized images based on 1:1 randomisation. Following exclusions, lesions were randomised into 12
image sets containing 39 (n = 8) or 40 (n = 7) unique lesions and 5 non-unique lesion images (2 melanoma, 3 benign) that were repeated in all sets.
Period of data collection NR
 
Country Multicentre (images contributed from PLCs in Australia, Austria, Germany, Italy, Spain, Switzerland, and the United States)
 
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Images of melanocytic lesions including melanomas with an unequivocal histopathologic diagnosis, and histopathologically verified nevi
or nevi demonstrating stability under sequential dermoscopic imaging over time.
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Setting: Specialist unit (skin cancer/pigmented lesions clinic) 12 PLCs
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: Acral, mucosal, or facial sites excluded; non-melanocytic appearance; Lesions with equivocal (final) diagnosis after review of the
pathology report or sequential imaging;
Sample size (patients): No. eligible: NR; No. included: NR
Sample size (lesions): No. eligible: 580 lesion images were contributed; No. included: 477 (103 excluded on review by Memorial Sloan Kettering Cancer
Center investigators)
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy 3-point rule; 7-point checklist; ABCD; Menzies criteria; Chaos and clues
Method of diagnosis: Dermoscopic images
Prior test data: Clinical image - Participants examined the close-up clinical image of each lesion before viewing the dermoscopic image; Image contributors
also asked to provide information on anatomical location, patient age and sex, and imaging modality (polarized vs nonpolarized) but unclear whether this
information was provided to observers or not.
Diagnostic threshold: Observers asked to evaluate "a comprehensive list" of dermoscopic structures abstracted from various algorithms; overlapping
criteria were merged into 1 criterion. Criteria were grouped into (1) global pattern, (2) pattern organization, (3) symmetry of contour, (4) symmetry of pattern,
(5) architectural disorder, (6) abruptness of lesion border, (7) colours, and (8) melanocytic structures, including network and vascular structures. Algorithm
performance was retrospectively assessed based on the following thresholds:7-point checklist - >=3; CASH - >=6; Menzies – NR; ABCD - >4.75; 3-point
checklist – NR; Chaos and clues NR. For NR thresholds, author communications state "We assessed all of the algorithms. There isn't a threshold for these
algorithms, there are just published rules of usage that determine the benign/malignant classification of the lesion"
Diagnosis based on: Consensus (>=50%) - when 50% or more of the observers identified a dermoscopic feature for a given study lesion, the attribute was
considered present; n= 130 (240 participants registered via the IDS website for the study; 103 completed all available images in their data sets and 130
evaluated >=20 lesions)
 
Observer qualifications: GP 24; Dermatology registrar 25; Dermatologist 73; 1 medical student and 7 'other'
Experience in practice: Mixed - mean 12 (SD 8.7) years of dermatology experience
Experience with dermoscopy: Mixed - 122 (93.8%) reported being comfortable using dermoscopy,and 121 (93.1%) were regular users of dermoscopy
Dermoscopy training: Algorithm tutorials were created and posted by dermoscopic experts through the International Dermoscopy Society (IDS) website;
review of these was encouraged but not mandatory.
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis plus follow up
Histology: All melanomas (n=119) and a proportion of benign lesions (n not reported)
Clinical FU plus histology of suspicious lesions: Sequential dermoscopic imaging over time'; not further detailed; Length of FU NR; nevi required to be either
histopathologically verified or to have demonstrated stability under sequential dermoscopic imaging over time.
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 119
Benign naevus: melanocytic nevus: 358
Is the reference standards likely to correctly classify the target condition? Unclear
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
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Flow and timing Excluded participants: Poor quality index test image as exclusion criterion
 
Time interval to reference test: NR
 
Time interval between index test(s): in-person; sequential
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC? Unclear
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less? Yes
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection 16 month period. Does not say the date
 
Country Germany
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Pigmented skin lesions undergoing excision due to diagnosis of melanoma or atypical nevus, to rule out melanoma or at the patient's
request. Paper states "Each of the three participating dermatologists in private practive sent their digital images via email attachment including anonymized
identification to the department of dermatology. (face to face diagnosis)
 
Setting: Secondary (general dermatology) (teledermatoscopy diagnosis); Private care- Face to face diagnosis
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): Not reported
Sample size (lesions): No. eligible: 90; No. included: 45
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
In person assessment (for those comparing FtF vs histology)
Method of diagnosis: Participating dermatologists with experience in dermatoscopy established a clinical diagnisis based on pattern analysis after personal
consultation with the patient in their private practice clinics.
Prior test data: Not reported
Diagnostic threshold: Not reported
Diagnosis based on: Single
Number of examiners: 3
Observer qualifications: Dermatologist (experts with great experience in dermoscopy)
Experience in practice: High
Experience with index test: High
Teledermatology
Acquisition and transmission of images: Each of the participating dermatologists acquired digital images after face to face consultation, and send them
via an email attachment with corresponding patient data and medical history.
Nature of images used: Clinical photographs and dermoscopic images
Any additional patient information provided: Clinical examination and/or case notes
Observer qualifications (remote diagnosis): Physician experienced in dermatoscopy
Diagnosis based on: Single observer
Method of diagnosis: A physician evaluated the images and made a diagnosis based on the images and history of the patient
Other detail: The participating dermatologists used the same technical equipment for the acquisition of digital images.
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
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For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard





Details: The histological diagnosis of majority of cases was performed at the Department of Dermatology Regensburg
 - No. patients/lesions: 45 patients; Disease positive: 16; Disease negative: 29
Target condition (Final diagnoses)
- Melanoma (invasive): 16; 'Benign' diagnoses: 29
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
1. Excluded participants: They reported that many images were of poor quality (10) and that only 45 biopsies were done 50 patients who did not have
histology excluded
 
2. Time interval to reference test:Unclear
 
3. Time interval between index test(s): most likely days (email transmission of images for remote assessment).
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Patients with pigmented lesions presenting during a campaign for the early diagnosis of cutaneous melanoma at the Dermatology
Department in Trento
 
Setting: Secondary (general dermatology)
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: Lesions that were not taken into consideration included benign lesions, naevi of Unna and Miescher types and naevi that showed no
inclusion criteria at the ABCDE clinical examination
 
Sample size (patients): No. eligible: 700 people; No. included: not reported
Sample size (lesions): No. eligible: 220; No. included: 220
Participant characteristics: None reported
Lesion characteristics: None reported
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Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Visual inspection (VI) ABCDE
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: lesions showing at least two of the ABCDE criteria all of which were shown the same diagnostic importance, were considered
positive.
Diagnosis based on: Unclear; n=4
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’; all trained in the recognition of pigmented lesions during a training course about the clinical diagnosis
of naevi and melanomas; all working in a department where the early diagnosis of melanoma had been dealt with for over 10 years.
Experience with dermoscopy: High experience /‘Expert’ users





Method of diagnosis: In person diagnosis
Prior test data: Clinical evaluation directly followed by dermoscopy
Diagnostic threshold: lesion positive for at least one criterion: irregular and multicomponent pigmentary network pattern, peripheral dark network patches,
sharp network margins, pseudopods(if network present), radial streaming (if network present), black dots at periphery (if network present), blue-grey areas
(if network present) and whitish veil (milky way, if network present).
Observers as described above.
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Target condition (Final diagnoses) TARGET CONDITION (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 33
Mild//moderate dysplasia: 23 dysplastic naevi; Sebhorrheic keratosis: 4; Benign naevus: 158 common naevus
 Other: 2 thrombosed angiomas
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing Excluded participants: No exclusions reported
Time interval to reference test: Not described
Time interval between index tests: clinical evaluation directly followed by dermoscopy
7/13/2018 #164 Dermoscopy, with and without visual inspection, for the diagnosis of melanoma in adults
https://archie.cochrane.org/popups/view.jsp?url=%2Fsections%2Fdocuments%2Fview%3Fdocument%3Dz150121160448282956572792131… 61/255
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative Clinical evaluation directly followed by dermoscopy
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? No
Was the interval between application of the index tests less than one month? Yes
Are there any concerns that the test comparison could have introduced bias? Low risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? Unclear





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective; dermoscopic images assessed remotely from the patient




Test set derived: "Training set" 218 pigmented lesions classified as: 45 melanomas (19 of which in situ), 38 epithelioid and/or spindle cell nevi; 45
melanocytc nevi; 45 mainly dermal melanocytic nevi."Test set"; 713 pigmented skin lesions-melanocytic in nature consecutively observed
 
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Pigmented skin lesions observed clinically and dermoscopically at the Institute of Dermatology Sciences University of Milan; all excised. 
 
Setting: Secondary (general dermatology)
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): NR
Sample size (lesions): No. eligible: test set - 713 PSLs; No. included: 713
Participant characteristics: Not reported
Lesion characteristics: Not reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy 7FFM (own new algorithm)
 
Method of diagnosis: Dermoscopic images
Prior test data: No further information used
Diagnostic threshold: The lesions where the sum of the features gave a score >=2 were diagnosed as being malignant.
Diagnosis based on: Consensus (3 observers); n= 3
 
Observer qualifications: Not reported; appears to be the three co-authors; likely expert dermatologists
Experience in practice: Not described
Experience with dermoscopy: Not described
Any other detail: Training set of 218 pigmented lesions used to develop new algorithm. All dermoscopic features recorded. Statistical significance of each
feature assessed using Chi square test and Fischer's exact test. Final features chosen according to reproducibility by different observers and relationships
with histopathological criteria predictive of malignancy. Final algorithm: To diagnose melanoma the presence of one major feature or the concurrent
presence of two minor features is regarded as sufficient. "We attributed a score of 2 to the major features and a score 1 to the minor features: major features
are regression erythema, radial streaming, gray-blue veil, irregularly distributed pseudopods; minor features are unhomogeneity, irregular pigment network,
sharp margin."
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
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Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 168; Disease negative: 545
Target condition (Final diagnoses)
Melanoma (invasive): 139; Melanoma (in situ): 29; BCC: 1
Sebhorrheic keratosis: 3; Benign naevus: Junctional melanocytic nevi-92; Mainly junctional compound melanocytic nevi-37; Compound melanocytic nevi-
224; Congenital melanocytic nevi-20; Melanocytic nevi showing regression and inflammatory infiltrate-102; Combined melanocytic nevi-8; Epithelioid and/or
spindle cell nevi-53;Lentigo simplex-3; Black reticulated solar lentigo-1; Melanoacanthoma-1
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
 
Time interval to reference test: none reported
  
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Melanocytic skin lesions that underwent excision
 
Setting: Secondary (general dermatology)
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Secondary (general dermatology)
Exclusion criteria: acral and mucosal lesions; dysplastic nevi excluded; Disagreement between evaluators on tumour histological classification - lesions
that did not meet at least two consents were excluded; Poor quality index test image (considered under flow and timing)
Sample size (patients): No. included: 125
Sample size (lesions): No. included: 125
Participant characteristics: Mean age: men 44.6y and women 50.0y; Male: 61; 58%
 Lesion characteristics: Thickness ≤1mm: all 32 melanomas
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match the review question? High
Index Test
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Index tests Dermoscopy 3-point checklist; scored 3-point '4-point checklist' (authors own scoring); CASH algorithm
Method of diagnosis: Dermoscopic images
Prior test data: No further information used
Diagnostic threshold: 3-point checklist - >= 2 criteria present; CASH score>7; 4-point checklist >2
Diagnosis based on: Unclear; lesions were "randomly assessed by two independent dermatologists" not clear if average or consensus; n= 2
 
Observer qualifications: Dermatologist
Experience in practice: High
Experience with dermoscopy: High - dermatologists with over 7 years of experience in dermoscopy
Any other detail:
The 3-point checklist criteria: asymmetry in colour and/or structures in one or two axes, pigmented network with thickened lines and irregular distribution,
and any blue and/or white structure within the lesion.
CASH algorithm has four criteria: colour, architectural disorder, symmetry and homo/heterogeneity. Scoring described in detail.
4-point checklist - doubled all three criteria of the 3-point checklist and chose the one conferring more sensitivity, specificity and accuracy (symmetry
parameter doubled).
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? Unclear
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
All lesions were excised and independently analysed by two dermatopathologists. The diagnosis of dysplastic nevus was based on the histopathological
diagnostic criteria set by the World Health Organization Melanoma Programme.3 It was considered as a benign lesion
 Disease positive: 32; Disease negative: 93
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 32
Mild//moderate dysplasia: 50; Benign naevus: 43
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: Dysplastic nevi (n=50) excluded from 2x2; Poor quality index test images - exclusion criterion
Interval between index and reference standard: Not clearly described
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less? Yes
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
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Patient Selection
A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Dermoscopy training study using a CD with five test sets of images, each with 40 images of melanocytic skin lesions. Only good-quality
macroscopic and dermoscopic images were included.
 
Setting: Specialist unit; Victorian Melanoma Service, Department of Dermatology, University of Melbourne
Prior testing: unclear
Setting for prior testing: Not reported
Exclusion criteria: Nonmelanocytic lesions; Poor quality index test image. Only good-quality macroscopic and dermoscopic images were included, where
the whole lesion was visible, including the entire periphery (considered under flow/timing)
Sample size (patients): NR
Sample size (lesions): No. eligible: 40; No. included: 40
Participant characteristics: None reported
Lesion characteristics: ≤1mm thickness: 14 invasive melanomas; median 0.50 mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Visual inspection (VI): No algorithm
Method of diagnosis: Clinical photographs alone
Prior test data: No further information used
Other test data: Dermoscopic images presented to observer subsequent to diagnosis using clinical images alone.
Diagnostic threshold: Not reported
Diagnosis based on: Average; 61 participants (invited to participate in a study comparing dermoscopic algorithms; advertised at several medical meetings
and on a Web site for primary care physicians).
 
Observer qualifications: 10 dermatologists, 16 dermatology trainees, 35 GPs
Experience in practice: Mixed. Participant (volunteers) "had a range of experience levels with assessment of skin lesions [outlined in detail in the paper] ..
and a significant number were novices in dermoscopy”. Paper reports 82% of participants responded that they assessed at least 2-4 PSL per week.
Experience in dermoscopy: Mixed (as above); some educational material provided
#
Dermoscopy: Pattern analysis; 7-point checklist; ABCD; Menzies criteria
Method of diagnosis: Dermoscopic images
Prior test data: No further information used. Macroscopic image not shown.
Diagnostic threshold: ABCD rule--lesions scoring > 4.75 (i.e. lesions 'of concern' were considered test positive along with those considered to be
melanomas, scoring >5.45); thresholds not reported for the other algorithms (original studies referenced).
Test observers as described for Visual Inspection (above)
#
Dermoscopy training: Participants were given explanatory written material as well as 3 compact discs (CDs). Two CDs contained educational material on
dermoscopy, one from the American Academy of Dermatology and the other from the Web site www.dermoscopy.org. Participants were advised to work
through all the educational material prior to assessing the test set of images.
 
Length of training: not clear
 
Post-training experience: <6 months
Training format Online/ Written materials/CD-Rom tutorial
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - image-based
A. Risk of Bias
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Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? Unclear
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis plus other (one lesion described as having no biopsy performed)
Histology (not further described) Disease positive: 20; Disease negative: 19
Expert dx: 1
Target condition (Final diagnoses)
Melanoma (invasive): 18; Lentigo maligna 2
Benign naevus: 7 dysplactic nevi; 3 spitz nevi; 3 junctional nevi; 2 compound nevi; 4 other (ink-spot lentigo, blue nevus, solar lentigo, ephelis)
Is the reference standards likely to correctly classify the target condition? No
Were the reference standard results interpreted without knowledge of the results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have introduced bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard No
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? High
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
 
Time interval to reference test: not reported
 Time interval between index test(s): not reported
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC? Unclear
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? Yes
Was the interval between application of the index tests less than one month? Unclear
Are there any concerns that the test comparison could have introduced bias? Unclear risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective




Test set derived Study focuses on test set but gives detail of separate study in which classifier was trained
 
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Patients presenting at pigmented skin lesion clinic
 
Setting: Specialist unit (skin cancer/pigmented lesions clinic) The pigmented skin lesion unit of the Department of Dermatology at the Medical University of
Vienna serves as a secondary and tertiary referral center.
Prior testing: Not reported
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: None reported
Sample size (patients): No. eligible: 511; No. included: 458 with complete information
Sample size (lesions): No. eligible: 3827; No. included: 3021; however data reported on a per patient basis
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? Yes
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Did the study avoid including participants with multiple lesions? Yes




Method of diagnosis: In person diagnosis; physicians were instructed to perform an independent routine examination on
 the study participants
Prior test data: Clinical examination and/or case notes
Diagnostic threshold: Not reported; decision to excise to rule out melanoma histopathologically
Diagnosis based on: Single observer (n=1)
 
Observer qualifications: Dermatologist; data reported for 6 additional less experienced observers using MoleMax II system (reported in CAD review)
Experience in practice: High experience; "Expert dermatologist"
Experience with dermoscopy: High experience
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis plus follow up
Histology (excision); No. patient/lesions: Not reported
Clinical FU plus histology of suspicious lesions Length of FU: 6 months; No. patients: Not reported
TARGET CONDITION (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 27 patients; 31 lesions
'Benign' diagnoses: 431 patients; 2990 lesions
Is the reference standards likely to correctly classify the target condition? Unclear
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: 806 lesions (53 patients) with inadequate follow-up
Index test to reference standard interval: 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC? Yes
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
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Patient Sampling Study design: Case series
Data collection: Retrospective




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Excised lesions recorded on pigmented lesion clinic database with data supplemented with hospital PAS and pathology database.
 
Setting: rapid-access PLC at Frenchay Hospital
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: None reported
Sample size (patients): No. eligible: 9968 attended clinic during time period; No. included: NR
Sample size (lesions): No. included: 2372 (1256 undertaken immediately)
Participant characteristics: Male: 40% (n=950)
Lesion characteristics: Mean thickness of melanomas reported graphically pa (all estimates are appoximate):1993 - 1.44mm; 1994 - 0.82mm; 1995 -
1.22mm; 1996 - 1.40mm; 1997 - 1.35; 1998 - 0.90mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear




Method of diagnosis: In person diagnosis
Prior test data: Clinical examination and/or case notes
Diagnostic threshold: Not reported; Diagnosis of melanoma
Diagnosis based on: Single observer; (n= 2 as reported in Kirkpatrick 1995)
 
Observer qualifications: Plastic surgeons
Experience in practice: NR
Experience with dermoscopy: Not described; "A consultant examines all lesions with a dermatoscope."
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histology alone; histopathologist with special interest in melanoproliferative lesions
Disease positive: 586; Disease negative: 1786
Target condition (Final diagnoses) 
Melanoma (invasive): 400; Melanoma (in situ): 186 (128 In situ 58 LMs)
 BCC: 316; cSCC: 97
Atypical/dysplastic 195; "other" 14; 'Benign': 1164
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
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Flow and timing Participant exclusions: None reported
Index test to reference standard interval: Not all lesions were excised immediately (2372 excisions were undertaken, of which 1256 were done
immediately
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective; dermoscopic images assessed remotely from the patient




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Patients with skin lesions difficult to diagnose clinically
 
Setting: Secondary
Prior testing: Clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic) a type of specialist care- dermatology based clinic
Exclusion criteria: Patients who had excisions performed in individual practices or where there was no histology or cases that were so obvious they didn't
need to have further investigation (clearly benign)
 
Sample size (patients):
Sample size (lesions): No. eligible: 824; No. included: 771
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Visual inspection: No algorithm
Method of diagnosis: In person
 
Prior test data: In person
Other test data: Dermoscopic images viewed separately
Diagnostic threshold: NR
 
Diagnosis based on: Single observer; (n=2 or 3)
 Observer qualifications: Unclear; clinician based in Dermatology clinic (assumed Dermatologist)
Experience in practice: Unclear
Experience with index test: Unclear
#
Dermoscopy: Pattern analysis
Method of diagnosis: Dermoscopic images
Prior test data: Unclear
Diagnostic threshold: Not reported
 
Observers: as described above
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - in-person
A. Risk of Bias
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B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 23MM; Disease negative: 748 benign
Target condition (Final diagnoses)
Invasive melanoma: 23
 Benign naevus 706; Sebhorrheic keratosis 4; Benign non-melanocytic naevus 32
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? No
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: 53 non-melanocytic lesions not included in the final analysis (no melanomas present in this group)
 
Time interval to reference test: Not reported
 Time interval between index test(s): Not reported
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Pigmented skin lesions that could not be diagnosed with only dermatologic physical examination
 
Setting: Secondary (general dermatology)
Prior testing: Clinical examination and dermoscopy
Setting for prior testing: Secondary (general dermatology)
Exclusion criteria: None reported
Sample size (patients): No. included: 176
Sample size (lesions): No. included: 200
Participant characteristics: Mean age: 48y (4 to 85y). Male: 64; 36.4%
Lesion characteristics: 9% nodulo-ulcerative, 56% papular, 17% macular, 10% nodular, 8% plaque.
Are the included patients and chosen study setting appropriate? Yes
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Did the study avoid including participants with multiple lesions? No




Method of diagnosis: In person diagnosis
Prior test data: Clinical examination
Diagnostic threshold: Two step process: step 1 melanocytic and non melanocytic were differentiated (Braun 2005; Zalaudek 2008); step 2 ABCD applied
to melanocytic lesions only (threshold >5.45)
Diagnosis based on: Single observer; n= 2; one for dermoscopy diagnosis and one for Tzanck smear
 
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with dermoscopy: Not described
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone (Excisional biopsies (n=166) or punch biopsy (n=34)
Details: "Biopsy specimens were stained with hematoxylin and eosin. Immunohistochemical (anti-S-100 and human melanoma black [HMB]-45) and
histochemical (Fontana-Masson) stains were also applied, if necessary"; interpretation by a 'pathologist'
Disease positive: 46; Disease negative: 154
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not reported): 10; BCC: 34; 1 pigmented mammary Paget disease; 1 pigmented metastatic mammary carcinoma
Sebhorrheic keratosis: 24; Benign melanocytic naevus: 100; Dermatofibroma 12; Warts 16; 1 Dirt; 1 hereditary hemorrhagic telangiectasia
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Time interval to reference test: appears consecutive. Following dermoscopic examination and cytology "either a punch or an excisional biopsy specimen
was taken from the lesions and was examined histopathologically"
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
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A. Risk of Bias
Patient Sampling
Study design: Randomised controlled trial of the effect of ambient stressors and time constraints on decision making; PSL images were randomised to
control group, ambient stress group and time stress* group (*result included in main analysis)
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Pigmented skin lesions suspicious for melanoma and with histopathological diagnoses
 
Setting: Secondary (general dermatology)
Prior testing: Clinical and/or dermatoscopic suspicion of melanoma or atypical
Setting for prior testing: Secondary (general dermatology)
Exclusion criteria: Not clearly reported however only melanomas and atypical nevi included
Sample size (patients): No. included: Appears to be one lesion per patient - 'consecutive PSL removed from different patients'
Sample size (lesions): No. included: 321; 102 in time stress group
Participant characteristics: None reported
Lesion characteristics: mean thickness 0.28 mm, range - in situ to 1.88 mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes




Method of diagnosis: Dermoscopic images
Prior test data: No further information used; "dermatologists "knew neither the aim of the study nor the number of nevi and melanomas within each sample
group
Diagnostic threshold: Not reported
Diagnosis based on: Unclear; Appears to be single (and different) observer per arm of the trial (n=3). The time stress group "simulated clinical decision
making by arbitrarily allowing a time of 10s for the evaluation of each PSL" using Microsoft Power Point slide show
Observer qualifications: Dermatologist
Experience in practice: High experience
Experience with dermoscopy: High experience; described as 'expert dermatologists' 'with at least 10 years experience in dermoscopy'
Any other detail Dermoscopic image acquisition was performed using DermLite ® II pro (3Gen; DermLite, San Juan Capistrano,Calif., USA) connected to a
Cyber-shot 7.2 megapixel camera(Sony Inc., Tokyo, Japan).
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Details: Diagnosis was based on AJCC guidelines (Balch 2001) and always made by the same pathologist
 Disease positive: 102 (34 per arm); Disease negative: 219 (73 per arm)
Target condition (Final diagnoses) 
Melanoma (invasive): 69 (33 per arm); Melanoma (in situ): 33 (11 per arm)
Benign naevus: Benign melanocytic nevi 219
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
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Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: Appear to have excluded on image quality "Among 686 PSL dermoscopic images acquired during the study period, 321 were
suitable for our study"
 
Time interval to reference test: NR
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Melanocytic lesions examined by dermatoscopy prior to excision
 
Setting: Secondary (general dermatology)
Prior testing: Not reported; "selection for excision was not exclusively based on the dermatoscopic findings but also according to the wishes of the
patients."
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): Not reported
Sample size (lesions): No. included: 500
Participant characteristics: None reported
Lesion characteristics: Mean Breslow thickness 0.49mm, range 0.12 to 1.38mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear




Method of diagnosis: In person diagnosis
Prior test data: Clinical examination
Diagnostic threshold: From Nachbar's study >5.45; from study results >4.2
Diagnosis based on: Unclear; n= unclear
 
Observer qualifications: Not reported
Experience in practice: Not described
Experience with dermoscopy: Not described
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Visual inspection - image-based
7/13/2018 #164 Dermoscopy, with and without visual inspection, for the diagnosis of melanoma in adults
https://archie.cochrane.org/popups/view.jsp?url=%2Fsections%2Fdocuments%2Fview%3Fdocument%3Dz150121160448282956572792131… 73/255
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Deatils: histology was performed with at least three incisions (naevi), and serial sections through the entire lesion (melanomas) . The assessment was
based on the generally accepted criteria for dysplasia and malignancy [1, 4]. In the case of diagnostic uncertainties, the Austrian reference center for
histopathological diagnostics carried out a second assessment.
Disease positive: 30 MM; Disease negative: 470
Target condition (Final diagnoses)
Melanoma (invasive): 25; Melanoma (in situ): 5
Mild//moderate dysplasia: 190; Benign naevus: 272; 7 Lentigines 1 lentigo nevi
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: Results not presented for 8 lesions
 
Time interval to reference test: Appears consecutive; dermoscopy described as used "prior to ... excision and histolog(y)"
 
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC? Unclear
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Melanocytic lesions with equivocal clinical and/or dermoscopic features that underwent excision and had a complete set of dermoscopy
and RCM images with histopathology report. [Only dermoscopically featureless (scoring 0-2 on 7-point checklist) or equicocal lesions (those scoring 3-4 on
dermoscopy 7-point checklist) were included in RCM evaluation.]
 
Setting: Secondary (general dermatology)
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Secondary (general dermatology)
Exclusion criteria: Incomplete histopathology report; 90 ‘positive-clear cut’ lesions (scoring 5 or more on 7-point checklist) were excluded from RCM
evaluation
 
Poor quality index test image "Only lesions with high quality dermoscopic images, a complete set of confocal images and histopathology report available
were included in the study"; considered under flow and timing. 
 
Sample size (patients): No. included: NR
Sample size (lesions): No. eligible: 322; No. included: 322 for dermoscopy; 232 for RCM
Participant characteristics: None reported
Lesion characteristics: Overall mean thickness 1.05 +/- 16 mm, range 0–10 mm (70 melanomas); Those scoring 0-2 on 7-point checklist: mean 0.18 +/-
0.42 mm; range 0–0.94 mm) (6 melanomas). Those scoring 3-4 on 7-point checklist: mean 0.36 +/-0.42, range 0-1.4mm (17 melanomas)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
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Index tests Dermoscopy: 7-point checklist
Method of diagnosis: Dermoscopic images
Prior test data: RCM and dermoscopy images interpreted by same observer; no indication of randomisation or interpretation in isolation
Diagnostic threshold: ‘Featureless’ lesions for score ranging between 0 and 2, ‘positive-borderline’ lesions for score between 3 and 4 and ‘positive- clear
cut’ lesions for score from 5 to 10.
Diagnosis based on: Single observer (n= 1)
 Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with dermoscopy: Assumed to be High - Described as "dermatologist trained in dermoscopy and RCM"
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Deatils: Histopathology was performed by a Board Certified Pathologist
Disease positive: 70; Disease negative: 252
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not reported): 70
'Benign' nevi: 252 (including 15 Spitz nevi)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: "Only lesions with high quality dermoscopic images, a complete set of confocal images and histopathology report available were
included in the study"
 
Time interval to reference test: Images taken 'before excision' "Before excision, all lesions were recorded by means of digital
 dermoscopy and RCM"
 
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling Study design: Unclear. Some dermoscopic images were collected prospectively and some were obtained from collection of existing images; selection
process not described.
Data collection: Retrospective image selection / Prospective interpretation
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Test set derived. Study developed a new CAD classifier using training/test set of images; plus a Reader study* conducted to compare accuracy with
dermatologist interpretation of images (*reported here). Some dermoscopic images used to train the classifier were obtained from publicly available or
purchased image libraries, these were not included in the reader study or used to test the performance of the classifier. The image set was randomly divided
into 2 by diagnosis, with half used for training and half used for testing, with the exception that all high-grade dysplastic nevi were exclusively assigned to the
training set to increase the representation of dermoscopic features that could be present in melanoma. Results are extracted only for the test set.
 
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Dermoscopic images of skin lesions excised on the basis of clinical suspicion of malignancy, with available histologic diagnoses. Reader
study included one melanoma that was misclassified as benign by the new CAD classifier plus random sample of images determined to be of suitable
quality for display on a computer screen.
Setting: Secondary (general dermatology)
Prior testing: Clinical suspicion (no further detail)
Setting for prior testing: Secondary (general dermatology)
Exclusion criteria: High-grade dysplastic nevi were not included in the test set or Reader study
 
Sample size (patients): No. eligible: not reported; No. included: not reported
Sample size (lesions): No. eligible: 473 (includes 273 randomised to training set and 27 non-biopsied lesions); No. included: CAD test set 173 lesions;
Dermscopy- 65 lesions
Participant characteristics: None reported
Lesion characteristics: Test set: mean lesion thickness 0.76 mm, median 0.5 mm, range 0.2-98 mm); Reader study: mean 0.93 mm, median 0.74 mm,
range 0.2 to 98 mm.
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear




Method of diagnosis: Dermoscopic images
Prior test data: No further information used
Diagnostic threshold: Not reported
Diagnosis based on: Average (n=30); 35 invited to participate. 
 
Observer qualifications: 2 board certified dermatologists, 10 dermatology residents, and 8 physician assistants currently practicing dermatology
Experience in practice: Mixed
Experience with dermoscopy: Mixed; all observers self reported some training and experience with the use of dermoscopy. Among board certified
dermatologists, 67% reported using dermoscopy ‘‘always/almost always’’ or ‘‘very frequently.’', compared to 90% of the dermatology residents and 75% of
the physician assistants.
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Details: All lesions were biopsied based on clinical suspicion of malignancy. All histologic diagnoses were rendered by at least 1 board-certified
dermatopathologist and were used as the reference standard for diagnosis
 Disease positive: Derm 25MM; CAD 39MM / Disease negative: Derm=40; CAD= 134
Target condition (Final diagnoses)
For Reader study only:
Invasive melanomas 15; Melanoma in situ 10 in situ
Low-grade dysplastic nevi 16, benign nevi 14 , blue nevi 2, lentigines 4 , seborrheic keratoses 4
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
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Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
 
Time interval to reference test: 'Dermoscopic images of skin lesions were collected before biopsy'
 
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective image selection / Prospective interpretation




Test set derived MelaFind data randomly split into training and test sets however Melafind has previously been evaluated, the only difference here being
that only small lesions were included. Full dataset included in review
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: A database of images of pigmented skin lesions <=6mm was used to sample images of melanoma and non melanoma lesions;
"approximately 80% of the lesions were biopsied to rule out melanoma, whereas the remaining lesions were biopsied mostly to rule out nonmelanoma skin
cancer or because of patient concern."
 
Setting: Mixed (private and secondary); digital dermoscopic database acquired by Electro-Optical Sciences Inc for the development and testing of
MelaFind; 26 clinical sites have contributed (Dermatologic hospital-based clinics and private practice offices).
Prior testing: Selected for excision (no further detail). All lesions excised or underwent shave biopsy
Setting for prior testing: Not reported
Exclusion criteria: High-grade dysplastic nevi were excluded. Previously biopsied, ulcerated, or bleeding lesions also excluded, as were those on mucosal
surfaces and lesions that contained foreign matter (eg, tattoos).
 
Sample size (patients): No. included: 94
Sample size (lesions): No. eligible: 1977; No. included: 99
Participant characteristics: None reported
Lesion characteristics 21 invasive MM: median thickness 0.32mm (0.10, 1.40mm). Lesion size: Range: 2mm to 22mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes




Method of diagnosis: Dermoscopic images. Readers were provided with a CD-ROM with colour dermoscopic images created using MelaFind multispectral
image; for some cases standard dermoscopic images were also available. The equivalence of the two image types was assessed for a sample of 10 lesions
by 3 readers.
Prior test data: Readers provided with participant gender, age, and lesion location; All evaluations were performed independently.
Diagnostic threshold: Clinical diagnosis; “Is this lesion a melanoma?” and “Would you biopsy/excise this lesion?”. If readers indicated that they would
biopsy the lesion because they were sure it was melanoma or to rule out melanoma, then the case was considered true positive (TP)
Diagnosis based on: Average; mean and median reported (n=10); used mean value for review purposes
Observer qualifications: 9 dermatologists; 1 nurse practitioner specializing in dermatology
Experience in practice: High experience or ‘Expert’; "All 10 readers were expert dermoscopists (9 dermatologists and 1 nurse practitioner specializing in
dermatology)
Experience with dermoscopy: High experience /‘Expert’ users
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
7/13/2018 #164 Dermoscopy, with and without visual inspection, for the diagnosis of melanoma in adults
https://archie.cochrane.org/popups/view.jsp?url=%2Fsections%2Fdocuments%2Fview%3Fdocument%3Dz150121160448282956572792131… 77/255
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard: Histological diagnosis alone
Deatils: The original histology slides were evaluated by 2 out of 4 study dermatopathologists without knowledge of any additional clinical information; in
cases of significant discordance in diagnoses, the slide was reviewed by a third study dermatopathologist. A lesion with at least 1 diagnosis of melanoma by
the study dermatopathologists is considered melanoma. Dysplastic nevi with severe cytologic atypia were considered high grade, and those with mild to
moderate atypia were considered low grade.
Disease positive: 49; Disease negative: 50
Target condition (Final diagnoses)
Melanoma (invasive): 21; Melanoma (in situ): 28; BCC: 2
Mild/moderate dysplasia: 32 low grade dysplastic; Sebhorrheic keratosis: 2; 14 other benign
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Timing between image acquisition and original histology not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Images of melanoma and nonmelanoma pigmented skin lesions; nonmelanoma lesions clinically considered to be atypical before
dermoscopic examination and excisional biopsy. Atypicality was determined by the presence of at least three of the following features: a diameter greater
than 5 mm, ill-defined borders, irregular margins, and the presence of papular and macular components. Melanoma and nonmelanoma lesions separately
sampled
Setting: Secondary (general dermatology) Auth inst: dept Dermatology, Istanbul, Turkey
Prior testing: Clinical suspicion of malignancy
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): Not reported
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Sample size (lesions): No. included: 96
Participant characteristics: None reported
Lesion characteristics: All > 5mm diameter
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy: 3-point rule; 7-point checklist
Method of diagnosis: Dermoscopic images
Prior test data: No further information used
Diagnostic threshold: 3-point rule: >=2 chars present (asymmetry, atypical pigment network, blue-white structures); 7-point checklist: >=3 chars present
(Atypical pigment network, blue-whitish veil, atypical vascular pattern, irregular streaks, irregular dots/globules, irregular pigmentation, regression structures)
Diagnosis based on: Average (n=3)
 
Observer qualifications: Not reported; likely dermatologists (co-authors based in dept Dermatology)
Experience in practice: Mixed: "two experienced and one inexperienced observers"
Experience with dermoscopy: Mixed 
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? Unclear
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone (no further details)
Disease positive: 48; Disease negative: 48
Target condition (Final diagnoses)
Melanoma (invasive): 44 (14 superficial spreading, 12 nodular, 10 acral, 4 lentiginous, 4 without classification of tumour thickness); Melanoma (in situ): 4
Sebhorrheic keratosis: 2; Blue nevi 2; Melanocytic nevi 44
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Not described
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes  




A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation




Test set derived: Not reported. Training set: 65 melanomas and 65 dysplastic naevi, Test set:36 melanomas and 33 dysplastic naevi (included in review).
 
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Atypical melanocytic lesions with polarised dermoscopic images; describes database as a "random, but representative, cohort" but does
not describe method of selection
Setting: Secondary (general dermatology)
Prior testing: Unclear
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): No. included: NR
Sample size (lesions): No. included: 199: Derivation set n=130 Test set n= 69
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear





Method of diagnosis: Dermoscopic images
Prior test data: No further information used; described as blinded assessment
Diagnostic threshold: Not reported - subjective impression; excise or not
Diagnosis based on: Single observer (n=1)
 
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with dermoscopy: Not described; implies High or expert assessment. Conducted by one of the co-authors.
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Details: "lesions were excised and examined microscopically by expert dermatopathologists using standard histopathologic diagnostic criteria"
Disease positive: 36=test set and 65=derivation set
 Disease negative: 33=test set and 65=derivation set
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 36 test set and 65 derivation set
Dysplastic naevi: 33 test set and 65 derivation set
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
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B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Not described
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective; dermoscopic images assessed remotely from the patient




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Patients referred for excision biopsy of pigmented lesions where the diagnosis of melanoma could not be excluded on clinical
investigation
 
Setting: Secondary (other); Dept Plastic Surgery and Burn Unit
Prior testing: Clinical suspicion of malignancy
Setting for prior testing: Secondary (not further specified)
Exclusion criteria: None reported
Sample size (patients): No. included: 65
Sample size (lesions): No. included: 83
Participant characteristics: Median age 47 yrs (18 to 90y); Male - 29; 45%
Lesion characteristics: melanoma thickness 0.29 mm to 18mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No




Method of diagnosis: Dermoscopic images
Prior test data: No further information used
Diagnostic threshold: Not reported - diagnosis of melanoma
Diagnosis based on: Single observer (n=1)
 
Observer qualifications: Dermatologist
Experience in practice: High
Experience with dermoscopy: High experience; "dermoscopic images were examined by an experienced dermatologist"
Any other detail The dermoscopic and SIAgraphic images were obtained by SIAscope II (Amon Clinica, Cambridge, UK) and stored using the proprietary
Dermetrics software (Astron Clinica).
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
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A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Details: Following image acquisition "the excision biopsy was performed and an experienced histopathologist examined the tissue". Breslow thickness and
Clark level were determined by standard histopathologic examination. Tumor staging was performed as described by Balch et al according to the 2001
melanoma staging system (Balch 2001).
 Disease positive: 12; Disease negative: 71
Target condition (Final diagnoses)
Melanoma (invasive): 7; Melanoma (in situ): 5; 1 melanoma metastasis (incl as benign)
Sebhorrheic keratosis: 1; Benign naevus: 57; 'Benign' diagnoses: bowens 1 haemangioma 1 lentigo simplex 2 epidermal naevi 2 DF 6
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Following image acquisition "the excision biopsy was performed"
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Not reported.




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Patients with melanocytic and non-melanocytic skin lesions excised due to dermoscopic suspicion of malignancy or dysplasia .
 
Setting: Secondary (general dermatology)
Prior testing: Not reported
Setting for prior testing: Unspecified
Exclusion criteria: None reported
 
Sample size (patients): No. eligible: 1264; No. included: 362
Sample size (lesions): No. included: 449
Participant characteristics: Mean age 40.3 yrs (+/- 1.08), range 1 to 89 yrs; Male: 160; 44.2%
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests Dermoscopy No algorithm
Method of diagnosis: Unclear; appears to be in-person diagnosis
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Prior test data: Clinical examination
Diagnostic threshold: Not reported; diagnosis of melanoma
Diagnosis based on: Unclear (n=NR)
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with dermoscopy: High experience - at least 2 years experience with Molemax II.
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Unclear
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone; not further described 
Disease positive 13; Disease negative 433
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 13; BCC: 45
Benign: Not described
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
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B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Cutaneous pigmented lesions with digital images forwarded by primary care physicians to a referral centre for confirmation of diagnosis.
 
Setting: Primary; Lesions selected for referral by GPs; accuracy of GP diagnosis assessed
 
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: Lesions whose removal had been explicitly demanded by the patients for aesthetic reasons, as well as those irritated or subjected to
trauma
 
Sample size (patients): No. included: 197
Sample size (lesions): No. included: 235
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Visual inspection (VI); No algorithm
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Other test data: "two-step judgment (before and after dermoscopy) formulated by the sending physician, who labelled each lesion as ‘benign’ or ‘suspicious
for malignancy’."
Diagnostic threshold: Not reported "Each physician was asked to formulate a written first judgment of every lesion before digital acquisition and to re-
evaluate it after dermoscopy"
Diagnosis based on: Single observer; (n= 13)
 
Observer qualifications: GP; From approximately 250 primary care clinicians attending a conference, 13 volunteered to participate
Experience in practice: Not clearly described; assumed to be Low experience with pigmented lesions
Experience in dermoscopy: Unclear; classified as 'trained' - “simple protocols for diagnosis were made up and given to the participants via e-learning




Method of diagnosis: In person diagnosis
Prior test data: Clinical examination and/or case notes
Diagnostic threshold: NR - "The evaluation method followed the ABCD rule of dermoscopy according to Nachbar et al"; not fully clear whether this relates
to GP in-person diagnosis or telediagnosis at reference centre - "two-step judgment (before and after dermoscopy) formulated by the sending physician,
who labelled each lesion as ‘benign’ or ‘suspicious for malignancy’."
#
Dermoscopy training: "During the first phase of the study, simple protocols for diagnosis were made up and given to the participants via e- learning
courses, direct meetings, and involving self- assessment procedures (Pagnanelli 2003)"
 
Length of training NR
 
Training format: Online/ In-person teaching/ Self assessment procedures
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis plus follow up (Reference is expert diagnosis for Teledermatology component of study)
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Histology (not further described): n=16; Disease positive: 5; Disease negative: 11
Clinical FU (6 months) plus histology of suspicious lesions: n=219; Disease positive: 0; Disease negative: 208
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 5
Other: 230 benign
Is the reference standards likely to correctly classify the target condition? No
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: NR
 Time interval to reference test: NR
 Time interval between index test(s): NR
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC? Yes
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? No
Was the interval between application of the index tests less than one month? Yes
Are there any concerns that the test comparison could have introduced bias? High risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? Yes





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: Sept 2004 - Aug 2007
 
Country: Italy (and Australia - see Guitera 2009b (Sydney))
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Lesions suspicious of melanoma based on dermatoscopic diagnostic criteria or lesion change; included only a random sample of 50% of
benign nevi observed during time period
 
Setting: Secondary (general dermatology); Department of Dermatology, University of Modena, Italy
 
Prior testing: Clinical and/or dermatoscopic suspicion/Changes on digital monitoring
Setting for prior testing: Secondary (general dermatology)
Exclusion criteria: Location/site of lesion lesions on soles/palms excluded; Lentigo maligna excluded; lesions used in previous assessments or RCM model
development
 
Sample size (patients): No. included: 195
Sample size (lesions): No. included: 195
Participant characteristics: Median age: 42 (7 to 88yrs); IQR 32, 59; Male: 51.3%
Lesion characteristics: Pigmented: 92%; 8% amelanotic lesions or those with tan, light gray, or pale blue pigment only). Median thickness 0.65mm (IQ 25,
75: 0.23, 0.98)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests Dermoscopy Pattern analysis
 
Method of diagnosis: In person diagnosis; at time of first consultation and prior to RCM
 
Prior test data: Clinical examination
Diagnostic threshold: Not reported
Diagnosis based on: Single observer (n=1)
 
Observer qualifications: Dermatologist; Not clearly reported, but is study co-author
Experience in practice: High experience
Experience with dermoscopy: High experience; described as Modena expert based in Dermatology Dept
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Other detail: hand-held dermoscope (Delta 10, Heine, Herrsching, Germany).
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone (not further described)
Disease positive: 79 / Disease negative: 116
Target condition (Final diagnoses)
Melanoma (invasive): 61; Melanoma (in situ): 18
Benign naevus: 116 (78 compound, 0 dermal, 16 junctional, and 22 Spitz)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: Only 50% of imaged nevi were included (randomly selected from the image database prior to analysis) to reduce the MM/nevus
ratio
 
Time interval to reference test: Consecutive; imaged prior to biopsy
 
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less? No
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective; dermoscopic images assessed remotely from the patient
Period of data collection Sept 2004 - Aug 2007
 
Country Australia (and Italy - see Guitera 2009a (Modena))
 
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Lesions suspicious of melanoma based on dermatoscopic diagnostic criteria or lesion change
 
Setting: Specialist clinic; Sydney Melanoma Diagnostic Centre, Australia
 
Prior testing: Clinical and/or dermatoscopic suspicion/Changes on digital monitoring
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Setting for prior testing: Specialist clinic
Exclusion criteria: Location/site of lesion lesions on soles/palms excluded. Lentigo maligna excluded; lesions used in previous assessments or RCM model
development
 
Sample size (patients): No. included: 131
Sample size (lesions): No. eligible 156 No. included: 131
Participant characteristics: Median age: 52 (19 to 90yrs); IQR 40, 63; Male: 58.8%
Lesion characteristics: Pigmented: 84%; 16% amelanotic lesions or those with tan, light gray, or pale blue pigment only). Median thickness 0.40mm (IQ
25, 75: 0, 0.84)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes





Method of diagnosis: Dermoscopic images
Prior test data: Lesion site and age available to observer; dermoscopy diagnosis of Sydney lesions was made retrospectively on the images in a random
order, blinded to RCM and pathological diagnosis but not to information of site and age, by a Modena expert (GP) using pattern analysis (Pehamberger
1993)
Diagnostic threshold: Not reported
Diagnosis based on: Single observer (n=1);
 
Observer qualifications: assume Dermatologist; described as Modena expert based in Dermatology Dept
Experience in practice: High experience
Experience with dermoscopy: High experience
Other detail: Sydney - high-resolution digital oil immersion dermoscopy camera (Sentry, Polartechnics Ltd, Sydney, NSW, Australia)
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone (no further details)
Disease positive: 44 / Disease negative: 87
Target condition (Final diagnoses)
Melanoma (invasive): 26; Melanoma (in situ): 16
Benign naevus: 87 (49 compound, 9 dermal, 26 junctional, and 3 Spitz)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: 25 lesions out of 156 were rejected for poor quality dermoscopy image, blinded to the diagnostician
 
Time interval to reference test: imaged prior to biopsy
 
Time interval between index test(s): N/A
 
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
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Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: 1998-2008
Country: Germany
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Participants at increased risk for melanoma: >50 common and/or <=3 atypical nevi; atypical mole syndrome (AMS); or familial atypical
mole and multiple melanoma syndrome. [FV - first visit data FU - follow-up data]
Setting: Secondary (Dermatology)
Prior testing: All identified as high risk
Setting for prior testing: NR
Exclusion criteria: Patients showing melanoma development on pre-existing pigmented lesions during the following 12 months after the analysed time
frame
Sample size (patients): 688
Sample size (lesions): 11,137
Participant characteristics: Mean age 42 (range NR). 60% male. Group 1 (50 common and/or <= atypical nevi) 67%; Group 2 (AMS) 31.8%; Group III
(familial atypical mole and multiple melanoma syndrome) 1.2%. Personal history of melanoma (29.2%); Family history of melanoma (13.1%); High number
(>50) of nevi (56.4%).
Lesion characteristics: NR
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No




Method of diagnosis: In person
Prior test data: Also considered lesional history (eg, increase in size, itching, scaling, change in color, intermittent bleeding), and the ugly duckling sign
(Grob 1998) and 'moles-breed-true' concept (Scope 2006). Lesions scoring <3 on 7PCL were excised if these other factors were present at first visit (FV).
Lesions scoring <3 with defined clinical or dermatoscopic criteria of atypia (eg, asymmetry in shape, irregular margin, variegated colour, prominent pigment
network) (Ascierto 2000) were marked on digital overview images and electronically stored by using two digital dermatoscopy systems for follow up (FU).
Diagnostic threshold: >=3
Diagnosis based on: Consensus of 2
Observer qualifications: Dermatology residents (n=13); supervised by experienced dermatologist
Experience in practice: NR
Experience with dermoscopy: High; formally trained in dermoscopy
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and Reference standard: Histology or FU (every 3, 6, or 12 mos)
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reference standard(s) Target condition (Final diagnoses)
Invasive melanoma 77; Melanoma in situ 50; BCC 2
Benign nevi 1047; Spitz nevi 16; Sbhorrheic keratosis 12; Other benign 9935 (not excised)
Is the reference standards likely to correctly classify the target condition? No
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: None reported
Time interval to reference test: Consecutive
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: 1998-2008
Country: Germany
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Participants at increased risk for melanoma: >50 common and/or <=3 atypical nevi; atypical mole syndrome (AMS); or familial atypical
mole and multiple melanoma syndrome. [FV - first visit data FU - follow-up data]
Setting: Secondary (Dermatology)
Prior testing: All identified as high risk
Setting for prior testing: NR
Exclusion criteria: Patients showing melanoma development on pre-existing pigmented lesions during the following 12 months after the analysed time
frame
Sample size (patients): 688
Sample size (lesions): 11,137
Participant characteristics: Mean age 42 (range NR). 60% male. Mean age 42 (range NR). 60% male. Group 1 (50 common and/or <= atypical nevi) 67%;
Group 2 (AMS) 31.8%; Group III (familial atypical mole and multiple melanoma syndrome) 1.2%. Personal history of melanoma (29.2%); Family history of
melanoma (13.1%); High number (>50) of nevi (56.4%).
Lesion characteristics: NR
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No




Method of diagnosis: In person
Prior test data: Also considered lesional history (eg, increase in size, itching, scaling, change in color, intermittent bleeding), and the ugly duckling sign
(Grob 1998) and 'moles-breed-true' concept (Scope 2006). Lesions scoring <3 on 7PCL were excised if these other factors were present at first visit (FV).
Lesions scoring <3 with defined clinical or dermatoscopic criteria of atypia (eg, asymmetry in shape, irregular margin, variegated colour, prominent pigment
network) (Ascierto 2000) were marked on digital overview images and electronically stored by using two digital dermatoscopy systems for follow up (FU).
Diagnostic threshold: >=3
Diagnosis based on: Consensus of 2
Observer qualifications: Dermatology residents (n=13); supervised by experienced dermatologist
Experience in practice: NR
Experience with dermoscopy: High; formally trained in dermoscopy
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
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Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard: Histology or FU (every 3, 6, or 12 mos); mean FU 44.28 (range 2-123) months
Target condition (Final diagnoses)
Invasive melanoma 77; Melanoma in situ 50; BCC 2
Benign nevi 1047; Spitz nevi 16; Sbhorrheic keratosis 12; Other benign 9935 (not excised)
Is the reference standards likely to correctly classify the target condition? No
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: None reported
Time interval to reference test: Consecutive
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: RCT of diagnosis based on clinical/dermoscopic images versus same plus MelaFind, with observers randomised between arms. Lesions
selected on a case control type basis with cases and controls sampled from a previous study (Monheit 2011).
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Subset of pigmented skin lesions evaluated in Monheit 2011; melanoma and non-melanoma randomly selected.
Setting: Mixed Secondary/Private; Lesions sampled from Monheit trial "Seven clinical sites with 23 investigators participated in this trial. Three sites were
academic institutions (University of Pittsburgh, Duke University, and Northwestern University), and 4 sites were dermatologic practices highly experienced in
managing PLs." (Monheit 2011)
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Not reported
Exclusion criteria: Ulcerated or non-pigmented lesions, or located on excluded anatomic sites. Lesions with
 prebiopsy clinical diagnoses of melanoma were excluded from Monheit 2011
Sample size (patients): No. included: 130
Sample size (lesions): No. eligible: 1632 lesions in Monheit trial; No. included: 130
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Participant characteristics: None reported
Lesion characteristics: Head/Neck: 23%; Trunk: 41.5%; Upper limbs/shoulder: 20%; Lower limbs/hip: 16.2%. Median thickness (melanomas) 0.39mm
(range 0.12 to 1.2mm)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear




Method of diagnosis: Clinical photographs and dermoscopic images (Arm 1 and Arm 3 of trial; Arm 2 included MelaFind images)
Prior test data: Clinical images (overview and close up); plus 24 items regarding patient demographics and risk factors for melanoma such as: personal or
family history of melanoma, number of atypical nevi, Fitzpatrick skin type, number of severe sunburns before and after age 20, etc.
Diagnostic threshold: Biopsy decision.
Diagnosis based on: Average. Board-certified dermatologists who were members of a public dermatology list volunteered to participate in the trial.
Selection was made on a first-come basis with randomisation between two study arms until at least 65 dermatologists participated in each Arm. Of the 227
dermatologists
 registered, 211 completed at least 78 cases and therefore were considered eligible. FInally included 101 of 108 dermatologists in Arm 1 and 101 of 108
dermatologists in Arm2 (MelaFind). A third arm included 9 of 12 Pigmented Skin Lesion experts "prospectively identified by the Principal Investigator based
on field standing prior to participant recruitment"
Observer qualifications: Dermatologists
Experience in practice: High; all board certified, in Arm 1 >90% had more than 10 years experience in practice; Arm 3 consisted of PSL experts
Experience with dermoscopy: High; for Arm 1 all except 6 were trained in dermoscopy use and 80/101always or almost always used dermoscopy for
PSLs; Arm 3 consisted of PSL experts
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Details: From Monheit 2011 - The electronic case record included details of the "prebiopsy diagnoses (without dermoscopy and, if available, with
dermoscopy) by the examining dermatologists", "if the dermatologic diagnosis was not melanoma, the reason for the biopsy was selected from the following:
nonmelanoma skin cancer, patient’s concern, patient’s discomfort, cosmetic, or, if dermoscopic evaluation was used, clinical concern. A histologic specimen
with the standard hematoxylin-eosin staining was provided for each lesion." "Histologic slides for each lesion ... were evaluated by 2 independent
dermatopathologists. In cases of significant discordance, histologic slides were evaluated independently by a third dermatopathologist. When 1
dermatopathologist diagnosed melanoma and 2 others diagnosed a benign lesion, histologic slides were sent again to the dermatopathologist who
diagnosed melanoma for a blind rereview."
Disease positive: 65; Disease negative: 65
Target condition (Final diagnoses)
Melanoma invasive: 36; Melanoma in situ: 29
'Benign' diagnoses: 65
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Appears consecutive
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
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Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Unclear
Data collection: Retrospective image selection / Prospective interpretation
Period of data collection: Not reported
Country: Austria
 
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Pigmented skin lesion (PSL) images 'selected' by PSL experts from pigmented lesion image database on the basis of quality of the
photograph and the difficulty of diagnosis; all "melanomas selected provided only subtle ELM features as clues to the malignancy of the lesion and were
difficult to differentiate from benign PSLs".
 
Setting: Secondary (not further specified)
Prior testing: Dermatoscopic suspicion in all cases
Setting for prior testing: Secondary (general dermatology); selected from PSL database
Exclusion criteria: None reported
Sample size (patients): Not reported
Sample size (lesions): No. included: 50
Participant characteristics: None reported
Lesion characteristics: median Breslow thickness of the MMs: 0.7mm (IQR 0.5-0.95mm)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear




Method of diagnosis: Dermoscopic images; both photographic slides and compressed digital images assessed to determine whether compressed images
are sufficiently informative for diagnosis; 2x2 based on digital images used for primary analysis
Prior test data: No further information used. Images viewed in two sessions; in each session 25 slides and 25 digital images were viewed
Diagnostic threshold: Clinical diagnosis; Rated as definitely or probably melanoma; unclear whether 2x2 based on 'definite' only as test positive or
definite/probable combined
Diagnosis based on: Single observer; n= 8 readers, reported separately.
 
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with dermoscopy: Not described; described as 'pre-trained in ELM'
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard: Histological diagnosis alone (no further details)
 Disease positive: 23; Disease negative: 27
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Target condition (Final diagnoses)
Melanoma (invasive or in situ): 23
Sebhorrheic keratosis: 1; Atypical naevus 17; Common naevus 9
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: Poor quality images excluded; "selected' from pigmented lesion image database on the basis of quality of the photograph"
Index test to reference standard interval: Not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: November 1996 to November 1997
 
Country Austria (from authors' institution)
 
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Pigmented skin lesions < 1 cm in diameter, consecutively excised
 
Setting: Secondary (general dermatology) From authors' institution
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Not reported
Exclusion criteria: lesion size >=1cm
 
Sample size (patients): No. included: 352
Sample size (lesions): No. included: 373
Participant characteristics: Mean age 52 (SD 17 years); Male: 49%
Lesion characteristics: median thickness 0.65mm (range, 0.2 to 2 mm).
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy: ABCD; ABCDE (developed in this study)
Method of diagnosis: In person diagnosis
Prior test data: Clinical examination
Diagnostic threshold: Range of numerical thresholds evaluated.
'Standard' ABCD applied as previously described by Stolz 1994 and Nachbar 1994. Sensitivities reported for a range of specificities but cut-offs not reported
(author communication suggested a threshold of >4.75 was used but not clear which se/sp pair this relates to); randomly selected dataset at 75%specificity
for inclusion in primary analysis.
'Enhanced' ABCD-E algorithm accounts for patient report of changes in the lesion within the previous year. The overall score was calculated by adding 1.2
to the standard ABCD score for changing lesions and subtracting 0.8 from the standard ABCD score for non-changing lesions according to the results of a
multivariate analysis. ABCDE results reported at cutoffs ranging from 1.30 to 7.35.
Diagnosis based on: Unclear; appears to be in clinic diagnoses (n=NR)
 
Observer qualifications: Not reported; likely dermatologists
Experience in practice: Not described
Experience with dermoscopy: Not described
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
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Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Details: "After excision all lesions were subjected to standard histopathologic examination. The histologic diagnosis of an atypical nevus was based on the
following criteria: cellular atypia, lentiginous hyperplasia of the epidermis,
 fibroplasia, bridging of rete ridges, suprabasal melanocytes, junctional nest disarray.
 Disease positive: 73; Disease negative: 283
Target condition (Final diagnoses)
Melanoma (invasive): 55 (51 superficial spreading,4 nodular, 15 lentigo maligna, 3 otherwise nonclassified melanomas); Melanoma (in situ): 18
 
Sebhorrheic keratosis: 4; 126 (35.4%) common nevi, 113 (31.7%) atypical (dysplastic) nevi, 3 (0.8%) congenital nevi, 13 (3.7%) pigmented Spitz nevi, 7
(0%) blue nevi, 2 (0.6%) combined nevi, 14 (3.9%) solar lentigines, 1 dermatofibroma
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: Non melanocytic lesions (n=17; including angiomatous tumours, pigmented seborrhoeic keratosis, dermatofibromas, and
pigmented basal cell carcinomas) easily distinguished by standard ELM criteria and pattern analysis
Index test to reference standard interval: Not described
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Images of naevi from patients with multiple atypical naevi undergoing digital dermoscopy follow-up. All melanomas were excised due to
changes on follow up; benign melanocytic skin lesions included were taken at random from the participants with melanoma plus other randomly selected
patients with multiple atypical naevi.
Setting: Secondary (assumed); states "a database" Auth inst: Dept Dermatology, Uni Vienna
Prior testing: All undergoing follow-up
Setting for prior testing: Not reported
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Exclusion criteria: None reported
Sample size (patients): No. eligible: NR; No. included: 20
Sample size (lesions): No. eligible: NR; No. included: 80
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No




Method of diagnosis: Dermoscopic images
Prior test data: Unclear
Diagnostic threshold: Data extracted for excise decision; data also presented for 3 option response of excise/follow-up or no intervention.
Diagnosis based on: Average (n=24); three groups were recruited according to experience but 2x2 can be extracted only for overall average result,
individual group results presented only graphically.
Observer qualifications: Dermatologist
Experience in practice: Not reported
Experience with dermoscopy: Mixed; group 1 (n=9) had basic dermoscopy experience with no formal training, group 2 (n=10) had dermoscopy training
but only basic experience with digital dermoscopy, and group 3 included experienced dermatologists trained in dermoscopy and using digital dermoscopy
routinely to follow-up melanocytic lesions. 
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis plus follow up
Details: All lesions were excised (n=20; including all 10 melanomas) or had at least 2 years of follow-up with no morphologic changes during multiple
examinations (n=60; all benign)
Target condition (Final diagnoses)
Melanoma (invasive): 5, Melanoma (in situ): 5
Benign melanocytic lesions: 70
Is the reference standards likely to correctly classify the target condition? No
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: None reported
 
Time interval to reference test: Not reported for histology; Clinical follow up lasted up to 2 years
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC? Yes
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
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A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: NR
Country: Germany
 
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Excised pigmented skin lesions
 
Setting: Secondary (general dermatology)
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): No. included: 80
Sample size (lesions): No. included: 80
Participant characteristics: None reported
Lesion characteristics range in thickness (melanomas) 0.18-1.9mm; 29/39 <0.76mm; 7/39 0.76-1.5mm; 3/39 >1.5mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Visual inspection (VI): No algorithm reported
 
Method of diagnosis: In person diagnosis
Prior test data: Unclear
Diagnostic threshold: Not reported no details
Diagnosis based on: Single observer (n=1)
Observer qualifications: Not reported; likely Dermatologist
Experience in practice: Not described
Experience with dermoscopy: Not described
#
Dermoscopy
Method of diagnosis: In person diagnosis
Prior test data: Unclear
Diagnostic threshold: Not reported no details
Test observers as described for Visual Inspection (above)
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
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A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone including histometrics
Disease positive: 39; Disease negative: 41
Target condition (Final diagnoses)
Melanoma (invasive): 39 (SSM, lentigo MM, nodular M)
Benign naevus: 37 common nevus; 3 dysplastic nevus, 1 Spitz nevus
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
 Time interval between index test(s): not reported
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative tbc
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? No
Was the interval between application of the index tests less than one month? Yes
Are there any concerns that the test comparison could have introduced bias? High risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? Yes





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation
Period of data collection: NR; 1.5 year period
Country: Germany
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Pigmented lesions suspected to be malignant melanoma with adequate photo- documentation and histology results
Setting: Secondary (dermatology)
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: Non-melanocytic lesions
Sample size (patients): Total 856; NR for final sample
Sample size (lesions): 265 melanocytic/1506 lesions included (317 excised and 52 NML excluded)
Participant characteristics: NR
Lesion characteristics: NR
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests Dermoscopy: Algorithm from Kreusch 1991
Method of diagnosis: Image based
Prior test data: None; slides labelled only with patient code and lesion localisation
Diagnostic threshold: >=9; scored diameter >5mm; border irregularity; loss of surface's microstructure; scaling/erosion/ulcer; capillaries (each 1 point);
multicomponent architecture; greyish colour (each 3 points) melanophages (6 points); pseduopods (10 points); regression (10 points)
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Diagnosis based on: Single observer
Observer qualifications: Dermatologist (assumed) (n=1; ‘experienced') [also presents results for inexperienced student – data not included]
Experience in practice: ‘experienced'
Experience with dermoscopy: ‘experienced'
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard




Target condition (Final diagnoses)
Invasive melanoma 96; benign nevi 169
Is the reference standards likely to correctly classify the target condition? Unclear
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: 52 NML excluded from second step evaluation
Time interval to reference test: NR
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Patients with suspicious pigmented lesions scheduled for biopsy due to clinical suspicion of malignancy determined by clinical
appearance or a history of change in the lesion.
 
Setting: Specialist unit (skin cancer/pigmented lesions clinic); Division of Dermatology Pigmented Lesion Clinic and the Plastic Surgery Clinics
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Prior testing: Clinical suspicion of malignancy
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: Non-pigmented; Physically inaccessible lesion site; previous diagnostic biopsy of the lesion.
 
Sample size (patients): No. eligible: 127; No. included: 125
Sample size (lesions): No. eligible: 127; No. included:
Participant characteristics: Mean age 44.2 yrs, range 16 to 84 yrs
Lesion characteristics: median thickness 0.62 mm, range 0.20 mm to 7.92 mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes




Method of diagnosis: In person diagnosis
Prior test data: Clinical examination and/or case notes
Diagnostic threshold: Pattern analysis; diagnosis of melanoma
Diagnosis based on: Single observer (n=1)
 
Observer qualifications: Not reported likely dermatologist; "Clinical, dermoscopic and confocal examinations were conducted sequentially by a single
reviewer" and a diagnosis recorded after each.
Experience in practice: Not described
Experience with dermoscopy: Not described
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Details: "When CSLM imaging was complete, the lesions were removed by excisional biopsy. A definitive diagnosis was made by a dermatopathologist
 with conventional hematoxylin-eosin stained histopathological sections."
 Disease positive: 37; Disease negative: 88
Target condition (Final diagnoses)
Melanoma (invasive): 22; Melanoma (in situ): 15
Benign naevus: 88
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: Two patients were excluded from the data- base due to technical difficulties with the imaging.
Index test to reference standard interval: When CSLM imaging was complete, the lesions were removed by excisional biopsy
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
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Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Patients with lesions suspicious for CMM referred to outpatients clinic; only excised included
 
Setting: Not reported
Prior testing: Clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: Not reported
Exclusion criteria: Poor quality index test image (considered under flow/timing)
 
Sample size (patients): No. eligible: 242; No. included: 232
Sample size (lesions): No. eligible: 242; No. included: 232*
Participant characteristics: None reported
Lesion characteristics: None reported
*NB Not all cases were assessed by all observers; 2x2 are based on presented sensitivity and specificity estimates for full dataset of lesions; "the
dermatoscopy experts assessed almost all cases (98 ± 100%), whereas the non-expert group completed fewer assessments, from 76 to 98%.
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: Clinical photographs
Prior test data: No further information used; no option to change clinical diagnosis after viewing dermoscopic image
Other test data: Dermoscopic images presented to observer subsequent to diagnosis using clinical images alone; clinical images presented before
dermoscopic images
Diagnostic threshold: Not reported; clinical diagnosis
Diagnosis based on: Average; n= 9 
 
Observer qualifications: Dermatologist
Experience in practice: High; Moderate; Mixed (average reported); 4 'experienced dermatologists' (4-5 years daily experience) & 5 'non-expert
dermatology residents' (1-2 years interest and formal training in dermatoscopy]
Experience with index test: High; Moderate; Mixed
#
Dermoscopy: No algorithm
Method of diagnosis: Dermoscopic images
Prior test data: Clinical image presented first
Diagnostic threshold: Clinical diagnosis"; observers were familiar with both the ABCD-rule of dermatoscopy proposed by Stolz et al. (6) and Kenet et al.'s
risk stratifying algorithm of pigment network features of dermatoscopy (8). The observers were not constrained by either of the rules. The ABCD scores were
not used to obtain the diagnoses. Rather a pattern recognition process was intended."
#
Dermoscopy training: described as "formal training"
 
Training format: Non experts had undergone prior training in dermoscopy (not documented)
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
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Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Details: a co-author from Dept of Pathology "re-evaluated all cases to confirm the pathology diagnosis, which was used as the gold standard in this study."
Disease positive: 65 ; Disease negative: 167
Target condition (Final diagnoses) 
Melanoma (invasive): 49 'malignant melanoma'
 BCC: 16
Sebhorrheic keratosis: 12; Benign naevus: 137 (pigmented nevi=116; blue nevi=16; atypical nevi=5); Other: 18 (spitz nevi, Bowen's disease, sarcoid, nevus
spilus, hemangioma, and others)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: 10 cases were "considered unfit for evaluation" due to poor quality image
Reference interval: "biopsy specimens...were obtained after the clinical and dermatoscopic photographs had been performed"
 
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative tbc
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? Yes
Was the interval between application of the index tests less than one month? Yes
Are there any concerns that the test comparison could have introduced bias? Low risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation
Period of data collection 1995-1999
 
Country Not clear; authors from Denmark and US
 
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Pigmented skin lesions from patients consecutively referred to the skin cancer outpatient clinic with available clinical photographs,
dermatophotographs and a subsequent excision biopsy were included
 
Setting: Specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Secondary (general dermatology)
Exclusion criteria: None reported
 
Sample size (patients): No. included: 258
Sample size (lesions): No. included: 258
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Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy ABCD; Kenet Risk Stratification 
 
Method of diagnosis: Dermoscopic images; "Slides were projected to an 80 x 120 cm screen in a darkened room. Based on time studies in the outpatient
clinic, each patient case was shown for approximately 3 min... additional time was allowed if any needed it."
Prior test data: Cliincal photographs also projected
Diagnostic threshold:
ABCD - 'possible' MM: >4.75; 'probable' MM: >5.45. 
 Risk stratification method: 'possible' MM: stratum 1 or 2; 'probable' MM: stratum 1 only (1: Probable CMM: Pseudopods; Radial streaming; Heterogeneity of
PN with thick dark extensions at the edge; Blue-grey areas, white scar like areas and presence of PN2: Possible CMM: Marked irregular network with
irregular pigment confluence)
Diagnosis based on: Single observer (n=3; performed independently)
Observer qualifications: Dermatologist
Experience in practice: High; Senior dermatologists - "Three senior dermatologists with more than 5 years daily experience in clinical use of dermatoscopy
and familiar with (both) dermatoscopic (algorithms)"
Experience with dermoscopy: High; > 5 years each
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? Unclear
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
- Details: Lesions underwent HE-staining, as well as HMB-45 and S-100 immunostaining to identify melanocytic lesions. Breslow depth and Clark level were
determined. All cases were assessed by an experienced dermatopathologist. 
 Disease positive: 64; Disease negative: 194
Target condition (Final diagnoses)
Melanoma (invasive): 64 CMM
 BCC: 25
 Sebhorrheic keratosis: 14
 Benign naevus: 135; Dysplastic naevus 3; Other: 11 blue naevi, 1 pigmented Spitz naevus, plus one each of were angioma, haemorraghia, papilloma and
dermatofibroma.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Time interval to reference test: Appears consecutive; "Only patients having taken clinical photographs, dermatophotographs and a subsequent excision
biopsy were included"
 
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less? Yes
Could the patient flow have introduced bias? Low risk
Comparative
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A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Unclear




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Patients referred to the specialist naevus clinic for lesion excision
 
Setting: Specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: Not specified
 
Sample size (patients): No. eligible: 120; No. included: 119
Sample size (lesions): No. included: 119
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy: Mixed/no algorithm; describes using "the risk stratification and pattern analysis procedure as described by Kenet 2001 and Lorentzen 2000".
 
Method of diagnosis: Dermoscopic images; compared accuracy using standard dermoscopy images (Dermaphot) and images obtained using a globe
magnifier. Slides were randomised and evaluated on 2 different occasions with 3 week intervals
 
Prior test data: No further information used
Diagnostic threshold: Observer correct diagnosis of each lesion type
Diagnosis based on: Unclear (assumed Average) (n=NR)
 
Observer qualifications: Dermatologist
Experience in practice: High; "dermatologists who have performed dermatoscopy for 5–10 years, published scientific papers on dermatoscopy and carried
out pre- and post specialist training in dermatoscopy"
Experience with dermoscopy: High
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard: Histological diagnosis alone
Details: used haematoxylin-eosin staining a well as histochemistry was performed using S-100 and HMB-45 on suspect melanoma lesions.
 Disease positive: 24; Disease negative: 95
Target condition (Final diagnoses) 
Melanoma (invasive): 24 
 BCC: 13
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Mild//moderate dysplasia: 2; Sebhorrheic keratosis: 9; Haemangioma: 2; Naevus pigmentosus- 69
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: One dermatofibroma excluded
Time interval to reference test: Not described
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective; dermoscopic images assessed remotely from the patient
Period of data collection: March 2010 and November 2011
Country: conducted at five American and 17 European investigational sites (Sweden, Germany, Austria, Hungary, U.K. and Spain);
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: All patients with skin lesions selected for total excision to rule out melanoma; dermatologists were encouraged to enrol a mix of lesions
with an even distribution of low-, medium and high-risk lesions.
Setting: Secondary; authors institutions primarily listed as Dept Dermatology with one "Dermatology Clinical Research Center"
Prior testing: Selected for excision
Exclusion criteria: lesions < 2 mm or > 20 mm and those located: on acral skin, e.g. sole or palm; areas of scars, crusts, psoriasis, eczema or similar skin
conditions; hair-covered areas, e.g. scalp, beards, moustaches or whiskers; genitalia; in an area that has been previously biopsied or subjected to any kind
of surgical intervention or trauma; mucosal surfaces; with foreign matter, e.g. tattoo or splinter; acute sunburn; or skin surface not measurable, e.g. lesion on
a stalk; surface not accessible, e.g. inside ears, under nails or not intact (measurement area),
Sample size (patients): No. eligible: 1951; No. included: 1611 for Nevisense and NR for visual inspection and dermoscopy
Sample size (lesions): No. eligible: 2416; No. included: 1943 for Nevisense and 1701 for visual inspection and dermoscopy
Participant characteristics: For Nevisense sample: median age: 48y (range 18 to 91); male 47.5%; 97.5% of white ethnicity. Fitzpatrick skin types: I
(7.3%); II (48.6%); III (37%); IV (9.8%); V (1.4%); VI (0.1%)
Lesion characteristics: median Breslow thickness of 0.57 mm (153 invasive melanomas);
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy; ABCD; 7-point checklist; revised 7-point checklist; overall diagnosis (methods describe evaluation of the clinical ABCD rule but results not
presented in Table)
Method of diagnosis: Image-based; "A photograph and dermoscopic image of each included lesion was taken before and after Nevisense measurements"
Prior test data available: Clinical and dermoscopic images presented together; observers were blinded to Nevisense result
Diagnostic threshold: ABCD - >4.75 and >5.45; 7-point checklist and revised 7-point checklist – NR, referenced to Argenziano 1998; overall diagnosis
based on grading (0 to 10) on a visual classification board with a fixed cut-off at 4.
Diagnosis based on: Unclear; (n=3)
 Observer qualifications: Dermatologists; "images were reviewed by three
 dermatologists with 2–5 years of experience in dermoscopy assessment. The option to reach out to additional experienced dermoscopists in difficult cases
was allowed"
Experience in practice: Not described
Experience with dermoscopy: High; 2-5 years
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
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B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? No
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Type of reference standard: Histological diagnosis alone
Details: Lesions were excised and underwent usual histopathology at investigational site. A further histopathological evaluation was undertaken for study
purposes by a panel of three experienced histopathologists who evaluated
 each lesion independently; blinded from the investigational site’s original histopathology diagnosis. If they agreed, the diagnosis was considered as the
histopathological gold standard (HGS); if there was significant disagreement regarding malignancy the slides were submitted to two additional experts
whose diagnosis was then chosen as the HGS if they reached agreement. In case of disagreement by the two additional reviewers, the corresponding lesion
was excluded from the efficacy analysis.
Disease positive: 238 for VI/dermoscopy; Disease negative: 1440
Target condition (Final diagnoses)
For VI/Dermoscopy sample – 238 melanomas including 112 in situ
Breakdon of non-diseased not provided for VI/dermoscopy sample
For Nevisense sample (includes additional 242 lesions:
153 invasive melanomas, 112 melanoma in situ,
48 BCC, 1 invasive SCC; 1 Merkel cell carcinoma
157 severely dysplastic, 988 mild to moderate dysplasia, 352 benign nevi, 5 spitz nevi, 51 seborrheic keratosis, 6 SCC in situ; 8 AK; 61 other
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: 473 excluded from Nevisense analysis; all reasons listed; primary reason was investigator oversight or the inability to render a final
histopathological diagnosis; 74 exclusions were device-related (60 with inadequate reference measurement quality and 14 to device failure). A further 242
were excluded from VI/Derm analysis due to image quality (12% of visual inspection/dermoscopy sample)
Index test to reference standard interval: Appears consecutive; prospective recruitment with imaging and then "eligible and evaluable lesions were
excised and subjected to the investigational site’s histopathology evaluation and managed accordingly." "A postprocedure follow-up either by a telephone
call or at a participant’s visit to the investigational site was conducted at 7 +/- 3 days after the Nevisense evaluation, at which time the patient was evaluated
for any adverse events."
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less? Yes
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
Interval between index tests Consecutive; "A photograph and dermoscopic image of each included lesion was taken before and after Nevisense
measurements to document evaluation according to the protocol.”





A. Risk of Bias
Patient Sampling
Study design: Unclear. Abstract describes including a random sample of excised lesions from a larger database.
Data collection: Retrospective image selection / Prospective interpretation




Test set derived NR; describes 'division' into a training set and a test set.
 
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Unclear
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Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Pigmented skin lesions from the Sydney Melanoma Unit with dermoscopic images and histological diagnoses; melanomas and randomly
selected clinically atypical nonmelanoma lesions were included.
 
Setting: Specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: Selected for excision
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: Unequivocal nonmelanoma excluded
 
Sample size (patients): No. included: NR
Sample size (lesions): No. included: 385
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear




Method of diagnosis: Dermoscopic images
Prior test data: No further information used
Diagnostic threshold: Presence of 2 negative features and at least one positive feature. Negative features: point and axial symmetry of pigmentation or
presence of only a single colour. Positive features of melanoma: multiple (5-6) colors; blue-white veil; multiple brown dots; multiple blue/gray; peripheral
black dots or globules; a broadened network; pseudopods; radial streaming; scarlike.
Diagnosis based on: Unclear (n=NR)
 
Observer qualifications: Not reported; likely dermatologists
Experience in practice: Not described
Experience with dermoscopy: Not described
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone (not further described)
Disease positive: 107; Disease negative: 278
Target condition (Final diagnoses)
Melanoma (invasive): 107; BCC: 18
Ephelis/lentigo 17; Sebhorrheic keratosis: 23; Benign acquired nevi - 58; Dysplastic nevi - 105; Blue nevi 11; Spiz nevi 6; spindle cell nevus 2;
dermatofibroma 2; hemangioma 13; solar keratosis 9; other 14
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Not described
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
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If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation
Period of data collection June 1998 to September 2003
 
Country Multicentre (Australia, US, Germany)
 
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: All melanocytic lesions from the independent test set taken at the Sydney Melanoma Unit that had clinical and dermoscopy photographic
images; lesions imaged prior to excision due to clinical suspicion of malignancy or because of short-term digital monitoring (study was part of a larger
multicentre study of SolarScan).
 
Setting: Specialist unit
Prior testing: Clinical suspicion of malignancy or requirement for short-term digitial monitoring
Setting for prior testing: Specialist unit
Exclusion criteria: Awkwardly situated lesions (eg, eyelids, some parts of the pinna, some genital sites, and perianal and mucosal surfaces); acral lesions;
non-pigmented pure amelanotic lesions (based on dermoscopy imaging); ulcerated lesions, or diagnosed as pigmented basal cell carcinoma, pigmented
Bowen disease, or squamous cell carcinoma
 
Sample size (patients): No. included: NR
Sample size (lesions): No. included for Dermoscopy review: 78 (For full SolarScan study - No. eligible: 2430/ No. included: 1644 training; 786 test set)
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear




Method of diagnosis: Dermoscopic images
Prior test data: Clinical photographs and patient histories (including details of age, sex, and lesion site; and a recorded history of whether the lesion had,
within the past 2 years, bled without being scratched, changed in color or pattern, or increased in size).
Diagnostic threshold: Data can be extracted at two thresholds:- correct diagnosis of melanoma (in situ or invasive) and excise decision; No details on
lesion characteristics used.
Diagnosis based on: Average according to qualification level (n=13)
 
Observer qualifications: GP 3; Dermatology registrar 3; Dermatologists 4; plus 3 international dermoscopy experts who headed pigmented lesion clinics
Experience in practice: Not described
Experience with dermoscopy: Expert/High/Moderate/Low
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
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Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis plus other (Full sample n=2430)
Histology: 71% of full SolarScan study sample including training and test set (n=1725)
Clinical FU plus histology of suspicious lesions; Length of FU: 3 mo. 26% of full SolarScan study sample (n=632)
Expert opinion. 3% of full SolarScan study sample were nonmelanocytic pigmented
 lesions that were diagnosed clinically but not excised (n=73)
Target condition (Final diagnoses).
All numbers are for Sydney Melanoma Unit test sample lesions only (n=78)
Melanoma (invasive): 5; Melanoma (in situ): 6; Lentigo maligna: 2
Benign melanocytic lesions: 65
Is the reference standards likely to correctly classify the target condition? No
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard No
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? High
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: Poor quality index test image as exclusion criterion - lesions outside the field of view (24x18 mm), contamination of calibration
surfaces, or excess artifacts (hair, air bubbles, or movement artifacts).
Index test to reference standard interval: Not described.
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series?
Data collection: Retrospective image selection / Prospective interpretation
Period of data collection: NR
Country: Multicentre
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Dermoscopic amelanotic (with no melanin pigmentation) or hypomelanotic (a melanin pigmentation area of less than 25% of the total
surface area or slightly pigmented but with no dark brown, deep blue, or black pigmentation) lesions. All melanomas included, and a random selection of
melanocytic and nonmelanocytic lesions on a non-melanoma to melanoma ratio of 3:1.
Setting: Multicentre
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: Lesions were excluded because of poor image quality or because they did not fit within any of the defined pigmentation categories
Sample size (patients): NR
Sample size (lesions): 497
Participant characteristics: NR
Lesion characteristics: NR
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests Dermoscopy: 7PCL; Menzies; 3PCL [new algorithm for distinguishing melanoma from nonmelanoma and any malignant from benign lesions was also
developed on 80% of sample and tested on 20% but numbers Disease positive and negative for the test set were not reported to allow 2x2 to be estimated.]
Method of diagnosis: Image-based
Prior test data: NR
Diagnostic threshold: >=3; Menzies standard threshold; >=2
Diagnosis based on: Single observer
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Observer qualifications: Dermatologist (assumed) (n=12); clinicians experienced in dermoscopic evaluation scored 99 individual morphological features in
approximately equal sample sizes.
Experience in practice: NR
Experience with dermoscopy: High
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? No
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histology and FU (no.s NR; some nevi included that showed no changes following consecutive digital monitoring)
Target condition (Final diagnoses)
Invasive melanoma 91; Melanoma in situ 14; BCC 126 BCC; cSCC 4
Benign nevi 159; Spitz nevi 11; Sebhorrheic keratosis 22; dermatofibroma 17; Bowen's disease 7; Keratoacanthoma 1; actinic keratosis 8; other 37
Is the reference standards likely to correctly classify the target condition? Unclear
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: None reported
Time interval to reference test: NR
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Pigmented lesions which, after routine naked eye examination by the GP, would have been biopsied or referred, i.e. a SPL (suspicious
pigmented lesion). GPs were recruited from practices with at least 3 clinicians; excluded if they already used dermoscopy or SDDI in their routine practice.
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Setting: Primary
Prior testing: Clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: Primary
Exclusion criteria: None reported
Sample size (patients): NR
Sample size (lesions): No. included: 374
Participant characteristics: None reported
Lesion characteristics None reported
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? Unclear
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Diagnostic threshold: Not reported. Initial diagnosis recorded along with confidence of diagnosis (scale 1 to 10; 1 not at all confident and 10 extremely
confident), certainty of melanoma (scale 0 to 100%; 0 definitely not melanoma and 100 definitely melanoma) and management (biopsy, referral).
Diagnosis based on: Single observer (n=63; 102 GPs initially recruited; 74 (75%) completed the educational intervention and online assessment; 63 GPs
from 19 practices finally participated)
 
Observer qualifications: GP
Experience in practice: Not described
Experience with dermoscopy: Not fully described; classified as 'trained'. GPs must have each excised or referred >=10 PSL in previous 12-mo period;
excluded if dermoscopy or SDDI already used in routine practice.
#
Dermoscopy No algorithm
Method of diagnosis: In person diagnosis
Prior test data: Clinical examination and/or case notes.
Diagnostic threshold: Not reported. After clinical exam and dermoscopy GP recorded the site of the lesion and the initial diagnosis, confidence of
diagnosis, certainty of melanoma and management (as for VI above). Approach to dermoscopy interpretation not further reported; 2x2 can be constructed
for decision to Excise or to Excise or Monitor. Triage management options included: biopsy due to clinician concern; biopsy due to patient concern; referral
due to clinician concern; referral due to patient concern; short-term SDDI; and patient to return if changes occur.
Test observers as described for Visual Inspection (above)
#
Dermoscopy training: Online textbook in dermoscopic diagnosis and the use of SDDI, a CD-rom tutorial showing examples of changed and unchanged
monitored lesions; a 2-h workshop on the use of the diagnostic devices and recruitment procedures. Assessment through online pre- and post-education
intervention test of 245 lesions not seen in the textbook or the CD-rom. Before formal patient recruitment began, GPs assessed at least one pretrial lesion to
determine the quality of imaging with the SDDI instrument and undertake completion of trial paperwork. GPs were allowed to practise using the dermoscopy
device during this pretrial phase. The pretrial phase of education and run-in period occurred from May 2005 to January 2006.
 
Length of training: Self learning plus 2-h workshop
 
Post-training experience: 6-12 months
Training format Online; CD-rom: workshop.
 
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias




Reference standard - Histological diagnosis plus other [author confirmed that all melanoma had histological diagnosis and >50% of benign had histology or
follow-up]
Histology: described as conducted to standard practice and not necessarily blinded to the GP’s diagnosis.Total excised or referred - 163. Immediate
excision/referral - 110. Excision/referral after SDDI - 48. Excision/examination after patient self referral - 5
 Disease positive: 37; Disease negative: total of 126 benign or unknown were 'excised OR referred'
Clinical FU plus histology of suspicious lesions: Short term digital monitoring (SDDI) available as an option for lesions considered not to be melanoma but
that were still considered suspicious; follow-up imaging occurred initially at 3 months with any morphological changes to result in biopsy or referral; some
lesions continued SDDI for a further 3 months; Length of FU: 3-6 months
 No. patients: Initially recommended for SDDI: 192; SDDI continued for further 3 months: 6; Underwent SDDI only (no excision): 146
 Disease positive: 15 (SDDI then histologically confirmed); Disease negative: 176 benign (incl 1 missed in situ melanoma); 4 unknown
Expert opinion: GPs could refer for specialist opinion or lesions could undergo dermoscopy telemedicine (images reviewed by an expert in dermoscopy and
SDDI). Dermoscopy telemedicine was blinded to the GP’s diagnosis.
 Observe for change group, i.e. discharged after dermoscopy: 72 (lus a proportion of those in Excise/refer group will have had expert dx alone but details not
given)
 Disease positive: 0; Disease negative: 71 benign; 1 unknown
Target condition (Final diagnoses) 
Melanoma (invasive): 33; Melanoma (in situ): 1
 BCC: 6
2 Bowen's disease; 323 benign; 9 unknown
Is the reference standards likely to correctly classify the target condition? No
Were the reference standard results interpreted without knowledge of the results of the index tests? No
Could the reference standard, its conduct, or its interpretation have introduced bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard No
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? High
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: nine lesions with unknown diagnoses, plus BCC and Bowen's excluded from some analyses
Time interval to reference test: Not reported; Histopathological and specialist examination occurred according to standard practice.
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC? Yes
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series?
Data collection: Retrospective image selection / Prospective interpretation
Period of data collection: NR
Country: Multicentre (photographic libraries at various institutions; obtained from members of the International Dermoscopy Society from 5 continents)
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Nodular malignant melanoma (an invasive melanoma without an in situ (junctional) component beyond 3 rete ridges of the dermal
invasive component) and a random selection of non-nodular invasive primary melanoma, benign nodular melanocytic lesions, and nodular nonmelanocytic
lesions at a ratio of NM to other subgroups of 1:2. Nodular benign melanocytic lesions and nodular nonmelanocytic lesions were identified by the clinical
appearance of a solitary nodule and confirmed using dermoscopic examination.
Setting: Mixed
Prior testing: NR
Setting for prior testing: NR
Exclusion criteria: excluded if the image quality was poor
Sample size (patients): NR
Sample size (lesions): 467
Participant characteristics: excluded if the image quality was poor
Lesion characteristics: Pigmented 314/467; 67%.
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests Dermoscopy: ABCD; Menzies; CASH; 7PCL; 3PCL; Menzies algorithm for amelanotic lesions (Menzies 2008)
Method of diagnosis: Image-based
Prior test data: NR
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Diagnostic threshold: >5.45; standard Menzies; >=8; standard 7PCL; standard 3PCL; >=1 and >=0
Diagnosis based on: Single
Observer qualifications: Dermatologist (n=2; exp NR) Twelve scorers blinded to the lesion diagnosis scored 99 individual features in each lesion of
approximately equal sample sizes, as previously described.
Experience in practice: NR
Experience with dermoscopy: High
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? No
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histology or FU (‘some’ benign melanocytic nevi showed no change over time compared with baseline photographs).
Target condition (Final diagnoses)
Invasive melanoma 217 (incl 83 nodular)
Benign naevi 115
Is the reference standards likely to correctly classify the target condition? Unclear
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Unclear risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: None reported
Time interval to reference test: NR
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability




Inclusion criteria: Randomly selected melanocytic lesions; melanocytic on both clinical and dermoscopic criteria
 
Setting: Secondary (general dermatology)
Prior testing: Dermatoscopic suspicion in all cases
Setting for prior testing: Not reported
Exclusion criteria: Palms, soles, mucous membranes of face, under nails; non-melanocytic appearance
Sample size (patients): No. included: 166
Sample size (lesions): No. included: 200
Participant characteristics: Mean age 33.7y (SD 14.5), range 8 to 84yrs; Male gender: 64 (38.6%); Fitzpatrick phototype II (44%); type III (41.5%)
Lesion characteristics: Macular component=181 (90.5%), Papular component=125 (65%) Both = 106 (53%), either one or other = 94 (47%). Asymmetrical
144 (72%). Irregular borders 154 (77%). 4 colours in 40 (20%), 3 colours in 96 (48%), 2 colours in 57 (28.5%), 1 colour in 1 (0.5%). History of bleeding 7
(3.5%). changes reported by patient 154 (77%). Lesion site: trunk 155 (77.5%), including the back in 106 (53%). Lesion size: mean long axis diameter
7.9mm (SD 8.6)mm, mean short axis diameter 5.1 (SD 5).
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
 
Method of diagnosis: In person diagnosis
 
Prior test data: Clinical examination and/or case notes
Other test data: Appears that dermoscopy was undertaken by same clinician(s) subsequent to clinical evaluation; clinical history was constructed following
a standardized protocol and a presumptive clinical diagnosis recorded. Each lesion was then photographed and immediately afterwards examined using a
manual dermatoscope
Diagnostic threshold: Not reported; presumptive clinical diagnosis
Diagnosis based on: Consensus (n=2)
 
Observer qualifications: Dermatologist
Experience in practice: Not clearly described; assumed to be High - “both dermatologists had experience in dermoscopy.”
Experience with dermoscopy: Not clearly described; assumed to be High - “both dermatologists had experience in dermoscopy.”
#
Dermoscopy Pattern analysis
Method of diagnosis: In person diagnosis
Prior test data: Clinical examination and/or case notes
Diagnostic threshold: Not reported; diagnosed "on the basis of predominant dermoscopic pattern(s) using the pattern analysis algorithm"
Test observers as described for Visual Inspection (above)
 
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Details: Lesions described using terminology proposed by US National Insts of Health
 Disease positive: 6/6 lesions; Disease negative: 194/194 lesions (assuming the 9 'Other' diagnosis lesions were not malignant), or 185/185 (removing the 9
'other' diagnosis lesions from dataset)
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 6 (3%)
Other: Atypical mole (104), Common mole (70), congenital nevus (6), Blue nevus (3), Spitz/Reed nevus (1), Spilus nevus (1), Others [unclear whether
benign or malignant] (9)
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Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Exclusions: none reported
Time interval to reference test: "Samples for histologic analysis were taken immediately after clinical and dermoscopic examination"
 
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative Time interval between index test(s): Images taken at same time
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? No
Was the interval between application of the index tests less than one month? Yes
Are there any concerns that the test comparison could have introduced bias? High risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection November 1991 to July 1992
 
Country NR (authors institutions Germany and US)
 
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Pigmented melanocytic skin lesions consecutively excised
 
Setting: Secondary (general dermatology)
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Not reported
Exclusion criteria: Unequivocal appearance/diagnosis criteria used to exclude nonmelanocytic described in detail in Table 1;
 
Sample size (patients): NR
Sample size (lesions): No. included: 194
Participant characteristics: None reported
Lesion characteristics: Thickness - 35/69 MM <=0.75mm (50.7%)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear




Method of diagnosis: In person diagnosis
Prior test data: Clinical examination and/or case notes
Diagnostic threshold: >5.45 (determined based on retrospective analysis of the data)
For the calculation of ABCD score the criteria of asymmetry (A), abrupt cutoff of the pigment pattern at the border (B), different colors (C), and different
structural components (D) were assessed to yield a semiquantitative score (all described in detail). "The results of the retrospective study showed that
melanocytic pigmented skin lesions could be differentiated into two diagnostic groups as follows: melanocytic nevi (MN) if the final score was less than 5.45
and MM if the score was higher than 5.45. Retrospective analysis showed an early melanoma could not be completely excluded in all lesions with an ABCD
score between 4.75 and 5.45.Therefore these lesions were excised. All lesions were examined by two independent dermatopathologists.
Diagnosis based on: Unclear (n=NR)
 
Observer qualifications: Not reported; Presumably dermatologists; 'colleagues in our department'
Experience in practice: High experience or ‘Expert’
Experience with dermoscopy: High experience /‘Expert’ users
Study also presents 2x2 data for visual inspection; excluded from review as clinicians 'mostly' also used dermoscope for diagnosis. From text: "In comparing
the clinical with the dermatoscopic diagnosis with the ABCD rule it must be noted that all our colleagues in this department referring patients for the study
were experienced and in most cases used the dermatoscope without applying the new ABCD rule. Thus clinical diagnosis in our study was expected to be
already biased by the dermatoscopic feature and therefore to be more accurate than by the naked eye"
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Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? No
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? High risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard




- Histological diagnosis alone
Histology (not further described) 
194
 Disease positive: 69
 Disease negative: 125
Target condition (Final diagnoses) TARGET CONDITION (Final diagnoses)
 




 'Benign' diagnoses: 103 melanocytic naevus
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
Flow and timing
Time interval to reference test: NR; 
 
Time interval between index test(s): appears consecutive
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation
Period of data collection 1989 to 1991
 
Country Germany
Derivation of test set: Images collected 1989-1990 were used to develop a new algorithm; lesions investigated in 1991 were used for model validation
(latter data included in review)
 
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
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Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Melanocytic skin lesions that underwent excision
 
Setting: Secondary (general dermatology)
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Not reported
Exclusion criteria: Non-melanocytic appearance
Sample size (patients): No. included: 260 (1989 to 1990 group); NR for 1991 group
Sample size (lesions): No. included: 260 (1989 to 1990 group); 209 for 1991 group
Participant characteristics: None reported
Lesion characteristics None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear





Method of diagnosis: For training set dermoscopic images were projected onto a screen; method NR for test set (assumed same procedures followed)
Prior test data: No further information used
Diagnostic threshold: Significance of '8 clues of malignancy' (ref Braun-Falco 1990) were investigated in data collected 1989-1990. A subset of relevant
components were identified and evaluated on the test set of lesions (appears to be presence of any one considered test positive): asymmetrical pigment
distribution, more than three colours, asymmetrical depigmentation, black pigment, sharp pigment border and atypical radial streaming
Diagnosis based on: Single observer (n=1)
 
Observer qualifications: NR, likely Dermatologist ('one of the authors')
Experience in practice: Not described
Experience with dermoscopy: Not described
Derivation aspect: The 8 clues of malignancy were graded from 0 (absent) to 3 (distinct) on the test set of lesions (including asymmetrical pigment
distribution, more than three colours, black-brown pigment, dark brown pigment, prominent pigment network, asymmetrical depigmentation, peripheral
stripes, sharp pigment border and atypical radial streaming). Stepwise logistical regression used to select the variables that resulted int he best model for
identification of melanoma
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone (not further described) 
Disease positive: 41 in test set; Disease negative: 168 in test set
Target condition (Final diagnoses)
Full breakdown reported only for training set; for test set:
Melanoma (invasive): 41
Benign naevus: 168
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Not described
Was there an appropriate interval between index test and reference standard? Unclear
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Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Unclear; likely a case control type selection process
Data collection: Retrospective image selection / Prospective interpretation (Dermoscopy training study)




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Images of pigmented skin lesions from the training set of the Consensus Net Meeting on Dermoscopy (CNMD) (referenced to Soyer
2001), selected by two experts
 
Setting: Unclear
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): Not reported
Sample size (lesions): No. included: 20
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy: Pattern analysis; 7-point checklist; ABCD; Menzies criteria
Method of diagnosis: Clinical photographs and dermoscopic images. Partipants were given a CD with lesion images and asked to evaluate the 20 cases
independently over a 20 day period. This was repeated approximately 5 weeks post-dermoscopy training.
Prior test data: Case notes; "Each case contained the following clinical information: age, sex, skin phototype, total number of naevi, personal and ⁄ or family
history of melanoma, location, diameter and duration of the lesion, as well as medical history concerning morphological changes within the year preceding
excision of the lesion." It appears as so though this information was given to participants along with lesion images.
Diagnostic threshold: Clinical diagnosis of melanoma; "For each case, the participants completed an electronic data sheet that listed criteria for diagnosing
PSLs by pattern analysis and by the various algorithms. Participants offered a dermoscopic diagnosis for each case"
Diagnosis based on: Average (n= 16); authors' colleagues from dept Dermatology were recruited to participate
Observer qualifications: Dermatology registrar 9; Dermatologist 4; Medical students 3.
Experience in practice: Not described
Experience with dermoscopy: Low; Dermoscopic knowledge of this group consisted only of limited personal experience; none had formal training in this
technique and ⁄ or used dermoscopy in daily professional practice
#
Dermoscopy training: A one hour lecture introduced the principles of dermoscopy and the algorithms to be evaluated. A Web-based tutorial was then
made available and participants were asked to spend one hour per day for two weeks to learn and improve dermoscopy knowledge
(http://www.dermoscopy.org)
 
Training format: In person and online
Post-training experience: none reported
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
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If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? No
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone (not further described) 
 Disease positive: 6 (30%); Disease negative: 14 (70%)
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 6 (30%)
 BCC: 2 (10%)
Sebhorrheic keratosis: 2 (10%); Clark nevi 8 (40%); Reed/Spitz nevi 2 (10%)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Not described
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC? Unclear
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Prospective
Period of data collection: states 3 months but no specific dates given
 
Country: Austria (Graz)
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Lesions included in the study were selected because of their diagnostic difficulty and were excised for a histopathological evaluation.
 
Setting: Unspecified described as a multicentre study
Prior testing: lesions included in the study were selected because of their diagnostic difficulty does not specify what prior tests were done
Setting for prior testing: Unspecified
Exclusion criteria: Poor quality index test image (all images scoring 4 were excluded from the study)
 
Sample size (patients): No. included: 40 patients
Sample size (lesions): No. included: 43
Participant characteristics: Median age 39.5 years, (range 3–91 years). Male: 21 (53%); Female 19 (47%)
Lesion characteristics: Site - Face 2; Head 1, Neck 1, Trunk 8, Arms 3, Legs 7, Back 20, Buttocks 1
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests Dermoscopy
Method of diagnosis: All lesions were examined with a dermatoscope during the face to face clinical diagnosis. Diagnosis was made by a expert
dermatologist based on clinical features and dermoscopic findings. No specific algorithm (e.g. the Stolz index) was used for dermoscopic diagnosis.
Prior test data: Unclear
Diagnostic threshold: Not reported
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Diagnosis based on: Single (n=1)
Observer qualifications: Dermatologist (an expert in the diagnosis of pigmented skin lesions)
Experience in practice: High
Experience with index test: High
[Also evaluated Teledermatology assessment of transmitted images]
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard: Histological diagnosis alone
Details:All lesions were excised for a histopathological evaluation
Target condition (Final diagnoses) 
- Melanoma (invasive): 11, BCC: 3
 - Sebhorrheic keratosis: 2, Benign naevus: Melanocytic naevus 23, 'Benign' diagnoses: Angiokeratoma 1, lentigines 3
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
1. Excluded participants: Not reported
 
2. Time interval to reference test: Not reported
 
3. Time interval between index test(s): Not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias?
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
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B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Pigmented lesions excised because of equivocal dermoscopic findings or at the patient’s request
 
Setting: Secondary (general dermatology); from authors' institution
Prior testing: Dermatoscopic suspicion; Patient request for evaluation/excision
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): No. included: 289
Sample size (lesions): No. included: 341
Participant characteristics: Mean age 33.6y, range 3–83y; Male gender: 127 (43.9%); Fitzpatrick phototype I to II (31.4%); Type III (42%); Type IV-V
(26.4%)
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No




Method of diagnosis: Clinical photographs and dermoscopic images. Cases were clinically and dermoscopically evaluated on a high-resolution colour
monitor, in a random sequence
Prior test data: None; appears to be based on images only
Diagnostic threshold: Correct diagnosis of melanoma
Diagnosis based on: Single observer (n=2)
Observer qualifications: Dermatologist; (Dermatology?) resident
Experience in practice: High - dermatologist had 5 years of experience; Low - resident with minimal training in PSLs
Experience with dermoscopy: High and Low (resident had 6 months of experience, comprising 8 h of specialized training on three consecutive days and
2h per week in the routine of dermoscopy)
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Details: "All excised lesions were examined histopathologically by a dermatopathologist"
Disease positive: 13; Disease negative: 328
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 13
Sebhorrheic keratosis: 3; Benign naevus: 316; Dermatofibromas 7; angiomas 2
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
Flow and timing Time interval to reference test: nr 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
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Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Dermoscopically atypical pigmented skin lesions selected from the archives of the Dermatology Department at the University of L’Aquila,
Italy; described as "a panel of ... retrospectively selected PSLs"
 
Setting: Secondary (general dermatology)
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: Location/site of lesion - acral sites and the face
Sample size (patients): No. included: 165
Sample size (lesions): No. included: 165
Participant characteristics: Mean age 43.5 yrs (range 12 to 84 years); Male gender: 59.4%
Lesion characteristics: lesion site - upper extremities 18 (11%); lower extremities 53 (31%); 62 (37.5%) on the back; 32 (19.4%) on the chest. Melanoma
thickness 87.9% (29/33) <0.75mm; 11% (4/33) >1.5 mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes




Method of diagnosis: Dermoscopic images
Prior test data: No further information used
Diagnostic threshold: Total dermoscopic score (TDS) >4.75 and >5.45.
Diagnosis based on: Single observer (n=4)
 
Observer qualifications: 3 dermatologists and 1 GP with different degrees of dermoscopic experience
 
Experience in practice: Mixed
Experience with dermoscopy: High (Observer 1 - dermatologist); Moderate (Observers 2 and 3 - dermatologists); Low (Observer 4 - GP; underwent
dermoscopic training by studying an interactive atlas of dermoscopy between time periods T0 and T1).
Any other detail: Experience was scored based on number of years specializing in dermoscopy; number of pigmented skin lesions assessed by
dermoscopy on a daily basis; number of relevant workshops/ seminars attended; and the number of authored publications on dermoscopy.
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias




Reference standard Histological diagnosis alone (not further described)
Target condition (Final diagnoses)
Melanoma (invasive): 23; Melanoma (in situ): 10
Benign naevus: 105 Clark nevi; 19 Spitz/Reed nevi; 5 blue nevi; 3 dermal nevi.
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
 
Time interval to reference test: not described
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Small (</=5mm) melanocytic skin lesions with "dermoscopic appearance not excluding melanona" that were surgically excised at the
Centro di Riferimento Oncologico (National Cancer Institute), Aviano.
 
Setting: Specialist unit; National Cancer Institute
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: size >5mm
 
Sample size (patients): No. included: 123
Sample size (lesions): No. included: 129
Participant characteristics: Median age 30y, range 13 to 65y. Lesion site: trunk: 67 (52%); upper limbs/shoulder: 16 (14%); lower limbs/hip: 21 (16.3%);
abdomen 21 (16.3%); foot 4 (3.1%)
Lesion characteristics: median diameter 4mm (range: 1.2 to 5mm)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy Pattern analysis; ABCD
Method of diagnosis: Dermoscopic images
Prior test data: No further information used; Only images assessed for presence/absence of dermoscopic criteria and dermoscopic diagnosis
Diagnostic threshold: ABCD >5.45 and >=4.75; Pattern analysis: "Dermoscopic criteria used for evaluation were pigment network alterations, irregular
extensions, branched streaks. gray·blue areas. pseudopods. brown globules. black dots, whitish blue veil, hypopigmentation, white scar-like areas and
linear and dotted vascular patterns."
Diagnosis based on: Single observer (n= 2)
 
Observer qualifications: Not reported; likely oncologist/dermatologist (one observer based in Dept Oncology, other in Dermatology dept)
Experience in practice: Not described
Experience with dermoscopy: Not described
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
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A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? Unclear
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Details: Histopathologic diagnosis of all specimens was performed by a single pathologist at the Department of Pathology of the Centro di Riferimento
Oncologico
 Disease positive: 5 lesions
 Disease negative: 124 lesions
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not reported): 5 lesions
Benign naevus: 124 lesions
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Each lesion imaged 'before surgery'
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation
Period of data collection Jan 1996 to Dec 2001
 
Country Participants recruited from 5 participating centres (4 in Italy and 1 in USA) study conducted in Italy
 
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Clinical and⁄or dermoscopic hypomelanotic (extent of pigmentation <=30%) and amelanotic skin lesions seen and excised at the five
participating centres
 
Setting: Secondary (general dermatology)
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Not reported
Exclusion criteria: Poor quality index test image (considered under Flow and TIming)
Sample size (patients): No. included: 151
Sample size (lesions): No. eligible: 174; No. included: 151
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Participant characteristics: mean age 47 years (± 17.5 SD); male gender: 73 (48%)
Lesion characteristics: Lesion site - head/neck (5.3%); trunk (20.5%); upper limbs/shoulder (11.9%); lower limbs/hip (25.2%); back (21.2%); abdomen
(11.3%); hand (3.3%); foot (1.3%). Melanoma thickness: ≤1mm 85.3% (n=29); >1mm 14.7% (n=15)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: Clinical photographs
Prior test data: Only gender, age at diagnosis and the site of the skin lesion were known to the observer
Other test data: File contained clinical and dermoscopic images; unclear whether both observed at the same time.
Diagnostic threshold: investigated clinical features such as elevation, ulceration, shape, borders, colour
Diagnosis based on: Single observer (n=1)
Observer qualifications: Not reported; assumedDermatologist
Experience in practice: Not described




Method of diagnosis: Dermoscopic images
Prior test data: Clinical image also available
Diagnostic threshold: Assessed the lesions using the following dermoscopic criteria associated with melanoma and non-melanocytic skin lesions: pigment
network, pigmentation, streaks, dots ⁄ globules, blue-whitish veil, regression structures, hypopigmentation, leaf-like areas, multiple grey-bluish globules,
central white patch and vascular pattern
Test observers as described for Visual Inspection (above)
Other detail: Any other detail 122 images were taken with a digital stereomicroscope and 52 were taken with a Dermaphot camera (Heine Optotechnik;
Herrsching, Germany) (· 10 magnification)and then digitalized with the Kodak PhotoCDsystem. Ultrasound gel was used on all the lesions (52)photographed
with the Dermaphot in the Avianocentre. The other centres used the digital stereomicroscope consisting of a stereomicroscope and a Sony 3CCDDXC-930P
colour video camera. The digital images were taken at a magnification of · 10–20.
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Target condition (Final diagnoses)
Melanoma (invasive): 34 (39 in full sample); Melanoma (in situ): 5;
Other diagnoses reported only for full sample of 151 (only 108 with clinical images for VI evaluation):
55 (40 with clinical images) "amelanotic ⁄ hypomelanotic non melanocytic lesions" (25 BCC, 4 SCC, 10 dermatofibroma, 8 Bowen’s disease, 8 seborrhoeic
keratosis)
52 (29 with clinical images) "amelanotic ⁄ hypomelanotic benign melanocytic lesions" (24 compound naevi, 17 dermal naevi, 5 Spitz naevi, 4 congenital naevi
and 2 combined naevi).
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Yes
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
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Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: 23 lesions excluded due to image quality; further 43 lesions were not available for evaluation by clinical images ("mainly benign
melanocytic lesions").
 
Time interval to reference test: Not reported
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative Time interval between index test(s): not reported
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? No
Was the interval between application of the index tests less than one month? Unclear
Are there any concerns that the test comparison could have introduced bias? Unclear risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No





A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Consecutively excised melanomas <5 mm diameter and 3 randomly sampled histologically proven small-diameter naevi for each
included melanoma
 
Setting: Specialist unit (skin cancer/pigmented lesions clinic) [from Author institution]
Prior testing: Selected for excision (no further detail); All had undergone dermoscopy and RCM in order to be included
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: lesion size >5mm excluded; Disagreement between evaluators on tumour histological classification
Sample size (patients): No. included: 96
Sample size (lesions): No. included: 96
Participant characteristics: Mean age: melanoma group 48y (IQR 17, 77y); naevi 41y (IQR 6, 82y). Male gender: 54% of melanoma group; 58% of naevi
group
Lesion characteristics: Lesion site - trunk: 62% naevi; lower limbs/hip: 46% melanomas; Melanoma thickness: mean 0.37mm (SD 0.44mm). Lesion size
(invasive melanoma): 77% (n=10) < 1 mm, 13% (n=3) >=1 mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes




Method of diagnosis: Dermoscopic images
Prior test data: body site and age; it appears that RCM images also available at time of image interpretation. "For each lesion a complete set of
dermoscopic and confocal images (including the whole lesion) was available"; "Dermoscopic and confocal microscopic images were evaluated – in blind
from histological diagnosis, but not from the body site or the age of the patient".
Diagnostic threshold: Score >=3
Diagnosis based on: Unclear likely single (n=NR)
 
Observer qualifications: Not reported; no description of observers was provided
Experience in practice: Not described
Experience with dermoscopy: Not described
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
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Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Details: histopathology performed by two independent board-certified pathologists; disagreements were reviewed by both pathologists to obtain a consensus
diagnosis.
Disease positive: 24; Disease negative: 72
Target condition (Final diagnoses)
Melanoma (invasive): 13; Melanoma (in situ): 11
Benign naevus: 72 ( 29 junctional, 19 compound, intra-dermal, eight blue, four lentigo simplex and seven Spitz)
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Not described
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Patients with atypical melanocytic lesions or suspected early malignant melanoma
 
Setting: Private care
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Private care
Exclusion criteria: lesions over 13mm in diameter were excluded as they could not fit entirely within the standardized photographs
Sample size (patients): No. included: 63
Sample size (lesions): No. included: 72
Participant characteristics: None reported
Lesion characteristics: Melaoma thickness - ≤1mm: 100% of MM (n=21)
Are the included patients and chosen study setting appropriate? No
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Did the study avoid including participants with multiple lesions? No




Method of diagnosis: Clinical photographs and dermoscopic images
Prior test data: Dermoscopic images also presented to observer but unclear whether both viewed at the same time or not; "Each color transparency was
independently analyzed" by observers. The 1) clinical, 2) ”overall” dermoscopic, and 3) ABCD ”scored dermoscopic diagnoses of either MM or AMN were
recorded for each lesion by the same observers. No indication of blinding between images
Diagnostic threshold: Clinical variables were defined as follows: Asymmetry (A): Both silhouette and colour distribution were considered. Border
irregularity (B): This was judged by the unevenness of the perimeter. Color (C): Color variegation and number of colours were evaluated. Diameter (D): The
largest in situ diameter in millimetres of each lesion was recorded
Diagnosis based on: Single observer (n=4)
Observer qualifications: Two experienced dermatologists, and two melanoma fellows
 
Experience in practice: Mixed experience (low and high experience combined)
Experience with dermoscopy: Not reported
#
 
Dermoscopy ABCD and no algorithm
Method of diagnosis: Clinical photographs and dermoscopic images
Prior test data: Clinical examination and/or case notes The 1) clinical, 2) ”overall” dermoscopic, and 3) ABCD ”scored dermoscopic diagnoses of either MM
or AMN were recorded for each lesion by the same observers. No indication of blinding between images
Diagnostic threshold: ABCD scored dermoscopic diagnosis [Lesions with a score of 4.75 or less were classified as benign, those with scores 4.76 to 5.45
as suspicious, and those with scores of more than 5.45 as melanomas. Each feature was given a score of”1”. Thus, the score ranged from 1 to 5]
 Overall dermoscopic diagnosis - no threshold reported; the overall dermoscopic impression was recorded based on criteria in the recently published
textbook by Stolz et al. (1994 Color Atlas).
Test observers as described for Visual Inspection (above)
Any other detail All photographs were taken with the dermophot standard lens-to-lesion distance, aperture, and flash. Fujichrome 50 color 35 mm-
transparency film was used and all exposed film was processed in the same laboratory (Colorite, New York, NY, USA)
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? Unclear
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Details: Each of the 72 melanocytic neoplasms was histopathologically diagnosed as with AMN or an early MM by a dermapathologist with special expertise
in melanocytic neoplasms. Each lesion was completed excised and step sectioned.
 Disease positive: 21 MMs; Disease negative: 51 AMN
Target condition (Final diagnoses) 
Melanoma (invasive): 21
51 atypical melanocytic nevus
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
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A. Risk of Bias
Flow and timing
Excluded participants: none reported
 
Time interval to reference test: not reported
 
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative Time interval between index test(s) : not reported
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? No
Was the interval between application of the index tests less than one month? Yes
Are there any concerns that the test comparison could have introduced bias? Low risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No





A. Risk of Bias
Patient Sampling
Study design: Unclear
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Pigmented skin lesions that had been analysed as part of a prior study using a MSDSLA system (Monheit 2011); melanomas and other
pigmented lesions presumably selected on a case-control type basis
 
Setting: Unclear
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): No. included: NR
Sample size (lesions): No. included: 24
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear




Method of diagnosis: Dermoscopic images; Interactive melanoma session where dermatologists were first presented with clinical and dermoscopic images
and asked to make a diagnosis; then presented with information from MelaFind
Prior test data: Patient history and clinical images were presented along with dermoscopic images
Diagnostic threshold: Clinical decision to excise or not
Diagnosis based on: Average (n=179)
Observer qualifications: Dermatologist; practicing dermatologists attending an educational conference
 
Experience in practice: Assumed High (median duration of practice 11-15 years)
Experience with dermoscopy: Not reported
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
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If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Histology (not further described); Disease positive: 5; Disease negative: 19
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 5; 'Benign' diagnoses: 19
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Not described
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation
Period of data collection 30-month period; dates NR
 
Country Australia
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Consecutive series of pigmented lesions submitted for histology from the primary care skin cancer practice of one author.
Setting: Primary/private; skin cancer practice of one author.
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Primary
Exclusion criteria: Poor image quality (considered under Flow and Timing)
Sample size (patients): No. included: 389
Sample size (lesions): No. eligible: 466 pigmented lesions out of 1959 lesions excised or biopsied; No. included: 463
Participant characteristics: Mean age: 57y (SD 17). Male gender: 67.4%
Lesion characteristics: (53.1%) melanocytic. Lesion site: 17.7% head or face; Trunk: 52.1%; 27.6% extremities; 2.2% palms or soles. Melanoma
thickness: ≤1mm: 1/29 melanoma (3.4%)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests Visual inspection (VI) No algorithm
Method of diagnosis: Clinical photographs overview and close up image presented
Prior test data: No further information used
Other test data: Dermoscopic images presented to observer subsequent to diagnosis using clinical images alone.
Diagnostic threshold: Clinical diagnosis/subjective impression. Observers gave a diagnosis with level of confidence (from 0 for definitely benign to 100 for
definitely malignant) after viewing the clinical images. (NB used authors threshold for detection of any skin cancer which includes lesions clinically
7/13/2018 #164 Dermoscopy, with and without visual inspection, for the diagnosis of melanoma in adults
https://archie.cochrane.org/popups/view.jsp?url=%2Fsections%2Fdocuments%2Fview%3Fdocument%3Dz15012116044828295657279213… 129/255
considered to be MM, BCC pigmented epithelial carcinoma including SCC, keratoacanthoma, actinic keratosis and Bowen's disease as test positive; review
only considered histologically confirmed MM, BCC or invasive SCC to be disease positive)
Diagnosis based on: Single observer (n=NR)
Observer qualifications: Expert dermatologist (based on author communication).
Experience in practice: Expert
Experience with dermoscopy: Expert
#
Dermoscopy Pattern analysis; new algorithm - Chaos and clues
Method of diagnosis: Clinical photographs (one overview and one close-up), followed by one dermoscopic image presented to a blinded observer on a
computer screen
Prior test data: Clinical image only; Diagnosis made based on clinical image before presentation of dermoscopic image
Diagnostic threshold: Observers gave a diagnosis with level of confidence (from 0 for definitely benign to 100 for definitely malignant).
Chaos and clues short algorithm - each assessed for evidence of ‘‘chaos’’ (asymmetry of colour or structure); if present then ‘‘clues’’ searched for. Chaos -
asymmetry of structure and colour defined according to the basic principles of pattern analysis as revised by Kittler (2007). Clues included: eccentric
structure-less zone (any colour except skin colour), grey or blue structures, peripheral black dots or clods, segmental radial lines or pseudopods,
polymorphous vessels, white lines,thick reticular or branched lines, and parallel lines on ridges (acral lesions).
Observers as for visual inspection
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? No
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Details: Excise or biopsy
 Disease positive: 138; Disease negative: 325
Target condition (Final diagnoses)
Melanoma (invasive): 9; Melanoma (in situ): 20; BCC: 72; cSCC: 5 (including 2 keratoacanthoma)
'Benign' diagnoses: 18 Bowen's disease and 14 actinic keratosis, 217 benign melanocytic plus additional 140 benign non melanocytic
*authors considered Bowen's disease, actinic keratosis and keratoacanthoma as malignant; all considered benign for review analysis
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: Lesions were excluded due to poor image quality (n=3)
Time interval to reference test: Unclear; lesions 'routinely photographed' if scheduled for excision or biopsy but not further described
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
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Comparative
A. Risk of Bias
Comparative Time interval between index test(s): consecutive
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? No
Was the interval between application of the index tests less than one month? Yes
Are there any concerns that the test comparison could have introduced bias? High risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: All palmoplantar pigmented skin lesions observed and removed because of the presence of clinical and/or dermoscopic suspicious
features and in the absence of any clear benignity pattern (parallel furrow pattern, lattice-like pattern or fibrillar pattern).
 
Setting: Secondary (general dermatology)
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Secondary (general dermatology)
Exclusion criteria: Non-acral lesions; site of lesion in volar skin of the folds near the toes; lesion size larger than 26mm diameter; non-melanocytic
appearance; elevated or ulcerated appearance
Sample size (patients): No. included: 107
Sample size (lesions): No. included: 107
Participant characteristics: Mean age: 49.8 years (women); 44.9 years (men); range 19 to 73 years; Male: 58.9%; Ethnicity white: 100%
Lesion characteristics 78 on soles and 19 on palms; 9 (36%) melanomas <=0.75 mm (incl 4 in situ); 11 (44%) 0.76 to 1.5 mm in 11/25 lesions; 5 (20%)
>=1.50mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy Pattern analysis; 3-step algorithm for palmoplantar lesions (Koga 2011)
Method of diagnosis: Dermoscopic images
Prior test data: No further information used
Diagnostic threshold: Clinical diagnosis (melanoma/no melanoma). For the 3-step algorithm the conventional options are "removal, follow-up or no follow-
up"; the latter two were combined under the term ‘no melanoma’ for study purposes
Diagnosis based on: Single observer (n=2; one per algorithm)
 
Observer qualifications: Dermatologist
Experience in practice: High
Experience with dermoscopy: High; two dermatologists with 20 years’ experience
 in dermoscopy
 
Any other detail: ELM images achieved with the DB-Mips System; (magnification x 16),
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? Yes
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
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Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Details: "Histopathological diagnosis was based on the criteria of the National Institute of Health Consensus Conference"
 Disease positive: 25; Disease negative: 82
Target condition (Final diagnoses) 
Melanoma (invasive): 21; Melanoma (in situ): 4
'Benign' diagnoses: 82
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Not described
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation
Period of data collection 2010–2014
 
Country Not reported. Majority of authors based in Italy, but source of lesion images not described
 
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Consecutive melanocytic skin lesions showing clear-cut dermoscopic features of regression that were excised for suspected malignancy.
Regression features included: blue-grey veil, blue grey globules and white scar-like areas, hypopigmented areas and atypical network (all of which may be
present in benign and malignant lesions)
 
Setting: Secondary; Not clearly reported but authors all based in Dermatology units or departments
Prior testing: Dermatoscopic suspicion in all cases
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): No. included: 95
Sample size (lesions): No. included: 95
Participant characteristics: Median age: nevi group 36y (14 to 59 y); melanoma group 54.4y (17 to 89y). Male gender : 43; 45.2%
Lesion characteristics: Lesion site: Head/Neck: 20 (40%) of Nevi; Trunk 23(46%) of nevi and 24 (55%) of melanoma group; extremities 7 (14%) of nevi
group; other areas 20 (45%) of melanomas. Lesion size: mean 7.63mm, range 4 to 16mm (nevi) and 10.33mm 5 to 19mm (melanomas)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests Dermoscopy Pattern analysis using 12 dermoscopic features of regression (study also developed a new classifier but data excluded from review due to use
of leave one out procedure for validation)
 
Method of diagnosis: Dermoscopic images; randomly presented to observers in blind to histopathological diagnosis.
Prior test data: Unclear; data on morphology, site, age and gender were collected but not clear if presented along with image
Diagnostic threshold: Diagnosis of melanoma or nevus following assessment of 12 dermoscopic structures suggestive of regression selected according to
the literature (Zalaudek 2004; Seidenari 2010) including blue-grey areas, blue-whitish veil, blue globules and blue-grey peppering, white scar-like areas,
white shiny streaks, atypical network, hypopigmented areas, irregular dots and globules, irregular streaks, irregular pigmented blotches and pink areas.
Diagnosis based on: Single observer and consensus of 2/3 (n=3)
Observer qualifications: Dermatologist
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Experience in practice: High; expert dermatologists
Experience with dermoscopy: High; "experienced dermoscopists"
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone;
Details: Every histological diagnosis was confirmed by 2 out of 3 expert dermopathologists
 Disease positive: 45; Disease negative: 50
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not reported): 45
Benign naevus: 50
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Not described
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation
Period of data collection NR
 
Country Italy (based on authors' institution)
 
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Melanocytic lesion images acquired consecutively by d-ELM at the Department of Dermatology of Santa Chiara Hospital, Trento.
 
Setting: Secondary (general dermatology)
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Prior testing: Selected for excision (no further detail)
Setting for prior testing: Not reported
Exclusion criteria: Seems that dysplastic nevi were excluded; "In this experimental setting, there were no dysplastic nevi"
Sample size (patients): Not reported
Sample size (lesions): No. included: 152
Participant characteristics: None reported
Lesion characteristics: mean Breslow thickness for the invasive lesions is 1.0 +/- 0.7mm; 81% <=1.5mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear




Method of diagnosis: Dermoscopic images; digitial-ELM images presented on video device
Prior test data: No further information used
Diagnostic threshold: Not reported; appears to be correct diagnosis of melanoma
Diagnosis based on: Single observer and average (n=8)
 Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with dermoscopy: Not described
Any other detail The d-ELM Image Acquisition consists of a Leica WILD M-650 stereomicroscope (Leica Microsystem, Heerbrugg, Switzerland), with a
SONY 3CCD DXC-930P colour camera (Sony Corporation,Tokyo, Japan). The software for image acquisition was DBDERMO MIPS (Dell’Eva/Burroni
Studio, Florence/Siena, Italy). The digital image size has a spatial resolution of 768 x 576 pixels and a 24-bit colour resolution
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 42; Disease negative: 110
Target condition (Final diagnoses)
Melanoma (invasive): 31; Melanoma (in situ): 11
Benign naevus: 110
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Not described
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
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Comparative





A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Melanomas and benign pigmented skin lesions from a larger series of pigmented skin lesions used to develop a new automated
classifier; all melanomas with x20 magnification images were included plus a random sample of benign lesions with the same magnification. For the larger
series, lesions were referred by dermatologists or general physicians because of one or more PSL that were difficult to interpret on clinical grounds alone,
numerous PSLs, or because the patients were at increased risk for melanoma or had had a malignant PSL in the past.
Setting: Secondary
Prior testing: Clinical suspicion of malignancy
Setting for prior testing: Primary; Secondary (general dermatology)
Exclusion criteria: None reported
Sample size (patients): Not reported
Sample size (lesions): No. eligible: 917; No. included: 100
Participant characteristics: None reported
Lesion characteristics: Melanoma thickness: ≤1mm : 70.8% (n=46), <1 mm 58.5% (n=38). mean thickness 0.73 ± 0.69 mm;
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear




Method of diagnosis: Dermoscopic images; (obtained via videomicroscopy)
Prior test data: No further information used; "Images appeared in a random sequence on the computer screen, and no information about the patient (such
as history, skin site, age of the patient, evolution of the lesion) was given to the evaluators"
Diagnostic threshold: Clinical diagnosis
Diagnosis based on: Single observer (n=2)
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with dermoscopy: Low - one 'untrained' dermatologist; High - one routinely used videomicroscopy
Any other detail For instrumental examination a 10- (39 cases), 20- (501 cases), or 50-fold–magnification (377 cases) was chosen according to the size of
the lesion, enabling the whole lesion to be seen on the monitor. For the study, the 31 MM with x20 magnification were selected plus a random sample of 59
benign
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Details: describes using "conventional histopathologic criteria."
7/13/2018 #164 Dermoscopy, with and without visual inspection, for the diagnosis of melanoma in adults
https://archie.cochrane.org/popups/view.jsp?url=%2Fsections%2Fdocuments%2Fview%3Fdocument%3Dz15012116044828295657279213… 135/255
Disease positive: 31; Disease negative: 59
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not reported): 31
'Benign' diagnoses: 59 "nonmelanoma cases consisted of nevi including dysplastic nevi"
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Not described
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Patients with melanocytic lesions referred to a pigmented lesion clinic by a dermatologist for examination of a particular lesion or the
whole skin; all lesions were excised for clinical, dermoscopic, or cosmetic reasons.
Setting: Specialist unit
Prior testing: Clinical and/or dermatoscopic suspicion; Patient request for evaluation/excision
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): NR
Sample size (lesions): No. included: 603
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear




Method of diagnosis: Dermoscopic images
Prior test data: No further information used; images were retrospectively subdivided into four groups according to diagnoses performed exclusively by
dermoscopy by two dermatologists trained in dermoscopy
Diagnostic threshold: Images grouped according to degree of atypia, with those grade 3 considered to be melanomas dermoscopically, and those at grade
2 as dermoscopically atypical, to be excised to rule out melanoma
Diagnosis based on: Not clear but appears to be consensus (2 observers) (n=2); "diagnoses performed exclusively by dermoscopy by two dermatologists
trained in dermoscopy and experienced in using polarized light videomicroscopes"
 
Observer qualifications: Dermatologist
Experience in practice: Not reported
Experience with dermoscopy: High
Any other detail images were captured using a digital videomicroscope(VMS-110A, Scalar Mitsubishi, Tama-shi, Tokyo, Japan), with a 20-fold magnification.
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
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Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone (no further details)
Disease positive: 112; Disease negative: 491
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 112
Benign naevus: 491
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: not reported
Time interval to reference test: not reported
 
Time interval between index test(s): not reported
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation




Test set derived NR; The training set consisted of 369 melanocytic lesion images (including 43 MMs); test set comprised 243 images (including 43 MMs).
 
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Dermoscopic images of melanocytic lesion that had undergone excision
 
Setting: Unclear
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (patients): Not reported
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Sample size (lesions): No. eligible: 612; No. included: 243 in test set
Participant characteristics: None reported
Lesion characteristics MMs of the test set included 8 in situ with mean thickness was 0.77 mm.
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear




Method of diagnosis: Dermoscopic images observed on a computer screen
Prior test data: No further information used; clinicians had no access to the clinical image or to clinical data
Diagnostic threshold: Clinial diagnosis of melanoma
Diagnosis based on: Single observer (n=4; results presented per observer, but not identifiable by experience level)
 
Observer qualifications: Dermatology registrar (n=3); Dermatologist (n=1)
Experience in practice: Not reported
Experience with dermoscopy: Mixed: Trained (residents had undergone 6-month daily training on dermoscopy); High (dermatologist employed
dermoscopy on a regular basis)
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone (no further details)
Disease positive: 43; Disease negative: 200
Target condition (Final diagnoses)
Melanoma (invasive): 35; Melanoma (in situ): 8
Benign naevus: 200
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Not described
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative
B. Concerns regarding applicability
Notes
Notes  




A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Consecutive lesions excised due to changes over time during digital dermoscopy follow-up (appear to be from patients with multiple
melanocytic naevi); all lesions were assessed for presence of dermoscopic characteristics and all melanomas plus random sample of same number of
benign were assessed by dermoscopic algorithms (included in review)
Setting: Secondary (general dermatology)
Prior testing: Not reported
Setting for prior testing: Unspecified
Exclusion criteria: Location/site of lesion - palmar, plantar, facial lesions; lesion size lesions that exceeded maximum field of view of the electronic camera
Sample size (patients): NR
Sample size (lesions): No. included: 126
Participant characteristics: None reported
Lesion characteristics None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy 7-point checklist and ABCD
Method of diagnosis: Dermoscopic images presented on a computer screen
Prior test data: No further information used
Diagnostic threshold: ABCD score >4.75; 7-point checklist score >2
Diagnosis based on: Single observer (n=2)
 
Observer qualifications: Dermatologist
Experience in practice: Assumed High; paper describes assessment of baseline images for dermoscopic criteria by "2 experienced dermatologists";
"additionally, the baseline images of (a subgroup of lesions) were evaluated by 2 blinded investigators). These appear to be separate groups of observers
but have assumed similar levels of experience.
Experience with dermoscopy: Assumed High (as above)
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? Unclear
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone (but all lesions followed up)
Details: "standard histopathology" following lesion changes over time
Disease positive: 63; Disease negative: 63
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 63
Benign naevus: 63
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
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B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Lesions suggestive of melanoma at baseline were removed at the patient’s initial visit (immediately); the others
were followed up for 3 to 6 months until lesion changes initiated excision
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC? Yes
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less? Yes
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Unclear




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Pigmented skin lesion, difficult to diagnose on clinical grounds alone
 
Setting: Specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: Clinical suspicion
Setting for prior testing: Secondary (general dermatology); referred by dermatologists or general physicians
Exclusion criteria: None reported
Sample size (patients): NR
Sample size (lesions): No. included: 159
Participant characteristics: None reported
Lesion characteristics "23 melanomas with a Breslow index of </= 0.75mm, 13 melanomas with a Breslow index >/=0.76mm and </= 1.5mm, 12
melanomas with a Breslow index >/=1.51mm and </=3.5mm, 2 melanomas with a Breslow index of >/=3.5mm."
Are the included patients and chosen study setting appropriate? Unclear
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? Unclear
Index Test
Index tests
Visual inspection (VI) No algorithm
 
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Other test data: Dermoscopy undertaken by same clinician(s) subsequent to clinical evaluation
Diagnostic threshold: Not reported
Diagnosis based on: n= 2 (1 or 2 per lesion)
 
Observer qualifications: Dermatologist
Experience in practice: Not clearly described; assumed to be High; "the examination was performed by a dermatologist expert in dermoscopy"
Experience with dermoscopy: High; "the examination was performed by a dermatologist expert in dermoscopy"




Method of diagnosis: In person diagnosis "After application of a drop of immersion oil, each lesion was examined with a hand-held dermatoscope"
Prior test data: Clinical examination and/or case notes
Diagnostic threshold: Criteria included: pigment network, irregular extensions, radial streaming, brown globules, black dots, whitish veil, white scar-like
areas, gray-blue areas, hypopigmented areas, reticular depigmentation, amongst others.
Any other detail "After application of a drop of immersion oil , each lesion was examined with a handheld dermatoscope (Heine, Optotechnik, Herrsching,
Germany) at a magnification of x 10 and with an incident light stereomicroscope (Wild M 650, Heerburg, Switzerland) with 6- to 40-fold magnification."
 
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
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For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 65 (41%); Disease negative: 94 (59%)
Target condition (Final diagnoses)
Melanoma (invasive): 50; Melanoma (in situ): 15
 BCC: pigmented basal cell carcinoma (3)
Sebhorrheic keratosis: 18; Clark's nevus of dysplastic nevus (61 cases); lentigo actinica lentigo (2), pigmented actinic keratosis (4), angioma (3),
angiokeratoma (2).
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative tbc
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? No
Was the interval between application of the index tests less than one month? Yes
Are there any concerns that the test comparison could have introduced bias? Low risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? Yes





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective (for expert observer data; previously acquired images prospectively interpreted by 6 inexperienced observers - data
excluded as 3/6 medical students)
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Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Lesions at pigmented lesion clinic considered by experienced dermatologists to merit excision on clinical grounds.
 
Setting: Specialist unit
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Specialist unit
Exclusion criteria: None reported
Sample size (patients): No. included: 225
Sample size (lesions): No. included: 231
Participant characteristics: Median age 34 years. Male gender: 110/225 (48.9%)
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy No algorithm (study also develops 3-point checklist but data ineligible due to use of medical student observers)
Method of diagnosis: In person
Prior test data: Clinical examination
Diagnostic threshold: Diagnosis of malignancy (melanoma or BCC)
Diagnosis based on: Single observer (n= 1)
 
Observer qualifications: Dermatologist
Experience in practice: High; "experienced dermatologists"
Experience with dermoscopy: High; "Each lesion was diagnosed dermoscopically by an experienced dermoscopist"
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone (not further described) 
 Disease positive: 77; Disease negative: 154
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 68
 BCC: 9
'Benign' diagnoses: 154
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Appears consecutive; "before excision, each lesion was diagnosed dermoscopically"
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
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If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Images of pigmented skin lesions selected from computerised files of the skin cancer clinic.
 
Setting: Training study; images selected from skin cancer clinic
Prior testing: Not reported
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (patients):
Sample size (lesions): No. included: 30PSLs
Participant characteristics: None reported
Lesion characteristics None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: Clinical photographs
Prior test data: No further information used
Other test data: Dermoscopic images presented to observer subsequent to diagnosis using clinical images alone (images were randomised).
Diagnostic threshold: Not reported
Diagnosis based on: Average; n= 20
Observer qualifications: Dermatologist
Experience in practice: Not described;
Experience with dermoscopy: 30 dermatologists with “experience in ELM but (with) no formal training” attended a seminar on clinical and ELM diagnosis




Method of diagnosis: Dermoscopic images
Prior test data: Post training, clinical image presented alongside dermoscopic image
Diagnostic threshold: Not reported
Test observers as described for Visual Inspection (above)
#
Dermoscopy training: Participants undertook 75 minute seminar on the overview of the principles of ELM using digital ELM (D-ELM) images from the files
at the clinic. A second session 45 minutes long focused on the major aspects of the differential diagnosis of PSL as evaluated by D-ELM.
 
Length of training 2 hrs
 
Post-training experience: <6months
Training format In-person teaching
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
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For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 10
 BCC: 4
Mild//moderate dysplasia: 3; Sebhorrheic keratosis: 3; Benign naevus: Melanocytic nevi-7
 Other: 1 hemangioma1 subungunal hemorraghe1 plantar intraepidermal hemorraghe
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative Time interval between index test(s): not reported 
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? No
Was the interval between application of the index tests less than one month? Unclear
Are there any concerns that the test comparison could have introduced bias? Unclear risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No





A. Risk of Bias
Patient Sampling
Study design: Case-control (dermoscopy training study)
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Pigmented skin lesion images (of melanomas, melanocytic naevi and non melanocytic naevi) selected from the dermoscopy files of two
skin cancer clinics
Setting: Specialist unit databases
Prior testing: Not reported (all lesions excised)
Setting for prior testing: Not reported
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Exclusion criteria: None reported
Sample size (patients): Not reported
Sample size (lesions): No. included: 30
Participant characteristics: None reported
Lesion characteristics: Melanoma thickness median 0.61mm, range 0.28-20mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy No algorithm (training course covered principles of clinical and dermoscopic diagnosis of PSLs and referred to a number of diagnostic
algorithms, however it did not teach any one particular method of diagnosis; same slides evaluated both pre- and post-dermoscopy training)
Method of diagnosis: Clinical photographs and dermoscopic images
Prior test data: No further information used; pairs of slides were projected onto a screen without access to patient information
Diagnostic threshold: Correct diagnosis of melanoma




Experience in practice: Mixed; "an average of 10y of general experience in dermatology (range 1-22yrs)"
Experience with dermoscopy: Mixed; "A routine use of ELM was reported by 52 (63%) individuals". 35 (42%) see >20 PSLs per week
#
Dermoscopy training: Attendees could choose from several classes: Clinical classification and diagnosis of PSLs; Management of patients with PSLs;
basic principles of ELM; ELM criteria; ELM diagnosis; Limitations of ELM.
 
Length of training 4+2hr for each session attended
 
Training format In-person teaching; delivered as one-day workshops and meetings
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone (not further described; original histological diagnosis used) 
 Disease positive: 11; Disease negative: 19
Target condition (Final diagnoses)
Melanoma (invasive): 10; Melanoma (in situ): 1
14 melanocytic nevi; 5 non-melanocytic lesions
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Not described
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
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A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Patients with pigmented skin lesions referred by dermatologists and general practitioners either for pre-surgical assessment or
consultation
 
Setting: Specialist unit; "skin cancer clinic of Ravenna"
Prior testing: patients referred for pre-surgical assessment or consultation indicating they have had prior tests
Setting for prior testing: Primary some patients referred for consultation only; dermoscopy findings are reported back and management decision remains
with referring clinician; Secondary (general dermatology)
Exclusion criteria: None reported
Sample size (patients): No. eligible: 1556
Sample size (lesions): No. eligible: 3372; No. included: 3372
Participant characteristics: Median age 30 years, range 10 to 94; Male: 522 (34%)
 
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? Yes
Did the study avoid including participants with multiple lesions? No
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Visual inspection (VI) ABCD
Method of diagnosis: In person diagnosis
Prior test data: N/A in-person diagnosis
Other test data: Dermoscopic and clinical images subsequently presented separately to observer subsequent to diagnosis using clinical images alone.
Diagnostic threshold: NR
Diagnosis based on: Single observer; n= 1
 
Observer qualifications: Not reported; described as one of the co-authors and study based in skin cancer clinic - likely dermatologist
Experience in practice: Not described
Experience with dermoscopy: Not described





Method of diagnosis: Unclear; Patients seen in-person but dermoscopic diagnosis made based on digital ELM image (by same clinician as in-person
clinical dx)
Prior test data: Combined clinical/dermoscopy diagnosis
Diagnostic threshold: Diagnosis described as based on an integrated synopsis of the patterns most commonly described in the literature (Steiner 1993)
and generally associated with known histologic counterparts. Features were assessed described in detail with multiple references, including: presence of
pigment network, sharp margins, abrupt edge of pigment network, branched streaks, pseudopods, radial streaming, brown globules, pigment dots, whitish or
whitish blue veil, gray-blue areas, white or depigmented areas, maple leaf areas, milia-cysts, horny plugs and vascular patterns.
Test observers as described for Visual Inspection (above)
Experience with dermoscopy:
Any other detail The equipment consisted of a Leica Wild M-650 stereomiscroscope (Leica AG, Heerbrugg, Switzerland), a Sony 3ccd DXC-930P color
video camera, an AT-Vista videographics adapter, and IBM personal computer, a Sony Trinitron Analog PVM-2043MD monitor, and the DBDERMO MIPS
software
 
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
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For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis plus follow up; histology report of known surgical excisions (n=262) plus a cancer-registry based follow up of
benign cases (n=3110)
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 55; BCC: 43
'Benign' diagnoses: 3274
Is the reference standards likely to correctly classify the target condition? No
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC? Yes
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative Time interval between index test(s): not clearly reported just indicated that D-ELM was performed soon after clinical examination
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? No
Was the interval between application of the index tests less than one month? Unclear
Are there any concerns that the test comparison could have introduced bias? Unclear risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? Unclear





A. Risk of Bias
Patient Sampling
Study design: Unclear (likely case series)
Data collection: Retrospective image selection / Prospective interpretation




Test set derived A training set of 22 melanomas and 218 melanocytic nevi was randomised from the dataset. The test set was formed by the complement
(the remaining 20 melanomas and 217 nevi). A further subset of images from the original dataset, consisting of 31 melanomas and 103 nevi, was used for
the comparison between observers and CAD; derivation of the subset not reported.
 
Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Unclear
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Melanocytic lesions from patients referred to the Skin Cancer Unit and undergoing clinical and dermoscopic evaluation; images were
'selected' from a larger image database. Potential overlap with Stanganelli 2000 (not possible to determine).
 
Setting: Specialist unit; Skin Cancer Unit in Ravenna
Prior testing: Clinical and/or dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: None reported
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Sample size (patients): No. eligible: 1556 referred / No. included: NR
Sample size (lesions): No. eligible: 3274 / No. included: 477 melanocytic lesions; 237 in test set and 134 in comparison between CAD and human
operators
Participant characteristics: None reported
Lesion characteristics: Melanoma thickness 61.2% <0.75mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: Clinical photographs
Prior test data: General practitioners evaluated only clinical images; Dermatologists examined both clinical and dermoscopic images but unclear whether
clinical diagnosis was made prior to presentation of dermoscopic images
Diagnostic threshold: Not reported
Diagnosis based on: Average (n=6)
 
Observer qualifications: GP 3; Dermatologist 3
Experience in practice: NR
Experience with dermoscopy: Assumed Low for GPs; High for dermatologists - described as “dermatologists with experience in ELM (2 years)”




Method of diagnosis: Dermoscopic images (dermatologists only)
Prior test data: Dermatologists examined both clinical and dermoscopic images
Diagnostic threshold: Not reported
Test observers as described for Visual Inspection (above)
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis plus cancer registry
All included lesions underwent histology but some were identified using a cancer-registry-based follow-up of benign diagnoses.
 
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 42 in full sample; 31 in CAD vs human observer interp and 20 in test set
'Benign' diagnoses: 435 melanocytic nevi; 103 in CAD-observer comp and 217 in test set
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Unclear
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
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Flow and timing Excluded participants: none reported
Time interval to reference test: not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? No
Was the interval between application of the index tests less than one month? Yes
Are there any concerns that the test comparison could have introduced bias? Low risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection/Prospective interpretation




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Melanocytic lesions excised at the Skin Cancer Unit on the basis of clinical and/ or dermoscopic changes at follow-up suggesting a
malignancy
 
Setting: Specialist unit; "conducted at the Skin Cancer Unit at the ‘Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori’ (IRST IRCCS), in
Ravenna/Forli and Meldola"
Prior testing: Changes on digital monitoring; Lesions showing clinical or dermoscopic changes on follow-up
Setting for prior testing: Specialist unit
Exclusion criteria: Lack of baseline and follow-up dermoscopic images; lack of RCM images; lack of histology.
Sample size (patients): No. included: 70
Sample size (lesions): No. included: 70
Participant characteristics: Mean age - women 39 years; men 40 years. Male gender: 54%. History of melanoma/skin cancer (37%). Total naevus counts,
27 (39%) with > 50 melanocytic naevi, 33 (47%) with 10–50 naevi; and 10 (14%) with <10 naevi. Fitzpatrick phototype I to II 19 (27%); Type III to IV 50
(73%). Median follow-up was 25 months (range 3–134 months)
Lesion characteristics: Lesion site Head/Neck 7.1%; Trunk: 80%; Upper limbs/shoulder: 1.4%; Lower limbs/hip: 11.4%. Melanoma thickness median
0.4mm (0.2-1mm). Lesion size: mean at baseline 8 mm (range 2–22 mm); mean at FU 9 mm (range 3–24 mm)
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy: Revised 7-point checklist (for follow-up purposes)
Method of diagnosis: Dermoscopic images; baseline images assessed using standard 7-point checklist and compared to follow-up images to determine
criteria indicating significant change
Prior test data: Baseline dermoscopic image
Diagnostic threshold: Presence of 'Major change' (asymmetrical structural and chromatic changes, or the appearance of melanoma-specific criteria, i.e.
major or minor criteria on original seven-point checklist as per Argenziano 1998). Revised approach referenced to Argenziano 2010. [‘Minor change’
assigned if there was only symmetrical change in structural or chromatic pattern; ‘moderate change’ if either structural or chromatic changes were
asymmetrical, but there were no melanoma-specific criteria; and ‘no change’ was assigned if all variables remained constant, with a tolerance of major axis
change of 2 mm (Beer 2011; Terushkin 2012)]
Diagnosis based on: Unclear; n= NR for dermoscopy
 
Observer qualifications: Not reported but likely dermatologists (RCM images in same study were evaluated jointly by three expert dermatologists who had
no knowledge of the clinical, dermoscopic or histopathology information)
Experience in practice: Not described
Experience with dermoscopy: Not described
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
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A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Details: "histopathological diagnosis was based on the consensus of at least two out of three board-certified pathologists"
 Disease positive: 12; Disease negative: 58
Target condition (Final diagnoses) 
Melanoma (invasive): 11; Melanoma (in situ): 1
 'Benign' diagnoses: 55 melanocytic naevi (79%) and three nonmelanocytic lesions (4%).
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Appears consecutive; "Lesions showing clinical and/or dermoscopic aspects suggesting a malignancy are
excised.
 RCM imaging is performed before surgical excision."
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation




Test set derived: 157 cases were randomly divided into a test and training set.
 
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? No
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Equivocal melanocytic skin lesions with size smaller than 9x13 mm, melanoma tumour thickness of <= 1mm and melanoma Clark's level
III or less
 
Setting: Secondary (general dermatology); Univerisity of Munich Department of Dermatology
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): Not reported
Sample size (lesions): No. eligible: 650 cases / No. included: 157 lesions
Participant characteristics: None reported
Lesion characteristics: Melanoma thickness: 50 <=0.4mm; 30 <=0.75mm; 15 <=1mm
Are the included patients and chosen study setting appropriate? No
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Did the study avoid including participants with multiple lesions? Unclear




Method of diagnosis: Dermoscopic images; colour prints examined for 31 dermoscopic features, most listed in the guidelines of the Consensus
Conference of Surface Microscopy held in Hamburg in 1989 (Bahmer 1990); described as a "blind study"
Prior test data: No further information used
Diagnostic threshold: > 5.45; Multivariate analysis of training set data identified 8 features with the lowest p-values; the total dermoscopic score (TDS) was
then developed based on: Asymmetry score x 1.3 + Border score x 0.1 +Colour score x 0.5 + Differential structure score x 0.5. New formula then evaluated
on the test set of images.
Diagnosis based on: Single observer (n=1)
 
Observer qualifications: Not reported; co-author, assumed to be dermatologist
Experience in practice: Not described
Experience with dermoscopy: Not described
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard - Histological diagnosis alone
Details: Histology undertaken by two independent histopathologists
Disease positive: Test set= 48; Disease negative: test set= 31
Target condition (Final diagnoses)
Melanoma (invasive): 85; Melanoma (in situ): 10
'Benign' diagnoses: 62 melanocytic naevi; 17 junctional; 40 compound; 5 dermal
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Not described
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative
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A. Risk of Bias
Patient Sampling
Study design: Case control (dermoscopy training study)
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Test series of images of melanomas and benign lesions; source of images not reported
 
Setting: Not described; Training images
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (patients): Not reported
Sample size (lesions): No. included: 30
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy (Modified) pattern analysis
Method of diagnosis: Clinical photographs and dermoscopic images
Prior test data: Particpants presented with a test card printed on A4 laminated paper for each lesion, each consisting of one macroscopic and one
dermatoscopic image
Diagnostic threshold: Excise or not (algorithm not further described)
Diagnosis based on: Average (n=6; all based at same University Hospital); the study authors presented 2x2 based on adding each 2x2 cell together for all
observers; to avoid double counting of lesions for this review, all 2x2 cells were divided by 6 to get average result.
 
Observer qualifications: Dermatology specialist registrar 3; Dermatologist 3
Experience in practice: Mixed
Experience with dermoscopy: Low; Before the study, none had routinely used a dermatoscope.
#
Dermoscopy training: Participants received an online tutorial (http://www.dermatoscopy.org) teaching the Modified Pattern Analysis Diagnostic Algorithm
(Steiner 1987; Carli 2003) and was given a dual polarizing LED dermatoscope to use in clinical practice for 10 months. At the end of the study, the test-card
questionnaire was repeated.
 
Length of training NR; online tutorial
 
Post-training experience: 10 months
Training format Online
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone (not further described) 
 Disease positive: 15; Disease negative: 15
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not reported): 15
Other: 15 (9 naevi, 1 blue naevus, 3 seborrhoeic keratoses, 1 lentigo and 1 vascular lesion).
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
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Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Not described
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective image selection / Prospective interpretation
Period of data collection: Not described
Country France
 
Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Dermoscopic images of all melanoma lesions recorded on two pigmented skin lesion databases, plus random sample of benign naevus
 
Setting: Secondary (general dermatology)
Prior testing: Not reported
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (patients): Not reported
Sample size (lesions): No. included: 227
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear




Method of diagnosis: Dermoscopic images
Prior test data: Clinical photographs
Diagnostic threshold: Clinical diagnosis of melanoma and Excise decision; presence of ABCD and "malignancy-predictive" dermoscopic features were
assessed (dichotomic answer) and diagnosis (melanoma, dysplastic or benign lesion) and therapeutic decision (dichotomic answer, excision/non-excision)
given.




Experience in practice: High; "senior dermatologists"
Experience with dermoscopy: Not described; assumed High
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
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Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Unclear
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Unclear
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Unclear
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis plus other
Histology: Excision and histopathology of lesions considered to be melanomas (n=32), dysplastic lesions (n=118) and some of those considered benign
(n=15).
Disease positive: 32; Disease negative: 165
Other: "lesions considered benign were not surgically excised"; assume observer diagnosis was used
Disease positive: 0; Disease negative: 62
Target condition (Final diagnoses)
Melanoma (invasive): 28; Lentigo maligna 4
Dysplastic nevus - 118; Blue benign naevus - 2;Congenitcal benign nevus - 5; junctional and dermic benign nevus - 7; Palmar-plantar benign nevus - 1;
'Benign naevus' not excised: 62
Is the reference standards likely to correctly classify the target condition? No
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? High risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard No
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? High
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Not described
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Unclear
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC? Unclear
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Images of pigmented skin lesions selected for a dermoscopy training study
 
Setting: Training study
Prior testing: Not reported
Setting for prior testing: Not reported
Exclusion criteria: lesions that were >13mm were not included
Sample size (patients):
Sample size (lesions): No. included: 50 lesions
Participant characteristics: None reported
Lesion characteristics: Melanoma thickness: ≤1mm: 100%
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
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Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Visual inspection (VI): No algorithm
Method of diagnosis: Clinical photographs and dermoscopic images
Other test data: Dermoscopic images presented to observer subsequent to diagnosis using clinical images alone.
Prior test data: No further information used
Diagnostic threshold: Not reported
Diagnosis based on: Average; n= 32
Observer qualifications: Dermatologist
Experience in practice: High experience or ‘Expert’
Experience with index test: Low experience / novice users; experienced in PSL field but not ELM
#
Dermoscopy: No algorithm; possibly Pattern analysis
 
Method of diagnosis: Dermoscopic images
Prior test data: No further information used. Previously made diagnosis based on clinical images only; dermoscopic images presented after all clinical
diagnoses had been made
Diagnostic threshold: Not reported
Test observers as described for Visual Inspection (above)
Dermoscopy training: The group of 32 volunteer dermatologists had no formal training in the use of ELM, but had good theoretical knowledge and
personal experience; participated in a teaching course comprised 6h of teaching on two consecutive days. The training was based on the presentation of
several hundred slides with oral explanation of the ELM criteria. Tests were performed at the beginning and end of the teaching course.
 
Length of training 2 days (12 hours in total)
 
Post-training experience: <6months
Training format: In-person teaching
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 25; Disease negative: 25
Target condition (Final diagnoses) 
Melanoma (invasive): 25
'Benign' diagnoses: 50 "not melanoma"
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing Excluded participants: none reported
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Time interval to reference test: not reported
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative Time interval between index test(s): not reported
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? Yes
Was the interval between application of the index tests less than one month? Yes
Are there any concerns that the test comparison could have introduced bias? Low risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Melanocytic lesions excised at Ankara University Department of Dermatology Pigmented Lesion Clinic
 
Setting: Specialist unit; Ankara University Department of Dermatology Pigmented Lesion Clinic
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: Location/site of lesion facial, nail and volar acral lesions were excluded; non-melanocytic appearance
Sample size (patients): No. included: 115
Sample size (lesions): No. included: 115
Participant characteristics: Mean age: 38.72y (+/- 18.46 y). Male gender: n=56 (49%).
Lesion characteristics: Lesion site: 100% trunk and limbs. Melanoma thickness: 10 (41.7%) <0.75mm; 14 (58.3%) >=0.75mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Yes
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm; Appears to be original clinical diagnosis at time of lesion presentation
 
Method of diagnosis: In person diagnosis Appears to be diagnosis on presentation
Prior test data: N/A in-person diagnosis
Other test data: Dermoscopic images presented to different observers
Diagnostic threshold: Not reported
Diagnosis based on: Unclear - for visual inspection appears to be single examiner at time of clinic diagnosis (n=NR); dermoscopic images "scored by three
other experienced dermatoscopists"
 
Observer qualifications: Not reported; assumed dermatologists; described as experienced dermatoscopists
Experience in practice: Unclear for clinic diagnosis; dermatoscopists described as "experienced"
Experience with index test: Described as "experienced"
#
Dermoscopy 3-point rule; 7-point checklist; ABCD; CASH algorithm
 
Method of diagnosis: Dermoscopic images
Prior test data: No further information used; Clinical image evaluation appears to be separate from dermoscopy interpretation
Diagnostic threshold: ABCD score- >=5.45 highly suggestive for melanoma; 7-point score- >=3; 3-point score- 2 or 3 criteria present; CASH algorithm-
>=8
Observers as described for VI
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
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Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? Unclear
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 24; Disease negative: 91
Target condition (Final diagnoses) 
Melanoma (in situ and invasive, or not reported): 24
'Benign' diagnoses: 91 melanocytic benign lesions; 37 (32.2%) dermal nevi; 15 (13%) clark's nevi; 14 (12.2%) compound nevi; 13 (11.3%) blue nevi; 6
(5.2%) spitz nevi; 4 (3.5%) congenital melanocytic nevi; 2 (1.7%) junctional nevi
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative Time interval between index test(s): Appear to be consecutively applied
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? Yes
Was the interval between application of the index tests less than one month? Unclear
Are there any concerns that the test comparison could have introduced bias? Unclear risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Not reported




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? Unclear risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Pigmented skin lesions examined at the Dermoscopy Service and undergoing excision; a modified version of Kenet's risk stratification
approach for dermoscopy (Ascierto 1998) was used to select high and very high risk lesions for excision; medium and low risk lesions were excised based
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on cosmetic or functional reasons. (2x2 data have been extracted only for melanocytic subgroup).
 
Setting: Specialist unit (skin cancer/pigmented lesions clinic) Dermoscopy service at a university department (Department of Endocrinologic and metabolic
disease)
Prior testing: Clinical suspicion of malignancy without dermatoscopic suspicion
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: None reported
Sample size (patients): No. eligible: 349 patients; No. included: not reported
Sample size (lesions): No. eligible: 520 lesions; No. included: 79 lesions excised included in the final analysis
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Visual inspection (VI). No algorithm
Method of diagnosis: In person diagnosis
Prior test data: Unclear
Diagnostic threshold: Not reported; correct diagnosis of melanoma
Diagnosis based on: Single observer (n=NR; "All dermoscopic
evaluations were performed by the same operators")
Observer qualifications: Not reported; "each lesion was .. diagnosed clinically and dermoscopically" at the Dermoscopy service
Experience in practice: Not described
Experience with dermoscopy: Not described; assumed High as diagnosis at 'Dermoscopy service'
#
Dermoscopy No algorithm; appears to be based on pattern analysis
Method of diagnosis: In person diagnosis
Prior test data: Clinical examination and/or case notes
Diagnostic threshold: Lesion classification based on typical dermoscopic features: lesions with a pigment network and any of the classical dermoscopic
features specific for melanoma, i.e. pseudopods, radial streaming or blue grey veil, were classified as very high risk. Lesions with a pigment network and
dermoscopic features that might suggest melanoma but often seen in atypical nevi were classified as high risk.
Test observers: as described above
Visual Inspection - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - in-person
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? Yes
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Yes
Are there concerns that the index test, its conduct, or interpretation differ from the review question? Low concern
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
B. Concerns regarding applicability
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Target condition (Final diagnoses) 
Melanoma (invasive): 12
 Melanocytic lesion: 67
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
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Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
 
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative Time interval between index tests: Not clearly reported but assumed consecutive as both recorded at Dermoscopy Service
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? No
Was the interval between application of the index tests less than one month? Yes
Are there any concerns that the test comparison could have introduced bias? Low risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? Yes





A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Pigmented lesions (melanomas and benign pigmented lesions) selected from a repository of lesions amassed during an acquisition
study conducted by MELA Sciences Inc for the US Food and Drug Administration
 
Setting: Company database (MELA Sciences Inc) of lesion images
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Not reported
Exclusion criteria: None reported
Sample size (patients): Not reported
Sample size (lesions): No. included: 47
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear




Method of diagnosis: Dermoscopic images
Prior test data: Clinical images and detailed clinical history; observers "viewed the images and a detailed case history for each lesion but were unaware of
the MelaFind recommendations"
Diagnostic threshold: Clinical diagnosis of melanoma or not; decision to biopsy the lesion
Diagnosis based on: Average (n=39)
 
Observer qualifications: Dermatologist
Experience in practice: Not described
Experience with dermoscopy: Not described
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
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Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Details: "Lesions were biopsied in toto and evaluated by a panel of dermatopathologists who were unaware of the MelaFind recommendations"
Disease positive: 23 / Disease negative: 24
Target condition (Final diagnoses)
Melanoma (in situ and invasive, or not reported): 23
'Benign' diagnoses: 24
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Yes
Are there concerns that the target condition as defined by the reference standard does not match the question? Low concern
Flow and Timing
A. Risk of Bias
Flow and timing
Participant exclusions: None reported
Index test to reference standard interval: Consecutive; "prior to biopsy of the lesion, photographs of the lesion were taken"
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Low risk
Comparative
A. Risk of Bias
Comparative





A. Risk of Bias
Patient Sampling
Study design: Case control (for lesion selection; study was an RCT of dermoscopy training for PCPs)
Data collection: Retrospective




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Clinically atypical pigmented skin lesions; 50 invasive melanomas and 50 non-melanomas randomly selected from the Sydney
Melanoma Unit pigmented skin lesions (PSL) image database.
 
Setting: Specialist unit (lesion selection)
Prior testing: Selected for excision or followed up
Setting for prior testing: Specialist unit (skin cancer/pigmented lesions clinic)
Exclusion criteria: None reported
Sample size (patients): No. included: NR
Sample size (lesions): No. included: 100
Participant characteristics: None reported
Lesion characteristics: median Breslow thickness 0.6mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
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Index tests Visual inspection (VI): No algorithm
Method of diagnosis: Clinical photographs
Prior test data: Unclear; all participants "were instructed not to look at the surface microscopic image until they had scored the clinical image"
Diagnostic threshold: Not reported
Diagnosis based on: Average (n=37; 74 practising primary care practitioners randomised to dermoscopy education intervention or not). **Diagnoses were
recorded for both groups of GPs at baseline (pre-test) and after the training intervention had been administered to the intervention group (post-test),




Experience in practice: Considered to be Low; Only practitioners who had had no formal training with surface microscopy and did not use a surface
microscope in their clinical practice were included.
Experience with dermoscopy: Low experience / novice users (non-training arm); 'Trained' for the intervention arm
Other detail: Any other detail Camera designed for close-up clinical photography (Elicar Macrolens, Japan)
#
 
Dermoscopy: No algorithm (non-training arm); Menzies criteria (training/intervention arm)
 
Method of diagnosis: Dermoscopic images
Prior test data: Diagnosis was first based on the clinical image and then the dermoscopic image for each lesion.
Diagnostic threshold: Not reported; intervention arm instructed in Menzies criteria.
Test observers: As above
Any other detail: Dermoscopy at X10 magnification with a Dermphot camera (Heine Ltd) using oil at the skin-lens interface.
#
Dermoscopy training: The education intervention included provision of the Menzies et al pictorial atlas which reportedly describes the Menzies approach to
dermoscopy diagnosis of melanoma (Menzies 1996); they also attended a 1-h presentation on dermoscopy reviewing the Menzies approach and including a
quiz based on images of 25 different pigmented skin lesions
Post-training experience: <6months; the median interval between pretest and education intervention was 46 days (range 5-155). median interval from
education intervention to post-test was 23 days (range 2-54).
Training format In-person teaching; Written materials
 
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others? Yes
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? No
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis plus follow up
Histology: All the lesions except two had been excised after photography and subjected to histopathological examination. Disease positive: 50 / Disease
negative: 48
Clinical FU plus histology of suspicious lesions: The two benign PSL that had not been excised were monitored over a longer period of time and had shown
no morphological change.
 Length of FU: NR; Disease positive: 0 / Disease negative: 2
Target condition (Final diagnoses)
Melanoma (invasive): 50 / 'Benign' diagnoses: 50
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
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Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
 
Time interval to reference test: "All the lesions except two had been excised after photography"
 
Was there an appropriate interval between index test and reference standard? Yes
Did all patients receive the same reference standard? No
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC? Unclear
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative Time interval between index test(s): Not reported; lesions described as "excised after photography" therefore assumed consecutive
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? Yes
Was the interval between application of the index tests less than one month? Yes
Are there any concerns that the test comparison could have introduced bias? Low risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No





A. Risk of Bias
Patient Sampling
Study design: Case control
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Unclear
Was a case-control design avoided? No
Did the study avoid inappropriate exclusions? Unclear
Could the selection of patients have introduced bias? High risk
B. Concerns regarding applicability
Patient characteristics
and setting
Inclusion criteria: Images of pigmented skin lesions previously analysed by a digital classifier MSDSLA; method of selection of the 12 not reported
 
Setting: Unclear; images selected for a Dermoscopy conference
Prior testing: Not reported
Setting for prior testing: Unspecified
Exclusion criteria: None reported
Sample size (patients): Not reported
Sample size (lesions): No. included: 12
Participant characteristics: None reported
Lesion characteristics: None reported
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Visual inspection (VI) No algorithm
Method of diagnosis: Clinical photographs
Prior test data: Unclear
Other test data: Dermoscopic images presented to observer subsequent to diagnosis using clinical images alone.
Diagnostic threshold: Not reported - biopsy decision
Diagnosis based on: Average (n=70)
 
Observer qualifications: Dermatologist
Experience in practice: Not described; recruited “dermatologists at a dermoscopy conference”. No further details
Other detail: Authors report that practitioners with a particular interest in skin cancer or technology may have chosen to attend this conference and/or self-




Method of diagnosis: Dermoscopic images
Prior test data: Clinical images provided
Diagnostic threshold: Not reported - biopsy decision
Test observers as described for Visual Inspection (above)
Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
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B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Unclear
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Unclear risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? No
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone
Disease positive: 5 / Disease negative: 7
Target condition (Final diagnoses) 
Melanoma (invasive): 3 / Melanoma (in situ): 2
Mild/moderate dysplasia: 7 low grade dysplastic nevi
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
Flow and timing
Excluded participants: none reported
Time interval to reference test: not reported
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? Yes
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC? Yes
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? Unclear risk
Comparative
A. Risk of Bias
Comparative tbc
Was each index test result interpreted without knowledge of the results of other index tests or testing strategies? No
Was the interval between application of the index tests less than one month? Yes
Are there any concerns that the test comparison could have introduced bias? Low risk
B. Concerns regarding applicability
Were all tests applied and interpreted in a clinically applicable manner? No





A. Risk of Bias
Patient Sampling
Study design: Case series
Data collection: Retrospective image selection / Prospective interpretation




Was a consecutive or random sample of patients enrolled? Yes
Was a case-control design avoided? Yes
Did the study avoid inappropriate exclusions? Yes
Could the selection of patients have introduced bias? Low risk
B. Concerns regarding applicability




Inclusion criteria: Excised, equivocal and nonequivocal, pigmented and nonpigmented skin lesions with good image quality and melanin or haemoglobin
pigmentation in all or part of the lesion.
 
Setting: Specialist unit; specialized Pigmented Lesion Clinic database
Prior testing: Selected for excision (no further detail)
Setting for prior testing: Specialist unit
Exclusion criteria: None reported
Sample size (patients): NR
Sample size (lesions): Eligible: 2621; Included - 150 (plus 15 lesions used for training purposes)
Participant characteristics: None reported
Lesion characteristics 37/165 (26%) considered equivocal on clinical and dermoscopic grounds
Thickness/depth: Mean breslow 0.9mm
Are the included patients and chosen study setting appropriate? No
Did the study avoid including participants with multiple lesions? Unclear
Are there concerns that the included patients and setting do not match the review question? High
Index Test
Index tests
Dermoscopy: 3 point checklist
 
Method of diagnosis: Dermoscopic images, 'optimized for colour, brightness and contrast by using Adobe photoshop standards'
Prior test data: Age, site, and gender provided
Diagnostic threshold: >= 1 criterion present indicates malignancy (asymmetry - in colour and ⁄or structure, not in shape; atypical network - pigment network
with thick lines and irregular holes; and blue white structures - presence of any blue and ⁄or white colour within the lesion
Diagnosis based on: Average (n=150 out of 170 participating observers, who finished all 15 training cases and performed at least one evaluation of the
main set of images (test set). Participation was open to all individuals regardless of professional profile and experience in dermoscopy; study was advertised
through personal communication, e-mail correspondences, adverts during congresses and courses, as well as via the website
(http://www.dermoscopy.org).).
Observer qualifications: For full sample of 170: Dermatologists (n=125); GPs (n=15); Other professionals in the field of skin lesions (n=12); Medical
students (n=7); Other medical specialty (n=11)
Experience in practice: Not described
Experience with dermoscopy: Mixed; 146/170 (86%) reported some experience with dermoscopy; 24 with no dermoscopy experience, 45 (26%) with >5
years experience.
#
Dermoscopy training: A web-based tutorial was provided to describe the concept of the three point checklist of dermoscopy including complete definitions
of criteria and example images. Following web-based tutorial, observers initially scored a random sample of 15 images, receiving real-time feedback for that




Visual Inspection - in-person
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - in-person
A. Risk of Bias
B. Concerns regarding applicability
Visual inspection - image-based
A. Risk of Bias
B. Concerns regarding applicability
Dermoscopy - image-based
A. Risk of Bias
Were the index test results interpreted without knowledge of the results of the reference standard? Yes
If a threshold was used, was it pre-specified? Yes
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?
Could the conduct or interpretation of the index test have introduced bias? Low risk
B. Concerns regarding applicability
Was the test applied and interpreted in a clinically applicable manner? No
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes
Was the test interpretation carried out by an experienced examiner? Unclear
Are there concerns that the index test, its conduct, or interpretation differ from the review question? High
Reference Standard
A. Risk of Bias
Target condition and
reference standard(s)
Reference standard Histological diagnosis alone (no further details)
Target condition (Final diagnoses) 
Melanoma (invasive): 18; Melanoma (in situ): 11
BCC: 18
79 melanocytic naevi; 26 seborrhoeic keratoses; 8 vascular tumours and 3 dermatofibromas
Is the reference standards likely to correctly classify the target condition? Yes
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear
Could the reference standard, its conduct, or its interpretation have introduced bias? Low risk
B. Concerns regarding applicability
Expert opinion (with no histological confirmation) was not used as a reference standard Yes
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear
Are there concerns that the target condition as defined by the reference standard does not match the question? Unclear
Flow and Timing
A. Risk of Bias
7/13/2018 #164 Dermoscopy, with and without visual inspection, for the diagnosis of melanoma in adults
https://archie.cochrane.org/popups/view.jsp?url=%2Fsections%2Fdocuments%2Fview%3Fdocument%3Dz15012116044828295657279213… 164/255
Flow and timing Participant exclusions: Poor quality index test image as exclusion criterion
Index test to reference standard interval: Not described
Was there an appropriate interval between index test and reference standard? Unclear
Did all patients receive the same reference standard? Yes
Were all patients included in the analysis? No
If the reference standard includes clinical follow-up of borderline/benign appearing lesions, was there a minimum follow-up following application of index test(s) of at
least: 3 months for melanoma or cSCC or 6 months for BCC?
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?
Could the patient flow have introduced bias? High risk
Comparative
A. Risk of Bias
Comparative




NR – not reported; PSL – pigmented skin lesion; PLC – pigmented lesion clinic; MM – malignant melanoma; MiS – melanoma in situ (or lentigo maligna); BCC – basal cell carcinoma;
cSCC – cutaneous squamous cell carcinoma; LS – lentigo simplex; SK – seborrhoeic keratosis; SN – Spitz nevi; AK – actinic keratosis; BN – benign naevi; BD – Bowen’s disease; DF –
dermatofibroma; FU – follow-up; R –retrospective; P – prospective; CS – case series; CCS – case control study; WPC – within person comparison (of tests); BPC – between person
comparison (of tests); NC – non comparative; RCM – reflectance confocal microscopy; CAD – computer-assisted diagnosis; FU - follow-up; ABCD(E) - asymmetry, border, colour,
differential structures (enlargement); 7FFM - seven features for melanoma; 7PCL - seven point checklist; rev - revised; 3PCL - three point checklist; CASH - colour, architecture,
symmetry and homogeneity
Characteristics of excluded studies
Ahnlide 2013




Reason for exclusion EXCLUDE on 2x2 data
no 2x2 data only describing the dermoscopic features present in the lesions
 
Al Jalbout 2013




Reason for exclusion EXCLUDE on reference standard
only 7 reported verified histologically
 
Altamura 2006
Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE on 2x2 data
looking for chars associated with acral melanoma; does not give 2x2 for overall dx
 
Altamura 2010
Reason for exclusion EXCLUDE on target condition (include for keratinocyte review only)
 
Amirnia 2016
Reason for exclusion EXCLUDE on target condition (include for keratinocyte review only)
 
Antonio 2013
Reason for exclusion EXCLUDE on target condition
Atypical nevi does not fall within our definition of D+
 
Antoszewski 2015
Reason for exclusion EXCLUDE on sample size
All excised lesions were benign.
EXCLUDE on 2x2 data
 
Aoyagi 2010
Reason for exclusion EXCLUDE on sample size
 
Argenziano 1997
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Reason for exclusion EXCLUDE not a primary study
 
Argenziano 2003
Reason for exclusion EXCLUDE on 2x2 data
Table V gives se/sp data for 108 lesions but can't derive the number of melanoma for this subset of the original 128
EXCLUDE but contact authors; contacted 10-5-16 and 24-6-16
 
Argenziano 2004
Reason for exclusion EXCLUDE if individual lesion characteristics
only lesions with vascular structures included; presence of 10 different characteristics assessed. 2x2 would be possible
 
Argenziano 2004a








Reason for exclusion EXCLUDE on index test
test used for follow-up looking at dermoscopic features of melanomas diagnosed 1 yr after follow up
EXCLUDE on 2x2 data
 
Argenziano 2011a
Reason for exclusion EXCLUDE on target condition




Reason for exclusion EXCLUDE on target condition
5 melanoma metastases included as D+
 
Argenziano 2012
Reason for exclusion EXCLUDE on reference standard
no follow-up of test negatives
 
Armstrong 2011
Reason for exclusion EXCLUDE on reference standard
No reference standard results presented for the screened lesions; just compares naked eye judgements with dermoscopy
 
Ascierto 1998
Reason for exclusion EXCLUDE on 2x2 data
the data presented does not contribute to the review
EXCLUDE duplicate or related publication Data included in Ascierto 2003
 
Ascierto 2000
Reason for exclusion EXCLUDE on 2x2 data
EXCLUDE but contact authors
For excised lesions, study cross-tabulates ELM high/very high risk classification against some histological classification (Table




Reason for exclusion EXCLUDE not a primary study
 
Bafounta 2001
Reason for exclusion EXCLUDE not a primary study
systematic review
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Bajaj 2016
Reason for exclusion EXCLUDE on reference standard
unclear ref standard for benign diagnoses
 
Bauer 2005




Reason for exclusion EXCLUDE on index test
dermoscopy used to improve histopathology diagnosis
 
Benati 2015
Reason for exclusion EXCLUDE if individual lesion characteristics
 
Benelli 2000a
Reason for exclusion EXCLUDE on 2x2 data
only inter-rater reliability data given (n=25); authors have published much larger evaluations of 7FFM and ABCD
 
Benvenuto-Andrade 2006
Reason for exclusion EXCLUDE on 2x2 data
diagnostic confidence rather than accuracy
 
Benvenuto-Andrade 2007
Reason for exclusion EXCLUDE on 2x2 data
agreement on lesion characterisation; not test accuracy
 
Binder 1997
Reason for exclusion EXCLUDE on 2x2 data
training study; only ROC curves/AUC presented pre and post-training
EXCLUDE but contact authors [contacted 10-5-16 and 24-6-16]
 
Blum 2003a
Reason for exclusion EXCLUDE not a primary study
 
Blum 2004a




Reason for exclusion EXCLUDE not a primary study
letter
Letter only; limited data presented - evaluates '3-colour' rule as developed By Mackie 1992 (excluded as assessment of
individual lesion features only)
 
Blum 2004d




Reason for exclusion EXCLUDE on target condition
differentiates melanocytic from non-melanocytic lesions only
 
Blum 2011








Reason for exclusion EXCLUDE on study population
study aim is estimate the efficacy of an online spaced educational training for dermoscopy




Reason for exclusion EXCLUDE on 2x2 data
aim of the study is to determine what features are present in amelanotic cutaneous melanoma
 
Borsari 2010
Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE but contact authors
Paper focuses on diagnostic prediction of dermoscopic island for early melanoma, however the Methods describe the
calculation of the total dermoscopy score and the 7-point checklist score; mean scores on each checklist per lesion type are
then presented [no reply from authors]
 
Bowns 2006
Reason for exclusion EXCLUDE on index test; teledermatology study
 
Braun 2000
Reason for exclusion EXCLUDE if derivation study
this is a pilot study on the new "wobble sign" in ELM no training/test sets used
 
Braun 2007
Reason for exclusion EXCLUDE if individual lesion characteristics
 
Braun-Falco 1990
Reason for exclusion EXCLUDE on 2x2 data
Not a test accuracy study
 
Brown 2000




Reason for exclusion EXCLUDE on index test
follow up/monitoring
EXCLUDE duplicate or related publication
same patients as Haenssle 2010 #191
 
Bystryn 2003




Reason for exclusion EXCLUDE on 2x2 data
can't get 2x2; reports % correct diagnoses for each different lesion classification and not % misdiagnosed as melanoma or
melanomas missed
EXCLUDE but contact authors
Study states "Dermatoscopic diagnosis were conformable with pathohistological diagnosis in 75 cases (72.82%) out of 103. The
highest conformation was in diagnosing melanoma, in 5 out of 6 cases (83.3%)." which would give us sensitivity; do you have




Reason for exclusion EXCLUDE if derivation study
looks at dermoscopic characteristics of acral lesions; only 4 suspicious lesions excised
 
Cardenas 2009
Reason for exclusion EXCLUDE on study population
Includes participants with palpable lesions; not all suspected of having skin cancer
 
Carli 1998
Reason for exclusion EXCLUDE on sample size
se/sp data are based on sample with only 4 MM
 
Carli 2000
Reason for exclusion EXCLUDE on target condition
only lesions histologically classified as common naevi or naevi with architectural disorder with/without cytological atypia were
considered for the study.




Reason for exclusion EXCLUDE on sample size
 
Carli 2004
Reason for exclusion EXCLUDE on sample size
<5 MM per arm
EXCLUDE on 2x2 data
 
Carli 2004a
Reason for exclusion EXCLUDE on index test; can only estimate 2x2 for the full time period 1997 to 2001 across all observers, however dermoscopy
was only introduced routinely in 1998 so some diagnoses prior to that will have been with visual inspection alone, and observers
were classed as dermoscopy ’users’ (those working in pigmented lesion clinics) and nonusers (general dermatology).
EXCLUDE but contact authors
Author passed away; unable to make contact with co-authors
 
Carli 2005
Reason for exclusion EXCLUDE on 2x2 data
EXCLUDE but contact authors
Study presents % MM correctly classified by naked eye +/- dermoscopy but doesn't give any detail on FPs, is thisavailable




Reason for exclusion EXCLUDE on 2x2 data
Gives se/sp for visual inspection and dermoscopy in the English abstract. 68 patients/70 lesions were included but only 36
seem to have had visual inspection results and all underwent dermoscopy. Two observers performed each test blinded to each
other. Table I gives 22 with BCC and 11 with melanoma overall (no. D+ not reported for those with VI results), but using either or
both of these numbers with the se/sp provided does not give the same PPV and NPV as given by the authors
EXCLUDE but contact authors
data not clearly presented for 2x2; translator suggested alternative but still does not work out to what is in paper; tried
contacting authors twice, no reply as of 28-07-16;
 
Carroll 1998
Reason for exclusion EXCLUDE if derivation study
Derivation study; proposes new dermoscopic criteria for dx of BCC
EXCLUDE on 2x2 data
 
Chen 2013
Reason for exclusion EXCLUDE on test observer
 
Ciudad-Blanco 2014
Reason for exclusion EXCLUDE on study population
Includes melanoma only
EXCLUDE if individual lesion characteristics
EXCLUDE on 2x2 data
 
de Giorgi 2006
Reason for exclusion EXCLUDE on sample size
<5 cases of participants with a final melanoma diagnosis
 
De Giorgi 2011
Reason for exclusion EXCLUDE duplicate or related publication
Assesses same lesions as in Carli 2003b but different observers
 
de Troya-Martin 2008




Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE if derivation study
EXCLUDE on 2x2 data
only reports association of each characteristics with D+/D-, not 2x2
 
Di Chiacchio 2010
Reason for exclusion EXCLUDE on target condition
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Excluding nail bed melanoma
EXCLUDE on 2x2 data
There is insufficient data to extract for a 2x2 table
 
Di Stefani 2007




Reason for exclusion EXCLUDE if individual lesion characteristics
 
Elwan 2016
Reason for exclusion EXCLUDE on sample size
EXCLUDE if derivation study
EXCLUDE on 2x2 data
 
Fabbrocini 2008
Reason for exclusion EXCLUDE on 2x2 data
there isn't sufficient data provided for each index test to populate 2x2 table
EXCLUDE but contact authors
As we can only include DTA studies - Do you have a cross tabulation of each clinician's diagnosis (e.g. at threshold of >=3 on 7
point checklist) against the histological diagnosis and/or a cross tabulation of the remote diagnosis against the Face to Face
diagnoses? [author reply; 30-6-16 cannot access data needed]
 
Ferrara 2002
Reason for exclusion EXCLUDE on index test
this study looks at histopathological and dermoscopic disagreements not necessarily looking at how well dermoscopy
differentiates between benign and malignant diagnosis
 
Fidalgo 2003
Reason for exclusion EXCLUDE on 2x2 data
EXCLUDE duplicate or related publication
Appears to be superseded by Serrao 2006
EXCLUDE but contact authors
Paper provides % of MM and of DN with DNAOS scores of >=5.5 and >7, is it possible for you to provide the same information
for the remaining 127 lesions in the study? Also can you advise as to whether any of the 247 lesions included in this study,
overlap with the 652 reported in Serrao 2006 (#1144)? [author contacted 10-5-16; 24-06-16]
 
Fruhauf 2012
Reason for exclusion EXCLUDE on reference standard
35/219 underwent histology; 13 followed-up; 171 expert clinical Dx
 
Fueyo-Casado 2009
Reason for exclusion EXCLUDE on reference standard
<50% of the study population received histology as a test. No information given on those who were followed up.
 
Giacomel 2005




Reason for exclusion EXCLUDE on sample size
 
Giannotti 2004




Reason for exclusion EXCLUDE on sample size
EXCLUDE if derivation study
 
Gilmore 2009
Reason for exclusion EXCLUDE if derivation study
Principle of lacunarity has been looked at before but not this particular application/approach to it
EXCLUDE on reference standard
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It is possible to get 2x2 for 'standard dermoscopy criteria' however dermoscopy negative were not excised and assumed
benign; 201/312 underwent excision so theoretically eligible
 
Grichnik 2003
Reason for exclusion EXCLUDE on sample size
 
Grichnik 2004




Reason for exclusion EXCLUDE if derivation study
 
Gunduz 2003




Reason for exclusion EXCLUDE on target condition
Does not provide sufficient data for detection of melanoma
 
Haenssle 2006
Reason for exclusion EXCLUDE on index test
[surveillance study estimating accuracy of different approaches to follow-up]
 
Haenssle 2010
Reason for exclusion EXCLUDE on 2x2 data
Does not report specificity
EXCLUDE duplicate or related publication
same patients as Haenssle 2010 #191
 
Haspeslagh 2016
Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE on 2x2 data
 
Henning 2007
Reason for exclusion EXCLUDE if derivation study
First application of CASH algorithm
 
Henning 2008
Reason for exclusion Exclude is a derivation study
 
Herschorn 2012




Reason for exclusion EXCLUDE on target condition
EXCLUDE on index test
 
Hoffmann 2003
Reason for exclusion EXCLUDE if derivation study
Uses leave one out cross validation procedure
EXCLUDE on 2x2 data
Only giving ROC values not able to extract a 2x2 table
 
Hoorens 2016
Reason for exclusion EXCLUDE on index test
EXCLUDE on reference standard
No info on numbers undergoing histology; and no follow-up reported for benign appearing lesions
EXCLUDE on 2x2 data
 
Ishioka 2009
Reason for exclusion EXCLUDE ON INDEX TEST - include for teledermatology only




Reason for exclusion EXCLUDE if derivation study
uses leave one out procedure and same lesions and tumour extraction method as Iyatomi 2006
EXCLUDE on 2x2 data
 
Iyatomi 2008
Reason for exclusion EXCLUDE if derivation study
the performance was evaluated by averaging both combinations (training and test sets) they did not present the data
separately; uses leave one out procedure
EXCLUDE on 2x2 data
Not test accuracy; compares automated with manual extraction of tumour area
 
Johr 2002
Reason for exclusion EXCLUDE not a primary study
 
Kawabata 1998
Reason for exclusion EXCLUDE if derivation study
aim of the study is to correlate findings between dermoscopy and histology findings of acral melanoma




Reason for exclusion EXCLUDE on study population MM of the nail bed
 
Kefel 2012
Reason for exclusion EXCLUDE if derivation study
no test set, first use of polarised light dermoscopy, various neural networks tested
EXCLUDE on 2x2 data
 
Kenet 1994
Reason for exclusion EXCLUDE not a primary study
EXCLUDE on 2x2 data
not an accuracy study
 
Kittler 2002




Reason for exclusion EXCLUDE conference abstract
 
Koga 2011
Reason for exclusion EXCLUDE on reference standard
~23% of patients have their final diagnosis reached by histopathology 43/191
 
Korotkov 2012




Reason for exclusion EXCLUDE if derivation study
Develops new algorithm and does not use separate training/test sets of lesions
 
Liebman 2011








Reason for exclusion EXCLUDE on target condition
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Reason for exclusion EXCLUDE if derivation study
ásymmetry detection; 10-fold cross validation
EXCLUDE on 2x2 data
 
Lorentzen 1999a
Reason for exclusion EXCLUDE on 2x2 data
EXCLUDE but contact authors
Can you provide us with the number of melanomas that were included in the study so that we can estimate the 2x2 contingency
tables using the se/sp data provided? Also is there overlap in the lesions included here with those included in the Lorentzen
2000 study? (see also author Qs for the 2000 study) [contacted 10-5-16; 24-6-16)
 
Luttrell 2012
Reason for exclusion EXCLUDE on test observer
Accuracy data only given for lay-persons not interested in this population of test observers
 
MacKie 1971
Reason for exclusion EXCLUDE on 2x2 data
only gives % with correct diagnosis rather than numbers misclassified as malignant
 
MacKie 2002
Reason for exclusion EXCLUDE if individual lesion characteristics
presence of 3 or more colours on dermoscopy
 
Markowitz 2015
Reason for exclusion EXCLUDE on target condition
Does not report sufficient data for detection of melanoma
INCLUDE based on full report
 
Massi 2001
Reason for exclusion EXCLUDE if individual lesion characteristics
 
Mayer 1997




Reason for exclusion EXCLUDE if individual lesion characteristics
only given the SE/SP of individual characteristics; lesions make up the training set for Menzies 1996 (#1971)
 
Menzies 1999
Reason for exclusion EXCLUDE not a primary study
 
Menzies 2000
Reason for exclusion EXCLUDE on target condition; BCC only
 
Menzies 2001




Reason for exclusion EXCLUDE on reference standard
Only 37% of benign group underwent adequate reference standard
 
Nathansohn 2007
Reason for exclusion EXCLUDE on 2x2 data
Not test accuracy; follow-up study
 
Navarrete-Dechent 2016
Reason for exclusion EXCLUDE on target population; 2x2 for BCC only
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Pan 2008
Reason for exclusion EXCLUDE if derivation study
looking to id characteristics assoc with superficial BCC; 2x2 could be extracted for combination of 3 selected characteristics.




Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE on reference standard
Of the 1543 lesions analysed on 321 received histopathology diagnosis. The accuracy data is based on this (only 20%) not sure
what happened to the 80% of participants as no mention of follow up is mentioned.
 
Pazzini 1996
Reason for exclusion EXCLUDE on 2x2 data
 
Pehamberger 1987
Reason for exclusion EXCLUDE on 2x2 data
Not test accuracy. This is a descriptive paper defining dermoscopic criteria. It is not a study testing accuracy of dermoscopy.
From the authors final sign off it looks like part 2 of this paper may have details on accuracy (Steiner 1987).
 
Pellacani 2002
Reason for exclusion EXCLUDE not a primary study
 
Pellacani 2006
Reason for exclusion EXCLUDE if derivation study
looks at detection of asymmetry between clinicians and computer
EXCLUDE on 2x2 data
2x2 could be derived for overall asymmetry or border cut-off but not overall diagnosis
 
Pellacani 2007
Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE if derivation study
looking at blue hue
 
Pellacani 2009
Reason for exclusion EXCLUDE on target condition
focus is on identifying Spitz nevi from melanoma and ‘clark’ naevi and it is looking to derive useful RCM characteristics.
Although some data is given in the text for an RCM score of >3 it is difficult to work out which are FP and which FN.
 
Peris 2002
Reason for exclusion EXCLUDE on study population
only patients with BCC diagnosis included
 
Peris 2002a
Reason for exclusion EXCLUDE not a primary study
 
Phan 2010
Reason for exclusion EXCLUDE on 2x2 data
Not test accuracy investigating dermoscopic features of acral melanoma including of the nail apparatus; no accuracy data given
 
Piccolo 2002a
Reason for exclusion EXCLUDE not a primary study
EXCLUDE on 2x2 data
not enough data to populate 2x2 table. No breakdown of index test results and ref standard.
 
Piccolo 2004
Reason for exclusion EXCLUDE on index test; include for teledermatology anyway
 
Piccolo 2006
Reason for exclusion EXCLUDE on sample size
3 MMs, but also 1 lentigo and 14 dysplastic nevus; data not presented to allow se/sp estimation
EXCLUDE if individual lesion characteristics
EXCLUDE if derivation study
Derivation for hypoluminescence microscopy;
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Pizzichetta 2001
Reason for exclusion EXCLUDE on study population
population in study only those with malignant disease
 
Pizzichetta 2001a




Reason for exclusion EXCLUDE on study population
Only patients with melanoma included
 
Pizzichetta 2010




Reason for exclusion EXCLUDE if individual lesion characteristics
presence of negative pigmented network
 
Pralong 2012
Reason for exclusion EXCLUDE on study population
only melanoma pts included
 
Provost 1998
Reason for exclusion EXCLUDE on 2x2 data
Not test accuracy; only reports concordance
 
Rader 2014
Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE on 2x2 data
 
Rajpara 2009




Reason for exclusion EXCLUDE not a primary study
systematic review kerationcyte skin cancer
 
Rigel 1997
Reason for exclusion EXCLUDE not a primary study
 
Ronger 2002
Reason for exclusion EXCLUDE if individual lesion characteristics
 
Rosendahl 2012
Reason for exclusion EXCLUDE if individual lesion characteristics
 
Rosendahl 2012a
Reason for exclusion EXCLUDE not a primary study
 
Rossi 2000
Reason for exclusion EXCLUDE on reference standard
Unclear reference standard in disease negative
 
Rubegni 2002
Reason for exclusion EXCLUDE not a primary study
 
Rubegni 2005
Reason for exclusion EXCLUDE not a primary study
Editorial
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Rubegni 2005a
Reason for exclusion EXCLUDE not a primary study
 
Rubegni 2010
Reason for exclusion EXCLUDE if derivation study
uses leave one out procedure
EXCLUDE on 2x2 data
 
Sahin 2004
Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE on 2x2 data
no accuracy data given, study looking at dermoscopic features of LM
 
Saida 2002
Reason for exclusion EXCLUDE if individual lesion characteristics
Decsriptive study looking at presence (%) of certain features. Not looking at accuracy. Has paragraph on diagnostic value of this
specific feature quoting sens & spec but this is based upon unpublished observations and the data is not given in this paper.
 
Saida 2004
Reason for exclusion EXCLUDE if individual lesion characteristics
 
Sakakibara 2010
Reason for exclusion EXCLUDE if individual lesion characteristics
only looking at different vascular structures
 
Salerni 2011




Reason for exclusion EXCLUDE on index test
surveillance study
EXCLUDE on 2x2 data
 
Salerni 2013
Reason for exclusion EXCLUDE not a primary study
systematic review of surveillance with digital dermoscopy
 
Salvio 2011
Reason for exclusion EXCLUDE not a primary study
EXCLUDE on sample size
 
Sanchez-Martin 2012








Reason for exclusion EXCLUDE not a primary study
 
Sboner 2003
Reason for exclusion EXCLUDE if derivation study
describes 10-fold cross-validation process for training/testing classifier
 
Schulz 2001




Reason for exclusion EXCLUDE not a primary study
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Segura 2009
Reason for exclusion EXCLUDE on index test; RCM evaluation
 
Seidenari 2004
Reason for exclusion EXCLUDE on 2x2 data
No data to populate 2x2 table just ROC curve values given.
EXCLUDE but contact authors
TABLE 5 provides AUC values for each diagnosis for both formats and observers; we are particularly interested in accuracy for
the diagnosis of melanoma, are you able to provide data in 2x2 format , e.g. for melanoma 'certain' against final diagnosis and
for melanoma 'certain or fairly certain' against final diagnosis? [no reply from authors]
 
Seidenari 2006
Reason for exclusion EXCLUDE on study population




Reason for exclusion EXCLUDE if individual lesion characteristics
looks like this study is only looking at asymmetry judgement
 
Seidenari 2012
Reason for exclusion EXCLUDE if individual lesion characteristics
looks at indvdl lesion chars to distinguish Mel in situ, also gives mean ABCD and seven point scores
EXCLUDE on 2x2 data
EXCLUDE but contact authors
Table 3 provides mean ABCD and seven point checklist scores, are you able to provide us with a cross tabulation of results with
each checklist at 'standard' thresholds against final diagnosis? e.g. ABCD >4.75 and >5.45 for MIS and benoign groups 7-point
checklist: presence >=2 chars and >=3 chars? [no reply]
 
Seidenari 2013
Reason for exclusion EXCLUDE on index test
 
Serrao 2006
Reason for exclusion EXCLUDE on index test; include for CAD review only
 
Sgouros 2014
Reason for exclusion EXCLUDE on index test; include for CAD review only
 
Shakya 2012
Reason for exclusion EXCLUDE on target condition
SCC in situ is not included in target condition
 
Shitara 2014
Reason for exclusion EXCLUDE if individual lesion characteristics
 
Shitara 2015
















Reason for exclusion EXCLUDE on 2x2 data
can't derive specificity; only gives 'exact diagnoses for MM and 2 benign categories and not number benign misdiagnosed as
MM
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Steiner 1987




Reason for exclusion EXCLUDE on 2x2 data
only given the correct diagnosis for malignant
EXCLUDE but contact authors
 
Steiner 1993
Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE if derivation study
 
Stephens 2013
Reason for exclusion EXCLUDE on sample size
 
Stoecker 2009
Reason for exclusion EXCLUDE if derivation study
translucency
EXCLUDE on 2x2 data
data presented only as ROC curve and AUC
 
Stoecker 2009a
Reason for exclusion EXCLUDE not a primary study
 
Stoecker 2011
Reason for exclusion EXCLUDE if individual lesion characteristics
EXCLUDE if derivation study
Uses leave one out
EXCLUDE on 2x2 data
data presented only as ROC curve and AUC
 
Stolz 2002
Reason for exclusion EXCLUDE not a primary study
 
Stratigos 2007
Reason for exclusion EXCLUDE on reference standard
EXCLUDE on 2x2 data
 
Stricklin 2011
Reason for exclusion EXCLUDE if individual lesion characteristics
 
Strumia 2003
Reason for exclusion EXCLUDE conference abstract; letter only
 
Tasli 2012
Reason for exclusion EXCLUDE not a primary study
systematic review looking at frequency of publications ion dermoscopy
 
Teban 2003
Reason for exclusion EXCLUDE on study population
classification of Clark nevi into 12 types
EXCLUDE on 2x2 data
No 2x2 data; classification of Clark nevi into 12 types
 
Terstappen 2007
Reason for exclusion EXCLUDE on study population
Includes only BCC - looking for BCC chars on Siascope
EXCLUDE if derivation study
Derivation study; first application of Siascope to pigmented BCC; 21/25 lesions were BCCs
 
Terushkin 2010
Reason for exclusion EXCLUDE on sample size
Only 2 invasive SCC
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EXCLUDE on 2x2 data
 
Terushkin 2010a
Reason for exclusion EXCLUDE on 2x2 data
Not test accuracy - reports final diagnoses of those excised over a number of time periods and benign-malignant ratio
 
Tromme 2012
Reason for exclusion EXCLUDE on reference standard
Inadequate ref test for disease negatives; expert dx only
 
Tschandl 2012
Reason for exclusion EXCLUDE on index test
Differentiating melanocytic from non-melanocytic lesions
 
Tschandl 2015




Reason for exclusion EXCLUDE if individual lesion characteristics
 
Ulrich 2015
Reason for exclusion EXCLUDE on target condition
Does not provide sufficient data for evaluation of melanoma
 
van der Leest 2011
Reason for exclusion EXCLUDE on reference standard
Inadequate ref test for test negatives; expert dx only
 
van der Rhee 2010
Reason for exclusion EXCLUDE on reference standard
<50% of disease negative have an adequate reference standard
 
van der Rhee 2011




Reason for exclusion EXCLUDE conference abstract
 
Verduzco-Martinez 2013




Reason for exclusion EXCLUDE not a primary study
systematic review; check reference list
 
Wang 2008
Reason for exclusion EXCLUDE on 2x2 data
Not test accuracy; no details of misdiagnoses of benign lesions as malignant
 
Warshaw 2009
Reason for exclusion EXCLUDE on 2x2 data
EXCLUDE duplicate or related publication
Subgroup of participants from Warshaw 2010
EXCLUDE but contact authors
Study presents diagnostic accuracy of teledermatology and clinic diagnosis in comparison to histopathology; we need the
underlying 2x2 contingency tables [see Warshaw 2010 for author response]
 
Warshaw 2009a
Reason for exclusion EXCLUDE on 2x2 data
EXCLUDE duplicate or related publication
Subgroup of participants from Warshaw 2010
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EXCLUDE but contact authors
Study presents diagnostic accuracy of teledermatology and clinic diagnosis in comparison to histopathology; we need the
underlying 2x2 contingency tables [see Warshaw 2010 for author response]
 
Warshaw 2010
Reason for exclusion EXCLUDE on 2x2 data
EXCLUDE but contact authors
Study presents diagnostic accuracy of teledermatology and clinic diagnosis in comparison to histopathology [author only able to
provide numbers test positive and negative for melanoma and not for the final 2 cells of the 2x2; data provided showed higher
sensitivity for melanoma as the primary diagnosis rather than as the ‘aggregate’ diagnosis and the 2x2 using the authors data
and the accuracy figures from the paper showed more T+ from the primary diagnosis as opposed to the aggregate
 
Weismann 2002
Reason for exclusion EXCLUDE not a primary study
 
Wilkes 2010
Reason for exclusion EXCLUDE not a primary study
 
Winkelmann 2015
Reason for exclusion EXCLUDE duplicate or related publication
 
Winkelmann 2015a
Reason for exclusion EXCLUDE duplicate or related publication
 
Witkowski 2016
Reason for exclusion Exclude on target population; include for keratinocyte review only
 
Yadav 1993




Reason for exclusion EXCLUDE if derivation study
gene amplification in acral lesions
 
Yelamos 2016
Reason for exclusion EXCLUDE not a primary study
commentary on Guitera 2016
 
Yoo 2015
Reason for exclusion EXCLUDE conference abstract
 
Youl 2007
Reason for exclusion EXCLUDE on index test; evaluates 'clinical diagnosis'
EXCLUDE but contact authors; author replied - dermoscopy used in some but not all lesions
 
Youl 2007a
Reason for exclusion EXCLUDE on index test; evaluates 'clinical diagnosis'
EXCLUDE but contact authors; author replied - dermoscopy used in some but not all lesions
 
Zaballos 2013
Reason for exclusion EXCLUDE on study population
They do not have enough benign cases to include as full report.
 
Zalaudek 2010








Reason for exclusion EXCLUDE if derivation study
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Although data are divided into training and test sets, the test set data is used more than once over 20 realisations of each
model, especially the melanomas, for which the same 10 are used in each realisation
 
Zou 2001
Reason for exclusion EXCLUDE not a primary study
Study uses results from Stolz et al 1994
EXCLUDE on 2x2 data
Just showing ROC curves
 
Footnotes
Characteristics of studies awaiting classification
Footnotes
Characteristics of ongoing studies
Footnotes
Summary of results tables
1 Summary of findings table
Question: What is the diagnostic accuracy of dermoscopy, in comparison to visual inspection, for the detection of cutaneous invasive melanoma and atypicalintraepidermal melanocytic variants in adults?
Population:
 
Adults with lesions suspicious for melanoma, including:
those with limited prior testing (presenting in primary, community or private dermatology settings), and
referred populations (presenting in secondary care or specialist skin cancer clinics).
Index test:
 
Dermoscopy with or without the use of any established algorithms or checklist to aid diagnosis, including:
in-person evaluations (face-to-face diagnosis), and




condition: Cutaneous invasive melanoma and atypical intraepidermal melanocytic variants
Reference
standard: Histology with or without follow-up to confirm absence of malignancy in benign appearing lesions
Action: If accurate, positive results ensure melanoma lesions are not missed but are appropriately excised (or referred) and those with negative results can be safely reassuredand discharged.
 Number of studies Total lesions Total melanomas
Quantity of






Potential risk for patient selection from use of case-control type design (19 image-based), inappropriate exclusion criteria (8; 25) or lack of detail (17; 27). All dermoscopy
interpretation was blinded to reference standard diagnosis. Dermoscopy thresholds were clearly pre-specified (25; 50). Low risk for reference standard (29; 63); high risk
from use of expert diagnosis or >20% of benign lesions with no histology (5; 11). Blinding of reference standard to clinical diagnosis reported only in one image-based








Participants restricted to those with melanocytic lesions only (10; 35) or other narrowly defined groups (5 image-based), or to those with histopathology results (29; 57)
and included multiple lesions per participant (8 in-person). High concern for dermoscopy (16; 57) with no description of diagnostic thresholds (8; 25) or reporting of
average or consensus diagnoses (9; 35). Dermoscopic image interpretation blinded to clinical images (51 image-based). Little information given concerning the expertise
of the histopathologist (28; 50).
FINDINGS:
104 study publications (providing data for 103 cohorts of lesions) were included; 83 publications providing 86 datasets for evaluation of the primary target condition were separated a
priori into in-person (n = 26) and image-based (n = 60) evaluations. Subsequent analysis confirmed differences in accuracy according to the different approaches to diagnosis (P <
0.0001). Analyses of studies by degree of prior testing revealed no obvious effect on accuracy; analyses were hampered by a lack of relevant information provided in the study
publications and by the majority of studies apparently conducted in referred populations. The findings presented are based on results for all studies regardless of position on the clinical
pathway. Sensitivities at fixed specificities and specificities at fixed sensitivities are given for illustrative purposes only and should not be taken as indicative of actual test performance.
Test: In-person visual inspection alone versus visual inspection plus dermoscopy – any algorithm or threshold
Data
analysed Visual inspection 13 datasets - 6740 lesions; 459 cases
 Dermoscopy 26 datasets - 23169 lesions; 1664 cases
Results* Sensitivity (95% CI) Fixed specificity Fixed sensitivity Specificity (95% CI)
Visual
inspection 76% (66, 85) 80% 80%
75% (57, 87)
Dermoscopy 92% (87, 95) 95% (90, 98)
Numbers applied to a hypothetical cohort of 1000 lesions**

































At a VI: 160 VI: 50 158 632 168 42 VI: 198 VI: 5935












Test: Image-based visual inspection alone versus visual inspection plus dermoscopy – any algorithm or threshold
Data
analysed Visual inspection 11 datasets - 1740 lesions; 305 cases
 Dermoscopy 60 datasets - 13475 lesions; 2851 cases
Results Sensitivity (95% CI) Fixed specificity Fixed sensitivity Specificity (95% CI)
Visual
inspection 47% (34, 59) 80% 80%
42% (28, 58)
Dermoscopy 81% (76, 86) 82% (75, 87)
Numbers applied to a hypothetical cohort of 1000 lesions***

















































Test: Results according to algorithm used to assist dermoscopy interpretation





Numbers in a cohort of 1000 lesions****
     TP FN FP TN
In-person At median prevalence of 12%





106 14 114 766
Pattern














97 235 70 810
Image-based At median prevalence of 24%





182 58 61 699
Pattern





199 41 99 661
ABCD at >





194 46 144 616





192 48 251 509





178 62 304 456
Footnotes
V - visual inspection; D - dermoscopy; CI - confidence interval; FU - follow-up; NR - not reported; ABCD(E) - asymmetry, border, colour, differential structures (enlargement); 7PCL -
seven point checklist; 3PCL - three point checklist; TP - true positive; FP - false positive; FN - false negative; TN - true negative
* Numbers for a hypothetical cohort of 1000 lesions are presented for two illustrative examples of points on the SROC curves: firstly for the sensitivities of tests at fixed specificities of
80%; and secondly for the specificities of tests at fixed sensitivities of 80%.
**Numbers estimated at 25th, 50th (median) and 75% percentiles of invasive melanoma or atypical intraepidermal melanocytic variants prevalence observed across 26 datasets
reporting in-person evaluations of dermoscopy added to visual inspection.
***Numbers estimated at 25th, 50th (median) and 75% percentiles of invasive melanoma or atypical intraepidermal melanocytic variants prevalence observed across 60 datasets
reporting diagnosis using dermoscopic images
***Numbers estimated at median prevalence (50th percentile) of invasive melanoma or atypical intraepidermal melanocytic variants observed across 26 datasets reporting in-person
evaluations of dermoscopy added to visual inspection and then for 60 datasets reporting diagnosis using dermoscopic images
Additional tables




























4 Referred (all lesions included)

































































b. Pathway (image based)




















4 Referred (all lesions included)









































































DOR - diagnostic odds ratio; CI - confidence interval; c – clearly position on clinical pathway; u – unclear position on clinical pathway
1 Test naïve; 2 Limited prior testing; 3 Limited prior testing (with selection on reference standard); 3* Limited prior testing (with selection on reference standard and equivocal nature of
lesions); 4 Referred for further assessment; 5 Referred for further assessment (with selection on reference standard); 5* Referred for further assessment (with selection on reference
standard and equivocal nature); 6 Referred for further assessment (equivocal on specialist review); 7 Lesions that have been undergoing follow-up
2 Comparison of visual inspection and dermoscopy for detection of invasive melanoma or intraepidermal melanocytic variants































dermoscopy to VI (95% CI)






In-person evaluations (direct studies)


















dermoscopy to VI (95% CI)
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VI with dermoscopy (95% CI)






Image based evaluations (direct studies)
















VI with dermoscopy (95% CI)







DOR - diagnostic odds ratio; CI - confidence interval; VI - visual inspection; LR - likelihood ratio test
3 Investigations of sources of heterogeneity in person studies positions for detection of invasive melanoma or intraepidermal melanocytic
variants












Difference in-person and image based























Differences in reference standard (in-person studies)























Use of an algorithm (in-person studies)























Lesion type (in-person studies)























Single or multiple individuals making diagnosis (in-person studies)


































































DOR - diagnostic odds ratio; CI - confidence interval; FU - follow-up; LR - likelihood ratio test
4 Investigations of sources of heterogeneity in image-based studies for detection of invasive melanoma or intraepidermal melanocytic
variants












Differences in reference standard (image based studies)























Use of an algorithm (image based studies)























Lesion type (image based studies)

























Single or multiple individuals making diagnosis (image based studies)























Prevalence (image based studies)








































DOR - diagnostic odds ratio; CI - confidence interval; FU - follow-up; LR - likelihood ratio test























a. Invasive melanoma and atypical intraepidermal
melanocytic variants
IN-PERSON IMAGE-BASED
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Menzies at NR - - - - 2 60 (26) 0.77 0.82
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(0.57, 0.89) (0.66, 0.92)
































b. Invasive melanoma IN-PERSON IMAGE-BASED










pattern analysis - threshold NR 1 45 (16) 0.81 (0.54,0.96) 0.97
(0.82, 1.00)








- - - -
























































Menzies for amelanotic at 1 - - - - 1 332
(217)
0.91 (0.87, 0.95) 0.70
(0.61, 0.79)
Menzies for amelanotic at 0 - - - - 1 332
(217)
1.00 (0.98, 1.00) 0.52 (0.43, 0.62)
c. Any skin cancer or lesion with high risk of progression to
melanoma
IN-PERSON IMAGE-BASED




















- - - -









All analyses by algorithm were undertaken using the bivariate normal model (BVN).
CI - confidence interval; FU - follow-up; NR - not reported; ABCD(E) - asymmetry, border, colour, differential structures (enlargement); 7FFM - seven features for melanoma; 7PCL -
seven point checklist; rev - revised; 3PCL - three point checklist; CASH - colour, architecture, symmetry and homogeneity
















































































































DOR - diagnostic odds ratio; CI - confidence interval; NR - not reported; LR - likelihood ratio test



















































































































































DOR - diagnostic odds ratio; CI - confidence interval; NR - not reported; LR - likelihood ratio test
(1) In-person model could not be fitted including the small number of studies in these groups. Estimates for these groups are obtained from computed the DOR for the individual study,
or random effects meta-analyses of DORs where there is more than one study. Estimates at the 80% sensitivity and specificity values are computed assuming symmetric SROC curves.
(2) Image-based model could not be fitted including the small number of studies in these groups. Estimates for these groups are obtained from computed the DOR for the individual
study, or random effects meta-analyses of DORs where there is more than one study. Estimates at the 80% sensitivity and specificity values are computed assuming symmetric SROC
curves.
8 Sensitivity analyses for in-person visual inspection and dermoscopy added to visual inspection for the detection of invasive melanoma
or atypical intraepidermal melanocytic variants
Test Studies Lesions(cases) DOR (95% CI)
Specificity at 80% sensitivity (95%
CI)





Visual inspection 13 6740 (459) 13.1 (7.0,
24.5)
75% (57, 87) 76% (66, 85) 4.7 (3.0, 7.5)
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Visual inspection + Dermoscopy 26 23169 (1664) 61.7 (34.9,109) 95% (90, 98) 92% (87, 95)  
Change with adding dermoscopy to VI (95%
CI)    +20% (+7, +33) +16% (+8, +23)  
In-person evaluations (direct comparison)
Visual inspection 11 5854 (412) 13.7 (5.9,31.8) 75% (49, 90) 77% (63, 87) 4.8 (2.8, 8.1)
Visual inspection + Dermoscopy 11 5854 (412) 65.7 (27.0,160) 95% (87, 99) 92% (84, 96)  
Change with adding dermoscopy to VI (95%
CI)    +21% (+2, +39) +15% (+7, +23)  
In-person evaluations (with histology and follow-up for those not having surgery)
Visual inspection 2 3607 (60) 18.4 (2.63,128) 82% (39, 97) 82% (40, 97) 14.4 (4.4, 47.6)
Visual inspection + Dermoscopy 6 17574 (800) 265 (49,1428) 99% (91, 100) 98% (87, 100)  
Change with adding dermoscopy to VI (95%
CI)    +16% (-23, 56) +16% (-20, 53)  
In-person evaluations with low risk of bias for the index test
Visual inspection 4 3957 (176) 16.9 (6.1,46.8) 80% (52, 94) 80% (63, 91) 3.1 (1.3, 7.4)
Visual inspection + Dermoscopy 20 19182 (831) 53.0 (25.8,109) 94% (87, 98) 91% (84,95)  
Change with adding dermoscopy to VI (95%
CI)    +14% (-6, +34) +11% (-1, +23)  
In-person evaluations with low risk of bias for the reference test
Visual inspection 10 2802 (367) 13.8 (7.3,26.3) 76% (59, 87) 77% (67, 85) 4.2 (2.5, 7.1)
Visual inspection + Dermoscopy 20 7636 (1418) 57.8 (32.2,104) 95% (89, 97) 92% (87, 95)  
Change with adding dermoscopy to VI (95%
CI)    +19% (+5, +32) +15% (+6, +23)  
In-person evaluations with low risk of bias for flow and timing
Visual inspection 2 601 (66) 11.0 (2.7,44.4) 61% (26, 87) 73% (55, 85) 5.1 (1.2, 20.9)
Visual inspection + Dermoscopy 4 984 (113) 55.7 (24.4,127) 95% (85, 98) 88% (79, 94)  
Change with adding dermoscopy to VI (95%
CI)    +34% (-45, +100) +16% (-28, +60)  
In-person evaluations excluding case-control studies
Visual inspection 13 6740 (459) 13.1 (7.0,24.5) 75% (57, 87) 76% (66, 85) 4.7 (3.0, 7.5)
Visual inspection + Dermoscopy 26 23169 (1664) 61.7 (34.9,109) 95% (90, 98) 92% (87, 95)  
Change with adding dermoscopy to VI (95%
CI)    +20% (+7, +33) +16% (+8, +23)  
Footnotes
DOR - diagnostic odds ratio; CI - confidence interval; NR - not reported
9 Sensitivity analyses for image-based visual inspection or dermoscopy for the detection of invasive melanoma or atypical intraepidermal
melanocytic variants
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10 Comparison of visual inspection and dermoscopy for the detection of invasive melanoma
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Dermoscopic images 4 454 40.4 89% 83%
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(145) (8.2, 198) (47, 99) (72, 90)







DOR - diagnostic odds ratio; CI - confidence interval; LR - likelihood ratio test
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Image based evaluations (direct studies)















DOR - diagnostic odds ratio; CI - confidence interval
Estimates are based on fitting models with symmetric ROC curves, and no formal comparisons between tests are made due to paucity of data. It is noted that the estimates for the
visual inspection studies change between the all data and paired data analyses for both in-person and image-based analyses. This is driven by differences in the heterogeneity in
accuracy between the models which affects all parameters in the analyses.
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Data and analyses
Data tables by test
Test Studies Participants
1 Visual inspection - in-person (MM) 2 147
2 VI+Dermoscopy - in-person (MM) 6 789
3 Visual inspection - image-based (MM) 4 454
4 Dermoscopy alone - image-based (MM) 13 5618
5 Visual inspection - in-person (MM+MiS) 13 6740
6 VI+Dermoscopy - in-person (MM+MiS) 26 23169
7 Visual inspection - image-based (MM+MiS) 11 1740
8 Dermoscopy alone - image-based (MM+MiS) 60 13475
9 Visual inspection - in-person (Any) 2 3457
10 VI+Dermoscopy - in-person (Any) 4 3880
11 Visual inspection - image-based (Any) 3 547
12 Dermoscopy alone - image-based (Any) 5 815
13 MM2- Dermoscopy - no algorithm - threshold NR - in-person 8 4707
14 MM2- Dermoscopy - pattern - at >=1 char present - in-person 1 220
15 MM2- Dermoscopy - pattern - at >=3 chars present - in-person 1 68
16 MM2- Dermoscopy - pattern - threshold NR - in-person 6 4307
17 MM2- Dermoscopy - ABCD at NR (likely >5.45) - in-person 1 235
18 MM2- Dermoscopy - ABCD at >5.45 - in-person 4 1203
19 MM2- Dermoscopy - ABCD at >4.75 - in-person 1 309
20 MM2- Dermoscopy - ABCD at 60% specificity - in-person 1 356
21 MM2- Dermoscopy - ABCD at 80% specificity - in-person 1 356
22 MM2- Dermoscopy - ABCD at 70% specificity - in-person 1 356
23 MM2- Dermoscopy - ABCD at 75% specificity - in-person 1 356
24 MM2- Dermoscopy - ABCD at 85% specificity - in-person 1 356
25 MM2- Dermoscopy - ABCD at 90% specificity - in-person 1 356
26 MM2- Dermoscopy - ABCDE at >1.3 - in-person 1 356
27 MM2- Dermoscopy - ABCDE at >2.65 - in-person 1 356
28 MM2- Dermoscopy - ABCDE at >3.05 - in-person 1 356
29 MM2- Dermoscopy - ABCDE at >3.6 - in-person 1 356
30 MM2- Dermoscopy - ABCDE at >4.25 - in-person 1 356
31 MM2- Dermoscopy - ABCDE at >4.9 - in-person 1 356
32 MM2- Dermoscopy - 7FFM at >=2 - in-person 1 401
33 MM2- Dermoscopy - 7point at >=2 - in-person 1 638
34 MM2- Dermoscopy - 7point at >=3 - in-person 2 11137
35 MM2- Dermoscopy - Menzies at 2 neg and >=1 pos - in-person 1 206
36 MM2- Dermoscopy - no algorithm - any threshold - image-based 24 4498
37 MM2- Dermoscopy - no algorithm - correct dx - image-based 18 4118
38 MM2- Dermoscopy - no algorithm - excise decision - image-based 10 831
39 MM2- Dermoscopy - pattern - any threshold - image-based 20 4621
40 MM2- Dermoscopy - pattern - correct dx - image-based 19 4095
41 MM2- Dermoscopy - pattern - excise decision - image-based 3 933
42 MM2- Dermoscopy - ABCD at >4.75 - image-based 10 4242
43 MM2- Dermoscopy - ABCD at >5.45 - image-based 7 2471
44 MM2- Dermoscopy - rev ABCD at >=4 - image-based 1 269
45 MM2- Dermoscopy - ABCDE at >=4 - image-based 1 269
46 MM2- Dermoscopy - 7point at NR - image-based 4 1936
47 MM2- Dermoscopy - 7point at >=3 - image-based 11 3408
48 MM2- Dermoscopy - 7point at >=5 - image-based 1 322
49 MM2- Dermoscopy - rev 7point at NR (likely >=1) - image-based 1 1678
50 MM2- Dermoscopy – rev 7point at >=1 - image-based 1 300
51 MM2- Dermoscopy - rev 7point for FU - major change - image-based 1 70
52 MM2- Dermoscopy - 7FFM at >=2 - image-based 4 2200
53 MM2- Dermoscopy - Menzies at 2neg and >=1 pos - image-based 4 1856
54 MM2- Dermoscopy - Menzies at NR - image-based 2 60
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55 MM2- Dermoscopy - 3point at >=2 - image-based 7 1505
56 MM2- Dermoscopy - 4point (scored 3-point) at >2 - image-based 1 75
57 MM2- Dermoscopy - Hofman algorithm at NR - image-based 1 254
58 MM2- Dermoscopy CASH at >=6 - image-based 1 477
59 MM2- Dermoscopy CASH at >=8 - image-based 2 190
60 MM2- Dermoscopy Chaos/Clues at =2 - image-based 2 940
61 MM2- Dermoscopy - Acral 3step - image-based 1 107
62 VI+Dermoscopy (in-person) - observer experience NR (MM+MiS) 10 8390
63 VI+Dermoscopy (in-person) - high experience (MM+MiS) 14 14213
65 VI+Dermoscopy (in-person) - trained observer (MM+MiS) 2 566
66 Dermoscopy (image-based) - observer experience NR (MM+MiS) 11 2777
67 Dermoscopy (image-based) - high experience (MM+MiS) 34 8933
68 Dermoscopy (image-based) - moderate experience (MM+MiS) 5 678
69 Dermoscopy (image-based) - low experience (MM+MiS) 6 448
70 Dermoscopy (image-based) - mixed experience (MM+MiS) 5 473
71 Dermoscopy (image-based) - trained observer (MM+MiS) 11 1087
72 VI+Dermoscopy (in-person) - Consultant expert (MM+MiS) 11 2767
73 VI+Dermoscopy (in-person) - Consultant (MM+MiS) 10 8390
74 VI+Dermoscopy (in-person) - Resident/registrar (MM+MiS) 2 11137
75 VI+Dermoscopy (in-person) - Mixed (secondary care based) (MM+MiS) 1 309
76 VI+Dermoscopy (in-person) - GP (MM+MiS) 2 566
77 Dermoscopy (image-based) - Consultant expert (MM+MiS) 33 8664
78 Dermoscopy (image-based) - Consultant (MM+MiS) 24 3986
79 Dermoscopy (image-based) - Resident (MM+MiS) 5 927
80 Dermoscopy (image-based) - Mixed (secondary care based) (MM+MiS) 4 399
81 Dermoscopy (image-based) - Mixed (other) (MM+MiS) 4 867
82 Dermoscopy (image-based) - GP/primary care (MM+MiS) 3 288
83 Dermoscopy (image-based) - Physician assistant (MM+MiS) 1 65
84 Dermoscopy - before training (MM+MiS) 4 245
85 Dermoscopy - after training (MM+MiS) 4 245
86 Dermoscopy - before training (MM) 2 150
87 Dermoscopy - after training (MM) 2 150
88 MM1- Dermoscopy - no algorithm - threshold NR - in-person 3 190
89 MM1- Dermoscopy - pattern analysis - threshold NR - in-person 1 45
90 MM1- Dermoscopy - ABCD at >4.2 - in-person 1 495
91 MM1- Dermoscopy - ABCD at >5.45 - in-person 2 832
92 MM1- Dermoscopy - Kenet (modified) at melanoma possible - in-person 1 54
93 MM1- Dermoscopy - Kenet (modified) at melanoma likely - in-person 1 54
94 MM1- Dermoscopy - no algorithm - threshold NR - image-based 6 683
95 MM1- Dermoscopy - no algorithm - decision to excise - image-based (paired data only) 1 99
96 MM1- Dermoscopy - pattern analysis - threshold NR - image-based 1 119
97 MM1- Dermoscopy - ABCD at >4.75 - image-based 2 330
98 MM1- Dermoscopy - ABCD at >5.45 - image-based 1 258
99 MM1- Dermoscopy - 7point at NR - image-based 1 332
100 MM1- Dermoscopy - Menzies at 2neg and >=1 pos - image-based 4 4184
101 MM1- Dermoscopy - 3point at >NR - image-based 1 332
102 MM1- Dermoscopy - Kenet at melanoma likely - image-based 1 258
103 MM1- Dermoscopy - Kenet at melanoma possible - image-based 1 258
104 MM1- Dermoscopy CASH at >=8 - image-based 1 332
105 MM1- Dermoscopy - Kreusch algorithm - image-based 1 265
106 MM1- Dermoscopy - Menzies for amelanotic at 1 - image-based 1 332
107 MM1- Dermoscopy - Menzies for amelanotic at 0 - image-based 1 332
108 MM3- Dermoscopy – no algorithm at NR - in-person 1 231
109 MM3- Dermoscopy - pattern analysis - threshold NR - in-person 1 3372
110 MM3- Dermoscopy – ABCD at >5.45 - in-person 1 200
111 MM3- Dermoscopy – 3point at >=2 - in-person 1 77
112 MM3- Dermoscopy – no algorithm at NR - image-based 2 83
113 MM3- Dermoscopy - pattern analysis - threshold NR - image-based 1 119
114 MM3- Dermoscopy – 3point at >=2 - image-based 1 150
115 MM2 - VI - in-person (w image-based dermoscopy) 2 886
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Caption
Sample photographs of superficial spreading melanoma (left) and nodular melanoma (right)
Figure 2
Caption
Current clinical pathway for people with skin lesions
Figure 3
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Caption
Risk of bias and applicability concerns graph for in-person evaluations: review authors' judgements about each domain presented as percentages across included studies
Figure 6
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Caption
Risk of bias and applicability concerns for in-person evaluations summary: review authors' judgements about each domain for each included study
Figure 7
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Caption
Risk of bias and applicability concerns graph for image-based evaluations: review authors' judgements about each domain presented as percentages across included studies
Figure 8
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Caption
Risk of bias and applicability concerns for image-based evaluations summary: review authors' judgements about each domain for each included study
Figure 9 (Analysis 1)
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Caption
In-person evaluations of the accuracy of dermoscopy added to visual inspection grouped by pathway categorisation for detecting invasive melanoma or melanocytic intraepidermal
variants
Figure 10 (Analysis 2)
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Caption
Image-based evaluations of the accuracy of dermoscopy grouped by pathway categorisation for detecting for detecting invasive melanoma or melanocytic intraepidermal variants
Figure 11 (Analysis 3)
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Caption
Comparison of the accuracy of visual inspection with visual inspection plus dermoscopy for detection of invasive melanoma or melanocytic intraepidermal variants (MM+MiS) from in-
person studies
Figure 12 (Analysis 4)
Caption
Paired comparisons of the accuracy of visual inspection with visual inspection plus dermoscopy for detection of invasive melanoma or melanocytic intraepidermal variants (MM+MiS)
from in-person studies
Figure 13 (Analysis 5)
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Caption
Comparison of the accuracy of visual inspection with dermoscopy for detection of invasive melanoma or melanocytic intraepidermal variants (MM+MiS) from image-based studies
Figure 14 (Analysis 6)
Caption
Paired comparison of the accuracy of visual inspection versus dermoscopy for detection of invasive melanoma or melanocytic intraepidermal variants (MM+MiS) from paired image-
based studies
Figure 15 (Analysis 7)
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Caption
Comparison of the accuracy of dermoscopy for detection of invasive melanoma or melanocytic intraepidermal variants (MM+MiS) between in-person (visual inspection plus
dermoscopy) and image-based (dermoscopy) studies
Figure 16 (Analysis 8)
Caption
Comparison of the accuracy of visual inspection plus dermoscopy for detection of invasive melanoma or melanocytic intraepidermal variants (MM+MiS) from in-person studies
according to reported observer experience
Figure 17 (Analysis 9)
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Caption
Comparison of the accuracy of dermoscopy for detection of invasive melanoma or melanocytic intraepidermal variants (MM+MiS) from image-based studies according to observer
experience
Figure 18 (Analysis 10)
Caption
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Comparison of the accuracy of visual inspection plus dermoscopy for detection of invasive melanoma or melanocytic intraepidermal variants (MM+MiS) from in-person studies
according to observer qualifications (summary ROC curves were not estimable from the model for Resident/Registrar and Mixed (secondary care based) experience groups)
Figure 19 (Analysis 11)
Caption
Comparison of the accuracy of dermoscopy for detection of invasive melanoma or melanocytic intraepidermal variants (MM+MiS) from image-based studies according to observer
qualification. (HSROC curves could not be estimated for Mixed (secondary care based) and Physician assistant groups).
Figure 20 (Analysis 12)
Caption
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Comparison of the accuracy of visual inspection with visual inspection plus dermoscopy for detection of invasive melanoma (MM) from in-person studies
Figure 21 (Analysis 13)
Caption
Comparison of the accuracy of visual inspection with dermoscopy for detection of invasive melanoma (MM) from image-based studies
Figure 22 (Analysis 14)
Caption
Forest plot of tests: 9 Visual inspection - in-person (Any), 10 VI+Dermoscopy - in-person (Any).
Figure 23 (Analysis 15)
Caption
Forest plot of tests: 11 Visual inspection - image-based (Any), 12 Dermoscopy alone - image-based (Any).
Figure 24 (Analysis 17)
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Caption
Forest plot of tests: Accuracy of dermoscopy before and after dermoscopy training (MM and MM+MiS)
Figure 25 (Analysis 18)
Caption
Forest plot of tests: 5 Visual inspection - in-person (MM+MiS), 7 Visual inspection - image-based (MM+MiS).
Figure 26 (Analysis 12)
Caption
Forest plot of tests: 1 Visual inspection - in-person (MM), 2 VI+Dermoscopy - in-person (MM).
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Figure 27 (Analysis 13)
Caption
Forest plot of tests: 3 Visual inspection - image-based (MM), 4 Dermoscopy alone - image-based (MM).
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1 Current content and structure of the Programme Grant
List of reviews  
Estimated number of studiesDiagnosis of melanoma
1. Visual inspection versus visual inspection plus dermoscopy 120
2. Teledermatology 12
3. Mobile phone applications 2
4. Computer-aided diagnosis: dermoscopy based and spectroscopy based techniques 37
5. Reflectance confocal microscopy 19
6. High frequency ultrasound 3
7. Overview: comparing the accuracy of tests for which sufficient evidence was identified either alone or in combination –
Diagnosis of keratinocyte skin cancer (basal cell carcinoma and cutaneous squamous cell carcinoma)  
8. Visual inspection ± dermoscopy 22
9. Computer aided diagnosis: dermoscopy based and spectroscopy based techniques 3
10. Optical coherence tomography 6
11. Reflectance confocal microscopy 9
12. High frequency ultrasound 1
13. Exfoliative cytology 5
14. Overview: comparing the accuracy of tests for which sufficient evidence was identified either alone or in combination –
Staging of melanoma  
15. Ultrasound 25 to 30
16. Computer tomography 5 to 10
17. Positron emission tomography or positron emission tomography-computer tomography 20 to 25
18. Magnetic resonance imaging 5
19. Sentinel lymph node biopsy ± high frequency ultrasound 70
20. Overview: comparing the accuracy of tests for which sufficient evidence was identified either alone or in combination –
Staging of cutaneous squamous cell carcinoma  
21. Imaging tests review 10 to 15
22. Sentinel lymph node biopsy ± high frequency ultrasound 15 to 20
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§ irregular and multicomponent pigmentary network pattern,
§ peripheral dark network patches,




§ pigment dots (blotches, black dots, brown globules),
§ black dots at periphery,
§ whitish veil,
§ depigmentation and hypopigmented areas,
§ erythema,
§ telangiectasia,
§ comedo-like openings, milia-like cysts,
§ red-blue areas.
 




the lesion and not only
with respect to the
contour of the lesion
§ + Border score x 0.1
for each of 8 lesion
segments presenting
with an abrupt cut-off of
pigment pattern the
score was increased by
one point. Maximum
border score 8
§ + Colour score x 0.5
Up to 6 different colours
counted: white, red, blue-
gray light-brown, dork-
brown, and black










§ Asymmetry of the
outer shape in at




the lesion in at least
1 axis (+1);
§ Border - Abrupt
cutoff of network at
the border of the
lesion in at least 1
quarter of the
circumference (+1);








As for ABCD but with addition of ‘E’ for
enlargement or change
Patient self-report of change in lesion
size, color, or shape within the last year
or whether they experienced any sign
of ulceration or spontaneous bleeding. De
novo appearance of a lesion within the
last year was regarded as change in size
ABCD-E score calculated by adding 1.2
to the standard ABCD score for changing
lesions and subtracting 0.8 from the
standard ABCD score for nonchanging
lesions













Major criteria score 2
points each; minor criteria
score 1 point each.
Threshold for excision >=
3.
For the revised seven-
point checklist, each
criterion is given a score
of 1 point, and the
threshold for excision is




















Ascierto 1998 , Ascierto
2003 , Ascierto 2010
§ A score of ‘no change’ was assigned if all variables remained
constant, with a tolerance of major axis change of 2 mm (Beer
2011; Terushkin 2012);
§ ‘minor change’ if there was only symmetrical change in structural
or chromatic pattern;
§ ‘moderate change’ if either structural or chromatic changes were
asymmetrical, but there were no melanoma-specific criteria; and
‘major change’ if there were asymmetrical structural and chromatic
changes, or the appearance of melanoma-specific criteria (i.e.
major or minor criteria on original seven-point checklist: blue-white
veil, atypical or negative pigment network, atypical vascular
patterns, irregular dots and globules, streaks, irregular blotches,
peripheral pigmented structureless areas and regression.)
 
§ Asymmetry - in color







§ Blue-white structures -
any blue and/or white
color within the lesion








points instead of 1
§ Asymmetry of
color and structure
1st axis 1 point
§ Asymmetry of
color and structure
2nd axis 1 point





A total score >2
was used as cut-off
 
Stratum 1 (probable MM):
§ Pseudopods,
§ Radial streaming,
§ Heterogeneity of pigment network with
thick dark extensions at the edge,
§ Blue-grey areas,
§ white scarlike areas and
§ presence of pigment network
Stratum 2 (possible MM):
§ Marked irregular network with irregular
pigment confluence,
§ Eccentricity of pigment network with
darkest regions near edge
 
Very high risk








§ - pigment network and
“subtle new ELM features
that may suggest
melanoma but often are






















§ Point and axial symmetry of pigmentation
§ Presence of only a single colour
Positive features:
§ Multiple (5-6) colors
§ Blue-white veil
§ Multiple brown dots
§ Multiple blue/gray
§ Peripheral black dots or globules



















Major features score 2
points each; minor
























Color: light brown, dark brown, black, red,
white, blue, each receive 1 point.
Architectural disorder: nonuniformity of
structures and their distribution in the
lesion; benign melanocytic lesions having
uniform structures and distribution.
Absent/mild, moderate and marked




§ biaxial symmetry scores 0
§ monoaxial symmetry scores 1
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§ regression structures (blue-gray areas
with or without peppering; scarring)
§ blotches (structureless regions of any
color occupying >10% of the area of the
lesion)
§ polymorphous blood vessels (dotted
and irregular linear).
A total CASH score (TCS) >=8
is suggestive for melanoma.




Unusual area of darker pigmentation contained within the epidermis that may progress to an invasive melanoma; includes melanoma in situ and lentigo
maligna
Atypical naevi Unusual looking but noncancerous mole or area of darker pigmentation of the skin
BRAF V600 mutation BRAF is a human gene that makes a protein called B-Raf which is involved in the control of cell growth. BRAF mutations (damaged DNA) occur in around
40% of melanomas, which can then be treated with particular drugs.
BRAF inhibitors Therapeutic agents which inhibit the serine-threonine protein kinase BRAF mutated metastatic melanoma.
Breslow thickness A scale for measuring the thickness of melanomas by the pathologist using a microscope, measured in mm from the top layer of skin to the bottom of the
tumour.
Congenital naevi A type of mole found on infants at birth
 
Dermoscopy
Whereby a handheld microscope is used to allow more detailed, magnified, examination of the skin compared to examination by the naked eye alone
False negative An individual who is truly positive for a disease, but whom a diagnostic test classifies them as disease-free.
False positive An individual who is truly disease-free, but whom a diagnostic test classifies them as having the disease.
Histopathology/Histology The study of tissue, usually obtained by biopsy or excision, for example under a microscope.
Incidence The number of new cases of a disease in a given time period.
Index test A diagnostic test under evaluation in a primary study
Lentigo maligna Unusual area of darker pigmentation contained within the epidermis which includes malignant cells but with no invasive growth. May progress to an invasive
melanoma
Lymph node Lymph nodes filter the lymphatic fluid (clear fluid containing white blood cells) that travels around the body to help fight disease; they are located throughout
the body often in clusters (nodal basins).
Melanocytic naevus An area of skin with darker pigmentation (or melanocytes) also referred to as ‘moles’
Meta-analysis A form of statistical analysis used to synthesise results from a collection of individual studies.
Metastases/metastatic
disease
Spread of cancer away from the primary site to somewhere else through the bloodstream or the lymphatic system.
Micrometastases Micrometastases are metastases so small that they can only be seen under a microscope.
Mitotic rate Microscopic evaluation of number of cells actively dividing in a tumour.
Morbidity Detrimental effects on health.
Mortality Either (1) the condition of being subject to death; or (2) the death rate, which reflects the number of deaths per unit of population in relation to any specific
region, age group, disease, treatment or other classification, usually expressed as deaths per 100, 1000, 10,000 or 100,000 people.
Multidisciplinary team A team with members from different healthcare professions and specialties (e.g. urology, oncology, pathology, radiology, and nursing). Cancer care in the
National Health Service (NHS) uses this system to ensure that all relevant health professionals are engaged to discuss the best possible care for that patient.
Prevalence The proportion of a population found to have a condition.
Prognostic
factors/indicators
Specific characteristics of a cancer or the person who has it which might affect the patient’s prognosis.
Receiver operating
characteristic (ROC) plot
A plot of the sensitivity and 1 minus the specificity of a test at the different possible thresholds for test positivity; represents the diagnostic capability of a test




The analysis of a ROC plot of a test to select an optimal threshold for test positivity
Recurrence Recurrence is when new cancer cells are detected following treatment. This can occur either at the site of the original tumour or at other sites in the body.
Reference Standard A test or combination of tests used to establish the final or ‘true’ diagnosis of a patient in an evaluation of a diagnostic test
Reflectance confocal
microscopy (RCM)
A microscopic technique using infrared light (either in a handheld device or a static unit) that can create images of the deeper layers of the skin
Sensitivity In this context the term is used to mean the proportion of individuals with a disease who have that disease correctly identified by the study test
Specificity The proportion of individuals without the disease of interest (in this case with benign skin lesions) who have that absence of disease correctly identified by the
study test
Staging Clinical description of the size and spread of a patient’s tumour, fitting into internationally agreed categories.
Subclinical (disease) Disease that is usually asymptomatic and not easily observable, e.g. by clinical or physical examination.
Systemic treatment Treatment, usually given by mouth or by injection, that reaches and affects cancer cells throughout the body rather than targeting one specific area.
4 Proposed sources of heterogeneity
i. Population characteristics
general versus higher risk populations
patient population: Primary /secondary / specialist unit
lesion suspicion: general suspicion/atypical/equivocal/NR
lesion type: any pigmented; melanocytic
inclusion of multiple lesions per participant
ethnicity
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ii. Index test characteristics
the nature of and definition of criteria for test positivity
observer experience with the index test
approaches to lesion preparation (e.g., the use of oil or antiseptic gel for dermoscopy)
iii. Reference standard characteristics
reference standard used
whether histology-reporting meets pathology-reporting guidelines
use of excisional versus diagnostic biopsy
whether two independent dermatopathologists reviewed histological diagnosis
iv. Study quality
consecutive or random sample of participants recruited
index test interpreted blinded to the reference standard result
index test interpreted blinded to the result of any other index test
presence of partial or differential verification bias (whereby only a sample of those subject to the index test are verified by the reference test or by the same reference test with
selection dependent on the index test result)
use of an adequate reference standard
overall risk of bias
5 Final search strategies
Melanoma search strategies to August 2016
Database: Ovid MEDLINE(R) 1946 to August week 3 2016
Search strategy:
1 exp melanoma/
2 exp skin cancer/
3 exp basal cell carcinoma/
4 basalioma$1.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or adenoma$1 or epithelioma$1 or lesion$1 or malignan$ or
nodule$1)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or epithelioma$1 or epithelial or lesion$1 or malignan$ or
nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.







17 exp epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
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50 (high adj3 ultraso$).ti,ab.
51 (canine adj2 detect$).ti,ab.
52 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
53 smartphone$.ti,ab.
54 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
55 Mole Detective.ti,ab.
56 Spot Check.ti,ab.
57 (mole$1 adj2 map$).ti,ab.
58 (total adj2 body).ti,ab.
59 exfoliative cytolog$.ti,ab.
60 digital analys$.ti,ab.
61 (image$1 adj3 software).ti,ab.
62 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$ or tele-dermatoscop$).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (computer adj2 diagnos$).ti,ab.
65 exp sentinel lymph node biopsy/
66 (sentinel adj2 node).ti,ab.
67 nevisense.mp. or HFUS.ti,ab.
68 electrical impedance spectroscopy.ti,ab.
69 history taking.ti,ab.
70 patient history.ti,ab.
71 (naked eye adj (exam$ or assess$)).ti,ab.
72 (skin adj exam$).ti,ab.
73 physical examination/
74 ugly duckling.mp. or UD.ti,ab.
75 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
76 ABCDE.mp. or VOC.ti,ab.
77 clinical accuracy.ti,ab.
78 Family Practice/ or Physicians, Family/ or clinical competence/




83 volatile organic compound$1.ti,ab.
84 dog$1.ti,ab.
85 gene expression analy$.ti,ab.




90 (CT or PET).ti,ab.
91 PET-CT.ti,ab.





97 exp Tomography, Emission-Computed/
98 exp Tomography, X-ray computed/
99 positron emission tomograph$.ti,ab.
100 exp magnetic resonance imaging/






107 magnetic resonance imag$.ti,ab.
108 or/90-107
109 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
110 "Sensitivity and Specificity"/
111 exp cancer staging/
112 or/109-111
113 108 and 112
114 89 or 113
115 13 and 114
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 29 August 2016
Search strategy:
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1 basalioma$1.ti,ab.
2 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or adenoma$1 or epithelioma$1 or lesion$1 or malignan$ or
nodule$1)).ti,ab.
3 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
4 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
5 nmsc.ti,ab.
6 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or epithelioma$1 or epithelial or lesion$1 or malignan$ or
nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.






13 (epiluminescence adj2 microscop$).ti,ab.
14 (confocal adj2 microscop$).ti,ab.
15 (incident light adj2 microscop$).ti,ab.
16 (surface adj2 microscop$).ti,ab.
17 (visual adj (inspect$ or examin$)).ti,ab.


























44 (high adj3 ultraso$).ti,ab.
45 (canine adj2 detect$).ti,ab.
46 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
47 smartphone$.ti,ab.
48 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
49 Mole Detective.ti,ab.
50 Spot Check.ti,ab.
51 (mole$1 adj2 map$).ti,ab.
52 (total adj2 body).ti,ab.
53 exfoliative cytolog$.ti,ab.
54 digital analys$.ti,ab.
55 (image$1 adj3 software).ti,ab.
56 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$ or tele-dermatoscop$).ti,ab.
57 (optical coherence adj (technolog$ or tomog$)).ti,ab.
58 (computer adj2 diagnos$).ti,ab.
59 (sentinel adj2 node).ti,ab.
60 nevisense.mp. or HFUS.ti,ab.
61 electrical impedance spectroscopy.ti,ab.
62 history taking.ti,ab.
63 patient history.ti,ab.
64 (naked eye adj (exam$ or assess$)).ti,ab.
65 (skin adj exam$).ti,ab.
66 ugly duckling.mp. or UD.ti,ab.
67 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
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68 ABCDE.mp. or VOC.ti,ab.
69 clinical accuracy.ti,ab.
70 (Family adj (Practice or Physicians)).ti,ab.





76 volatile organic compound$1.ti,ab.
77 dog$1.ti,ab.
78 gene expression analy$.ti,ab.




83 (CT or PET).ti,ab.
84 PET-CT.ti,ab.




89 positron emission tomograph$.ti,ab.





95 magnetic resonance imag$.ti,ab.
96 or/83-95
97 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
98 96 and 97
99 82 or 98
100 9 and 99




3 *basal cell carcinoma/
4 basalioma$.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$ or adenoma$ or epithelioma$ or lesion$ or malignan$ or nodule$)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1)
adj2 (skin or epiderm$ or cutaneous)).ti,ab.








18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.








31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.




















51 (high adj3 ultraso$).ti,ab.
52 (canine adj2 detect$).ti,ab.
53 ((mobile or cell$ or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
54 smartphone$.ti,ab.
55 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
56 Spot Check.ti,ab.
57 Mole Detective.ti,ab.
58 (mole$1 adj2 map$).ti,ab.
59 (total adj2 body).ti,ab.
60 exfoliative cytolog$.ti,ab.
61 digital analys$.ti,ab.
62 (image$1 adj3 software).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$).mp. or tele-dermatoscop$.ti,ab.
65 (computer adj2 diagnos$).ti,ab.
66 *sentinel lymph node biopsy/
67 (sentinel adj2 node).ti,ab.
68 nevisense.ti,ab.
69 HFUS.ti,ab.
70 electrical impedance spectroscopy.ti,ab.
71 history taking.ti,ab.
72 patient history.ti,ab.
73 (naked eye adj (exam$ or assess$)).ti,ab.













87 volatile organic compound$1.ti,ab.
88 VOC.ti,ab.
89 dog$1.ti,ab.
90 gene expression analys$.ti,ab.




95 gene expression analys$.ti,ab.
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101 (CT or PET).ti,ab.





107 *positron emission tomography/
108 *computer assisted tomography/
109 positron emission tomograph$.ti,ab.
110 *nuclear magnetic resonance imaging/





116 magnetic resonance imag$.ti,ab.
117 or/100-116
118 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
119 "Sensitivity and Specificity"/
120 *cancer staging/
121 or/118-120
122 117 and 121
123 99 or 122
124 13 and 123
Database: Cochrane Library (Wiley) 2016 searched 30 August 2016 CDSR Issue 8 of 12 2016 CENTRAL Issue 7 of 12 2016 HTA Issue 3 of 4 July 2016 DARE Issue 3 of 4
2015
Search strategy:
#1 melanoma* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyte*
#2 MeSH descriptor: [Melanoma] explode all trees
#3 "skin cancer*"
#4 MeSH descriptor: [Skin Neoplasms] explode all trees
#5 skin near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion* or malignan* or nodule*)
#6 nmsc
#7 "squamous cell" near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion* or malignan* or nodule*) near/2 (skin or
epiderm* or cutaneous)
#8 "basal cell" near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion* or malignan* or nodule*)
#9 pigmented near/2 (lesion* or nevus or mole* or naevi or naevus or nevi or skin)




#14 MeSH descriptor: [Dermoscopy] explode all trees
#15 confocal near/2 microscop*
#16 epiluminescence near/2 microscop*
#17 incident next light near/2 microscop*
#18 surface near/2 microscop*
#19 "visual inspect*"
#20 "visual exam*"
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#50 high near/3 ultraso*
#51 canine near/2 detect*
#52 Mole* near/2 map*
#53 total near/2 body
#54 mobile* or smart near/2 phone*
#55 cell next phone*
#56 smartphone*
#57 "mitotic index"
#58 DermoScan or SkinVision or DermLink or SpotCheck
#59 "Mole Detective"
#60 "Spot Check"
#61 mole* near/2 map*
#62 total near/2 body
#63 "exfoliative cytolog*"
#64 "digital analys*"
#65 image near/3 software
#66 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop* or tele-dermatolog*
#67 "optical coherence" next (technolog* or tomog*)
#68 computer near/2 diagnos*
#69 sentinel near/2 node*
#70 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36
or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62
or #63 or #64 or #65 or #66 or #67 or #68 or #69
#71 ultraso*
#72 sonograph*
#73 MeSH descriptor: [Ultrasonography] explode all trees
#74 Doppler
#75 CT or PET or PET-CT
#76 "CAT SCAN" or "CATSCAN"
#77 MeSH descriptor: [Positron-Emission Tomography] explode all trees
#78 MeSH descriptor: [Tomography, X-Ray Computed] explode all trees
#79 MRI
#80 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees
#81 MRI or fMRI or NMRI or scintigraph*
#82 "magnetic resonance imag*"
#83 MeSH descriptor: [Deoxyglucose] explode all trees
#84 deoxyglucose or deoxy-glucose
#85 "positron emission tomograph*"
#86 #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85
#87 stage* or staging or metasta* or recurrence or sensitivity or specificity or "false negative*" or thickness*
#88 MeSH descriptor: [Neoplasm Staging] explode all trees
#89 #87 or #88
#90 #89 and #86
#91 #70 or #90
#92 #10 and #91
#93 BCC or CSCC or NMCS
#94 keratinocy*
#95 #93 or #94
#96 #10 or #95
#97 nevisense
#98 HFUS
#99 "electrical impedance spectroscopy"
#100 "history taking"
#101 "patient history"
#102 naked next eye near/1 (exam* or assess*)
#103 skin next exam*
#104 "ugly duckling" or (UD sign*)
#105 MeSH descriptor: [Physical Examination] explode all trees
#106 (physician* or clinical or physical) near/1 (exam* or recog* or triage*)
#107 ABCDE
#108 "clinical accuracy"
7/13/2018 #164 Dermoscopy, with and without visual inspection, for the diagnosis of melanoma in adults
https://archie.cochrane.org/popups/view.jsp?url=%2Fsections%2Fdocuments%2Fview%3Fdocument%3Dz15012116044828295657279213… 235/255
#109 MeSH descriptor: [General Practice] explode all trees
#110 confocal near microscop*
#111 "diagnostic algorithm*"
#112 MeSH descriptor: [Clinical Competence] explode all trees
#113 checklist*
#114 "virtual image*"
#115 "volatile organic compound*"
#116 dog or dogs
#117 VOC
#118 "gene expression analys*"
#119 "reflex transmission imaging"
#120 "thermal imaging"
#121 elastography
#122 #97 or #98 or #99 or #100 or #101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111 or #112 or #113 or #114 or #115 or #116 or #117 or #118 or
#119 or #120 or #121
#123 #70 or #122
#124 #96 and #123
#125 #96 and #90
#126 #125 or #124
#127 #10 and #126
Database : CINAHL Plus (EBSCO) 1937 to 30 August 2016
Search strategy:
S1 (MH "Melanoma") OR (MH "Nevi and Melanomas+")
S2 (MH "Skin Neoplasms+")
S3 (MH "Carcinoma, Basal Cell+")
S4 basalioma*
S5 (basal cell) N2 (cancer* or carcinoma* or mass or masses or tumor* or tumour* or neoplasm* or adenoma* or epithelioma* or lesion* or malignan* or nodule*)
S6 (pigmented) N2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin)
S7 melanom* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt*
S8 nmsc
S9 TX BCC or cscc or NMSC
S10 (MH "Keratinocytes")
S11 keratinocyt*
S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S13 dermoscop* or dermatoscop* or photomicrograph* or (3 point) or (three point) or ABCD* or menzies or (7 point) or (seven point) or AI or Molemax or SIASCOP* or Aura or
MelaFind or SIMSYS or MoleMate or SolarScan or smartphone* or DermoScan or SkinVision or DermLink or SpotCheck
S14 (epiluminescence or confocal or incident or surface) N2 (microscop*)
S15 visual N1 (inspect* or examin*)
S16 (clinical or physical) N1 (examin*)
S17 pattern analys*
S18 (digital) N2 (dermoscop* or dermatoscop*)
S19 (artificial intelligence)
S20 (computer) N2 (assisted or aided)
S21 (neural network*)





S27 (optical) N2 (scan*)
S28 (high) N3 (ultraso*)
S29 elastography
S30 (mobile or cell or cellular or smart) N2 (phone*) N2 (app or application*)
S31 (mole*) N2 (map*)
S32 total N2 body
S33 exfoliative cytolog*
S34 digital analys*
S35 image N3 software
S36 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop* or tele-dermatoscop* teledermatolog* or tele-dermatolog*
or telederm or tele-derm or teledermoscop*
S37 (optical coherence) N1 (technolog* or tomog*)
S38 computer N2 diagnos*
S39 sentinel N2 node
S40 (MH "Sentinel Lymph Node Biopsy")
S41 nevisense or HFUS or checklist* or VOC or dog*










S50 (physician* or clinical or physical) N1 (exam*)
S51 clinical accuracy
S52 general practice






S59 volatile organic compound*
S60 gene expression analys*
S61 reflex transmission imag*
S62 thermal imaging
S63 S13 or S14 or S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR
S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR
S55 OR S56 OR S57 OR S58 OR S59 OR S60 OR S61 OR S62
S64 CT or PET
S65 PET-CT
S66 FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical*
S67 (MH "Deoxyglucose+")




S72 (MH "Tomography, Emission-Computed+")
S73 (MH "Tomography, X-Ray Computed")
S74 positron emission tomograph*
S75 (MH "Magnetic Resonance Imaging+")





S81 magnetic resonance imag*
S82 S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77 OR S78 OR S79 OR S80 OR S81
S83 stage* or staging or metasta* or recurrence or sensitivity or specificity or (false negative*) or thickness
S84 (MH "Neoplasm Staging")
S85 S83 OR S84
S86 S82 AND S85
S87 S63 OR S86
S88 S12 AND S87
Database: Science Citation Index SCI Expanded (Web of Science) 1900 to 30 August 2016
Conference Proceedings Citation Index (Web of Science) 1900 to 1 September 2016
Search strategy:
#1 (melanom* or nonmelanom* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyt*)
#2 (basalioma*)
#3 ((skin) near/2 (cancer* or carcinoma or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion* or malignan* or nodule*))
#4 ((basal) near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion* or malignan* or nodule*))
#5 ((pigmented) near/2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin))
#6 (nmsc or BCC or NMSC or keratinocy*)
#7 ((squamous cell (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion* or malignan* or nodule*))
#8 (skin or epiderm* or cutaneous)
#9 #8 AND #7
#10 #9 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#11 ((dermoscop* or dermatoscop* or photomicrograph* or epiluminescence or confocal or "incident light" or "surface microscop*" or "visual inspect*" or "physical exam*" or 3 point or
three point or pattern analy* or ABCDE or menzies or 7 point or seven point or dermoscop* or dermatoscop* or AI or artificial or computer aided or computer assisted or neural network*
or Molemax or image process* or automatic classif* or image analysis or siascope or optical scan* or Aura or melafind or simsys or molemate or solarscan or vivascope or confocal
microscop* or high ultraso* or canine detect* or cellphone* or mobile* or phone* or smartphone or dermoscan or skinvision or dermlink or spotcheck or spot check or mole detective or
mole map* or total body or exfoliative psychology or digital or image software or optical coherence or teledermatology or telederm* or teledermoscop* or teledermatoscop* or computer
diagnos* or sentinel))
#12 ((nevisense or HFUS or impedance spectroscopy or history taking or patient history or naked eye or skin exam* or physical exam* or ugly duckling or UD sign* or physician* exam*
or physical exam* or ABCDE or clinical accuracy or general practice or confocal microscop* or clinical competence or diagnostic algorithm* or checklist* or virtual image* or volatile
organic or VOC or dog* or gene expression or reflex transmission or thermal imag* or elastography))
#13 #11 or #12
#14 ((PET or CT or FDG or deoxyglucose or deoxy-glucose or fluorodeoxy* or radiopharma* or CATSCAN or positron emission or computer assisted or nuclear magnetic or MRI or
FMRI or NMRI or scintigraph* or echograph* or Doppler or sonograph* or ultraso* or magnetic reson*))
#15 ((stage* or staging or metast* or recurrence or sensitivity or specificity or false negative* or thickness*))
#16 #14 AND #15
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#17 #16 OR #13
#18 #10 AND #17
Refined by: DOCUMENT TYPES: (MEETING ABSTRACT OR PROCEEDINGS PAPER)






For diagnostic and staging reviews
Any study for which a 2×2 contingency table can be extracted, e.g.
diagnostic case control studies
'cross-sectional' test accuracy study with retrospective or prospective data
collection
studies where estimation of test accuracy was not the primary objective but
test results for both index and reference standard were available
RCTs of tests or testing strategies where participants were randomised
between index tests and all undergo a reference standard (i.e. accuracy
RCTs)
 
< 5 melanoma cases (diagnosis reviews)
< 10 participants (staging reviews)
Studies developing new criteria for diagnosis unless a separate 'test set' of images
were used to evaluate the criteria (mainly digital dermoscopy)
Studies using 'normal' skin as controls
Letters, editorials, comment papers, narrative reviews









Studies exclusively conducted in children
Studies of non-cutaneous melanoma or SCC
Population For diagnostic reviews
Adults with a skin lesion suspicious for melanoma, BCC, or cSCC (other terms
include pigmented skin lesion/nevi, melanocytic, keratinocyte, etc.)
Adults at high risk of developing melanoma skin cancer, BCC, or cSCC
For staging reviews
Adults with a diagnosis of melanoma or cSCC undergoing tests for staging of
lymph nodes or distant metastases or both
 
People suspected of other forms of skin cancer
Studies conducted exclusively in children


















Ultrasound +/fine needle aspiration cytology FNAC
SLNB +/high frequency ultrasound
Other
Any test combination and in any order
Any test positivity threshold
Any variation in testing procedure (e.g. radioisotope used)
 
Sentinel lymph biopsy for therapeutic rather than staging purposes
Tests to determine melanoma thickness
Tests to determine surgical margins/lesion borders






Histopathology of the excised lesion
Clinical follow-up of non-excised/benign appearing lesions with later
histopathology if suspicious
Expert diagnosis (studies should not be included if expert diagnosis is the sole
reference standard)
For studies of imaging tests for staging
Histopathology (via LND or SLMB)
Clinical/radiological follow-up
A combination of the above
For studies of SLNB accuracy for staging
LND of both SLN+ and SLn participants to identify all diseased nodes
LND of SLN+ participants and follow-up of SLN participants to identify a
subsequent nodal recurrence in a previously investigated nodal basin
 
For diagnostic studies
Exclude if any disease positive participants have diagnosis unconfirmed by
histology
Exclude if > 50% of disease negative participants have diagnosis confirmed by
expert opinion with no histology or follow-up
Exclude studies of referral accuracy, i.e. comparing referral decision with expert
diagnosis, unless evaluations of teledermatology or mobile phone applications
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma; CT: computed tomography; FNAC: fine needle aspiration cytology; LND: lymph node dissection; MRI:
magnetic resonance imaging; PET: positron emission tomography; PET-CT: positron emission tomography computed tomography; RCT: randomised controlled trial; SCC: squamous
cell carcinoma; SLN+: positive sentinel lymph node; SLn: negative sentinel lymph node; SLNB: sentinel lymph node biopsy.
7 Quality assessment (based on QUADAS-2)
Patient selection domain (1)
Selective recruitment of study participants can be a key influence on test accuracy. In general terms, all participants eligible to undergo a test should be included in a study, allowing for
the intended use of that test within the context of the study. We considered studies that separately sampled malignant and benign lesions to have used a case-control design; and those
that supplemented a series of suspicious lesions with additional malignant or benign lesions to be at unclear risk of bias
In terms of exclusions, we considered studies that excluded particular lesion types (e.g. lentigo maligna), particular lesion sites, or excluded lesions with lack of observer agreement
(e.g. on histopathology) to be at high risk of bias. For image-based evaluations, some studies excluded lesions on the basis of image quality as an a priori exclusion criterion while
others excluded lesions with inadequate images post hoc. In order to judge studies consistently, we considered all exclusions due to image quality in the Flow and Timing domain (Were
all participants included in the analysis?).
In judging the applicability of patient populations to the review question, we considered restriction to particular lesion populations, such as melanocytic, nodular, high risk or restrictions
by size to be of high concern for applicability. Studies that included only lesions with histopathology results were also considered of high concern for applicability on the basis that in
usual practice, whether in primary, secondary or specialist care, a greater or lesser proportion of patients will have lesions with low levels of suspicion of malignancy such that they can
be reassured and discharged, or followed up over a period of time. The restriction of a study sample to those with lesions undergoing biopsy or excision will therefore not adequately
reflect a usual care setting. Furthermore, due to the invasive nature of sampling lesions for histology, studies are not likely to mandate biopsy or excision as a study requirement
regardless of the index of suspicion (in which case restriction to those with histology would not be of concern in terms of having a representative population).
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Given that diagnosis of skin cancer is primarily lesion-based, there is the potential for study participants with multiple lesions to contribute disproportionately to estimates of test
accuracy, especially if they are at particular risk of having skin cancer. We considered studies that include a high number of lesions in relation to the number of study to be less
representative than studies conducted in a more general population participants (i.e., if the difference between the number of included lesions and number of included participants is
greater than 5%).
Index test domain (2)
Given the potential for subjective differences in test interpretation for melanoma, the interpretation of the index test blinded to the result of the reference standard is a key means of
reducing bias. For prospective studies and retrospective studies that used the original index test interpretation, the diagnosis will by nature be interpreted and recorded before the result
of the reference standard is known; however, studies using previously acquired images could be particularly susceptible to information bias. For these studies to be at low risk of bias,
we required a clear indication that observers were unaware of the reference standard diagnosis at time of test interpretation. An item was also added to assess the presence of blinding
between interpretations of different algorithms, however this item was not included in the overall assessment of risk of bias.
Pre-specification of the index test threshold was considered present if the study clearly reported that the threshold used was not data driven, i.e., was not based on study results.
Studies that did not clearly describe the threshold used but that required clinicians to record a diagnosis or management decision for a lesion were considered to be unclear on this
criterion. Studies reporting accuracy for multiple numeric thresholds, where ROC analysis was used to select the threshold, or that reported accuracy for the presence of independently
significant lesion characteristics with no separate test set of lesions were considered at high risk of bias.
In terms of applicability of the index test to the review question, we required the test to be applied and interpreted as it would be in a clinical practice setting, i.e., in-person or face-to-
face with the study participant, and by a single observer as opposed to a consensus decision or average across multiple observers. Image-based studies were considered to be of high
concern.
Despite the often subjective nature of test interpretation, it is also important for study authors to outline the particular lesion characteristics that were considered to be indicative for
melanoma, particularly where established algorithms or checklists were not used. Studies were considered of low concern if the threshold used was established in a prior study or
sufficient threshold details were presented to allow replication.
The experience of the examiner will also impact on the applicability of study results. We required studies to describe the test interpreter as ‘experienced’ or ‘expert’ to have low concern
about applicability.
Reference standard domain (3)
In an ideal study, consecutively recruited participants should all undergo incisional or excisional biopsy of the skin lesion regardless of level of clinical suspicion of melanoma. In reality,
both partial and differential verification bias are likely. Partial verification bias may occur where histology is the only reference standard used, and only those participants with a certain
degree of suspicion of malignancy based on the result of the index test undergo verification, the others either being excluded from the study or defined as being disease-negative
without further assessment or follow-up, as discussed under ‘Patient selection domain’.
Differential verification bias will be present where other reference standards are used in addition to histological verification of suspicious lesions. A typical example of verification bias in
skin cancer occurs when investigators do not biopsy people with benign-appearing lesions but instead follow them up for a period of time to determine whether any malignancy
subsequently develops (these would be false-negatives on the index test). We defined an 'adequate' reference standard as: all disease-positive individuals having a histological
reference standard either at the time of application of the index test or after a period of clinical follow-up; and at least 80% of disease-negative participants have received a histological
diagnosis, with up to 20% undergoing at least three months' follow-up of benign-appearing lesions.
A further challenge is the potential for incorporation bias, i.e., where the result of the index test is used to help determine the reference standard diagnosis. It is normal practice for the
clinical diagnosis (usually by visual inspection or dermoscopy) to be included on pathology request forms and for the histopathologist to use this diagnosis to help with the pathology
interpretation. Although inclusion of such clinical information on the histopathology request form is theoretically a form of incorporation bias, blinded interpretation of the histopathology
reference standard is not normal practice, and enforcement of such conditions would significantly limit the generalisability of the study results. Blinding to the index test (visual
inspection or clinical diagnosis) was therefore recorded but did not contribute to our overall assessment of risk of bias for the reference standard domain.
In judging the applicability of the reference standard to our review question, scored studies as high concern around applicability if they used expert diagnosis (with no follow-up) as a
reference standard in any patient, or did not report histology interpretation by a dermatopathologist.
Flow and timing domain (4)
In the ideal study, the diagnosis based on the index test and reference standard should be made consecutively or as near to each other in time as possible to avoid changes in lesion
over time. For lesions with a histological reference standard, we have defined a one-month period as an appropriate interval between application of the index test and the reference
standard. Studies reporting biopsy or excision ‘following’, ‘after’ or ‘subsequent to’ the visual inspection diagnosis (or using similar descriptors) were considered to have met this
criterion. For studies using clinical follow-up, a minimum three-month follow-up period has been defined as at low risk of bias for detecting false-negatives. This interval was chosen
based on a study showing that most false-negative melanomas will be diagnosed within three months of the initial negative index test although a small number will be diagnosed up to
12 months subsequently (Altamura 2008).
In assessing whether all patients were included in the analysis, we considered studies at high risk of bias if participants were excluded following recruitment. As discussed in the ‘Patient
selection domain’, a priori exclusion of images on the basis of image quality was also considered under this item.
The following tables use text that was originally published in the QUADAS-2 tool by Whiting and colleagues ( Whiting 2011 ).
Item Response (delete as required)
PARTICIPANT SELECTION (1) RISK OF BIAS
1) Was a consecutive or random sample of participants or images enrolled? Yes – if paper states consecutive or random
No – if paper describes other method of sampling
Unclear – if participant sampling not described
2) Was a case-control design avoided? Yes – if consecutive or random or case-control design clearly not used
No – if study described as case-control or describes sampling specific numbers of
participants with particular diagnoses
Unclear – if not described
 
3) Did the study avoid inappropriate exclusions, e.g.,
'difficult to diagnose' lesions not excluded
lesions not excluded on basis of disagreement between evaluators
Yes - if inappropriate exclusions were avoided
No – if lesions were excluded that might affect test accuracy, e.g., 'difficult to
diagnose' lesions, or where disagreement between evaluators was observed
Unclear – if not clearly reported but there is suspicion that difficult to diagnose
lesions may have been excluded
 
4) For between-person comparative studies only (i.e., allocating different tests to different study
participants):
A) were the same participant selection criteria used for those allocated to each test?
B) was the potential for biased allocation between tests avoided through adequate generation
of a randomised sequence?
C) was the potential for biased allocation between tests avoided through concealment of
allocation prior to assignment?
For A)
Yes – if same selection criteria were used for each index test, No – if different
selection criteria were used for each index test, Unclear – if selection criteria per
test were not described, N/A – if only 1 index test was evaluated or all
participants received all tests
For B)
Yes – if adequate randomisation procedures are described, No – if inadequate
randomisation procedures are described, Unclear – if the method of allocation to
groups is not described (a description of 'random' or 'randomised' is insufficient),
N/A – if only 1 index test was evaluated or all participants received all tests
For C)
Yes – if appropriate methods of allocation concealment are described, No – if
appropriate methods of allocation concealment are not described, Unclear – if
the method of allocation concealment is not described (sufficient detail to allow a
definite judgement is required), N/A – if only 1 index test was evaluated
 
Could the selection of participants have introduced bias?
For non-comparative and within-person-comparative studies
1. If answers to all of questions 1), 2), and 3) 'Yes':
2. If answers to any 1 of questions 1), 2), or 3) 'No':
3. If answers to any 1 of questions 1), 2), or 3) 'Unclear':
 
For non-comparative and within-person-comparative studies
1. Risk is low
2. Risk is high
3. Risk unclear
For between-person comparative studies
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For between-person comparative studies
1. If answers to all of questions 1), 2), 3), and 4) 'Yes':
2. If answers to any 1 of questions 1), 2), 3), or 4) 'No':
3. If answers to any 1 of questions 1), 2), 3), or 4) 'Unclear':
1. Risk is low
2. Risk is high
3. Risk unclear
PARTICIPANT SELECTION (1) CONCERNS REGARDING APPLICABILITY
 
1) Are the included participants and chosen study setting appropriate to answer the review
question, i.e., are the study results generalisable?
This item is not asking whether exclusion of certain participant groups might bias the study's
results (as in Risk of Bias above), but is asking whether the chosen study participants and
setting are appropriate to answer our review question. Because we are looking to establish
test accuracy in both primary presentation and referred participants, a study could be
appropriate for 1 setting and not for the other, or it could be unclear as to whether the study
can appropriately answer either question
For each study assessed, please consider whether it is more relevant for A) participants with
a primary presentation of a skin lesion or B) referred participants, and respond to the
questions in either A) or B) accordingly. If the study gives insufficient details, please respond
Unclear to both parts of the question
 
A) For studies that will contribute to the analysis of participants with a primary
presentation of a skin lesion (i.e., test naive)
Yes – if participants included in the study appear to be generally representative of
those who might present in a usual practice setting
No – if study participants appear to be unrepresentative of usual practice, e.g., in
terms of severity of disease, demographic features, presence of differential diagnosis
or comorbidity, setting of the study, and previous testing protocols
Unclear – if insufficient details are provided to determine the generalisability of study
participants
B) For studies that will contribute to the analysis of referred participants (i.e.,
who have already undergone some form of testing)
Yes – if study participants appear to be representative of those who might be
referred for further investigation. If the study focuses only on those with equivocal
lesions, for example, we would suggest that this is not representative of the wider
referred population
No – if study participants appear to be unrepresentative of usual practice, e.g., if a
particularly high proportion of participants have been self-referred or referred for
cosmetic reasons. Other factors to consider include severity of disease, demographic
features, presence of differential diagnosis or comorbidity, setting of the study, and
previous testing protocols
Unclear – if insufficient details are provided to determine the generalisability of study
participants
2) Did the study avoid including participants with multiple lesions? Yes – if the difference between the number of included lesions and number of
included participants is less than 5%
No – if the difference between the number of included lesions and number of
included participants is greater than 5%
Unclear – if it is not possible to assess
 
Is there concern that the included participants do not match the review question?
1. If the answer to question 1) or 2) 'Yes':
2. If the answer to question 1) or 2) 'No':
3. If the answer to question 1) or 2) 'Unclear':
 
1. Concern is low
2. Concern is high
3. Concern is unclear
INDEX TEST (2) RISK OF BIAS (to be completed per test evaluated)
1) Was the index test or testing strategy result interpreted without knowledge of the results of the
reference standard?
Yes – if index test described as interpreted without knowledge of reference standard
result or, for prospective studies, if index test is always conducted and interpreted
prior to the reference standard
No – if index test described as interpreted in knowledge of reference standard result
Unclear – if index test blinding is not described
2) Was the diagnostic threshold at which the test was considered positive (i.e., melanoma
present) prespecified?
Yes – if threshold was prespecified (i.e., prior to analysing study results)
No – if threshold was not prespecified
Unclear – if not possible to tell whether or not diagnostic threshold was prespecified
3) For within-person comparisons of index tests or testing strategies (i.e., > 1 index test applied
per participant): was each index test result interpreted without knowledge of the results of other
index tests or testing strategies?
Yes – if all index tests were described as interpreted without knowledge of the results
of the others
No – if the index tests were described as interpreted in the knowledge of the results
of the others
Unclear – if it is not possible to tell whether knowledge of other index tests could
have influenced test interpretation
N/A – if only 1 index test was evaluated
 
Could the conduct or interpretation of the index test have introduced bias?
For non-comparative and between-person comparison studies
1. If answers to questions 1) and 2) 'Yes':
2. If answers to either questions 1) or 2) 'No':
3. If answers to either questions 1) or 2) 'Unclear':
For within-person comparative studies
1. If answers to all questions 1), 2), for any index test and 3) 'Yes':
2. If answers to any 1 of questions 1) or 2) for any index test or 3) 'No':
3. If answers to any 1 of questions 1) or 2) for any index test or 3) 'Unclear':
 
For non-comparative and between-person comparison studies
1. Risk is low
2. Risk is high
3. Risk is unclear
For within-person comparative studies
1. Risk is low
2. Risk is high
3. Risk is unclear
INDEX TEST (2) CONCERN ABOUT APPLICABILITY
 




lesion characteristics indicative of melanoma used
objective (usually numerical) threshold used
Yes – if a previously evaluated/established tool to aid diagnosis of melanoma was
used or if the diagnostic threshold used was established in a previously published
study
No – if an unfamiliar/new tool to aid diagnosis of melanoma was used, if no particular
algorithm was used, or if the objective threshold reported was chosen based on
results in the current study
Unclear – if insufficient information was reported
 
2) Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication?
Study results can only be reproduced if the diagnostic threshold is described in sufficient detail.
This item applies equally to studies using pattern recognition and those using checklists or
algorithms to aid test interpretation
Yes – If the criteria for diagnosis of melanoma were reported in sufficient detail to
allow replication
No – if the criteria for diagnosis of melanoma were not reported in sufficient detail to
allow replication
Unclear – If some but not sufficient information on criteria for diagnosis to allow
replication were provided
3) Was the test interpretation carried out by an experienced examiner? Yes – if the test was interpreted by 1 or more speciality-accredited dermatologists, or
by examiners of any clinical background with special interest in dermatology and with
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any formal training in the use of the test
No – if the test was not interpreted by an experienced examiner (see above)
Unclear – if the experience of the examiner(s) was not reported in sufficient detail to
judge or if examiners were described as 'Expert' with no further detail given
N/A – if system-based diagnosis, i.e., no observer interpretation
 
Is there concern that the index test, its conduct, or interpretation differ from the review question?
1. If answers to questions 1), 2), and 3) 'Yes':
2. If answers to questions 1), 2), or 3) 'No':
3. If answers to questions 1), 2), or 3) 'Unclear':
 
1. Concern is low
2. Concern is high
3. Concern is unclear
REFERENCE STANDARD (3) RISK OF BIAS
 
1) Is the reference standard likely to correctly classify the target condition?
A) Disease-positive – 1 or more of the following:
histological confirmation of melanoma following biopsy or lesion excision
clinical follow-up of benign-appearing lesions for at least 3 months following the application of
the index test, leading to a histological diagnosis of melanoma
B) Disease-negative – 1 or more of the following:
histological confirmation of absence of melanoma following biopsy or lesion excision in at
least 80% of disease-negative participants
clinical follow-up of benign-appearing lesions for a minimum of 3 months following the index
test in up to 20% of disease-negative participants
 
A) Disease-positive
Yes – if all participants with a final diagnosis of melanoma underwent 1 of the listed
reference standards
No – If a final diagnosis of melanoma for any participant was reached without
histopathology
Unclear – if the method of final diagnosis was not reported for any participant with a
final diagnosis of melanoma or if the length of clinical follow-up used was not clear or
if a clinical follow-up reference standard was reported in combination with a
participant-based analysis and it was not possible to determine whether the detection
of a malignant lesion during follow-up is the same lesion that originally tested
negative on the index test
B) Disease-negative
Yes – If at least 80% of benign diagnoses were reached by histology and up to 20%
were reached by clinical follow-up for a minimum of 3 months following the index test
No – if more than 20% of benign diagnoses were reached by clinical follow-up for a
minimum of 3 months following the index test or if clinical follow-up period was less
than 3 months
Unclear – if the method of final diagnosis was not reported for any participant with
benign or non-melanoma diagnosis
 
2) Were the reference standard results interpreted without knowledge of the results of the index
test?
Please score this item for all studies even though histopathology interpretation is usually
conducted with knowledge of the clinical diagnosis (from visual inspection or dermoscopy or
both). We will deal with this by not including the response to this item in the 'Risk of bias'
assessment for these tests. For reviews of all other tests, this item will be retained
Yes – if the reference standard diagnosis was reached blinded to the index test result
No – if the reference standard diagnosis was reached with knowledge of the index
test result
Unclear – if blinded reference test interpretation was not clearly reported
 
Could the reference standard, its conduct, or its interpretation have introduced bias?
For visual inspection/dermoscopy evaluations
1. If answer to question 1) 'Yes':
2. If answer to question 1) 'No':
3. If answer to question 1) 'Unclear':
For all other tests
1. If answers to questions 1) and 2) 'Yes':
2. If answers to questions 1) or 2) 'No':
3. If answers to questions 1) or 2) 'Unclear':
 
For visual inspection/dermoscopy evaluations
1. Risk is low
2. Risk is high
3. Risk is unclear
For all other tests
1. Risk is low
2. Risk is high
3. Risk is unclear
REFERENCE STANDARD (3) CONCERN ABOUT APPLICABILITY
1) Are index test results presented separately for each component of the target condition (i.e.,
separate results presented for those with invasive melanoma, melanoma in situ, lentigo maligna,
severe dysplasia, BCC, and cSCC)?
Yes – if index test results for each component of the target condition can be
disaggregated
No – if index test results for the different components of the target condition cannot
be disaggregated
Unclear – if not clearly reported
 
2) Expert opinion (with no histological confirmation) was not used as a reference standard
'Expert opinion' means diagnosis based on the standard clinical examination, with no histology or
lesion follow-up
***do not complete this item for teledermatology studies
Yes – if expert opinion was not used as a reference standard for any participant
No – if expert opinion was used as a reference standard for any participant
Unclear – if not clearly reported
3) Was histology interpretation carried out by an experienced histopathologist or by a
dermatopathologist?
Yes – if histology interpretation was reported to be carried out by an experienced
histopathologist or dermatopathologist
No – if histology interpretation was reported to be carried out by a less experienced
histopathologist
Unclear – if the experience/qualifications of the pathologist were not reported
 
Is there concern that the target condition as defined by the reference standard does not match
the review question?
1. If answers to all questions 1), 2), and 3) 'Yes':
2. If answers to any 1 of questions 1), 2), or 3) 'No':
3. If answers to any 1 of questions 1), 2), or 3) 'Unclear':
***For teledermatology studies only
1. If answers to all questions 1) and 3) 'Yes':
2. If answers to questions 1) or 3) 'No':
3. If answers to questions 1) or 3) 'Unclear':
1. Concern is low
2. Concern is high
3. Concern is unclear
***For teledermatology studies only
1. Concern is low
2. Concern is high
3. Concern is unclear
FLOW AND TIMING (4): RISK OF BIAS
 
1) Was there an appropriate interval between index test and reference standard?
A) For histopathological reference standard, was the interval between index test and reference
standard ≤ 1 month?
 
A)
Yes – if study reports ≤ 1 month between index and reference standard
No – if study reports > 1 month between index and reference standard
Unclear – if study does not report interval between index and reference standard
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B) If the reference standard includes clinical follow-up of borderline/benign-appearing lesions,
was there at least 3 months' follow-up following application of index test(s)?
B)
Yes – if study reports ≥ 3 months' follow-up
No – if study reports < 3 months' follow-up
Unclear – if study does not report the length of clinical follow-up
2) Did all participants receive the same reference standard? Yes – if all participants underwent the same reference standard
No – if more than 1 reference standard was used
Unclear – if not clearly reported
3) Were all participants included in the analysis? Yes – if all participants were included in the analysis
No – if some participants were excluded from the analysis
Unclear– if not clearly reported
 
4) For within-person comparisons of index tests
Was the interval between application of index tests ≤ 1 month?
Yes – if study reports ≤ 1 month between index tests
No – if study reports > 1 month between index tests
Unclear – if study does not report the interval between index tests
 
Could the participant flow have introduced bias?
For non-comparative and between-person comparison studies
1. If answers to questions 1), 2), and 3) 'Yes':
2. If answers to any 1 of questions 1), 2), or 3) 'No':
3. If answers to any 1 of questions 1), 2), or 3) 'Unclear':
For within-person comparative studies
1. If answers to all questions 1), 2), 3), and 4) 'Yes':
2. If answers to any 1 of questions 1), 2), 3), or 4) 'No':
3. If answers to any 1 of questions 1), 2), 3), or 4) 'Unclear':
For non-comparative and between-person comparison studies
1. Risk is low
2. Risk is high
3. Risk is unclear
For within-person comparative studies
1. Risk is low
2. Risk is high
3. Risk is unclear
BCC = basal cell carcinoma; cSCC = cutaneous squamous cell carcinoma.
 









































Excised melanocytic skin lesions
with recorded dermoscopy ABCD
score and clinician's preliminary
diagnosis. Preliminary diagnosis of














visiting residents data excluded
Histology
MM 23; MiS 23
BN: 263
57 lesions with missing
scoring; 5 non-melanocytic
diagnosis; 5 with pre-op dx














PSL examined during a campaign for











Dermatologist (n=3; trained in
recognition of PSLs)
Consensus of 3 (expert consult
for disagreements)
Histology
























1. >/=1 to all 5
chars present
 2. Score >=2
 





MM 54; MiS 6
BCC 1
















PSL with a more or less important












 Dermosc - >=1
char present
Surgical oncologist (n=4; high)
Single obs
Histology
MM 55; MiS 11
















PSL <=6mm requiring surgical
biopsy for diagnosis based on









 Dermosc - >=1
char present
Surgical oncologist (n=2; high)
Single obs
Histology
MM 10; MiS 3
















PSL <=3mm undergoing excision
due to a more or less important









 Dermosc - NR
NR; assumed surgical
oncologist as per Bono 2002;
Bono 2002b (n=4; exp NR)
Single obs
Histology
MM 19; MiS 4




























> 1 change in
minor criteria or























lesions undergoing excision for












Dermatologist (n=2; exp High)
Consensus of 2
Histology
















Clinically equivocal and suspicious
PSL subjected to excisional biopsy












Dermatologist (n=2; High exp –






MM 40; MiS 14
BCC 5

















Patients with PSL presenting during
a campaign for the early diagnosis of









 2. >=1 char
present
 
Dermatologist (n=4; High exp -
dermatologists had all been






















Patients presenting at PSL clinic









































Plastic surgeon (n=1; exp NR)
Single observer
Histology or FU


























PSL that could not be diagnosed
with only dermatologic physical



















SK 24; BN 100;
DF 12; Warts 16;

















Melanocytic lesions examined by




>5.45 NR(n=NR; exp NR)
Unclear obs interp
Histology


















Patients with melanocytic and non-











Dermatologist (n=NR; exp High








Bham team: 1 BCC moved






























Assumed Low (Expertise NR;
simple protocols for diagnosis

















Dermatologist (n=2; exp High)  
Histology
Only 50% of imaged nevi
were included (randomly


















of MM) Single observer MM 61; MiS 18
BN 116 (incl 22
SN)
79/198; 41%
selected from the image
database prior to analysis) to














Participants at increased risk for
melanoma: >50 common and/or <=3
atypical nevi; atypical mole
syndrome (AMS); or familial atypical
mole and multiple melanoma






formally trained in dermoscopy





(every 3, 6, or 12
mos)
Full sample: MM
77; MiS 50; BCC 2






















Participants at increased risk for
melanoma: >50 common and/or <=3
atypical nevi; atypical mole
syndrome (AMS); or familial atypical
mole and multiple melanoma







formally trained in dermoscopy





(every 3, 6, or 12
mos)
Full sample: MM
77; MiS 50; BCC 2









































MM 55; MiS 18
SK 4; BN 126;
atypical nevi 113;
congenital nevi 3,








pigmented SK, DF, and
pigmented BCC) ‘easily
distinguished by standard















Patients with lesions scheduled for
excision at the PLC to either remove
atypical nevi or to rule out melanoma
or for cosmetic reasons; excluded if































PSL that would be biopsied or


















Assumed Low (trained in
dermoscopy for study; required
history of excision or referral of
at least 10 pigmented skin
lesions over the previous 12-







BD 2; Benign 323;
Unknown 9
4%
6 BCC and 2 BD excluded

































































BN 103; SK 19





















NR Dermatologist (n=2; exp High;
"the examination was





MM 50; MiS 15
BCC 3; SK 18; AK















PSL referred by dermatologists and
general practitioners either for pre-









NR (assumed dermatologist -










BCC: 3 BCCs considered to
be MM were classed as TN
rather than FP for review
purposes




1 Test naïve; 2 Limited prior testing; 3 Limited prior testing (with selection on reference standard); 3* Limited prior testing (with selection on reference standard and equivocal nature of
lesions); 4 Referred for further assessment; 5 Referred for further assessment (with selection on reference standard); 5* Referred for further assessment (with selection on reference
standard and equivocal nature); 6 Referred for further assessment (equivocal on specialist review); 7 Lesions that have been undergoing follow-up
c- clearly positioned on clinical pathway; u – unclear position on clinical pathway; NR – not reported; PSL – pigmented skin lesion; PLC – pigmented lesion clinic; MM – malignant
melanoma; MiS – melanoma in situ (or lentigo maligna); BCC – basal cell carcinoma; cSCC – cutaneous squamous cell carcinoma; LS – lentigo simplex; SK – seborrheic keratosis;
SN – Spitz nevi; AK – actinic keratosis; BN – benign naevi; BD – Bowen’s disease; DF – dermatofibroma; FU – follow-up; R –retropsective; P – prospective; CS – case series; CCS –
case control study; WPC – within person comparison (of tests); BPC – between person comparison (of tests); NC – non comparative; RCM – reflectance confocal microscopy; CAD –
computer-assisted diagnosis

















































NR; dx of MM  
Dermatologist (n=3; exp








BN 107; 53 SK
and AK
92/343; 27%
79 lesions without criteria of
malignancy on RCM were















lesions; all >5 mm diameter, with a
flat or barely elevated surface and
at least 3 of the following features:
(a) asymmetry, (b) irregular
margins, (c) ill-defined borders,

































Atypical melanocytic skin lesions
with dermoscopic images that had






















MM 99; MiS 18
BN 225
















melanomas; 100 excised BN 100
BN that showed no relevant
changes to warrant excision during





































All small (<= 6 mm) melanomas
and melanocytic nevi








Both >=2  
Dermatologist
(assumed) (n=3; exp
NR) evaluated by 3
different observers; in






















Slides of PSL selected for
evaluation during a training course
on dermoscopy. Lesions not












Single author - High





MM 10, MiS 2
BCC 2


















Images of PSL randomly selected
































PSL with available dermoscopy




























Test results not disaggregated
for BCC





































MM 34; MiS 7
















Melanocytic skin lesions to be
excised because of clinically
and/or dermoscopically clear or
suspicious malignancy, or by the

















*dataset overlaps Blum 2004b
so not included in primary
analysis, only algorithm
comparisons (recruited













All lesions of patients with multiple


























*dataset overlaps Blum 2004b
so not included in primary
analysis, only algorithm
comparisons (recruited














PSL excised due to suspicious

























*dataset overlaps Blum 2004b
so not included in primary
analysis, only observer
comparisons (recruited












Melanocytic skin lesions imaged










































All skin lesions excised to exclude
skin cancer (and 3 examples
common lesions assessed as

















FU / Expert dx
MM 1; MiS 8
BCC 6; SK 5;




(not further identified) in the set
of 50 were excluded from
dermoscopic evaluations














Clinically equivocal and suspicious
PSL
 




















MM 40; MiS 14
 BCC: 5



















Clinically suspicious or equivocal
PSL undergoing excision for










experience in the field of
'); consensus of 2
 
Histology
MM 6, MiS 5
BCC 10
BN 31, SK 1;
Other 4
11/57; 19%
4 ‘not evaluables’ excluded (NB
these differ between clinical
images and dermoscopic














Melanocytic lesions <14 mm in
diameter, excised because they



































Clinically difficult to diagnose or
equivocal melanocytic lesions
randomly selected; all melanomas
<1mm thickness.
 




























Images of melanocytic lesions
including MM with unequivocal
histology, and histologically
verified nevi or nevi demonstrating
stability under sequential












GP 24; Derm registrar
25; Dermatologist 73; 1










* Up to 50 lesions per PLC (1:3
ratio of MEL to BN; 1:1
polarized or nonpolarized















images); randomized into 12
image sets of 39 (n = 8) or 40 (n
= 7) unique lesions and 5
nonunique lesion images (2
















































Melanocytic skin lesions that
underwent excision (*accuracy































Melanocytic skin lesions randomly
selected from a collection of
dermoscopic images belonging to
one author.
 


























MM 18, MiS 2
BN 12; SN 3;
Other 4
20/20; 50%














Patients with skin lesions difficult
to diagnose clinically
 




















lesions not included prior to
examination (no melanomas













PSL suspicious for melanoma and
excised; observers randomly







NR; dx of MM Dermatologist (n=3; exp
High) 'expert
dermatologists' 'with at

























Melanocytic lesions examined by




>5.45; >4.2 NR(n=NR; exp NR)
Unclear obs interp
Histology





















Melanocytic lesions with equivocal
clinical and/or dermoscopic



















90 ‘positive-clear cut’ lesions
scoring 5 or more were













Dermoscopic images of skin
lesions excised on the basis of
clinical suspicion of malignancy,




















MM 15; MiS 10
BN 20, blue nevi

















An industry database of images of
PSL <=6mm was used to sample
images of melanoma and non
melanoma lesions; high-grade



















MM 21; MiS 28;





































MM 44 MiS 4





(*determined by >=3 of:
diameter >5 mm, ill-defined
borders, irregular margins,




















130 in derivation set of lesions




























Patients referred for excision
biopsy of where the diagnosis of















MM 7; MiS 5; 1
mel mets (incl as
D-)
SK 1; BN 57; BD
































MM 28; MiS 16
BN 87 (incl 3
SN)
44/131; 34%
(25 lesions out of 156 were
rejected for poor quality
















Subset of PSL evaluated in a
MelaFind study (Monheit 2011); 65
melanoma and 65 non-melanoma
randomly selected. Excluded
ulcerated, non-pigmented, or

























*RCT of dx based on
clinical/dermoscopic images















PSL images selected on image
quality and difficulty of diagnosis;
all melanomas has “only subtle
ELM features as clues to the
malignancy of the lesion .. difficult





































Images retrieved from a PSL
database; melanocytic skin lesions
from patients with multiple atypical







NR; Excise  
Dermatologist (n=24;















*10 patients with early
melanomas and 10 other
patients randomly selected;
benign melanocytic skin lesions













Patients with skin lesions selected
for total excision to rule out
melanoma; dermatologists were
encouraged to enrol a mix of
lesions with an even distribution of



































cSCC 1; MCC 1
BN 1497; 5 SN,
51 SK, 6 SCC in
situ; 8 AK; 61
other]
238/1678; 14%
473 excluded from total sample
– mainly due to investigator
 oversight or inability to render a
final histopathological
diagnosis; 74 were device-
related (60 with inadequate
reference measurement
 quality and 14 to device failure).
  
242 excluded from














PSL imaged using SolarScan at 9
different clinical centres including
specialist referral centres and
































*Only the 78 lesions from the
Sydney Melanoma Unit













Dermoscopic amelanotic (with no
melanin pigmentation) or
hypomelanotic (a melanin
pigmentation area of less than
25% of the total surface area or

























* All melanomas included, and a
random selection of melanocytic
and nonmelanocytic lesions on
7/13/2018 #164 Dermoscopy, with and without visual inspection, for the diagnosis of melanoma in adults
https://archie.cochrane.org/popups/view.jsp?url=%2Fsections%2Fdocuments%2Fview%3Fdocument%3Dz15012116044828295657279213… 248/255




80% of sample and
tested on 20% but
numbers D+/D- NR
for the test set to









MM 91; 14 MiS;
126 BCC; 4
cSCC
BN 159; SN 11;
SK 22; DF 17;
BD 7; KA 1; AK
8; other 37
105/497; 21%















Images of PSL from the training
set of the Consensus Net Meeting




















MEL 6; BCC: 2





Data not disaggregated for BCC
*pre- and post- dermoscopy














PSL excised because of equivocal






















































MM 23; MiS 10
BN 105; CN; 19





































































Exp NR; single obs
 
Histology
AHM 34, MiS 5
BCC 25, SCC 5




23 lesions excluded due to
image quality; further 43 lesions
were not available for















Melanomas <5 mm consecutively
excised; plus 3 histologically

















MM 13; MiS 11
















PSL analyzed as part of a prior





































PSL submitted for histology from
the primary care skin cancer
practice of one author
 














MM 9; MiS 20
BCC 72; SCC 5





3 poor quality images excluded














Palmoplantar (acral) PSL excised
over a 3 year period. All with
clinical/ dermoscopic suspicious


























  Melanocytic skin lesions showing  NR; dx of MM   None reported












clear-cut dermoscopic features of






















































Patients referred by dermatologists
or general physicians with >=1
PSL difficult to interpret on clinical
grounds alone, numerous PSLs, or
because the patients were at





































Melanocytic lesions, which had
undergone surgical excision for
clinical, dermoscopic, or cosmetic
reasons after referral by a
dermatologist for examination of a











































NR; dx of MM  



















changes over time during digital
dermoscopy follow-up that were






























PSL images selected from
computerised files of the skin
cancer clinic.
 
1. VI (no algorithm)






NR; clin dx  
Dermatologists (n=20)
Exp NR (“experience in


























PSL images selected from

















MM 10; MiS 1














Melanocytic lesions referred to
Skin Cancer Unit for clinical and
dermoscopic evaluation.
 
1. VI (no algorithm)













High exp (“2 years
dermoscopy





















Lesions excised on the basis of
clinical and/ or dermoscopic


















MM 11; MiS 1















[79 in test set incl]
Equivocal PSLs with size smaller
than 9x13 mm, melanoma tumour
































Test series of images of










Mixed (n=6; exp mixed)





















Dermoscopic images of all
melanoma lesions recorded on two










































Melanocytic lesions excised at
Pigmented Lesion Clinic
 














VI appears to be in
clinic dx (single
observer); derm images























PSL selected from a repository of
lesions amassed during an
acquisition study conducted by
MELA Sciences Inc for the US



































1. VI (no algorithm)


























Random sample of excised,
equivocal and nonequivocal, PSL
and and non-PSLs with melanin or
haemoglobin pigmentation in all or















MM 18; MiS 11
BCC: 18




15 used for training purposes
5 BCC moved from FP to to TN
 
FOOTNOTES: 1 Test naïve; 2 Limited prior testing; 3 Limited prior testing (with selection on reference standard); 3* Limited prior testing (with selection on reference standard and
equivocal nature of lesions); 4 Referred for further assessment; 5 Referred for further assessment (with selection on reference standard); 5* Referred for further assessment (with
selection on reference standard and equivocal nature); 6 Referred for further assessment (equivocal on specialist review); 7 Lesions that have been undergoing follow-up
c- clearly positioned on clinical pathway; u – unclear position on clinical pathway; NR – not reported; PSL – pigmented skin lesion; PLC – pigmented lesion clinic; MM – malignant
melanoma; MiS – melanoma in situ (or lentigo maligna); BCC – basal cell carcinoma; cSCC – cutaneous squamous cell carcinoma; LS – lentigo simplex; SK – seborrheic keratosis;
SN – Spitz nevi; AK – actinic keratosis; BN – benign naevi; BD – Bowen’s disease; DF – dermatofibroma; FU – follow-up; R –retropsective; P – prospective; CS – case series; CCS –
case control study; WPC – within person comparison (of tests); BPC – between person comparison (of tests); NC – non comparative; RCM – reflectance confocal microscopy; CAD –
computer-assisted diagnosis
10 Forest plots of sensitivity and specificity for visual inspection for the detection of invasive melanoma and intraepidermal melanocytic
variants (MM+MiS)
Figure 25







































Clinically relevant cutaneous pigmented










high or very high
risk; correct dx of
MM





















PSLs undergoing excision due to diagnosis of
melanoma or atypical nevus, to rule out

















Correct dx of MM
Dermatologist (n=3; exp High)








10 excluded due to
poor image quality;












Melanocytic lesions examined by




>5.45; >4.2 NR(n=NR; exp NR)
Unclear obs interp
Histology





























































correct dx of MM
Dermatologists (n=1; exp High)
Single observer
Histology
MM 11; BCC 3
























PSLs examined at the Dermoscopy Service
and undergoing excisions; high and medium
risk on dermoscopy were selected for excision






























Melanocytic lesions imaged at the Sydney
Melanoma Unit with a histopathologic diagnosis
or that remained unchanged following short-











correct dx of MM
Dermatologist (assumed) (n=2;
exp NR)




















An industry database of images of PSL <=6mm
was used to sample images of melanoma and















Mixed - sec (n=10; exp High)
Average result (reports mean





















Subset of PSL evaluated in a MelaFind study
(Monheit 2011); 65 melanoma and 65 non-
melanoma randomly selected. Excluded






































Pigmented lesions suspected to be malignant














results for inexperienced student






















Patients with lesions suspicious for CMM











correct dx of MM























PSL from patients consecutively referred to the
skin cancer outpatient clinic with available
clinical photographs, dermatophotographs and













Dermatologist (n=3; exp High; 3
senior dermatologists with >5 y
daily experience in
dermatoscopy




















Patients referred to the specialist naevus clinic;




























PSL from the Sydney Melanoma Unit with
dermoscopic images and histological
diagnoses; melanomas and randomly selected







































Nodular malignant melanoma* and a random
selection of non-nodular invasive primary
melanoma, benign nodular melanocytic lesions,
and nodular nonmelanocytic lesions at a ratio
of NM to other subgroups of 1:2. Nodular
benign melanocytic lesions and nodular
nonmelanocytic lesions were identified by the
clinical appearance of a solitary nodule and














and >1; others at
standard
thresholds
Dermatologist (n=1; exp NR)
Twelve scorers blinded to the
lesion diagnosis scored 99
individual features in each lesion
of approximately equal sample
sizes, as previously
described.7Following the review
of the article for publication, an
additional feature (blue-black
structures) was scored for all






































































Patients with atypical melanocytic lesions or








































NR; correct dx of
MM


















Clinically atypical pigmented skin lesions








NR; dx of MM  
GPs (n=74; no formal training in
dermoscopy, randomised to
dermoscopy education










groups of GPs at
baseline (pre-test)
and after training of
one arm (post-test);
post-test data for





group of GPs was
used for the Visual
Inspection analysis
NR – not reported; PSL – pigmented skin lesion; PLC – pigmented lesion clinic; MM – malignant melanoma; MiS – melanoma in situ (or lentigo maligna); BCC – basal cell carcinoma;
cSCC – cutaneous squamous cell carcinoma; LS – lentigo simplex; SK – seborrheic keratosis; SN – Spitz nevi; AK – actinic keratosis; BN – benign naevi; BD – Bowen’s disease; DF –
dermatofibroma; FU – follow-up; R –retropsective; P – prospective; CS – case series; CCS – case control study; WPC – within person comparison (of tests); BPC – between person
comparison (of tests); NC – non comparative; RCM – reflectance confocal microscopy; CAD – computer-assisted diagnosis; Obs - observer; alg - algorithm
12 Forest plots of sensitivity and specificity for visual inspection and for visual inspection plus dermoscopy for the detection of invasive
melanoma (MM)
Figure 26; Figure 27








































Patients asking for screening or exhibiting
one or more skin tumours as seen during
routine physical examination (patient-
finding screening).
Participating PCPs randomised to either
visual inspection alone or visual inspection
plus dermoscopy; only excised lesions can





















*Only those patients who were considered to have
lesions suggestive of skin cancer had histology and
could be included; rest had expert diagnosis












PSL that could not be diagnosed with only
dermatologic physical examination; 2x2





































Lesions at pigmented lesion clinic
considered by experienced dermatologists














*Also reports data for 6 inexperienced observers
interpretation of the acquired dermoscopic images;













PSL referred by dermatologists and


































Clinically suspicious or equivocal PSL
undergoing excision for diagnostic















MM 6, MiS 5
BCC 10
BN 31, SK 1;
Other 4
11/57; 19%
4 ‘not evaluables’ excluded (NB these differ
between clinical images and dermoscopic images











Patients referred to the specialist naevus






























PSL submitted for histology from the































3 poor quality images excluded
















PSL images selected from computerised








































Random sample of excised, equivocal and
nonequivocal, PSL and and non-PSLs with
melanin or haemoglobin pigmentation in

























15 used for training purposes
5 BCC moved from FP to to TN
NR – not reported; PSL – pigmented skin lesion; PLC – pigmented lesion clinic; MM – malignant melanoma; MiS – melanoma in situ (or lentigo maligna); BCC – basal cell carcinoma;
cSCC – cutaneous squamous cell carcinoma; LS – lentigo simplex; SK – seborrheic keratosis; SN – Spitz nevi; AK – actinic keratosis; BN – benign naevi; BD – Bowen’s disease; DF –
dermatofibroma; FU – follow-up; R –retropsective; P – prospective; CS – case series; CCS – case control study; WPC – within person comparison (of tests); BPC – between person
comparison (of tests); NC – non comparative; RCM – reflectance confocal microscopy; CAD – computer-assisted diagnosis











Clinicians recruited for training Pre-training Training approach Post-training










of PSL from the













Recruited 16 ‘colleagues’, incl medical
Students (n=3), dermatology residents (n=9) and
Dermatologists (n=4).
All reported limited personal experience of dermoscopy, no
formal training and did not use dermoscopy in daily
professional practice
 
After the 1h lecture at the





electronic data sheet listing
criteria for diagnosing PSLs
by pattern analysis and by
the various algorithms and
to offer a dermoscopic




· basic principles of dermoscopy,
the dermoscopic
· features of PSLs,
· pattern analysis and the
diagnostic
algorithms (ABCD rule, seven-
point checklist, Menzies’
method).
Plus a web-based tutorial
(http://www.dermoscopy.org);
participants requested to devote







evaluated the same 20

















3 dermatologists and 1 GP scored according to number of
years specializing in dermoscopy, number of pigmented skin
lesions assessed by dermoscopy on a daily basis, number of
relevant workshops/seminars attended, and number of
authored publications on dermoscopy: highly experienced





assessed by each observer
using ABCD at T0
Between T0 and T1, Observer 4
underwent dermoscopic training
by studying an interactive atlas
of dermoscopy (Argenziano





each of the four
observers using ABCD















Of 223 dermatologists who participated in one of the six
workshops, 83 (37%) were reported on; average of 10 y of
general experience in dermatology (range 1 - 22) with routine
use of ELM by 52 individuals (conventional dermatoscope for
43 and digital equipment for 9).
 
Pre-training test conducted
after the opening lecture of
each workshop (clinical
classification of PSLs).
Images projected onto a
screen in pairs (clinical and
ELM image); classified by
as CMM, MN, NML,
unclassifiable or equivocal;




programme in ELM; one-day
meetings and workshops
(duration 4 + 2 h) held with free
registration. Topics included:
· clinical classification and
diagnosis of PSLs
· management of patients with
PSLs;
· basic principles of ELM;
· ELM criteria
· ELM diagnosis;
· limitations of ELM
 
Same set of slides re-
evaluated at the end



















3 consultant dermatologists and 3 specialist registrars; none
had routinely used a dermatoscope.
 














teaching the MPADA (Modified
Pattern Analysis Diagnostic
Algorithm), which could be
referred to during the study
period.
Also each given a dermatoscope
to use in clinical practice for 10
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https://archie.cochrane.org/popups/view.jsp?url=%2Fsections%2Fdocuments%2Fview%3Fdocument%3Dz15012116044828295657279213… 255/255
‘malignant’ or ‘not known’,
gave a diagnosis if known,
and indicated whether they
would excise the lesion.
months
 















Volunteer dermatologists (n=32); experienced in clinical
diagnosis of PSLs, but had no formal training in dermoscopy.
ELM qualification based on good theoretical knowledge of the










Each image shown for 30
s; no discussion of
assumed diagnosis was
permitted. None of the test
slides used for training.
 
6 h of teaching daily for two
consecutive days. Training was
based on presentation of several
hundred slides with oral
explanation of the ELM criteria.
 
Tests were performed
in the beginning and in
the end of the
teaching course
Same test performed

















GPs (n=74) recruited by
telephone from a list of current practitioners. Required to have
no
formal training in dermoscopy and did not
use dermoscopy in their clinical practice
Participants randomized into an education intervention group
or non-education intervention
group (each n . 37).
 
















Supplied with pictorial atlas by
Menzies et al.21 and a 1-h
presentation on dermoscopy
that specifically reviewed the
Menzies method and included a
quiz with images of 25 different
PSL (not used in test)
As for pre-test
 
